EP3294732B1 - Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase - Google Patents
Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase Download PDFInfo
- Publication number
- EP3294732B1 EP3294732B1 EP16730065.6A EP16730065A EP3294732B1 EP 3294732 B1 EP3294732 B1 EP 3294732B1 EP 16730065 A EP16730065 A EP 16730065A EP 3294732 B1 EP3294732 B1 EP 3294732B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydroxy
- carboximidamide
- fluorophenyl
- chloro
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 285
- 239000003112 inhibitor Substances 0.000 title claims description 177
- 230000000694 effects Effects 0.000 title claims description 26
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title description 5
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title description 2
- -1 tetrahydrofuran-3-yl Chemical group 0.000 claims description 142
- 150000003839 salts Chemical class 0.000 claims description 111
- 239000000203 mixture Substances 0.000 claims description 82
- 125000000623 heterocyclic group Chemical group 0.000 claims description 80
- 125000001072 heteroaryl group Chemical group 0.000 claims description 64
- 125000001424 substituent group Chemical group 0.000 claims description 57
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 56
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 53
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 52
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 51
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 38
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 35
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 34
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 32
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 18
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- ZVKMPCIYSWINQG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=CNC=21)F)F ZVKMPCIYSWINQG-UHFFFAOYSA-N 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- XBHZZDYRSJGASC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-5-fluoro-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C(C=CC=2N=CNC=21)F XBHZZDYRSJGASC-UHFFFAOYSA-N 0.000 claims description 5
- OHUJOHIKTMRDFY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6-fluoro-N-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=CNC=21)C)F OHUJOHIKTMRDFY-UHFFFAOYSA-N 0.000 claims description 5
- YJLDNYGQYFTRTF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-7-(trifluoromethoxy)-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C=2N=CNC=21)OC(F)(F)F YJLDNYGQYFTRTF-UHFFFAOYSA-N 0.000 claims description 5
- PKHZDTRESWIASP-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C=2N=CNC=21)C PKHZDTRESWIASP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- DBIHNTUXQRFBBC-UHFFFAOYSA-N 2-amino-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=C(C=C2C(NC1=CC(=C(C=C1)F)Cl)=NO)F)F DBIHNTUXQRFBBC-UHFFFAOYSA-N 0.000 claims description 4
- PHDWADHAFGADGX-UHFFFAOYSA-N 6-chloro-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C2=C(N=CN2)C=1)C(NC1=CC(=C(C=C1)F)Cl)=NO PHDWADHAFGADGX-UHFFFAOYSA-N 0.000 claims description 4
- DTWHYGIVYKPWEM-UHFFFAOYSA-N 7-bromo-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC1=CC=C(C2=C1N=CN2)C(NC1=CC(=C(C=C1)F)Cl)=NO DTWHYGIVYKPWEM-UHFFFAOYSA-N 0.000 claims description 4
- OAYATPCIXXIMLN-UHFFFAOYSA-N 7-chloro-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC1=CC=C(C2=C1N=CN2)C(NC1=CC(=C(C=C1)F)Cl)=NO OAYATPCIXXIMLN-UHFFFAOYSA-N 0.000 claims description 4
- MXHJDDYAYITAJJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6-fluoro-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=CC=2NC=NC=21)F MXHJDDYAYITAJJ-UHFFFAOYSA-N 0.000 claims description 4
- VPWDYMGEKQBIOX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C=2N=CNC=21)F VPWDYMGEKQBIOX-UHFFFAOYSA-N 0.000 claims description 4
- HLEZYLNMJDHRDG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(2-methoxyethylamino)ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCNCCOC HLEZYLNMJDHRDG-UHFFFAOYSA-N 0.000 claims description 4
- PZLAJMQAASONIR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-7-(trifluoromethyl)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C=2NC=NC=21)C(F)(F)F PZLAJMQAASONIR-UHFFFAOYSA-N 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- DRZGZRZPQNZOPQ-UHFFFAOYSA-N 2-amino-6,7-difluoro-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=C(C=C2C(NC1=CC(=C(C=C1)F)C(F)(F)F)=NO)F)F DRZGZRZPQNZOPQ-UHFFFAOYSA-N 0.000 claims description 3
- OOQPOTADUXQCCR-UHFFFAOYSA-N 2-amino-7-fluoro-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=CC=C2C(NC1=CC(=C(C=C1)F)C(F)(F)F)=NO)F OOQPOTADUXQCCR-UHFFFAOYSA-N 0.000 claims description 3
- TXWZQIMDNKUEQF-UHFFFAOYSA-N 2-amino-N'-(3-bromo-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=C(C=C2C(NC1=CC(=C(C=C1)F)Br)=NO)F)F TXWZQIMDNKUEQF-UHFFFAOYSA-N 0.000 claims description 3
- SZEDBAHUAYBZQR-UHFFFAOYSA-N 2-amino-N'-(3-bromo-4-fluorophenyl)-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=CC=C2C(NC1=CC(=C(C=C1)F)Br)=NO)F SZEDBAHUAYBZQR-UHFFFAOYSA-N 0.000 claims description 3
- HZKKBFRSFIBMMO-UHFFFAOYSA-N 2-amino-N'-(3-bromophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=C(C=C2C(NC1=CC(=CC=C1)Br)=NO)F)F HZKKBFRSFIBMMO-UHFFFAOYSA-N 0.000 claims description 3
- WZJSSFPEIFJITD-UHFFFAOYSA-N 2-amino-N'-(3-bromophenyl)-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=CC=C2C(NC1=CC(=CC=C1)Br)=NO)F WZJSSFPEIFJITD-UHFFFAOYSA-N 0.000 claims description 3
- LTEZAKDOAUZMHP-UHFFFAOYSA-N 2-amino-N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=CC=C2C(NC1=CC(=C(C=C1)F)Cl)=NO)F LTEZAKDOAUZMHP-UHFFFAOYSA-N 0.000 claims description 3
- DIZPLHZORLKMOQ-UHFFFAOYSA-N 2-amino-N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=C(C=C2C(NC1=CC(=CC=C1)Cl)=NO)F)F DIZPLHZORLKMOQ-UHFFFAOYSA-N 0.000 claims description 3
- UGSTXFFWSGQALS-UHFFFAOYSA-N 2-amino-N'-(3-chlorophenyl)-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC=1NC2=C(N=1)C(=CC=C2C(NC1=CC(=CC=C1)Cl)=NO)F UGSTXFFWSGQALS-UHFFFAOYSA-N 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- PHNNEGFJXHICEE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(methylaminomethyl)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CNC)F)F PHNNEGFJXHICEE-UHFFFAOYSA-N 0.000 claims description 3
- KITNWHRACPRSKA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=CC=2N=CNC=21 KITNWHRACPRSKA-UHFFFAOYSA-N 0.000 claims description 3
- NDWORAUPSZDAKB-UHFFFAOYSA-N N'-(3-chlorophenyl)-2-[(dimethylamino)methyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CN(C)C)F)F NDWORAUPSZDAKB-UHFFFAOYSA-N 0.000 claims description 3
- BSGYOBOTMMLIED-UHFFFAOYSA-N N-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]methyl]acetamide Chemical compound ClC=1C=C(C=CC=1F)N\C(=N/O)\C1=C2C(=NC=C1)NC(=N2)CNC(C)=O BSGYOBOTMMLIED-UHFFFAOYSA-N 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- GODZSWCJEFMUDZ-UHFFFAOYSA-N ethyl N-[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]carbamate Chemical compound ClC=1C=C(C=CC=1F)N\C(=N/O)\C1=C2C(=NC=C1)N=C(N2)NC(OCC)=O GODZSWCJEFMUDZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- ORUSUCDYMDXUAH-UHFFFAOYSA-N 2-(2-aminoethyl)-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound NCCC1=NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N1 ORUSUCDYMDXUAH-UHFFFAOYSA-N 0.000 claims description 2
- AGQFCTTXCAYRSI-UHFFFAOYSA-N 2-(aminomethyl)-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NCC1=NC2=C(N1)C(=C(C=C2C(NC1=CC(=C(C=C1)F)Cl)=NO)F)F AGQFCTTXCAYRSI-UHFFFAOYSA-N 0.000 claims description 2
- SWNOMRMCNIQILG-UHFFFAOYSA-N 2-(aminomethyl)-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound NCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 SWNOMRMCNIQILG-UHFFFAOYSA-N 0.000 claims description 2
- WSQFMRPHHPKJLY-UHFFFAOYSA-N 2-(aminomethyl)-N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NCC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=CC=C1)Cl)=NO WSQFMRPHHPKJLY-UHFFFAOYSA-N 0.000 claims description 2
- FCUDNCMXPBNBKA-UHFFFAOYSA-N 2-(anilinomethyl)-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N(C1=CC=CC=C1)CC1=NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N1 FCUDNCMXPBNBKA-UHFFFAOYSA-N 0.000 claims description 2
- JWMOMUWDFRGECL-UHFFFAOYSA-N 2-(benzenesulfonamidomethyl)-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C1(=CC=CC=C1)S(=O)(=O)NCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 JWMOMUWDFRGECL-UHFFFAOYSA-N 0.000 claims description 2
- OYZAEKHKJJTSTD-UHFFFAOYSA-N 2-(chloromethyl)-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)C(F)(F)F)=NO)N=1 OYZAEKHKJJTSTD-UHFFFAOYSA-N 0.000 claims description 2
- GNSRMBCGGYNIHV-UHFFFAOYSA-N 2-[(benzylamino)methyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(C1=CC=CC=C1)NCC1=NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N1 GNSRMBCGGYNIHV-UHFFFAOYSA-N 0.000 claims description 2
- WOIDOZOXCPDCHS-UHFFFAOYSA-N 2-amino-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound NC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 WOIDOZOXCPDCHS-UHFFFAOYSA-N 0.000 claims description 2
- QKGILBBEFFKELC-UHFFFAOYSA-N 2-anilino-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N(C1=CC=CC=C1)C=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 QKGILBBEFFKELC-UHFFFAOYSA-N 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- IUFJLDMGGMUGOC-UHFFFAOYSA-N N'-(1-benzofuran-4-yl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound O1C=CC2=C1C=CC=C2NC(=NO)C1=C2C(=NC=C1)N=CN2 IUFJLDMGGMUGOC-UHFFFAOYSA-N 0.000 claims description 2
- WTOUUPLQPNRADM-UHFFFAOYSA-N N'-(1-benzofuran-5-yl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound O1C=CC2=C1C=CC(=C2)NC(=NO)C1=C2C(=NC=C1)N=CN2 WTOUUPLQPNRADM-UHFFFAOYSA-N 0.000 claims description 2
- YHHIVTKOHXDBTP-UHFFFAOYSA-N N'-(1-benzofuran-6-yl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound O1C=CC2=C1C=C(C=C2)NC(=NO)C1=C2C(=NC=C1)N=CN2 YHHIVTKOHXDBTP-UHFFFAOYSA-N 0.000 claims description 2
- JFNVOKYKLBGLNZ-UHFFFAOYSA-N N'-(1-benzofuran-7-yl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound O1C=CC2=C1C(=CC=C2)NC(=NO)C1=C2C(=NC=C1)N=CN2 JFNVOKYKLBGLNZ-UHFFFAOYSA-N 0.000 claims description 2
- XGSVVXHBKBZFGZ-UHFFFAOYSA-N N'-(2,5-dichlorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC1=C(C=C(C=C1)Cl)NC(=NO)C1=C2C(=NC=C1)N=CN2 XGSVVXHBKBZFGZ-UHFFFAOYSA-N 0.000 claims description 2
- QYNAGGRSCXKAKL-UHFFFAOYSA-N N'-(3,4-dichlorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1Cl)NC(=NO)C1=C2C(=NC=C1)NC=N2 QYNAGGRSCXKAKL-UHFFFAOYSA-N 0.000 claims description 2
- ORGOMKXSQGSVFG-UHFFFAOYSA-N N'-(3,5-dichloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=C(C=1F)Cl)NC(=NO)C1=C2C(=NC=C1)N=CN2 ORGOMKXSQGSVFG-UHFFFAOYSA-N 0.000 claims description 2
- GGMACUAIQMVLMX-UHFFFAOYSA-N N'-(3-bromo-4-chlorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1Cl)NC(=NO)C1=C2C(=NC=C1)NC=N2 GGMACUAIQMVLMX-UHFFFAOYSA-N 0.000 claims description 2
- LXWFAXYTTSGCGF-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CCN(C)C)F)F LXWFAXYTTSGCGF-UHFFFAOYSA-N 0.000 claims description 2
- QNUXETSMJNROPX-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC=N2 QNUXETSMJNROPX-UHFFFAOYSA-N 0.000 claims description 2
- CCAAJZDZFKRLBW-UHFFFAOYSA-N N'-(3-bromo-5-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=C(C=1)F)NC(=NO)C1=C2C(=NC=C1)N=CN2 CCAAJZDZFKRLBW-UHFFFAOYSA-N 0.000 claims description 2
- CNZMYFRFGBETQA-UHFFFAOYSA-N N'-(3-bromophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CCN(C)C)F)F CNZMYFRFGBETQA-UHFFFAOYSA-N 0.000 claims description 2
- UPPKJOIPXZWQCK-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)NC=N2 UPPKJOIPXZWQCK-UHFFFAOYSA-N 0.000 claims description 2
- OWQRGNTUGYCXAL-UHFFFAOYSA-N N'-(3-but-1-ynyl-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(#CCC)C=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=CN2 OWQRGNTUGYCXAL-UHFFFAOYSA-N 0.000 claims description 2
- SNHQFJIQLHMCGD-UHFFFAOYSA-N N'-(3-chloro-2,4-difluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C(=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=CN2)F SNHQFJIQLHMCGD-UHFFFAOYSA-N 0.000 claims description 2
- MTRAXBVDCYDFBV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(cyclobutylamino)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CCC1 MTRAXBVDCYDFBV-UHFFFAOYSA-N 0.000 claims description 2
- XQNITAUEWIGERJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(cyclopropylamino)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CC1 XQNITAUEWIGERJ-UHFFFAOYSA-N 0.000 claims description 2
- SVEKRVKWOOLJMR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(cyclopropylmethylamino)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1CC1 SVEKRVKWOOLJMR-UHFFFAOYSA-N 0.000 claims description 2
- AOIWNGSRGXXKDJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(dimethylamino)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)N(C)C AOIWNGSRGXXKDJ-UHFFFAOYSA-N 0.000 claims description 2
- SKFWVJMTTRJMRF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(ethylamino)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC SKFWVJMTTRJMRF-UHFFFAOYSA-N 0.000 claims description 2
- WVQUMARQEJNJOY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(ethylaminomethyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CNCC)F)F WVQUMARQEJNJOY-UHFFFAOYSA-N 0.000 claims description 2
- GHCXWTXFOJZKIF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(ethylaminomethyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCC GHCXWTXFOJZKIF-UHFFFAOYSA-N 0.000 claims description 2
- KUSOYOYZFOTIIN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(2,2-difluoroethylamino)methyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC(F)F KUSOYOYZFOTIIN-UHFFFAOYSA-N 0.000 claims description 2
- BPSNKWTVXCHYAF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(2,2-dimethylpropylamino)methyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC(C)(C)C BPSNKWTVXCHYAF-UHFFFAOYSA-N 0.000 claims description 2
- TYYQHNGPESPLPE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CC(C1)(F)F TYYQHNGPESPLPE-UHFFFAOYSA-N 0.000 claims description 2
- KARGSPQURZETEM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(cyclopropylamino)methyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNC1CC1 KARGSPQURZETEM-UHFFFAOYSA-N 0.000 claims description 2
- RVGMWBGHUFZVOB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(cyclopropylmethylamino)methyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CNCC1CC1)F)F RVGMWBGHUFZVOB-UHFFFAOYSA-N 0.000 claims description 2
- ZOXHUEHGQTULFP-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(cyclopropylmethylamino)methyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCC1CC1 ZOXHUEHGQTULFP-UHFFFAOYSA-N 0.000 claims description 2
- CSAWCUIHGVTJJF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(dimethylamino)methyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CN(C)C)F)F CSAWCUIHGVTJJF-UHFFFAOYSA-N 0.000 claims description 2
- DIAGVYPMGPYYFU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(dimethylamino)methyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CN(C)C DIAGVYPMGPYYFU-UHFFFAOYSA-N 0.000 claims description 2
- IAXGPAXPFYKJSZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(4,4-difluoropiperidin-1-yl)ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NCCN1CCC(CC1)(F)F)F)F IAXGPAXPFYKJSZ-UHFFFAOYSA-N 0.000 claims description 2
- BZCUKGCMDJZMJV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CCN(CC)CC)F)F BZCUKGCMDJZMJV-UHFFFAOYSA-N 0.000 claims description 2
- FSBHCJZAQITAOG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(CC)CC FSBHCJZAQITAOG-UHFFFAOYSA-N 0.000 claims description 2
- WXJCOLNNRJFIQV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NCCN(CC)CC)F)F WXJCOLNNRJFIQV-UHFFFAOYSA-N 0.000 claims description 2
- QPIJJVNUTUQSBD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(CC)CC QPIJJVNUTUQSBD-UHFFFAOYSA-N 0.000 claims description 2
- ULPUAYPQQFIJBG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)-1-hydroxyethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C(CN(C)C)O ULPUAYPQQFIJBG-UHFFFAOYSA-N 0.000 claims description 2
- JCAYYFGAMULCNL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CCN(C)C)F)F JCAYYFGAMULCNL-UHFFFAOYSA-N 0.000 claims description 2
- KXTPBRHGGFMWCW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CCN(C)C KXTPBRHGGFMWCW-UHFFFAOYSA-N 0.000 claims description 2
- KYWAWOMMFDMCCN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NCCN(C)C)F)F KYWAWOMMFDMCCN-UHFFFAOYSA-N 0.000 claims description 2
- YHHTUKHBCVAKTC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C=2N=C(NC=21)NCCN(C)C)F YHHTUKHBCVAKTC-UHFFFAOYSA-N 0.000 claims description 2
- ONUWUNQCCQEZHI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[2,2-difluoroethyl(methyl)amino]ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(C)CC(F)F ONUWUNQCCQEZHI-UHFFFAOYSA-N 0.000 claims description 2
- WIWPZRMNPHNJFQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[cyclopropylmethyl(methyl)amino]ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(C)CC1CC1 WIWPZRMNPHNJFQ-UHFFFAOYSA-N 0.000 claims description 2
- AFVXUUHGLFOYCG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)CCCN(C)C)F)F AFVXUUHGLFOYCG-UHFFFAOYSA-N 0.000 claims description 2
- FPONHWHUSZGCEV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NCCCN(C)C)F)F FPONHWHUSZGCEV-UHFFFAOYSA-N 0.000 claims description 2
- JMSWFIGOVUZBHU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[2-(dimethylamino)ethylamino]methyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCCN(C)C JMSWFIGOVUZBHU-UHFFFAOYSA-N 0.000 claims description 2
- LSJNIRHTSZBSIV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[cyclopropyl(hydroxy)methyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C(O)C1CC1 LSJNIRHTSZBSIV-UHFFFAOYSA-N 0.000 claims description 2
- NLYZAAFSUAGOQZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-cyclopropyl-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C1CC1 NLYZAAFSUAGOQZ-UHFFFAOYSA-N 0.000 claims description 2
- GLBVFMABBFZTNJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-ethyl-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CC GLBVFMABBFZTNJ-UHFFFAOYSA-N 0.000 claims description 2
- BLWCQCSQKFBCKX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(1-morpholin-4-ylpropan-2-ylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NC(CN1CCOCC1)C)F)F BLWCQCSQKFBCKX-UHFFFAOYSA-N 0.000 claims description 2
- NMDJHDHADCVFEA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-methoxyethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NCCOC)F)F NMDJHDHADCVFEA-UHFFFAOYSA-N 0.000 claims description 2
- CNGVVSVNOSMQGX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-methylsulfonylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NCCS(=O)(=O)C)F)F CNGVVSVNOSMQGX-UHFFFAOYSA-N 0.000 claims description 2
- XSAJORKGYJDHKI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NCCN1CCCC1)F)F XSAJORKGYJDHKI-UHFFFAOYSA-N 0.000 claims description 2
- ZOJKONNIMMYXNL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(hydroxymethyl)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)CO)F)F ZOJKONNIMMYXNL-UHFFFAOYSA-N 0.000 claims description 2
- ZAWPBXDWMWPLFS-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(methylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NC)F)F ZAWPBXDWMWPLFS-UHFFFAOYSA-N 0.000 claims description 2
- GMBAHRFPXXBPQB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(3-methoxypropylamino)methyl]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CNCCCOC)F)F GMBAHRFPXXBPQB-UHFFFAOYSA-N 0.000 claims description 2
- UKYUHWAOODHNBI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(propan-2-ylamino)methyl]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CNC(C)C)F)F UKYUHWAOODHNBI-UHFFFAOYSA-N 0.000 claims description 2
- SGYQQPPEVMZLDA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(methylamino)ethyl]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CCNC)F)F SGYQQPPEVMZLDA-UHFFFAOYSA-N 0.000 claims description 2
- PGGVESZUBGBVGO-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-morpholin-4-yl-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)N1CCOCC1)F)F PGGVESZUBGBVGO-UHFFFAOYSA-N 0.000 claims description 2
- XIMUSPIZHOASFN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-2-(2-methylsulfonylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C=2N=C(NC=21)NCCS(=O)(=O)C)F XIMUSPIZHOASFN-UHFFFAOYSA-N 0.000 claims description 2
- JVXJQQQCZZBTMN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-2-(2-morpholin-4-ylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)NCCN1CCOCC1)F JVXJQQQCZZBTMN-UHFFFAOYSA-N 0.000 claims description 2
- NEEOJRZQXNSFPI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-2-(3-morpholin-4-ylpropylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C=2N=C(NC=21)NCCCN1CCOCC1)F NEEOJRZQXNSFPI-UHFFFAOYSA-N 0.000 claims description 2
- GTZNQZCEUUPRNY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=CN2 GTZNQZCEUUPRNY-UHFFFAOYSA-N 0.000 claims description 2
- OEOHAJBVHXVIMG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C(C)O OEOHAJBVHXVIMG-UHFFFAOYSA-N 0.000 claims description 2
- WOXMDPAPYXKQAS-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C=1NC=CN=1 WOXMDPAPYXKQAS-UHFFFAOYSA-N 0.000 claims description 2
- ROLIFZGTLTWXAA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(1H-pyrazol-5-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C1=CC=NN1 ROLIFZGTLTWXAA-UHFFFAOYSA-N 0.000 claims description 2
- UJMGELGPVAHELA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(1H-pyrrol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C=1NC=CC=1 UJMGELGPVAHELA-UHFFFAOYSA-N 0.000 claims description 2
- NIUXWZLEIILVSW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2,2,2-trifluoro-1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C(C(F)(F)F)O NIUXWZLEIILVSW-UHFFFAOYSA-N 0.000 claims description 2
- KAWBBXBDTZZMOT-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2,2,2-trifluoroethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC(F)(F)F KAWBBXBDTZZMOT-UHFFFAOYSA-N 0.000 claims description 2
- PYCLXODOFXZKDK-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCO PYCLXODOFXZKDK-UHFFFAOYSA-N 0.000 claims description 2
- VZLHDDHRGHJWGL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-hydroxypropan-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C(C)(C)O VZLHDDHRGHJWGL-UHFFFAOYSA-N 0.000 claims description 2
- UEZHCZKHMLRDQQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-morpholin-4-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CCN1CCOCC1 UEZHCZKHMLRDQQ-UHFFFAOYSA-N 0.000 claims description 2
- ZQHRJWCGDGKXFG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-morpholin-4-ylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CCOCC1 ZQHRJWCGDGKXFG-UHFFFAOYSA-N 0.000 claims description 2
- DIQRHJBCLIBGNE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-phenylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCC1=CC=CC=C1 DIQRHJBCLIBGNE-UHFFFAOYSA-N 0.000 claims description 2
- XKVCCKKUNUOTCM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-piperidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1CCCCC1 XKVCCKKUNUOTCM-UHFFFAOYSA-N 0.000 claims description 2
- HAUKZAAAXOUUQD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-pyrrolidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1CCCC1 HAUKZAAAXOUUQD-UHFFFAOYSA-N 0.000 claims description 2
- ZRSDCCSKFVCLMI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(5-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C=1NC(=CN=1)C ZRSDCCSKFVCLMI-UHFFFAOYSA-N 0.000 claims description 2
- LOLIBBHURMPRTI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CO LOLIBBHURMPRTI-UHFFFAOYSA-N 0.000 claims description 2
- FEWCNXHGQUXKHJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(methanesulfonamidomethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNS(=O)(=O)C FEWCNXHGQUXKHJ-UHFFFAOYSA-N 0.000 claims description 2
- LHCVVTPTUFLRLC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)COC LHCVVTPTUFLRLC-UHFFFAOYSA-N 0.000 claims description 2
- QYSPOJDBIHMAMH-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC QYSPOJDBIHMAMH-UHFFFAOYSA-N 0.000 claims description 2
- WZBUGDROWLOZQJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(methylaminomethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNC WZBUGDROWLOZQJ-UHFFFAOYSA-N 0.000 claims description 2
- JOMGBHUBTBSLCI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(morpholin-4-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CN1CCOCC1 JOMGBHUBTBSLCI-UHFFFAOYSA-N 0.000 claims description 2
- ZDTWRCADMKRIMD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(piperidin-1-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CN1CCCCC1 ZDTWRCADMKRIMD-UHFFFAOYSA-N 0.000 claims description 2
- RAFBJPAHUGHUGZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(propan-2-ylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC(C)C RAFBJPAHUGHUGZ-UHFFFAOYSA-N 0.000 claims description 2
- KTZGCKJEKUPJFC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(pyrrolidin-1-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CN1CCCC1 KTZGCKJEKUPJFC-UHFFFAOYSA-N 0.000 claims description 2
- PYRVZFJGSUYMAW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(1,3-thiazol-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC=1SC=CN=1 PYRVZFJGSUYMAW-UHFFFAOYSA-N 0.000 claims description 2
- LZPHBVSWGRZVEK-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(1-methylpiperidin-2-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1N(CCCC1)C LZPHBVSWGRZVEK-UHFFFAOYSA-N 0.000 claims description 2
- VZFUJFFMKSIMBK-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(1-methylpyrrolidin-3-yl)amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CN(CC1)C VZFUJFFMKSIMBK-UHFFFAOYSA-N 0.000 claims description 2
- AHARYYHCLUKSQF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(2,2,2-trifluoroethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCC(F)(F)F AHARYYHCLUKSQF-UHFFFAOYSA-N 0.000 claims description 2
- DYWDQVDDMPVOKK-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(2-methoxyethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCCOC DYWDQVDDMPVOKK-UHFFFAOYSA-N 0.000 claims description 2
- RLUFWYOWJRVHIP-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(2-methylpropylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC(C)C RLUFWYOWJRVHIP-UHFFFAOYSA-N 0.000 claims description 2
- ITINMDRKXSUZER-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(2-pyridin-2-ylethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCCC1=NC=CC=C1 ITINMDRKXSUZER-UHFFFAOYSA-N 0.000 claims description 2
- JDACHECCLNLQOI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(2-pyrimidin-2-ylethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCCC1=NC=CC=N1 JDACHECCLNLQOI-UHFFFAOYSA-N 0.000 claims description 2
- ZPXLODYDPIPZGA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(3-hydroxypropylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCCCO ZPXLODYDPIPZGA-UHFFFAOYSA-N 0.000 claims description 2
- FBGBXUMIMPEBJJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(3-methoxypropylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCCCOC FBGBXUMIMPEBJJ-UHFFFAOYSA-N 0.000 claims description 2
- LXIVLXZNHGCAHH-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(3-morpholin-4-ylpropylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCCCN1CCOCC1 LXIVLXZNHGCAHH-UHFFFAOYSA-N 0.000 claims description 2
- UUWYVNNIBFDKEV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(oxan-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC1OCCCC1 UUWYVNNIBFDKEV-UHFFFAOYSA-N 0.000 claims description 2
- LSRJQNMZLBNFLN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(oxan-3-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC1COCCC1 LSRJQNMZLBNFLN-UHFFFAOYSA-N 0.000 claims description 2
- FNTNSMZBHMJKJW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(oxan-4-ylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNC1CCOCC1 FNTNSMZBHMJKJW-UHFFFAOYSA-N 0.000 claims description 2
- TVTXFPFNWOGYGJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(oxolan-3-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC1COCC1 TVTXFPFNWOGYGJ-UHFFFAOYSA-N 0.000 claims description 2
- FJRLOCGDOUTCMR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(propan-2-ylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNC(C)C FJRLOCGDOUTCMR-UHFFFAOYSA-N 0.000 claims description 2
- NCSZHIMFAVTIOU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(pyrazin-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC1=NC=CN=C1 NCSZHIMFAVTIOU-UHFFFAOYSA-N 0.000 claims description 2
- RKMKIIHDQBZJPW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(pyridin-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCC1=NC=CC=C1 RKMKIIHDQBZJPW-UHFFFAOYSA-N 0.000 claims description 2
- QDKNXZVOSJXJCY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(pyridin-3-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCC=1C=NC=CC=1 QDKNXZVOSJXJCY-UHFFFAOYSA-N 0.000 claims description 2
- IXNKEPWBQORPNR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(pyridin-4-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCC1=CC=NC=C1 IXNKEPWBQORPNR-UHFFFAOYSA-N 0.000 claims description 2
- WBALPTLVTMDFFO-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(pyrimidin-2-ylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNC1=NC=CC=N1 WBALPTLVTMDFFO-UHFFFAOYSA-N 0.000 claims description 2
- ROVGCNPDFPYSLV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(pyrimidin-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CNCC1=NC=CC=N1 ROVGCNPDFPYSLV-UHFFFAOYSA-N 0.000 claims description 2
- PXFXHIFJSHNNAN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(methylamino)ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CCNC PXFXHIFJSHNNAN-UHFFFAOYSA-N 0.000 claims description 2
- CYOIQBDCFBPERB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[2-methoxyethyl(methyl)amino]ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(C)CCOC CYOIQBDCFBPERB-UHFFFAOYSA-N 0.000 claims description 2
- LDPZNXNEQMUBMB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[(2-methoxyphenyl)methylamino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC1=C(C=CC=C1)OC LDPZNXNEQMUBMB-UHFFFAOYSA-N 0.000 claims description 2
- RBGDLZYRRJXHOD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[(3-hydroxy-2,2-dimethylpropyl)amino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CNCC(CO)(C)C RBGDLZYRRJXHOD-UHFFFAOYSA-N 0.000 claims description 2
- PQHMSNWUEWLJPI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[3-methoxypropyl(methyl)amino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CN(C)CCCOC PQHMSNWUEWLJPI-UHFFFAOYSA-N 0.000 claims description 2
- JYVVUZZIXAUFIR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[hydroxy(phenyl)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C(C1=CC=CC=C1)O JYVVUZZIXAUFIR-UHFFFAOYSA-N 0.000 claims description 2
- ZAASBOMMWKYVIY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C ZAASBOMMWKYVIY-UHFFFAOYSA-N 0.000 claims description 2
- DCNFAZCKLOTMKT-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-pyridin-3-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C=1C=NC=CC=1 DCNFAZCKLOTMKT-UHFFFAOYSA-N 0.000 claims description 2
- XPOOOBJUOPGWPD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-thiophen-2-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)C=1SC=CC=1 XPOOOBJUOPGWPD-UHFFFAOYSA-N 0.000 claims description 2
- LSEKRSRVTXYDAA-UHFFFAOYSA-N N'-(3-chloronaphthalen-2-yl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C(=CC2=CC=CC=C2C=1)NC(=NO)C1=C2C(=NC=C1)N=CN2 LSEKRSRVTXYDAA-UHFFFAOYSA-N 0.000 claims description 2
- ZKSGSCJBBLIHPY-UHFFFAOYSA-N N'-(3-chlorophenyl)-2-(ethylaminomethyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CNCC)F)F ZKSGSCJBBLIHPY-UHFFFAOYSA-N 0.000 claims description 2
- FCJQXQVYARSILH-UHFFFAOYSA-N N'-(3-chlorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C=2NC(=NC=21)CCN(C)C)F)F FCJQXQVYARSILH-UHFFFAOYSA-N 0.000 claims description 2
- RFCBLTSARUUMGR-UHFFFAOYSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-(1-methylpiperidin-3-yl)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C=2N=C(NC=21)C1CN(CCC1)C)F)F RFCBLTSARUUMGR-UHFFFAOYSA-N 0.000 claims description 2
- GQTXCARBOPJJCN-UHFFFAOYSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-(hydroxymethyl)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CO)F)F GQTXCARBOPJJCN-UHFFFAOYSA-N 0.000 claims description 2
- DSAKIHQFMCDCET-UHFFFAOYSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-(methylaminomethyl)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CNC)F)F DSAKIHQFMCDCET-UHFFFAOYSA-N 0.000 claims description 2
- YKSARDAVUSQOIB-UHFFFAOYSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-[(3-methoxypropylamino)methyl]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CNCCCOC)F)F YKSARDAVUSQOIB-UHFFFAOYSA-N 0.000 claims description 2
- ZABFWDKMNBJXTO-UHFFFAOYSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-[(propan-2-ylamino)methyl]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CNC(C)C)F)F ZABFWDKMNBJXTO-UHFFFAOYSA-N 0.000 claims description 2
- ITTZRERWJQQJOV-UHFFFAOYSA-N N'-(3-chlorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)NC=N2 ITTZRERWJQQJOV-UHFFFAOYSA-N 0.000 claims description 2
- FNPBMJDWTXJGCO-UHFFFAOYSA-N N'-(3-chlorophenyl)-N-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC FNPBMJDWTXJGCO-UHFFFAOYSA-N 0.000 claims description 2
- PUYFPFYBTWUOSC-UHFFFAOYSA-N N'-(3-cyano-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(#N)C=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=CN2 PUYFPFYBTWUOSC-UHFFFAOYSA-N 0.000 claims description 2
- BCUMJUFBKGYCRG-UHFFFAOYSA-N N'-(3-cyclopropyl-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C1(CC1)C=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=CN2 BCUMJUFBKGYCRG-UHFFFAOYSA-N 0.000 claims description 2
- JKIMMOSABATOPN-UHFFFAOYSA-N N'-(3-ethylphenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(C)C=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=CN2 JKIMMOSABATOPN-UHFFFAOYSA-N 0.000 claims description 2
- CUZOMASHYSWBGU-UHFFFAOYSA-N N'-(3-ethynyl-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(#C)C=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=CN2 CUZOMASHYSWBGU-UHFFFAOYSA-N 0.000 claims description 2
- IYADZTKHLUPTGW-UHFFFAOYSA-N N'-(4-bromophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC1=CC=C(C=C1)NC(=NO)C1=C2C(=NC=C1)NC=N2 IYADZTKHLUPTGW-UHFFFAOYSA-N 0.000 claims description 2
- VWROKQHNFUDZOE-UHFFFAOYSA-N N'-(4-chloronaphthalen-1-yl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC1=CC=C(C2=CC=CC=C12)NC(=NO)C1=C2C(=NC=C1)N=CN2 VWROKQHNFUDZOE-UHFFFAOYSA-N 0.000 claims description 2
- CEIYPCHWHGHAPH-UHFFFAOYSA-N N'-(4-chlorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC1=CC=C(C=C1)NC(=NO)C1=C2C(=NC=C1)NC=N2 CEIYPCHWHGHAPH-UHFFFAOYSA-N 0.000 claims description 2
- JPXXBRPRQLCSBZ-UHFFFAOYSA-N N'-(4-fluoro-3-methoxyphenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1=C(C=C(C=C1)NC(=NO)C1=C2C(=NC=C1)N=CN2)OC JPXXBRPRQLCSBZ-UHFFFAOYSA-N 0.000 claims description 2
- HFAANUDYLRHYSW-UHFFFAOYSA-N N'-(4-fluoro-3-phenylphenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1=C(C=C(C=C1)NC(=NO)C1=C2C(=NC=C1)N=CN2)C1=CC=CC=C1 HFAANUDYLRHYSW-UHFFFAOYSA-N 0.000 claims description 2
- ADZCYZUWONMIDP-UHFFFAOYSA-N N'-(4-fluoro-3-prop-1-ynylphenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1=C(C=C(C=C1)NC(=NO)C1=C2C(=NC=C1)N=CN2)C#CC ADZCYZUWONMIDP-UHFFFAOYSA-N 0.000 claims description 2
- WMPNSHFUXDHXNV-UHFFFAOYSA-N N'-(4-fluoro-3-propan-2-ylphenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1=C(C=C(C=C1)NC(=NO)C1=C2C(=NC=C1)N=CN2)C(C)C WMPNSHFUXDHXNV-UHFFFAOYSA-N 0.000 claims description 2
- PXRALVPNQGDJCV-UHFFFAOYSA-N N'-(4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1=CC=C(C=C1)NC(=NO)C1=C2C(=NC=C1)NC=N2 PXRALVPNQGDJCV-UHFFFAOYSA-N 0.000 claims description 2
- PKPIQGPYHISCMK-UHFFFAOYSA-N N'-(5-bromo-2,4-difluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C(=CC(=C(C=1)NC(=NO)C1=C2C(=NC=C1)N=CN2)F)F PKPIQGPYHISCMK-UHFFFAOYSA-N 0.000 claims description 2
- ICYUXHQWCLVFTL-UHFFFAOYSA-N N'-(5-bromo-2-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=CC(=C(C=1)NC(=NO)C1=C2C(=NC=C1)NC=N2)F ICYUXHQWCLVFTL-UHFFFAOYSA-N 0.000 claims description 2
- OZRLMOWWTISYLK-UHFFFAOYSA-N N'-(5-chloro-2,4-difluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C(=CC(=C(C=1)NC(=NO)C1=C2C(=NC=C1)N=CN2)F)F OZRLMOWWTISYLK-UHFFFAOYSA-N 0.000 claims description 2
- XAXITBBCCGJNPN-UHFFFAOYSA-N N'-(5-chloro-2-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=CC(=C(C=1)NC(=NO)C1=C2C(=NC=C1)N=CN2)F XAXITBBCCGJNPN-UHFFFAOYSA-N 0.000 claims description 2
- PEXROSHIJYOFMH-UHFFFAOYSA-N N'-[3-(2-cyclopropylethynyl)-4-fluorophenyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C1(CC1)C#CC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=CN2 PEXROSHIJYOFMH-UHFFFAOYSA-N 0.000 claims description 2
- OJUIUOASMYJFTH-UHFFFAOYSA-N N'-[3-(difluoromethyl)phenyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC(C=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=CN2)F OJUIUOASMYJFTH-UHFFFAOYSA-N 0.000 claims description 2
- ZFNNBSHBGBHURX-UHFFFAOYSA-N N'-[3-fluoro-5-(trifluoromethyl)phenyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)NC(=NO)C1=C2C(=NC=C1)N=CN2 ZFNNBSHBGBHURX-UHFFFAOYSA-N 0.000 claims description 2
- GWCBBMKNDWYLEA-UHFFFAOYSA-N N'-[4-fluoro-3-(trifluoromethoxy)phenyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1=C(C=C(C=C1)NC(=NO)C1=C2C(=NC=C1)N=CN2)OC(F)(F)F GWCBBMKNDWYLEA-UHFFFAOYSA-N 0.000 claims description 2
- YOZKSXCLESMHCJ-UHFFFAOYSA-N N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1=C(C=C(C=C1)NC(=NO)C1=C2C(=NC=C1)NC=N2)C(F)(F)F YOZKSXCLESMHCJ-UHFFFAOYSA-N 0.000 claims description 2
- YPRSUMSJJNJUGI-UHFFFAOYSA-N N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-hydroxy-2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1=C(C=C(C=C1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CO)C(F)(F)F YPRSUMSJJNJUGI-UHFFFAOYSA-N 0.000 claims description 2
- HCIDZUGCYBTCIR-UHFFFAOYSA-N N-hydroxy-N'-(3-methoxyphenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC(=CC=C1)OC)C1=C2C(=NC=C1)NC=N2 HCIDZUGCYBTCIR-UHFFFAOYSA-N 0.000 claims description 2
- LJAJFMZSQRFTKS-UHFFFAOYSA-N N-hydroxy-N'-(4-methylphenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC=C(C=C1)C)C1=C2C(=NC=C1)NC=N2 LJAJFMZSQRFTKS-UHFFFAOYSA-N 0.000 claims description 2
- MNMOJFBHHBULEM-UHFFFAOYSA-N N-hydroxy-N'-[3-(trifluoromethyl)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC(=CC=C1)C(F)(F)F)C1=C2C(=NC=C1)N=CN2 MNMOJFBHHBULEM-UHFFFAOYSA-N 0.000 claims description 2
- YAFIKZPBNGYIFL-UHFFFAOYSA-N N-hydroxy-N'-[4-(trifluoromethoxy)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC=C(C=C1)OC(F)(F)F)C1=C2C(=NC=C1)N=CN2 YAFIKZPBNGYIFL-UHFFFAOYSA-N 0.000 claims description 2
- WKQHYCAVNLGHTK-UHFFFAOYSA-N N-hydroxy-N'-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC=C(C=C1)C(F)(F)F)C1=C2C(=NC=C1)NC=N2 WKQHYCAVNLGHTK-UHFFFAOYSA-N 0.000 claims description 2
- MPLZQSHWBDKFPH-UHFFFAOYSA-N N-hydroxy-N'-naphthalen-1-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC=CC2=CC=CC=C12)C1=C2C(=NC=C1)N=CN2 MPLZQSHWBDKFPH-UHFFFAOYSA-N 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- DJNPNJTVKAEJEG-UHFFFAOYSA-N propan-2-yl N-[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]carbamate Chemical compound ClC=1C=C(C=CC=1F)N\C(=N/O)\C1=C2C(=NC=C1)N=C(N2)NC(OC(C)C)=O DJNPNJTVKAEJEG-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 2
- KBESQZXQIIRDCI-LLVKDONJSA-N 1-(3-chloro-4-fluorophenyl)-2-[2-[(3R)-3-fluoropyrrolidin-1-yl]ethylamino]-N'-hydroxyimidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)N1C(=NC2=NC=CC(=C21)C(NO)=N)NCCN1C[C@@H](CC1)F KBESQZXQIIRDCI-LLVKDONJSA-N 0.000 claims 1
- KBESQZXQIIRDCI-NSHDSACASA-N 1-(3-chloro-4-fluorophenyl)-2-[2-[(3S)-3-fluoropyrrolidin-1-yl]ethylamino]-N'-hydroxyimidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)N1C(=NC2=NC=CC(=C21)C(NO)=N)NCCN1C[C@H](CC1)F KBESQZXQIIRDCI-NSHDSACASA-N 0.000 claims 1
- YXJDVJNGZBHWFG-UHFFFAOYSA-N 1-[2-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-4,5-difluoro-1H-benzimidazol-2-yl]amino]ethyl]-3-ethylurea Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCNC(=O)NCC)F)F YXJDVJNGZBHWFG-UHFFFAOYSA-N 0.000 claims 1
- DGSHRKPXDWVNDS-UHFFFAOYSA-N 2-(2-aminoethyl)-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NCCC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO DGSHRKPXDWVNDS-UHFFFAOYSA-N 0.000 claims 1
- HSSUYXRTIBJBMS-UHFFFAOYSA-N 2-(2-aminoethylamino)-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NCCNC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO HSSUYXRTIBJBMS-UHFFFAOYSA-N 0.000 claims 1
- VYUAYBLMICIOGW-UHFFFAOYSA-N 2-(2-aminoethylamino)-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound NCCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 VYUAYBLMICIOGW-UHFFFAOYSA-N 0.000 claims 1
- SCOLNCCBFLEOKH-UHFFFAOYSA-N 2-(2-anilinoethylamino)-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNC1=CC=CC=C1 SCOLNCCBFLEOKH-UHFFFAOYSA-N 0.000 claims 1
- BXNBAAAYRKMIAD-UHFFFAOYSA-N 2-(3-aminopropylamino)-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound NCCCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 BXNBAAAYRKMIAD-UHFFFAOYSA-N 0.000 claims 1
- MOGDJSVPOGWODU-UHFFFAOYSA-N 2-(aminomethyl)-N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NCC1=NC2=C(N1)C(=CC=C2F)C(NC1=CC(=C(C=C1)F)Cl)=NO MOGDJSVPOGWODU-UHFFFAOYSA-N 0.000 claims 1
- LZWRMQWGVQKOBG-UHFFFAOYSA-N 2-[(1-acetylpiperidin-3-yl)amino]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(C)(=O)N1CC(CCC1)NC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 LZWRMQWGVQKOBG-UHFFFAOYSA-N 0.000 claims 1
- UPDQAKUVMBATJF-UHFFFAOYSA-N 2-[(1-acetylpyrrolidin-3-yl)amino]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(C)(=O)N1CC(CC1)NC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 UPDQAKUVMBATJF-UHFFFAOYSA-N 0.000 claims 1
- GHXUMWVZYRFZEB-UHFFFAOYSA-N 2-[(1-aminocyclopropyl)methylamino]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound NC1(CC1)CNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 GHXUMWVZYRFZEB-UHFFFAOYSA-N 0.000 claims 1
- UBCJKYDYGRQSRT-UHFFFAOYSA-N 2-[(2-aminophenyl)methylamino]-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC1=C(CNC2=NC3=C(N2)C(=CC(=C3F)F)C(NC2=CC(=C(C=C2)F)Cl)=NO)C=CC=C1 UBCJKYDYGRQSRT-UHFFFAOYSA-N 0.000 claims 1
- OPCOXUMJTKYQJZ-UHFFFAOYSA-N 2-[2-(1-aminocyclopropyl)ethylamino]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound NC1(CC1)CCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 OPCOXUMJTKYQJZ-UHFFFAOYSA-N 0.000 claims 1
- WLNRTNZJWHWCFY-UHFFFAOYSA-N 2-[2-(2-amino-4,5-dihydroimidazol-1-yl)ethyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound NC=1N(CCN=1)CCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 WLNRTNZJWHWCFY-UHFFFAOYSA-N 0.000 claims 1
- OTIMYURWBXYLLZ-UHFFFAOYSA-N 2-[2-(3-azabicyclo[3.2.1]octan-3-yl)ethyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C12CN(CC(CC1)C2)CCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 OTIMYURWBXYLLZ-UHFFFAOYSA-N 0.000 claims 1
- KVVOKCZMKLLPAH-UHFFFAOYSA-N 2-[2-(3-azabicyclo[3.3.1]nonan-3-yl)ethyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C12CN(CC(CCC1)C2)CCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 KVVOKCZMKLLPAH-UHFFFAOYSA-N 0.000 claims 1
- IUFULTXYKBBTKN-UHFFFAOYSA-N 2-[2-(4-azaspiro[2.4]heptan-4-yl)ethylamino]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C1CC11N(CCC1)CCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 IUFULTXYKBBTKN-UHFFFAOYSA-N 0.000 claims 1
- LCOQFLBVULHSPM-UHFFFAOYSA-N 2-[2-(4-azaspiro[2.5]octan-4-yl)ethylamino]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C1CC11N(CCCC1)CCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 LCOQFLBVULHSPM-UHFFFAOYSA-N 0.000 claims 1
- LNBYNCDNINZRQQ-UHFFFAOYSA-N 2-[2-(4-benzylpiperidin-1-yl)ethyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(C1=CC=CC=C1)C1CCN(CC1)CCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 LNBYNCDNINZRQQ-UHFFFAOYSA-N 0.000 claims 1
- KLSCUGYQJYXJKV-UHFFFAOYSA-N 2-[2-(azepan-1-yl)ethyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N1(CCCCCC1)CCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 KLSCUGYQJYXJKV-UHFFFAOYSA-N 0.000 claims 1
- VFQWPYTWIAGEHU-UHFFFAOYSA-N 2-[2-(azetidin-1-yl)ethyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N1(CCC1)CCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 VFQWPYTWIAGEHU-UHFFFAOYSA-N 0.000 claims 1
- MIEWWHBJQVVUFR-UHFFFAOYSA-N 2-[2-(azetidin-1-yl)ethylamino]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N1(CCC1)CCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 MIEWWHBJQVVUFR-UHFFFAOYSA-N 0.000 claims 1
- XWGZEKDZYJCWAI-UHFFFAOYSA-N 2-[2-(benzenesulfonamido)ethylamino]-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCNS(=O)(=O)C1=CC=CC=C1)F)F XWGZEKDZYJCWAI-UHFFFAOYSA-N 0.000 claims 1
- OVIFLRSLJGCCCY-UHFFFAOYSA-N 2-[2-(benzenesulfonamido)ethylamino]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNS(=O)(=O)C1=CC=CC=C1 OVIFLRSLJGCCCY-UHFFFAOYSA-N 0.000 claims 1
- WTRRKAUACWEQBV-UHFFFAOYSA-N 2-[2-[benzyl(methyl)amino]ethyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(C1=CC=CC=C1)N(CCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1)C WTRRKAUACWEQBV-UHFFFAOYSA-N 0.000 claims 1
- OMLJMFOJGOOUBN-UHFFFAOYSA-N 2-[2-[benzyl(methyl)amino]ethylamino]-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound C(C1=CC=CC=C1)N(CCNC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO)C OMLJMFOJGOOUBN-UHFFFAOYSA-N 0.000 claims 1
- QSEIUGABURZQOP-CABCVRRESA-N 2-[[(1S,2R)-2-aminocyclohexyl]amino]-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound N[C@H]1[C@H](CCCC1)NC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO QSEIUGABURZQOP-CABCVRRESA-N 0.000 claims 1
- XWMYGWAOFHPHKC-ARLHGKGLSA-N 2-[[(3R)-4-amino-1-methylpyrrolidin-3-yl]amino]-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound NC1[C@@H](CN(C1)C)NC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO XWMYGWAOFHPHKC-ARLHGKGLSA-N 0.000 claims 1
- IDZNPVUUZHNTHA-LLVKDONJSA-N 2-[[(3R)-azepan-3-yl]amino]-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound N1C[C@@H](CCCC1)NC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO IDZNPVUUZHNTHA-LLVKDONJSA-N 0.000 claims 1
- IDZNPVUUZHNTHA-NSHDSACASA-N 2-[[(3S)-azepan-3-yl]amino]-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound N1C[C@H](CCCC1)NC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO IDZNPVUUZHNTHA-NSHDSACASA-N 0.000 claims 1
- SXUOTQGZOLZWPL-UHFFFAOYSA-N 2-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]amino]-N,N-dimethylacetamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC(=O)N(C)C SXUOTQGZOLZWPL-UHFFFAOYSA-N 0.000 claims 1
- UJNNKVPVIJKLQU-UHFFFAOYSA-N 2-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-4,5-difluoro-1H-benzimidazol-2-yl]amino]-N,N-dimethylacetamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC(=O)N(C)C)F)F UJNNKVPVIJKLQU-UHFFFAOYSA-N 0.000 claims 1
- QRQBHIJFNPEHDG-UHFFFAOYSA-N 2-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-4,5-difluoro-1H-benzimidazol-2-yl]amino]acetamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC(=O)N)F)F QRQBHIJFNPEHDG-UHFFFAOYSA-N 0.000 claims 1
- JGLHSYJTNHLABL-UHFFFAOYSA-N 2-amino-N'-(3-bromo-4-fluorophenyl)-6-fluoro-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound NC1=NC2=C(N1)C(=CC(=C2)F)C(NC1=CC(=C(C=C1)F)Br)=NO JGLHSYJTNHLABL-UHFFFAOYSA-N 0.000 claims 1
- BFEPNJKANROCEJ-UHFFFAOYSA-N 2-amino-N'-(3-bromophenyl)-6-fluoro-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound NC1=NC2=C(N1)C(=CC(=C2)F)C(NC1=CC(=CC=C1)Br)=NO BFEPNJKANROCEJ-UHFFFAOYSA-N 0.000 claims 1
- ABRWCYCOKDNAMV-UHFFFAOYSA-N 2-amino-N'-(3-chloro-4-fluorophenyl)-6-fluoro-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound NC1=NC2=C(N1)C(=CC(=C2)F)C(NC1=CC(=C(C=C1)F)Cl)=NO ABRWCYCOKDNAMV-UHFFFAOYSA-N 0.000 claims 1
- AJBCBJWXEQHXRW-UHFFFAOYSA-N 2-amino-N'-(3-chlorophenyl)-6-fluoro-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound NC1=NC2=C(N1)C(=CC(=C2)F)C(NC1=CC(=CC=C1)Cl)=NO AJBCBJWXEQHXRW-UHFFFAOYSA-N 0.000 claims 1
- ZZIQIFKRUIIZEX-UHFFFAOYSA-N 2-chloro-N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO ZZIQIFKRUIIZEX-UHFFFAOYSA-N 0.000 claims 1
- XTKHKFKRHKQATQ-UHFFFAOYSA-N 3-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-4,5-difluoro-1H-benzimidazol-2-yl]amino]propanamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCC(=O)N)F)F XTKHKFKRHKQATQ-UHFFFAOYSA-N 0.000 claims 1
- YCDBBXJXTVGAEL-UHFFFAOYSA-N 4-(3-chloro-4-fluorophenyl)-3-[2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl]-1,2,4-oxadiazol-5-one Chemical compound ClC=1C=C(C=CC=1F)N1C(=NOC1=O)C1=C2C(=NC=C1)N=C(N2)CO YCDBBXJXTVGAEL-UHFFFAOYSA-N 0.000 claims 1
- IFQRBOHNCMOVBK-UHFFFAOYSA-N N'-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound FC1(OC2=C(O1)C=CC(=C2)NC(=NO)C1=C2C(=NC=C1)N=CN2)F IFQRBOHNCMOVBK-UHFFFAOYSA-N 0.000 claims 1
- FIAPXDAFTCNWHQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(C)C FIAPXDAFTCNWHQ-UHFFFAOYSA-N 0.000 claims 1
- BTZNLTIMYAKXFA-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN(C)C)F)F BTZNLTIMYAKXFA-UHFFFAOYSA-N 0.000 claims 1
- DXFRGJOEQSZJHF-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)NCCN(C)C)F DXFRGJOEQSZJHF-UHFFFAOYSA-N 0.000 claims 1
- RDTRKJJQSZHJHR-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-2-[3-(dimethylamino)propylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCCN(C)C)F)F RDTRKJJQSZHJHR-UHFFFAOYSA-N 0.000 claims 1
- VFBUKYKJZVGASA-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1CCCC1)F)F VFBUKYKJZVGASA-UHFFFAOYSA-N 0.000 claims 1
- QMGGKQCYAOTSSQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-2-(2-morpholin-4-ylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CCOCC1 QMGGKQCYAOTSSQ-UHFFFAOYSA-N 0.000 claims 1
- NIVNSIQWRQDIFV-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC NIVNSIQWRQDIFV-UHFFFAOYSA-N 0.000 claims 1
- CXGATLHOBKAIIZ-UHFFFAOYSA-N N'-(3-bromophenyl)-2-[2-(dimethylamino)ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(C)C CXGATLHOBKAIIZ-UHFFFAOYSA-N 0.000 claims 1
- PCJADFKOMBSAQM-UHFFFAOYSA-N N'-(3-bromophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN(C)C)F)F PCJADFKOMBSAQM-UHFFFAOYSA-N 0.000 claims 1
- LUYUKGNAHTYACL-UHFFFAOYSA-N N'-(3-bromophenyl)-2-[3-(dimethylamino)propylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCCN(C)C)F)F LUYUKGNAHTYACL-UHFFFAOYSA-N 0.000 claims 1
- CDTJFBPQNHGYJJ-UHFFFAOYSA-N N'-(3-bromophenyl)-6,7-difluoro-N-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1CCCC1)F)F CDTJFBPQNHGYJJ-UHFFFAOYSA-N 0.000 claims 1
- KISKTBBEJBDKKO-CQSZACIVSA-N N'-(3-bromophenyl)-6,7-difluoro-N-hydroxy-2-[[(3R)-1-(2-methoxyethyl)pyrrolidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@H]1CN(CC1)CCOC)F)F KISKTBBEJBDKKO-CQSZACIVSA-N 0.000 claims 1
- KEUOQTZVYGNKFJ-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-2-(2-methylsulfonylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCS(=O)(=O)C KEUOQTZVYGNKFJ-UHFFFAOYSA-N 0.000 claims 1
- UHNSVANLPHIHQK-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-2-(2-morpholin-4-ylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CCOCC1 UHNSVANLPHIHQK-UHFFFAOYSA-N 0.000 claims 1
- DKXQAXUBFUNCOO-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-2-(2-piperidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1CCCCC1 DKXQAXUBFUNCOO-UHFFFAOYSA-N 0.000 claims 1
- BJSIWVOUMFEQQQ-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-2-(2-pyrrolidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1CCCC1 BJSIWVOUMFEQQQ-UHFFFAOYSA-N 0.000 claims 1
- BEYAMVHERFEIRN-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-2-(2-sulfamoylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCS(N)(=O)=O BEYAMVHERFEIRN-UHFFFAOYSA-N 0.000 claims 1
- OMABCNBBSPSENF-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC OMABCNBBSPSENF-UHFFFAOYSA-N 0.000 claims 1
- MWWHGFAQHGNLRE-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-2-[2-(methanesulfonamido)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNS(=O)(=O)C MWWHGFAQHGNLRE-UHFFFAOYSA-N 0.000 claims 1
- KSIRGSMZOGKKGB-UHFFFAOYSA-N N'-(3-bromophenyl)-N-hydroxy-2-methoxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound BrC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)OC KSIRGSMZOGKKGB-UHFFFAOYSA-N 0.000 claims 1
- LEQTYKAGEKRUIB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(2,2-difluoroethylamino)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC(F)F LEQTYKAGEKRUIB-UHFFFAOYSA-N 0.000 claims 1
- OZBBBLSOADOFNC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(2,2-dimethylpropylamino)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC(C)(C)C OZBBBLSOADOFNC-UHFFFAOYSA-N 0.000 claims 1
- XSTIGCHHHLFMLV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(2-cyanoethylamino)-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCC#N)F)F XSTIGCHHHLFMLV-UHFFFAOYSA-N 0.000 claims 1
- OCGZCGZTOKHLTE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(2-cyclohexylethylamino)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCC1CCCCC1 OCGZCGZTOKHLTE-UHFFFAOYSA-N 0.000 claims 1
- FKXDLSLWPJXKTM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-(ethylaminomethyl)-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)CNCC)F FKXDLSLWPJXKTM-UHFFFAOYSA-N 0.000 claims 1
- LNOAHZKTDNBMID-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(1,1-dioxothian-3-yl)methylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1CS(CCC1)(=O)=O LNOAHZKTDNBMID-UHFFFAOYSA-N 0.000 claims 1
- IWDIKLWAWKJUNY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(1,1-dioxothiolan-3-yl)methylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1CS(CC1)(=O)=O IWDIKLWAWKJUNY-UHFFFAOYSA-N 0.000 claims 1
- DGSLBJROUNGEJI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(1,4-dimethylpiperidin-2-yl)methylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1N(CCC(C1)C)C)F)F DGSLBJROUNGEJI-UHFFFAOYSA-N 0.000 claims 1
- OQDTXWYIVAKNQM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(1-cyclopropylpyrrolidin-3-yl)amino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CN(CC1)C1CC1 OQDTXWYIVAKNQM-UHFFFAOYSA-N 0.000 claims 1
- DTNOPWGEKXSPSJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(2-ethoxycyclopropyl)amino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1C(C1)OCC DTNOPWGEKXSPSJ-UHFFFAOYSA-N 0.000 claims 1
- NSZJFVQNEVLCBG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(3,3-dimethylazetidin-2-yl)methylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1NCC1(C)C)F)F NSZJFVQNEVLCBG-UHFFFAOYSA-N 0.000 claims 1
- ZYMYUALXGLKJEB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[(dimethylamino)methyl]-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)CN(C)C)F ZYMYUALXGLKJEB-UHFFFAOYSA-N 0.000 claims 1
- OMCIYEJPUSWSRQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[1-(dimethylamino)propan-2-yl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C(CN(C)C)C OMCIYEJPUSWSRQ-UHFFFAOYSA-N 0.000 claims 1
- FRZFNVVZISUVHR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[1-(dimethylamino)propan-2-ylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC(CN(C)C)C)F)F FRZFNVVZISUVHR-UHFFFAOYSA-N 0.000 claims 1
- XKGYPYRLRYAJEW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1CCS(CC1)(=O)=O)F)F XKGYPYRLRYAJEW-UHFFFAOYSA-N 0.000 claims 1
- UDXRMGGWWYMEDI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CCS(CC1)(=O)=O UDXRMGGWWYMEDI-UHFFFAOYSA-N 0.000 claims 1
- MSAKQWPAIFACFT-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(2,2-difluoroethylamino)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNCC(F)F MSAKQWPAIFACFT-UHFFFAOYSA-N 0.000 claims 1
- BIJWNZRQJUNEHD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(2,5-dimethylmorpholin-4-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CC(OCC1C)C BIJWNZRQJUNEHD-UHFFFAOYSA-N 0.000 claims 1
- DHYGVJGJRXBPLF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(2,6-dimethylmorpholin-4-yl)propylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC(C)N1CC(OC(C1)C)C DHYGVJGJRXBPLF-UHFFFAOYSA-N 0.000 claims 1
- UJVKAKOYIDTIJP-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(3,3-difluoroazetidin-1-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CC(C1)(F)F UJVKAKOYIDTIJP-UHFFFAOYSA-N 0.000 claims 1
- BDMUUWVEITXQOQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(3,3-difluoropiperidin-1-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CC(CCC1)(F)F BDMUUWVEITXQOQ-UHFFFAOYSA-N 0.000 claims 1
- OTANJRACNGFSJG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(3,3-difluoropyrrolidin-1-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CC(CC1)(F)F OTANJRACNGFSJG-UHFFFAOYSA-N 0.000 claims 1
- JCYRKRRUYREOMR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(3-fluoroazetidin-1-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CC(C1)F JCYRKRRUYREOMR-UHFFFAOYSA-N 0.000 claims 1
- YMIUZBCBDQAUFW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(3-fluoropiperidin-1-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CC(CCC1)F YMIUZBCBDQAUFW-UHFFFAOYSA-N 0.000 claims 1
- DTZKWBCJFVTSCB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(4,4-difluoropiperidin-1-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CCC(CC1)(F)F DTZKWBCJFVTSCB-UHFFFAOYSA-N 0.000 claims 1
- ZQCOIVKBLNLDDY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(4-fluoropiperidin-1-yl)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CCC(CC1)F ZQCOIVKBLNLDDY-UHFFFAOYSA-N 0.000 claims 1
- KJKSQYPFZNNALU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(cyclopropylamino)ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CCNC1CC1 KJKSQYPFZNNALU-UHFFFAOYSA-N 0.000 claims 1
- XOALJZKCJLNQPR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(cyclopropylamino)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNC1CC1 XOALJZKCJLNQPR-UHFFFAOYSA-N 0.000 claims 1
- ZEUFQOYHOYOOGX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(cyclopropylmethylamino)ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CCNCC1CC1 ZEUFQOYHOYOOGX-UHFFFAOYSA-N 0.000 claims 1
- LUOJIPQVSDIXBX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(cyclopropylsulfonylamino)ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCNS(=O)(=O)C1CC1)F)F LUOJIPQVSDIXBX-UHFFFAOYSA-N 0.000 claims 1
- BZEDJIWAYGBOJD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(cyclopropylsulfonylamino)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNS(=O)(=O)C1CC1 BZEDJIWAYGBOJD-UHFFFAOYSA-N 0.000 claims 1
- ICCQWEFSZOVGKY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethylamino]-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)NCCN(CC)CC)F ICCQWEFSZOVGKY-UHFFFAOYSA-N 0.000 claims 1
- XVAFPTYXLUMCQE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6-fluoro-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=CC2=C1NC(=N2)NCCN(C)C)F XVAFPTYXLUMCQE-UHFFFAOYSA-N 0.000 claims 1
- JPXVAGHZWYFETG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(C)C JPXVAGHZWYFETG-UHFFFAOYSA-N 0.000 claims 1
- ACMKEYUQSBHTHD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylsulfanyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)SCCN(C)C)F)F ACMKEYUQSBHTHD-UHFFFAOYSA-N 0.000 claims 1
- JTNQJXZOORUFMC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylsulfanyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)SCCN(C)C JTNQJXZOORUFMC-UHFFFAOYSA-N 0.000 claims 1
- NNEMSCRQEUFYOE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)propyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CC(C)N(C)C NNEMSCRQEUFYOE-UHFFFAOYSA-N 0.000 claims 1
- WKICKGPUAHCRNX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-(ethylamino)ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CCNCC WKICKGPUAHCRNX-UHFFFAOYSA-N 0.000 claims 1
- DJRDLCQSGBECOE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[(2,4-dimethoxyphenyl)methylamino]ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCNCC1=C(C=C(C=C1)OC)OC DJRDLCQSGBECOE-UHFFFAOYSA-N 0.000 claims 1
- IQCPAQCZSBXUMD-BETUJISGSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1C[C@@H](O[C@@H](C1)C)C IQCPAQCZSBXUMD-BETUJISGSA-N 0.000 claims 1
- NPUJQBYKOLPOMX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[1,4-dioxan-2-ylmethyl(methyl)amino]ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound O1C(COCC1)CN(CCC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1)C NPUJQBYKOLPOMX-UHFFFAOYSA-N 0.000 claims 1
- QGWVBYQXQZRWKQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[2,2-difluoroethyl(methyl)amino]ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(C)CC(F)F QGWVBYQXQZRWKQ-UHFFFAOYSA-N 0.000 claims 1
- MQXRVBLAOCHWEA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[2-ethylbutyl(methyl)amino]ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN(C)CC(CC)CC)F)F MQXRVBLAOCHWEA-UHFFFAOYSA-N 0.000 claims 1
- RDIBEVUHTGRPQM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[cyclohexyl(methyl)amino]ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(C)C1CCCCC1 RDIBEVUHTGRPQM-UHFFFAOYSA-N 0.000 claims 1
- JNHNCMZKOVDBDJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[cyclohexylmethyl(methyl)amino]ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(C)CC1CCCCC1 JNHNCMZKOVDBDJ-UHFFFAOYSA-N 0.000 claims 1
- DSKMVSVIXWKTRG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[cyclopropyl(2-hydroxyethyl)amino]ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(CCO)C1CC1 DSKMVSVIXWKTRG-UHFFFAOYSA-N 0.000 claims 1
- XDHWMYMCXKIWHY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[cyclopropyl(2-methoxyethyl)amino]ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(CCOC)C1CC1 XDHWMYMCXKIWHY-UHFFFAOYSA-N 0.000 claims 1
- AEWMPYFPDCRHDW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[cyclopropyl(ethyl)amino]ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(CC)C1CC1 AEWMPYFPDCRHDW-UHFFFAOYSA-N 0.000 claims 1
- PWNNVZMNAJIVLV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[cyclopropyl(propan-2-yl)amino]ethylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(C(C)C)C1CC1 PWNNVZMNAJIVLV-UHFFFAOYSA-N 0.000 claims 1
- ZNRCJBMQQLBPIY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[2-[cyclopropylmethyl(methyl)amino]ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN(C)CC1CC1)F)F ZNRCJBMQQLBPIY-UHFFFAOYSA-N 0.000 claims 1
- SGMGSVMFOLWCNC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(3-fluoropiperidin-1-yl)propylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCN1CC(CCC1)F SGMGSVMFOLWCNC-UHFFFAOYSA-N 0.000 claims 1
- DFCBPFUOHBLRNZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(4-fluorophenyl)sulfonylpropylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCS(=O)(=O)C1=CC=C(C=C1)F DFCBPFUOHBLRNZ-UHFFFAOYSA-N 0.000 claims 1
- FURXTNFDUIKPPX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(cyclopropylamino)propylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCNC1CC1 FURXTNFDUIKPPX-UHFFFAOYSA-N 0.000 claims 1
- NMGRHYWCLVQEHU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(difluoromethoxy)propylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCOC(F)F NMGRHYWCLVQEHU-UHFFFAOYSA-N 0.000 claims 1
- CMYMCEBEJKJPFL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)butylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCC(C)N(C)C)F)F CMYMCEBEJKJPFL-UHFFFAOYSA-N 0.000 claims 1
- GURYKHOZSFXZFG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propylamino]-6-fluoro-N-hydroxy-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=CC2=C1NC(=N2)NCCCN(C)C)F GURYKHOZSFXZFG-UHFFFAOYSA-N 0.000 claims 1
- LDEZLHWRKVISAS-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propylamino]-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)NCCCN(C)C)F LDEZLHWRKVISAS-UHFFFAOYSA-N 0.000 claims 1
- MHAGDRPEYNORBR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-[cyclopropyl(ethyl)amino]propylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCN(CC)C1CC1 MHAGDRPEYNORBR-UHFFFAOYSA-N 0.000 claims 1
- XNOJYOWAURLKAZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[3-[cyclopropyl(methyl)amino]propylamino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCN(C)C1CC1 XNOJYOWAURLKAZ-UHFFFAOYSA-N 0.000 claims 1
- ULLZCKKRDUEKQK-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[4-(dimethylamino)butylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCCCN(C)C)F)F ULLZCKKRDUEKQK-UHFFFAOYSA-N 0.000 claims 1
- QHDJEPOCFWVSMD-IAGOWNOFSA-N N'-(3-chloro-4-fluorophenyl)-2-[[(1R,2R)-2-(dimethylamino)cyclohexyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@H]1[C@@H](CCCC1)N(C)C)F)F QHDJEPOCFWVSMD-IAGOWNOFSA-N 0.000 claims 1
- AYOBUQKPLRNIPV-HZPDHXFCSA-N N'-(3-chloro-4-fluorophenyl)-2-[[(1R,2R)-2-(dimethylamino)cyclopentyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@H]1[C@@H](CCC1)N(C)C)F)F AYOBUQKPLRNIPV-HZPDHXFCSA-N 0.000 claims 1
- KQVSPYPRZVSHDI-WCQYABFASA-N N'-(3-chloro-4-fluorophenyl)-2-[[(1S,3R)-3-(dimethylamino)cyclohexyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@@H]1C[C@@H](CCC1)N(C)C)F)F KQVSPYPRZVSHDI-WCQYABFASA-N 0.000 claims 1
- KQVSPYPRZVSHDI-AAEUAGOBSA-N N'-(3-chloro-4-fluorophenyl)-2-[[(1S,3S)-3-(dimethylamino)cyclohexyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@@H]1C[C@H](CCC1)N(C)C)F)F KQVSPYPRZVSHDI-AAEUAGOBSA-N 0.000 claims 1
- VLKREZAQBLVZTI-IRXDYDNUSA-N N'-(3-chloro-4-fluorophenyl)-2-[[(3R,4R)-4-(diethylamino)oxolan-3-yl]amino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)N[C@H]1COC[C@@H]1N(CC)CC VLKREZAQBLVZTI-IRXDYDNUSA-N 0.000 claims 1
- PJJAYPVWAWPRIL-IAGOWNOFSA-N N'-(3-chloro-4-fluorophenyl)-2-[[(3S,4S)-4-(diethylamino)oxolan-3-yl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@@H]1COC[C@H]1N(CC)CC)F)F PJJAYPVWAWPRIL-IAGOWNOFSA-N 0.000 claims 1
- MZWJRVNRYFIOGF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[1-(dimethylamino)cyclobutyl]methylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1(CCC1)N(C)C)F)F MZWJRVNRYFIOGF-UHFFFAOYSA-N 0.000 claims 1
- UYDCYFLISUMYLC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[1-(dimethylamino)cyclohexyl]methylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1(CCCCC1)N(C)C)F)F UYDCYFLISUMYLC-UHFFFAOYSA-N 0.000 claims 1
- SGHXREJLOMGDLV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[1-(dimethylamino)cyclopentyl]methylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1(CCCC1)N(C)C)F)F SGHXREJLOMGDLV-UHFFFAOYSA-N 0.000 claims 1
- DRIORPYSWNUSSW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[2-(2,6-dimethylmorpholin-4-yl)-2-methylpropyl]amino]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC(C)(C)N1CC(OC(C1)C)C DRIORPYSWNUSSW-UHFFFAOYSA-N 0.000 claims 1
- MNNDQNSCKQJCBE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[2-(dimethylamino)-2-phenylethyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC(C1=CC=CC=C1)N(C)C)F)F MNNDQNSCKQJCBE-UHFFFAOYSA-N 0.000 claims 1
- AYOBUQKPLRNIPV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[2-(dimethylamino)cyclopentyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1C(CCC1)N(C)C)F)F AYOBUQKPLRNIPV-UHFFFAOYSA-N 0.000 claims 1
- GQKOHUZEDPHJDA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC(CN(C)C)(C)C)F)F GQKOHUZEDPHJDA-UHFFFAOYSA-N 0.000 claims 1
- GGILCTUPSDXHOE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[3-(dimethylamino)-2-hydroxypropyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC(CN(C)C)O)F)F GGILCTUPSDXHOE-UHFFFAOYSA-N 0.000 claims 1
- FVQLAOBYAJCLLM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-2-[[3-(dimethylamino)-2-methylpropyl]amino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC(CN(C)C)C)F)F FVQLAOBYAJCLLM-UHFFFAOYSA-N 0.000 claims 1
- LGTSRXSRFGKEFL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethylamino)-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC12CCCN2CCC1)F)F LGTSRXSRFGKEFL-UHFFFAOYSA-N 0.000 claims 1
- AJBQJCGIIRXZOA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(1,4-oxazepan-6-ylamino)-3H-benzimidazole-4-carboximidamide Chemical compound O1CCNCC(C1)NC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO AJBQJCGIIRXZOA-UHFFFAOYSA-N 0.000 claims 1
- DPYLQGPCBMCBBW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(1H-imidazol-2-ylmethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound N1C(=NC=C1)CNC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO DPYLQGPCBMCBBW-UHFFFAOYSA-N 0.000 claims 1
- LNVZCQGQWCLIFA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-hydroxy-2-methylpropyl)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CC(C)(C)O)F)F LNVZCQGQWCLIFA-UHFFFAOYSA-N 0.000 claims 1
- WALPDNBPHBLAQH-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-hydroxyethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCO)F)F WALPDNBPHBLAQH-UHFFFAOYSA-N 0.000 claims 1
- RTFDEQDVEXSVBI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-hydroxypropylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC(C)O)F)F RTFDEQDVEXSVBI-UHFFFAOYSA-N 0.000 claims 1
- UBHREUSHOHRIMW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-morpholin-4-ylpropylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC(C)N1CCOCC1)F)F UBHREUSHOHRIMW-UHFFFAOYSA-N 0.000 claims 1
- GBLGEHAZWACAPP-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-pyrazol-1-ylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound N1(N=CC=C1)CCNC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=NO GBLGEHAZWACAPP-UHFFFAOYSA-N 0.000 claims 1
- PJNLMCWGMNJLJR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-sulfamoylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCS(N)(=O)=O)F)F PJNLMCWGMNJLJR-UHFFFAOYSA-N 0.000 claims 1
- FAYGOEPXKQZAMD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(3-pyrrolidin-1-ylpropylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCCN1CCCC1)F)F FAYGOEPXKQZAMD-UHFFFAOYSA-N 0.000 claims 1
- SCIYZQUXHMYSPF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(morpholin-3-ylmethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1NCCOC1)F)F SCIYZQUXHMYSPF-UHFFFAOYSA-N 0.000 claims 1
- AMNZSWUDRUVPCO-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(piperidin-3-ylmethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1CNCCC1)F)F AMNZSWUDRUVPCO-UHFFFAOYSA-N 0.000 claims 1
- ZHISSWLFEIYUBD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(pyridin-2-ylmethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1=NC=CC=C1)F)F ZHISSWLFEIYUBD-UHFFFAOYSA-N 0.000 claims 1
- NDOLLDPQVSZPKO-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(pyridin-3-ylmethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC=1C=NC=CC=1)F)F NDOLLDPQVSZPKO-UHFFFAOYSA-N 0.000 claims 1
- UYUXWVAXYKMPJE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(pyrimidin-2-ylmethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1=NC=CC=N1)F)F UYUXWVAXYKMPJE-UHFFFAOYSA-N 0.000 claims 1
- IXHIJDAGHSHXMM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(pyrrolidin-3-ylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CNCC1)F)F IXHIJDAGHSHXMM-UHFFFAOYSA-N 0.000 claims 1
- XTCICUDVGDIFGL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(1-methylazepan-3-yl)amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CN(CCCC1)C)F)F XTCICUDVGDIFGL-UHFFFAOYSA-N 0.000 claims 1
- VKKPUBOGVXLQEQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(1-methylimidazol-2-yl)methylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC=1N(C=CN=1)C)F)F VKKPUBOGVXLQEQ-UHFFFAOYSA-N 0.000 claims 1
- FYKYNTLYPPCUCC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(1-methylpiperidin-2-yl)methylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1N(CCCC1)C)F)F FYKYNTLYPPCUCC-UHFFFAOYSA-N 0.000 claims 1
- PABZLTHMPLCYNC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(1-methylpiperidin-3-yl)amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CN(CCC1)C)F)F PABZLTHMPLCYNC-UHFFFAOYSA-N 0.000 claims 1
- VIODEHAGLAEWBY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(1-methylpiperidin-4-yl)amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CCN(CC1)C)F)F VIODEHAGLAEWBY-UHFFFAOYSA-N 0.000 claims 1
- YBQDOGIVRLTTOX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(1-propan-2-ylpiperidin-3-yl)amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CN(CCC1)C(C)C)F)F YBQDOGIVRLTTOX-UHFFFAOYSA-N 0.000 claims 1
- SMLNPRWYLYFANU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CN(CC2=CC=CC=C12)C)F)F SMLNPRWYLYFANU-UHFFFAOYSA-N 0.000 claims 1
- HRIPLDRUOJUQJW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(2-methylpyrazol-3-yl)methylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1=CC=NN1C)F)F HRIPLDRUOJUQJW-UHFFFAOYSA-N 0.000 claims 1
- XSUWEWCNFCPRKU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(3-hydroxycyclobutyl)amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CC(C1)O)F)F XSUWEWCNFCPRKU-UHFFFAOYSA-N 0.000 claims 1
- NFQAGZVARBUBKC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(4-methylmorpholin-2-yl)methylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1CN(CCO1)C)F)F NFQAGZVARBUBKC-UHFFFAOYSA-N 0.000 claims 1
- GENHIDVLDAUVJR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(4-methylmorpholin-3-yl)methylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCC1N(CCOC1)C)F)F GENHIDVLDAUVJR-UHFFFAOYSA-N 0.000 claims 1
- QCGKDMMNAMHWOI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[(4-pyrrolidin-1-yloxan-3-yl)amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1COCCC1N1CCCC1)F)F QCGKDMMNAMHWOI-UHFFFAOYSA-N 0.000 claims 1
- JRWWGPIOTCLJOE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(1-methylpiperidin-2-yl)ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCC1N(CCCC1)C)F)F JRWWGPIOTCLJOE-UHFFFAOYSA-N 0.000 claims 1
- BFRODKRTUYNNGS-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(1-methylpyrrolidin-2-yl)ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCC1N(CCC1)C)F)F BFRODKRTUYNNGS-UHFFFAOYSA-N 0.000 claims 1
- DZOQWZPMCBWTQQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(3-methoxyazetidin-1-yl)ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1CC(C1)OC)F)F DZOQWZPMCBWTQQ-UHFFFAOYSA-N 0.000 claims 1
- ZXWWYCVHWQBLLK-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(4-methyl-3-oxopiperazin-1-yl)ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1CC(N(CC1)C)=O)F)F ZXWWYCVHWQBLLK-UHFFFAOYSA-N 0.000 claims 1
- ZWIVUPAYPOTNSY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(methanesulfonamido)ethyl]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CCNS(=O)(=O)C)F)F ZWIVUPAYPOTNSY-UHFFFAOYSA-N 0.000 claims 1
- TVMCFYNEJNTJTG-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(methanesulfonamido)ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCNS(=O)(=O)C)F)F TVMCFYNEJNTJTG-UHFFFAOYSA-N 0.000 claims 1
- HYNBIIMRYRGLOU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(methylamino)ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCNC)F)F HYNBIIMRYRGLOU-UHFFFAOYSA-N 0.000 claims 1
- HUTFROGBBRMFEE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(sulfamoylamino)ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCNS(N)(=O)=O)F)F HUTFROGBBRMFEE-UHFFFAOYSA-N 0.000 claims 1
- PEPHYKFUARKWIY-HNNXBMFYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1[C@@H](CCC1)C(F)(F)F)F)F PEPHYKFUARKWIY-HNNXBMFYSA-N 0.000 claims 1
- ZXKOFLSFCXJVFM-NSHDSACASA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-[(3S)-3-hydroxypyrrolidin-1-yl]ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1C[C@H](CC1)O)F)F ZXKOFLSFCXJVFM-NSHDSACASA-N 0.000 claims 1
- BDRPPCZAMBBLFA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-[2-(hydroxymethyl)piperidin-1-yl]ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1C(CCCC1)CO)F)F BDRPPCZAMBBLFA-UHFFFAOYSA-N 0.000 claims 1
- ASZPTGGLBSZFRC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1C(CCC1)CO)F)F ASZPTGGLBSZFRC-UHFFFAOYSA-N 0.000 claims 1
- LYUDUZSHLUZPGV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-[methyl(oxan-4-ylmethyl)amino]ethylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN(CC1CCOCC1)C)F)F LYUDUZSHLUZPGV-UHFFFAOYSA-N 0.000 claims 1
- JTJHMFSJUGGFQE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[3-(pyridin-2-ylamino)propylamino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCCNC1=NC=CC=C1)F)F JTJHMFSJUGGFQE-UHFFFAOYSA-N 0.000 claims 1
- HJJPWLBOJWRNPK-NUPKVRKVSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[(1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1[C@H]2CC[C@@H](CC1)N2C)F)F HJJPWLBOJWRNPK-NUPKVRKVSA-N 0.000 claims 1
- OWYKAVVUVHRQOY-GFCCVEGCSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3R)-1-(oxetan-3-yl)piperidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@H]1CN(CCC1)C1COC1)F)F OWYKAVVUVHRQOY-GFCCVEGCSA-N 0.000 claims 1
- OPFVXCRJGSSNGL-SNVBAGLBSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3R)-1-methylpyrrolidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@H]1CN(CC1)C)F)F OPFVXCRJGSSNGL-SNVBAGLBSA-N 0.000 claims 1
- ODLNATSDXLVVLQ-SNVBAGLBSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3R)-piperidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@H]1CNCCC1)F)F ODLNATSDXLVVLQ-SNVBAGLBSA-N 0.000 claims 1
- FQUSRHKNFZODNH-HUUCEWRRSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@@H]1CN(C[C@H]1OC)C)F)F FQUSRHKNFZODNH-HUUCEWRRSA-N 0.000 claims 1
- RPJADYWZCLLGSW-OLZOCXBDSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3R,4S)-4-hydroxypyrrolidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@@H]1CNC[C@@H]1O)F)F RPJADYWZCLLGSW-OLZOCXBDSA-N 0.000 claims 1
- OPFVXCRJGSSNGL-JTQLQIEISA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3S)-1-methylpyrrolidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@@H]1CN(CC1)C)F)F OPFVXCRJGSSNGL-JTQLQIEISA-N 0.000 claims 1
- ODLNATSDXLVVLQ-JTQLQIEISA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3S)-piperidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@@H]1CNCCC1)F)F ODLNATSDXLVVLQ-JTQLQIEISA-N 0.000 claims 1
- UKZGSQRKOBFLAX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[1-(2-methoxyethyl)piperidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CN(CCC1)CCOC)F)F UKZGSQRKOBFLAX-UHFFFAOYSA-N 0.000 claims 1
- PFTAYZGZUGJIAS-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[[1-(2-methoxyethyl)pyrrolidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NC1CN(CC1)CCOC)F)F PFTAYZGZUGJIAS-UHFFFAOYSA-N 0.000 claims 1
- HXFJMFORQLZVBI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6-fluoro-N-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=CC2=C1NC(=N2)NCCN1CCCC1)F HXFJMFORQLZVBI-UHFFFAOYSA-N 0.000 claims 1
- PXLSNHLEQPKADQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6-fluoro-N-hydroxy-7-methoxy-1H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC=N2)OC)F PXLSNHLEQPKADQ-UHFFFAOYSA-N 0.000 claims 1
- AASPDZHSKLHIKL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)NCCN1CCCC1)F AASPDZHSKLHIKL-UHFFFAOYSA-N 0.000 claims 1
- DBPHDJRQPVEACZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-2-(methylaminomethyl)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)CNC)F DBPHDJRQPVEACZ-UHFFFAOYSA-N 0.000 claims 1
- PRATXBAEECVTMB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-7-fluoro-N-hydroxy-2-[(propan-2-ylamino)methyl]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC=C(C2=C1NC(=N2)CNC(C)C)F PRATXBAEECVTMB-UHFFFAOYSA-N 0.000 claims 1
- OMJFZBYKCDVAMC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(1H-imidazol-2-ylmethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N1C(=NC=C1)CNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 OMJFZBYKCDVAMC-UHFFFAOYSA-N 0.000 claims 1
- IDXUYORXXFZIGB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(1H-imidazol-5-ylmethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N1C=NC=C1CNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 IDXUYORXXFZIGB-UHFFFAOYSA-N 0.000 claims 1
- CYNSEKMWBISABY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(1H-pyrazol-5-ylmethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N1N=CC=C1CNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 CYNSEKMWBISABY-UHFFFAOYSA-N 0.000 claims 1
- CVPKOBHIAVAQDL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-methoxyethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCOC CVPKOBHIAVAQDL-UHFFFAOYSA-N 0.000 claims 1
- WUDFYAYTLXNKRF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-methylpropylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC(C)C WUDFYAYTLXNKRF-UHFFFAOYSA-N 0.000 claims 1
- LYCSRMWULPSLLC-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-methylsulfonylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCS(=O)(=O)C LYCSRMWULPSLLC-UHFFFAOYSA-N 0.000 claims 1
- PFIGDFHAJSTJIZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-morpholin-4-ylsulfonylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCS(=O)(=O)N1CCOCC1 PFIGDFHAJSTJIZ-UHFFFAOYSA-N 0.000 claims 1
- GJOXSCMDJUFTIM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-piperidin-1-ylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CCCCC1 GJOXSCMDJUFTIM-UHFFFAOYSA-N 0.000 claims 1
- ODBXHWCSUOCGKM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-pyrazol-1-ylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound N1(N=CC=C1)CCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 ODBXHWCSUOCGKM-UHFFFAOYSA-N 0.000 claims 1
- WSFIZRITBDDNRZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CCCC1 WSFIZRITBDDNRZ-UHFFFAOYSA-N 0.000 claims 1
- PEAMFEPMGSZQNS-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(2-sulfamoylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCS(N)(=O)=O PEAMFEPMGSZQNS-UHFFFAOYSA-N 0.000 claims 1
- XXFYZIWPWSKJMY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(3,3,3-trifluoropropylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCC(F)(F)F XXFYZIWPWSKJMY-UHFFFAOYSA-N 0.000 claims 1
- GLIPATIWXLTRBN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(3-methoxypropylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCOC GLIPATIWXLTRBN-UHFFFAOYSA-N 0.000 claims 1
- CLPNPDXMSDOHSR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(3-methylsulfonylpropylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCS(=O)(=O)C CLPNPDXMSDOHSR-UHFFFAOYSA-N 0.000 claims 1
- IEMJJJAYZNCVJQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(3-morpholin-4-ylpropylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCN1CCOCC1 IEMJJJAYZNCVJQ-UHFFFAOYSA-N 0.000 claims 1
- KBFAWVUYEVPKDE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(4,4,4-trifluorobutylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCC(F)(F)F KBFAWVUYEVPKDE-UHFFFAOYSA-N 0.000 claims 1
- BXRIFBQRNIBRJD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(oxan-2-ylmethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1OCCCC1 BXRIFBQRNIBRJD-UHFFFAOYSA-N 0.000 claims 1
- GGUSILYNRCSIBU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(oxan-4-ylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CCOCC1 GGUSILYNRCSIBU-UHFFFAOYSA-N 0.000 claims 1
- VBYWUJUIVRUZTA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(oxetan-3-ylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1COC1 VBYWUJUIVRUZTA-UHFFFAOYSA-N 0.000 claims 1
- GRVXGWHCGRGKTD-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(oxetan-3-ylmethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1COC1 GRVXGWHCGRGKTD-UHFFFAOYSA-N 0.000 claims 1
- ZTTKKVUAXOKJMJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(oxolan-3-ylmethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1COCC1 ZTTKKVUAXOKJMJ-UHFFFAOYSA-N 0.000 claims 1
- YYVVUYHPOUALPV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(piperidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CC1NCCCC1 YYVVUYHPOUALPV-UHFFFAOYSA-N 0.000 claims 1
- KARDGKSMQKJNMK-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(pyridin-2-ylmethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1=NC=CC=C1 KARDGKSMQKJNMK-UHFFFAOYSA-N 0.000 claims 1
- MQRMAQIYLBEGGR-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(pyrimidin-2-ylmethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1=NC=CC=N1 MQRMAQIYLBEGGR-UHFFFAOYSA-N 0.000 claims 1
- JZOYNTUGHUWNAE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-(pyrrolidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CC1NCCC1 JZOYNTUGHUWNAE-UHFFFAOYSA-N 0.000 claims 1
- TXOCYMRNBDPIEE-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(1-methylazepan-3-yl)amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CN(CCCC1)C TXOCYMRNBDPIEE-UHFFFAOYSA-N 0.000 claims 1
- BWWVEULIPCSTPQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(1-methylpiperidin-2-yl)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CC1N(CCCC1)C BWWVEULIPCSTPQ-UHFFFAOYSA-N 0.000 claims 1
- JGYJVKJZRJCVPB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(1-methylpiperidin-3-yl)amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CN(CCC1)C JGYJVKJZRJCVPB-UHFFFAOYSA-N 0.000 claims 1
- KSLAEGXHMRFQBX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(1-methylpyrazol-3-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1=NN(C=C1)C KSLAEGXHMRFQBX-UHFFFAOYSA-N 0.000 claims 1
- OKYLQVDHVYAHPP-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(1-methylsulfonylpyrrolidin-3-yl)amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CN(CC1)S(=O)(=O)C OKYLQVDHVYAHPP-UHFFFAOYSA-N 0.000 claims 1
- YHVWNQYOKSLAIL-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(2-methylpyrazol-3-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1=CC=NN1C YHVWNQYOKSLAIL-UHFFFAOYSA-N 0.000 claims 1
- HLVHSMQMGLIKOZ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(2-methylsulfonylphenyl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1=C(C=CC=C1)S(=O)(=O)C HLVHSMQMGLIKOZ-UHFFFAOYSA-N 0.000 claims 1
- JYRUJSGYWIJHIT-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1=NC(=NO1)C JYRUJSGYWIJHIT-UHFFFAOYSA-N 0.000 claims 1
- HDEYOJHFRWERPL-JTQLQIEISA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)N1C[C@H](CC1)O HDEYOJHFRWERPL-JTQLQIEISA-N 0.000 claims 1
- YAWKSQAWYOWWBU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(4-methylmorpholin-2-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1CN(CCO1)C YAWKSQAWYOWWBU-UHFFFAOYSA-N 0.000 claims 1
- KEKDDAPUHHQTFP-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(4-methylmorpholin-3-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1N(CCOC1)C KEKDDAPUHHQTFP-UHFFFAOYSA-N 0.000 claims 1
- DIRFQMHMJFWPDA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(5-methyl-1,3,4-oxadiazol-2-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC=1OC(=NN=1)C DIRFQMHMJFWPDA-UHFFFAOYSA-N 0.000 claims 1
- SPZQHAOMQIHHBI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(5-oxopyrrolidin-3-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1CNC(C1)=O SPZQHAOMQIHHBI-UHFFFAOYSA-N 0.000 claims 1
- QLHWBAXMJRZWOT-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(1-methylimidazol-2-yl)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCC=1N(C=CN=1)C QLHWBAXMJRZWOT-UHFFFAOYSA-N 0.000 claims 1
- CSCCARSWKPFZQH-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(2,2,2-trifluoroethoxy)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCOCC(F)(F)F CSCCARSWKPFZQH-UHFFFAOYSA-N 0.000 claims 1
- NKIBNNOBFVBQPA-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(2-methoxyethoxy)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCOCCOC NKIBNNOBFVBQPA-UHFFFAOYSA-N 0.000 claims 1
- WMJGTDGOLSOZKI-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(2-methylpropylamino)ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CCNCC(C)C WMJGTDGOLSOZKI-UHFFFAOYSA-N 0.000 claims 1
- IORRKVKGBUGGRO-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C12OCCN(C2C1)CCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 IORRKVKGBUGGRO-UHFFFAOYSA-N 0.000 claims 1
- JHPSGNQUPUUNPJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(2-oxopyrrolidin-1-yl)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1C(CCC1)=O JHPSGNQUPUUNPJ-UHFFFAOYSA-N 0.000 claims 1
- KUYWIZCMULEBEU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(3-methoxypiperidin-1-yl)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CC(CCC1)OC KUYWIZCMULEBEU-UHFFFAOYSA-N 0.000 claims 1
- DULVBRITMYHCJW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(4-hydroxypiperidin-1-yl)ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1CCC(CC1)O DULVBRITMYHCJW-UHFFFAOYSA-N 0.000 claims 1
- UTPBBHWOWCKTHF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(4-methyl-3-oxopiperazin-1-yl)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1CC(N(CC1)C)=O UTPBBHWOWCKTHF-UHFFFAOYSA-N 0.000 claims 1
- XEWUBUJXPXCWKH-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(7-oxa-4-azaspiro[2.5]octan-4-yl)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C1CC11N(CCOC1)CCNC=1NC=2C(=NC=CC=2C(NC2=CC(=C(C=C2)F)Cl)=NO)N=1 XEWUBUJXPXCWKH-UHFFFAOYSA-N 0.000 claims 1
- ZYJNASIIGPRIEB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(N-methylanilino)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(C1=CC=CC=C1)C ZYJNASIIGPRIEB-UHFFFAOYSA-N 0.000 claims 1
- YCUVPXDBYFUDSX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(methanesulfonamido)ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCNS(=O)(=O)C YCUVPXDBYFUDSX-UHFFFAOYSA-N 0.000 claims 1
- PZOLSILUUCNCBU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(methanesulfonamido)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNS(=O)(=O)C PZOLSILUUCNCBU-UHFFFAOYSA-N 0.000 claims 1
- AWKNONUMEVSUBS-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(methylamino)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNC AWKNONUMEVSUBS-UHFFFAOYSA-N 0.000 claims 1
- WJZYPBXMTRMDLO-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(methylamino)propyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CC(C)NC WJZYPBXMTRMDLO-UHFFFAOYSA-N 0.000 claims 1
- JLRWLFCHZAPYNV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(oxan-4-yl)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCC1CCOCC1 JLRWLFCHZAPYNV-UHFFFAOYSA-N 0.000 claims 1
- OXXMYILYJKSTAF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(oxolan-2-yl)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCC1OCCC1 OXXMYILYJKSTAF-UHFFFAOYSA-N 0.000 claims 1
- UMERGXSYOBEKII-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(propan-2-ylamino)ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)NC(=N2)CCNC(C)C UMERGXSYOBEKII-UHFFFAOYSA-N 0.000 claims 1
- OZSJAEDFNRIVJN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(sulfamoylamino)ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCNS(N)(=O)=O OZSJAEDFNRIVJN-UHFFFAOYSA-N 0.000 claims 1
- HTQHTFXECUTHMQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(sulfamoylamino)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNS(N)(=O)=O HTQHTFXECUTHMQ-UHFFFAOYSA-N 0.000 claims 1
- SQBJZNLGSWNJIK-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-(trifluoromethylsulfonylamino)ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNS(=O)(=O)C(F)(F)F SQBJZNLGSWNJIK-UHFFFAOYSA-N 0.000 claims 1
- BCWCCAAXJWKIQS-HNNXBMFYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1[C@@H](CCC1)C(F)(F)F BCWCCAAXJWKIQS-HNNXBMFYSA-N 0.000 claims 1
- ICYBLOSRNUDCHR-GFCCVEGCSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1C[C@@H](CC1)O ICYBLOSRNUDCHR-GFCCVEGCSA-N 0.000 claims 1
- ICYBLOSRNUDCHR-LBPRGKRZSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[(3S)-3-hydroxypyrrolidin-1-yl]ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1C[C@H](CC1)O ICYBLOSRNUDCHR-LBPRGKRZSA-N 0.000 claims 1
- FISJIUSNGJRJBJ-LBPRGKRZSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[(3S)-3-hydroxypyrrolidin-1-yl]ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN1C[C@H](CC1)O FISJIUSNGJRJBJ-LBPRGKRZSA-N 0.000 claims 1
- QUUHGMORMRSMEF-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[2-methoxyethyl(methyl)amino]ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(C)CCOC QUUHGMORMRSMEF-UHFFFAOYSA-N 0.000 claims 1
- QLSHCESIUKIMJO-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[methyl(oxan-4-yl)amino]ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(C1CCOCC1)C QLSHCESIUKIMJO-UHFFFAOYSA-N 0.000 claims 1
- DTNMCHGLPIQNGJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[methyl(oxan-4-ylmethyl)amino]ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(CC1CCOCC1)C DTNMCHGLPIQNGJ-UHFFFAOYSA-N 0.000 claims 1
- XLTYVZXWLLINSN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[methyl(propan-2-yl)amino]ethylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCN(C)C(C)C XLTYVZXWLLINSN-UHFFFAOYSA-N 0.000 claims 1
- DKWGETKESOVHBJ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[2-[methyl-[2-(oxan-4-yl)ethyl]amino]ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(CCC1CCOCC1)C DKWGETKESOVHBJ-UHFFFAOYSA-N 0.000 claims 1
- GIEYMFYWYAVAHU-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[3-(2,2,2-trifluoroethoxy)propylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCOCC(F)(F)F GIEYMFYWYAVAHU-UHFFFAOYSA-N 0.000 claims 1
- TWVPMLBBSPUZIX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[3-(hydroxymethyl)azetidin-1-yl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)N1CC(C1)CO TWVPMLBBSPUZIX-UHFFFAOYSA-N 0.000 claims 1
- LSYPBKSYFUZWLN-LLVKDONJSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[(2R)-oxolan-2-yl]methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC[C@@H]1OCCC1 LSYPBKSYFUZWLN-LLVKDONJSA-N 0.000 claims 1
- LSYPBKSYFUZWLN-NSHDSACASA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[(2S)-oxolan-2-yl]methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC[C@H]1OCCC1 LSYPBKSYFUZWLN-NSHDSACASA-N 0.000 claims 1
- RKVXCSVLSCRQNK-CYBMUJFWSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[(3R)-1-(oxetan-3-yl)piperidin-3-yl]amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)N[C@H]1CN(CCC1)C1COC1 RKVXCSVLSCRQNK-CYBMUJFWSA-N 0.000 claims 1
- ADTZWXJRMDXSCK-GFCCVEGCSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)N[C@H]1CN(CC1)C1COC1 ADTZWXJRMDXSCK-GFCCVEGCSA-N 0.000 claims 1
- SQWFZDYIOSXEEK-HUUCEWRRSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[(3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl]amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)N[C@@H]1CN(C[C@H]1OC)C SQWFZDYIOSXEEK-HUUCEWRRSA-N 0.000 claims 1
- RKVXCSVLSCRQNK-ZDUSSCGKSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[(3S)-1-(oxetan-3-yl)piperidin-3-yl]amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)N[C@@H]1CN(CCC1)C1COC1 RKVXCSVLSCRQNK-ZDUSSCGKSA-N 0.000 claims 1
- QKJVFHOMVUTDJB-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[1-(2-methoxyethyl)piperidin-3-yl]amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CN(CCC1)CCOC QKJVFHOMVUTDJB-UHFFFAOYSA-N 0.000 claims 1
- SGPWASJMVNWHOS-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[1-(2-methoxyethyl)pyrrolidin-3-yl]amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NC1CN(CC1)CCOC SGPWASJMVNWHOS-UHFFFAOYSA-N 0.000 claims 1
- ZYTVGDNFZMNBOW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[[4-(methylsulfonylmethyl)oxan-4-yl]methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCC1(CCOCC1)CS(=O)(=O)C ZYTVGDNFZMNBOW-UHFFFAOYSA-N 0.000 claims 1
- LQVZVAUEYQBXFV-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-pyrrolidin-2-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)C1NCCC1 LQVZVAUEYQBXFV-UHFFFAOYSA-N 0.000 claims 1
- DPMKCLMUYWVMNW-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-3-methylimidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N(C=N2)C DPMKCLMUYWVMNW-UHFFFAOYSA-N 0.000 claims 1
- QRURQDDUQDMZSK-UHFFFAOYSA-N N'-(3-chlorophenyl)-2-[2-(dimethylamino)ethyl]-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN(C)C QRURQDDUQDMZSK-UHFFFAOYSA-N 0.000 claims 1
- HHIDBQAIBGGXSV-UHFFFAOYSA-N N'-(3-chlorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN(C)C)F)F HHIDBQAIBGGXSV-UHFFFAOYSA-N 0.000 claims 1
- JJYFUASBBDFLBQ-UHFFFAOYSA-N N'-(3-chlorophenyl)-2-[2-(dimethylamino)ethylamino]-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC=C(C2=C1NC(=N2)NCCN(C)C)F JJYFUASBBDFLBQ-UHFFFAOYSA-N 0.000 claims 1
- ZFYQRRNSOKJFFW-UHFFFAOYSA-N N'-(3-chlorophenyl)-2-[3-(dimethylamino)propylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCCN(C)C)F)F ZFYQRRNSOKJFFW-UHFFFAOYSA-N 0.000 claims 1
- RQKQLIDQHHOSBK-UHFFFAOYSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCN1CCCC1)F)F RQKQLIDQHHOSBK-UHFFFAOYSA-N 0.000 claims 1
- SDXOHZROPRVEEK-CQSZACIVSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3R)-1-(2-methoxyethyl)pyrrolidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@H]1CN(CC1)CCOC)F)F SDXOHZROPRVEEK-CQSZACIVSA-N 0.000 claims 1
- QJEJLBVTAVIMQD-CYBMUJFWSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3R)-1-methylpiperidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@H]1CN(CCC1)C)F)F QJEJLBVTAVIMQD-CYBMUJFWSA-N 0.000 claims 1
- QJEJLBVTAVIMQD-ZDUSSCGKSA-N N'-(3-chlorophenyl)-6,7-difluoro-N-hydroxy-2-[[(3S)-1-methylpiperidin-3-yl]amino]-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)N[C@@H]1CN(CCC1)C)F)F QJEJLBVTAVIMQD-ZDUSSCGKSA-N 0.000 claims 1
- LVJSEVBOOFQRPC-UHFFFAOYSA-N N'-(3-chlorophenyl)-N-hydroxy-2-(2-piperidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1CCCCC1 LVJSEVBOOFQRPC-UHFFFAOYSA-N 0.000 claims 1
- GLKNGTSKXBUNLQ-UHFFFAOYSA-N N'-(3-chlorophenyl)-N-hydroxy-2-(2-pyrrolidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCN1CCCC1 GLKNGTSKXBUNLQ-UHFFFAOYSA-N 0.000 claims 1
- IQHKSAREFQVNJV-UHFFFAOYSA-N N-(3-bromophenyl)-2-[2-(dimethylamino)ethylamino]-7-fluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound BrC=1C=C(C=CC=1)N(C(=N)C1=CC=C(C2=C1NC(=N2)NCCN(C)C)F)O IQHKSAREFQVNJV-UHFFFAOYSA-N 0.000 claims 1
- IOUSWWWBSUDTLQ-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-2-[[2-(dimethylamino)phenyl]methylamino]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)N(C(=N)C1=CC(=C(C2=C1NC(=N2)NCC1=C(C=CC=C1)N(C)C)F)F)O IOUSWWWBSUDTLQ-UHFFFAOYSA-N 0.000 claims 1
- JRTZSLIKBBEFKK-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-6,7-difluoro-2-(3-morpholin-4-ylpropylamino)-3H-benzimidazole-4-carboxamide Chemical compound ClC=1C=C(C=CC=1F)NC(=O)C1=CC(=C(C2=C1NC(=N2)NCCCN1CCOCC1)F)F JRTZSLIKBBEFKK-UHFFFAOYSA-N 0.000 claims 1
- MEOBAGWQVLEBAN-ZHZULCJRSA-N N-(3-chloro-4-fluorophenyl)-N'-hydroxy-N-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound CN(\C(=N/O)c1ccnc2nc[nH]c12)c1ccc(F)c(Cl)c1 MEOBAGWQVLEBAN-ZHZULCJRSA-N 0.000 claims 1
- HYMAQLIGLNQNLD-UHFFFAOYSA-N N-(3-chlorophenyl)-2-[(cyclopropylmethylamino)methyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)N(C(=N)C1=CC(=C(C2=C1NC(=N2)CNCC1CC1)F)F)O HYMAQLIGLNQNLD-UHFFFAOYSA-N 0.000 claims 1
- PXWVQKLORDCZDR-UHFFFAOYSA-N N-[2-[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]acetamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCNC(C)=O PXWVQKLORDCZDR-UHFFFAOYSA-N 0.000 claims 1
- WDXLTBNSSIMTCC-UHFFFAOYSA-N N-[2-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]amino]ethyl]acetamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNC(C)=O WDXLTBNSSIMTCC-UHFFFAOYSA-N 0.000 claims 1
- AVCFQVSCYCSLPT-UHFFFAOYSA-N N-[2-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-4,5-difluoro-1H-benzimidazol-2-yl]amino]ethyl]acetamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCNC(C)=O)F)F AVCFQVSCYCSLPT-UHFFFAOYSA-N 0.000 claims 1
- FIRNNBMEFXSXBY-UHFFFAOYSA-N N-[3-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]amino]propyl]acetamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCNC(C)=O FIRNNBMEFXSXBY-UHFFFAOYSA-N 0.000 claims 1
- IKQWZMWIAJZLSC-UHFFFAOYSA-N N-hydroxy-N-naphthalen-2-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON(C(=N)C1=C2C(=NC=C1)N=CN2)C1=CC2=CC=CC=C2C=C1 IKQWZMWIAJZLSC-UHFFFAOYSA-N 0.000 claims 1
- YKPSIWWVYPACBB-UHFFFAOYSA-N N-hydroxy-N-phenyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON(C(=N)C1=C2C(=NC=C1)N=CN2)C1=CC=CC=C1 YKPSIWWVYPACBB-UHFFFAOYSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- AKYVFSAQSJQGOQ-UHFFFAOYSA-N methyl N-[2-[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]carbamate Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)CCNC(OC)=O AKYVFSAQSJQGOQ-UHFFFAOYSA-N 0.000 claims 1
- QBROTZRFTOKFSP-UHFFFAOYSA-N methyl N-[2-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]amino]ethyl]carbamate Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCNC(OC)=O QBROTZRFTOKFSP-UHFFFAOYSA-N 0.000 claims 1
- GSRQSJQDQYHSIV-UHFFFAOYSA-N methyl N-[2-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-4,5-difluoro-1H-benzimidazol-2-yl]amino]ethyl]carbamate Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)NCCNC(OC)=O)F)F GSRQSJQDQYHSIV-UHFFFAOYSA-N 0.000 claims 1
- GVRMGDFXOSECAA-UHFFFAOYSA-N methyl N-[3-[[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]amino]propyl]carbamate Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)NCCCNC(OC)=O GVRMGDFXOSECAA-UHFFFAOYSA-N 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- BFSRVENTMGUTEF-UHFFFAOYSA-N tert-butyl N-[2-[7-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-4,5-difluoro-1H-benzimidazol-2-yl]ethyl]carbamate Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CCNC(OC(C)(C)C)=O)F)F BFSRVENTMGUTEF-UHFFFAOYSA-N 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 description 108
- 229940124597 therapeutic agent Drugs 0.000 description 87
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 48
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 45
- 125000005843 halogen group Chemical group 0.000 description 38
- 125000004432 carbon atom Chemical group C* 0.000 description 34
- 238000011282 treatment Methods 0.000 description 34
- 239000003795 chemical substances by application Substances 0.000 description 30
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 27
- 108010078049 Interferon alpha-2 Proteins 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 229960001355 tenofovir disoproxil Drugs 0.000 description 27
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 241000700721 Hepatitis B virus Species 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 229940126656 GS-4224 Drugs 0.000 description 25
- 125000000217 alkyl group Chemical group 0.000 description 25
- 239000000427 antigen Substances 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 229910001868 water Inorganic materials 0.000 description 24
- 230000008685 targeting Effects 0.000 description 23
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 22
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 229960004397 cyclophosphamide Drugs 0.000 description 21
- 229960003507 interferon alfa-2b Drugs 0.000 description 21
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 21
- 229960004641 rituximab Drugs 0.000 description 21
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 21
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 21
- 108020004459 Small interfering RNA Proteins 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 150000002431 hydrogen Chemical class 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- QDGZDCVAUDNJFG-FXQIFTODSA-N entecavir (anhydrous) Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 description 18
- 125000005842 heteroatom Chemical group 0.000 description 18
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 18
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 18
- 238000002512 chemotherapy Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- 229960004946 tenofovir alafenamide Drugs 0.000 description 17
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 229910052805 deuterium Inorganic materials 0.000 description 16
- 229960004556 tenofovir Drugs 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000012828 PI3K inhibitor Substances 0.000 description 13
- 239000002246 antineoplastic agent Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 208000002672 hepatitis B Diseases 0.000 description 13
- 239000002955 immunomodulating agent Substances 0.000 description 13
- 239000002777 nucleoside Substances 0.000 description 13
- 150000003833 nucleoside derivatives Chemical class 0.000 description 13
- 229940121649 protein inhibitor Drugs 0.000 description 13
- 239000012268 protein inhibitor Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108091006611 SLC10A1 Proteins 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229960001997 adefovir Drugs 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 229960000390 fludarabine Drugs 0.000 description 12
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 12
- 125000001188 haloalkyl group Chemical group 0.000 description 12
- 229960001627 lamivudine Drugs 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 229960003560 tenofovir alafenamide fumarate Drugs 0.000 description 12
- 108091036055 CccDNA Proteins 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 229960001156 mitoxantrone Drugs 0.000 description 11
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 108090000565 Capsid Proteins Proteins 0.000 description 10
- 102100023321 Ceruloplasmin Human genes 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 10
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 10
- 102100034343 Integrase Human genes 0.000 description 10
- 102000011931 Nucleoproteins Human genes 0.000 description 10
- 108010061100 Nucleoproteins Proteins 0.000 description 10
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 10
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 10
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 10
- 229940118555 Viral entry inhibitor Drugs 0.000 description 10
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 10
- 239000000134 cyclophilin inhibitor Substances 0.000 description 10
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 229940021747 therapeutic vaccine Drugs 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- 239000012270 PD-1 inhibitor Substances 0.000 description 9
- 239000012668 PD-1-inhibitor Substances 0.000 description 9
- 239000012271 PD-L1 inhibitor Substances 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 102000002689 Toll-like receptor Human genes 0.000 description 9
- 108020000411 Toll-like receptor Proteins 0.000 description 9
- 229940002637 baraclude Drugs 0.000 description 9
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
- 229960004316 cisplatin Drugs 0.000 description 9
- 229960000980 entecavir Drugs 0.000 description 9
- 229940074057 epivir hbv Drugs 0.000 description 9
- 229960005420 etoposide Drugs 0.000 description 9
- 229940097709 hepsera Drugs 0.000 description 9
- 125000004404 heteroalkyl group Chemical group 0.000 description 9
- 229940121354 immunomodulator Drugs 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 229960001592 paclitaxel Drugs 0.000 description 9
- 229940121655 pd-1 inhibitor Drugs 0.000 description 9
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 9
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 9
- 125000003107 substituted aryl group Chemical group 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
- 229960005311 telbivudine Drugs 0.000 description 9
- 229940063032 tyzeka Drugs 0.000 description 9
- 229960004528 vincristine Drugs 0.000 description 9
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 9
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 8
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 8
- 102100021723 Arginase-1 Human genes 0.000 description 8
- 101710129000 Arginase-1 Proteins 0.000 description 8
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 8
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 8
- 101100481584 Mus musculus Tlr1 gene Proteins 0.000 description 8
- 108091027967 Small hairpin RNA Proteins 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- 108091070501 miRNA Proteins 0.000 description 8
- 239000002679 microRNA Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 8
- 229940124291 BTK inhibitor Drugs 0.000 description 7
- 108091033409 CRISPR Proteins 0.000 description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 7
- 108010092160 Dactinomycin Proteins 0.000 description 7
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 7
- 108010078233 Thymalfasin Proteins 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 7
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 7
- 229960004562 carboplatin Drugs 0.000 description 7
- 229960004630 chlorambucil Drugs 0.000 description 7
- IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 238000000375 direct analysis in real time Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000012063 dual-affinity re-targeting Methods 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 229960001101 ifosfamide Drugs 0.000 description 7
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 7
- 229960004866 mycophenolate mofetil Drugs 0.000 description 7
- 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 7
- 229960004231 thymalfasin Drugs 0.000 description 7
- CEZJOKOKGRAPMR-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyridine-7-carboxylic acid Chemical compound OC(=O)C1=CC=NC2=C1NC=N2 CEZJOKOKGRAPMR-UHFFFAOYSA-N 0.000 description 6
- KKMFSVNFPUPGCA-UHFFFAOYSA-N 4-fluoro-3-(4-hydroxypiperidin-1-yl)sulfonyl-n-(3,4,5-trifluorophenyl)benzamide Chemical compound C1CC(O)CCN1S(=O)(=O)C1=CC(C(=O)NC=2C=C(F)C(F)=C(F)C=2)=CC=C1F KKMFSVNFPUPGCA-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 6
- 102100040018 Interferon alpha-2 Human genes 0.000 description 6
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 6
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 108010046075 Thymosin Proteins 0.000 description 6
- 102000007501 Thymosin Human genes 0.000 description 6
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000003510 anti-fibrotic effect Effects 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 229960000684 cytarabine Drugs 0.000 description 6
- 229960000366 emtricitabine Drugs 0.000 description 6
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 6
- 229960001924 melphalan Drugs 0.000 description 6
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 6
- XFVAFONTHBTMBL-UHFFFAOYSA-N methyl 2-amino-7-fluoro-3H-benzimidazole-4-carboxylate Chemical compound NC1=NC2=C(N1)C(=CC=C2F)C(=O)OC XFVAFONTHBTMBL-UHFFFAOYSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Chemical group 0.000 description 6
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229940021993 prophylactic vaccine Drugs 0.000 description 6
- 238000013456 study Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 6
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- PGGGECCHDQOWKI-UHFFFAOYSA-N 2-amino-6,7-difluoro-3H-benzimidazole-4-carboxylic acid Chemical compound Nc1nc2c(F)c(F)cc(C(O)=O)c2[nH]1 PGGGECCHDQOWKI-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 5
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 5
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 5
- 102100031780 Endonuclease Human genes 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 208000037357 HIV infectious disease Diseases 0.000 description 5
- 101001125032 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 1 Proteins 0.000 description 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 5
- 108010003272 Hyaluronate lyase Proteins 0.000 description 5
- 102000001974 Hyaluronidases Human genes 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- RRWJUIGOGXTQDH-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-7-methyl-3H-benzimidazole-4-carboxamide Chemical compound ClC=1C=C(C=CC=1F)NC(=O)C1=CC=C(C2=C1NC=N2)C RRWJUIGOGXTQDH-UHFFFAOYSA-N 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 102100029424 Nucleotide-binding oligomerization domain-containing protein 1 Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 5
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 5
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000003636 chemical group Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 5
- 229960000640 dactinomycin Drugs 0.000 description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 229940093499 ethyl acetate Drugs 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
- 229960002773 hyaluronidase Drugs 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- REBMQZZDLLKFFI-UHFFFAOYSA-N methyl 3-formamido-4-methyl-2-nitrobenzoate Chemical compound COC(=O)C1=CC=C(C)C(NC=O)=C1[N+]([O-])=O REBMQZZDLLKFFI-UHFFFAOYSA-N 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229960004618 prednisone Drugs 0.000 description 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 229910052717 sulfur Chemical group 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 229960005267 tositumomab Drugs 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 4
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 4
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 4
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 102100027207 CD27 antigen Human genes 0.000 description 4
- 102100025221 CD70 antigen Human genes 0.000 description 4
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 229910020323 ClF3 Inorganic materials 0.000 description 4
- 229940127399 DNA Polymerase Inhibitors Drugs 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 4
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 4
- 108010005716 Interferon beta-1a Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 4
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 4
- 101150069255 KLRC1 gene Proteins 0.000 description 4
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 4
- 101710150988 Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 4
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 4
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 4
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 4
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 4
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 4
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- 102000003923 Protein Kinase C Human genes 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 229940044665 STING agonist Drugs 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 102000000551 Syk Kinase Human genes 0.000 description 4
- 108010016672 Syk Kinase Proteins 0.000 description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 4
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 4
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 4
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 4
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 4
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229960001467 bortezomib Drugs 0.000 description 4
- 229960005243 carmustine Drugs 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000036267 drug metabolism Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 229950006370 epacadostat Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 4
- 235000008191 folinic acid Nutrition 0.000 description 4
- 239000011672 folinic acid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- 229960004768 irinotecan Drugs 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229960001691 leucovorin Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- GZWQYCIGWHVNDR-UHFFFAOYSA-N methyl 2,3-diamino-4,5-difluorobenzoate Chemical compound NC1=C(C(=O)OC)C=C(C(=C1N)F)F GZWQYCIGWHVNDR-UHFFFAOYSA-N 0.000 description 4
- IAVUCCIRHLGKCG-UHFFFAOYSA-N methyl 7-methyl-3h-benzimidazole-4-carboxylate Chemical compound COC(=O)C1=CC=C(C)C2=C1NC=N2 IAVUCCIRHLGKCG-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 4
- 108010078070 scavenger receptors Proteins 0.000 description 4
- 102000014452 scavenger receptors Human genes 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 description 4
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 4
- 108010087686 src-Family Kinases Proteins 0.000 description 4
- 102000009076 src-Family Kinases Human genes 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 229960003433 thalidomide Drugs 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- 229960003048 vinblastine Drugs 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- RLMNJYLIJGOVNP-OYUXLBQNSA-N (2e,3e)-1-(4-bromophenyl)-3-hydrazinylidene-2-[(3-methylphenyl)hydrazinylidene]propan-1-one Chemical compound CC1=CC=CC(N\N=C(/C=N/N)\C(=O)C=2C=CC(Br)=CC=2)=C1 RLMNJYLIJGOVNP-OYUXLBQNSA-N 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 3
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 3
- HDXDQPRPFRKGKZ-INIZCTEOSA-N 3-(3-fluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)propyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3NC=NC=3N=CN=2)CC)OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HDXDQPRPFRKGKZ-INIZCTEOSA-N 0.000 description 3
- FSLFOYRAPKXZLD-UHFFFAOYSA-N 3-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-4-methyl-2-nitrobenzamide Chemical compound NC=1C(=C(C(=O)NC2=CC(=C(C=C2)F)Cl)C=C(C=1C)F)[N+](=O)[O-] FSLFOYRAPKXZLD-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101150078577 Adora2b gene Proteins 0.000 description 3
- 108010019182 Alloferon Proteins 0.000 description 3
- 102100036465 Autoimmune regulator Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000002706 Discoidin Domain Receptors Human genes 0.000 description 3
- 108010043648 Discoidin Domain Receptors Proteins 0.000 description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 3
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229940043367 IDO1 inhibitor Drugs 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 description 3
- 108010024121 Janus Kinases Proteins 0.000 description 3
- 102000015617 Janus Kinases Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101150010110 Map3k8 gene Proteins 0.000 description 3
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 3
- BMUISEIVGBOWBM-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-(2-morpholin-4-ylethylamino)-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=CC(=C(C=2N=C(NC=21)NCCN1CCOCC1)F)F BMUISEIVGBOWBM-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010459 TALEN Methods 0.000 description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 3
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- CJCYTUJOSMYXLE-JDLSZIHUSA-N [[(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxyphosphoryl]sulfanylmethyl propan-2-yl carbonate Chemical compound N1([C@@H]2O[C@H](CO)[C@@H](OP(=O)(OC[C@@H]3[C@H](C[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)SCOC(=O)OC(C)C)[C@H]2OC)C=CC(=O)NC1=O CJCYTUJOSMYXLE-JDLSZIHUSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229940009456 adriamycin Drugs 0.000 description 3
- 108700025316 aldesleukin Proteins 0.000 description 3
- 229960000548 alemtuzumab Drugs 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000003281 allosteric effect Effects 0.000 description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 3
- 229960003437 aminoglutethimide Drugs 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 229940003504 avonex Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 229950001357 celmoleukin Drugs 0.000 description 3
- 229960005338 clevudine Drugs 0.000 description 3
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 229960003901 dacarbazine Drugs 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 3
- 108010086162 human BT088 immunoglobulin Proteins 0.000 description 3
- 102000007442 human BT088 immunoglobulin Human genes 0.000 description 3
- 102000055277 human IL2 Human genes 0.000 description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 3
- 229960000908 idarubicin Drugs 0.000 description 3
- 229960003445 idelalisib Drugs 0.000 description 3
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229940124524 integrase inhibitor Drugs 0.000 description 3
- 239000002850 integrase inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960004061 interferon alfa-n1 Drugs 0.000 description 3
- 108010006088 interferon alfa-n1 Proteins 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940065638 intron a Drugs 0.000 description 3
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- CMNTUNQGMQBYDK-UHFFFAOYSA-N methyl 6,7-difluoro-3H-benzimidazole-4-carboxylate Chemical compound FC1=C(C=C(C=2NC=NC=21)C(=O)OC)F CMNTUNQGMQBYDK-UHFFFAOYSA-N 0.000 description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- RRTPWQXEERTRRK-UHFFFAOYSA-N n-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide Chemical compound C1=CC=CC2=C3N(OCCCCNC(=O)CCCCCCCCCCCCCCCCC)C(CCCC)=NC3=C(N)N=C21 RRTPWQXEERTRRK-UHFFFAOYSA-N 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 229960000435 oblimersen Drugs 0.000 description 3
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229940002988 pegasys Drugs 0.000 description 3
- 229940106366 pegintron Drugs 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 3
- 229950010632 perifosine Drugs 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 3
- 229960000624 procarbazine Drugs 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 229950010550 resiquimod Drugs 0.000 description 3
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 229960000235 temsirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 3
- 229960001278 teniposide Drugs 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 229960001196 thiotepa Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229940091440 uniferon Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229940099039 velcade Drugs 0.000 description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 3
- CUFQBQOBLVLKRF-RZDMPUFOSA-N (4r)-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@@H]1C(C)(C)SCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=C(O)C=CC=1)C)CC1=CC=CC=C1 CUFQBQOBLVLKRF-RZDMPUFOSA-N 0.000 description 2
- KYRSNWPSSXSNEP-ZRTHHSRSSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one Chemical compound NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 KYRSNWPSSXSNEP-ZRTHHSRSSA-N 0.000 description 2
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- LYMICVBGNUEHGE-FUQPUAIBSA-N 1-[(2r,3r,4r,5r)-4-[[(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]pyrimidine-2,4-dione Chemical compound N1([C@@H]2O[C@H](CO)[C@@H](OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)[C@H]2OC)C=CC(=O)NC1=O LYMICVBGNUEHGE-FUQPUAIBSA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 2
- LSONWRHLFZYHIN-UHFFFAOYSA-N 2-[(4-phenoxyphenyl)sulfonylmethyl]thiirane Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)CC1CS1 LSONWRHLFZYHIN-UHFFFAOYSA-N 0.000 description 2
- DIIRQMZZIZFGOT-UHFFFAOYSA-N 2-amino-N-(3-chloro-4-fluorophenyl)-6,7-difluoro-3H-benzimidazole-4-carbothioamide Chemical compound NC1=NC2=C(N1)C(=CC(=C2F)F)C(NC1=CC(=C(C=C1)F)Cl)=S DIIRQMZZIZFGOT-UHFFFAOYSA-N 0.000 description 2
- MUNVWFHTBXXBFX-UHFFFAOYSA-N 2-amino-N-(3-chloro-4-fluorophenyl)-6,7-difluoro-3H-benzimidazole-4-carboxamide Chemical compound NC1=NC2=C(N1)C(=CC(=C2F)F)C(=O)NC1=CC(=C(C=C1)F)Cl MUNVWFHTBXXBFX-UHFFFAOYSA-N 0.000 description 2
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 2
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 description 2
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 description 2
- IZMJMFMGDBQRAR-UHFFFAOYSA-N 3,5-difluoro-4-methyl-2-nitrobenzoic acid Chemical compound FC=1C(=C(C(=O)O)C=C(C=1C)F)[N+](=O)[O-] IZMJMFMGDBQRAR-UHFFFAOYSA-N 0.000 description 2
- GUGYSPMUBOSRDE-UHFFFAOYSA-N 3-amino-4,5-difluoro-2-nitrobenzoic acid Chemical compound NC1=C(F)C(F)=CC(C(O)=O)=C1[N+]([O-])=O GUGYSPMUBOSRDE-UHFFFAOYSA-N 0.000 description 2
- YSSVFSCEZMFQIA-UHFFFAOYSA-N 3-amino-4-fluoro-2-nitrobenzoic acid Chemical compound NC=1C(=C(C(=O)O)C=CC=1F)[N+](=O)[O-] YSSVFSCEZMFQIA-UHFFFAOYSA-N 0.000 description 2
- RHXPZYPZHJMQSP-UHFFFAOYSA-N 6-chloro-N-(3-chloro-4-fluorophenyl)-1H-benzimidazole-4-carboxamide Chemical compound ClC=1C=C(C2=C(NC=N2)C=1)C(=O)NC1=CC(=C(C=C1)F)Cl RHXPZYPZHJMQSP-UHFFFAOYSA-N 0.000 description 2
- SUSIIKACSIQZMS-UHFFFAOYSA-N 7-bromo-N-(3-chloro-4-fluorophenyl)-3H-benzimidazole-4-carboxamide Chemical compound BrC1=CC=C(C=2NC=NC=21)C(=O)NC1=CC(=C(C=C1)F)Cl SUSIIKACSIQZMS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 230000035502 ADME Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102000007470 Adenosine A2B Receptor Human genes 0.000 description 2
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- 108091005625 BRD4 Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 2
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 2
- 102000001805 Bromodomains Human genes 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 102100031788 E3 ubiquitin-protein ligase MYLIP Human genes 0.000 description 2
- 101710190174 E3 ubiquitin-protein ligase MYLIP Proteins 0.000 description 2
- 231100000491 EC50 Toxicity 0.000 description 2
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 2
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 2
- 208000030644 Esophageal Motility disease Diseases 0.000 description 2
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 2
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FDCOHGHEADZEGF-OCEACIFDSA-N Glycerol 1,3-dihexadecanoate 2-(9Z-octadecenoate) Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC\C=C\CCCCCCCC FDCOHGHEADZEGF-OCEACIFDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 108010010369 HIV Protease Proteins 0.000 description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- QPJBONAWFAURGB-UHFFFAOYSA-L Lobenzarit disodium Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C([O-])=O QPJBONAWFAURGB-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- AHBUSKQITAVTPQ-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-3,5-difluoro-4-methyl-2-nitrobenzamide Chemical compound ClC=1C=C(C=CC=1F)NC(C1=C(C(=C(C(=C1)F)C)F)[N+](=O)[O-])=O AHBUSKQITAVTPQ-UHFFFAOYSA-N 0.000 description 2
- MWRLJYIWLOIAQJ-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-5-fluoro-3-formamido-4-methyl-2-nitrobenzamide Chemical compound ClC=1C=C(C=CC=1F)NC(C1=C(C(=C(C(=C1)F)C)NC=O)[N+](=O)[O-])=O MWRLJYIWLOIAQJ-UHFFFAOYSA-N 0.000 description 2
- ZAPVCRUWYIQMSR-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-6-fluoro-7-methyl-3H-benzimidazole-4-carboxamide Chemical compound ClC=1C=C(C=CC=1F)NC(=O)C1=CC(=C(C2=C1NC=N2)C)F ZAPVCRUWYIQMSR-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 108010007843 NADH oxidase Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 2
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 2
- 229960000531 abacavir sulfate Drugs 0.000 description 2
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 229960005107 darunavir Drugs 0.000 description 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 201000011191 dyskinesia of esophagus Diseases 0.000 description 2
- 229940001018 emtriva Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 229930013356 epothilone Natural products 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019000 fluorine Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- 229940124784 gp41 inhibitor Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003084 hiv integrase inhibitor Substances 0.000 description 2
- 239000004030 hiv protease inhibitor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229950010245 ibalizumab Drugs 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229940036646 iodine-131-tositumomab Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000005445 isotope effect Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229950004563 lucatumumab Drugs 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- JOXPUYQPWZGJBW-UHFFFAOYSA-N methyl 2,3-diamino-4-fluorobenzoate Chemical compound NC1=C(C(=O)OC)C=CC(=C1N)F JOXPUYQPWZGJBW-UHFFFAOYSA-N 0.000 description 2
- WQMCUZRDQSSPEQ-UHFFFAOYSA-N methyl 2-amino-6,7-difluoro-3H-benzimidazole-4-carboxylate Chemical compound NC1=NC2=C(N1)C(=CC(=C2F)F)C(=O)OC WQMCUZRDQSSPEQ-UHFFFAOYSA-N 0.000 description 2
- WCVGNACDUFPIBI-UHFFFAOYSA-N methyl 2-formamido-3-nitro-4-(trifluoromethoxy)benzoate Chemical compound C(=O)NC1=C(C(=O)OC)C=CC(=C1[N+](=O)[O-])OC(F)(F)F WCVGNACDUFPIBI-UHFFFAOYSA-N 0.000 description 2
- MMUOLJKIGQPLPT-UHFFFAOYSA-N methyl 3-amino-2-formamido-4-(trifluoromethoxy)benzoate Chemical compound NC=1C(=C(C(=O)OC)C=CC=1OC(F)(F)F)NC=O MMUOLJKIGQPLPT-UHFFFAOYSA-N 0.000 description 2
- PYXJEFKCBZCVMV-UHFFFAOYSA-N methyl 3-formamido-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(NC=O)=C1 PYXJEFKCBZCVMV-UHFFFAOYSA-N 0.000 description 2
- VSFXMUPQUQMGSF-UHFFFAOYSA-N methyl 4-bromo-3-formamido-2-nitrobenzoate Chemical compound BrC1=C(C(=C(C(=O)OC)C=C1)[N+](=O)[O-])NC=O VSFXMUPQUQMGSF-UHFFFAOYSA-N 0.000 description 2
- MWGRAKVJBSNKGH-UHFFFAOYSA-N methyl 4-bromo-3-formamidobenzoate Chemical compound BrC1=C(C=C(C(=O)OC)C=C1)NC=O MWGRAKVJBSNKGH-UHFFFAOYSA-N 0.000 description 2
- PXDOSIVVNWUZDI-UHFFFAOYSA-N methyl 5-chloro-3-formamido-2-nitrobenzoate Chemical compound ClC=1C=C(C(=C(C(=O)OC)C=1)[N+](=O)[O-])NC=O PXDOSIVVNWUZDI-UHFFFAOYSA-N 0.000 description 2
- ILAPAGNXJPPAKG-UHFFFAOYSA-N methyl 6,7-difluoro-2-(2-morpholin-4-ylethylamino)-3H-benzimidazole-4-carboxylate Chemical compound FC1=C(C=C(C=2NC(=NC=21)NCCN1CCOCC1)C(=O)OC)F ILAPAGNXJPPAKG-UHFFFAOYSA-N 0.000 description 2
- YNWCMSGYTITKQT-UHFFFAOYSA-N methyl 6-chloro-1H-benzimidazole-4-carboxylate Chemical compound ClC=1C=C(C2=C(NC=N2)C=1)C(=O)OC YNWCMSGYTITKQT-UHFFFAOYSA-N 0.000 description 2
- YLSTVOATYWGXCL-UHFFFAOYSA-N methyl 7-(trifluoromethoxy)-1H-benzimidazole-4-carboxylate Chemical compound FC(OC1=CC=C(C=2NC=NC=21)C(=O)OC)(F)F YLSTVOATYWGXCL-UHFFFAOYSA-N 0.000 description 2
- HPCIVMQCKFDBDP-UHFFFAOYSA-N methyl 7-bromo-3H-benzimidazole-4-carboxylate Chemical compound BrC1=CC=C(C=2NC=NC=21)C(=O)OC HPCIVMQCKFDBDP-UHFFFAOYSA-N 0.000 description 2
- 229950003734 milatuzumab Drugs 0.000 description 2
- 229950002142 minretumomab Drugs 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 229950007627 motolimod Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 description 2
- 229940086322 navelbine Drugs 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 2
- 229960002653 nilutamide Drugs 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 229960002450 ofatumumab Drugs 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- KNUXHTWUIVMBBY-JRJYXWDASA-N rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 2
- 229950006564 rintatolimod Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
- 238000011452 sequencing regimen Methods 0.000 description 2
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 229940008349 truvada Drugs 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 229950000815 veltuzumab Drugs 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- NIDRYBLTWYFCFV-FMTVUPSXSA-N (+)-calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- QSIOZNXDXNWPNX-AKEJEFCPSA-N (1r,2s,3r,5r)-3-(6-aminopurin-9-yl)-2-fluoro-5-(hydroxymethyl)-4-methylidenecyclopentan-1-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1[C@H](F)[C@H](O)[C@@H](CO)C1=C QSIOZNXDXNWPNX-AKEJEFCPSA-N 0.000 description 1
- TXIOIJSYWOLKNU-FLQODOFBSA-N (1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1 Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C TXIOIJSYWOLKNU-FLQODOFBSA-N 0.000 description 1
- JHXLLEDIXXOJQD-WELGVCPWSA-N (2-decoxy-3-dodecylsulfanylpropyl) [(2r,3s,5r)-3-fluoro-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate Chemical compound C1[C@H](F)[C@@H](COP(O)(=O)OCC(CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 JHXLLEDIXXOJQD-WELGVCPWSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-BYPYZUCNSA-N (2s)-2,5-dihydro-1h-pyrrole-2-carboxylic acid Chemical compound OC(=O)[C@H]1NCC=C1 OMGHIGVFLOPEHJ-BYPYZUCNSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
- PNIFFZXGBAYVMQ-RKKDRKJOSA-N (2s)-n-[(2s,3r)-4-[(3-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C(N)C=CC=1)NC(=O)[C@@H](NC(=O)CNCC=1C=C(F)C=CC=1)C(C)(C)C)C1=CC=CC=C1 PNIFFZXGBAYVMQ-RKKDRKJOSA-N 0.000 description 1
- IXZYCIFRVZKVRJ-RKKDRKJOSA-N (2s)-n-[(2s,3r)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)[C@@H](NC(=O)CNCC=1C=C(F)C=CC=1)C(C)(C)C)C1=CC=CC=C1 IXZYCIFRVZKVRJ-RKKDRKJOSA-N 0.000 description 1
- JLUPGSPHOGFEOB-WQLSENKSSA-N (2z)-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(4-fluorophenyl)methyl]-n-methoxyacetamide Chemical compound O\1C(C)(C)OC(=O)C/1=C/C(=O)N(OC)CC1=CC=C(F)C=C1 JLUPGSPHOGFEOB-WQLSENKSSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- QLRRJMOBVVGXEJ-XHSDSOJGSA-N (3r,4s)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-[(3r)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxopiperidin-1-yl]piperidine-4-carboxamide Chemical compound N([C@@H]1CCCN(C1=O)[C@H]1CN(CC[C@@H]1C(=O)N)C=1C(=C(N)N=CN=1)F)C1=CC(Cl)=CC(C(F)(F)F)=C1 QLRRJMOBVVGXEJ-XHSDSOJGSA-N 0.000 description 1
- QRBIFAKBTSNLCS-ZTFBILFISA-N (3s,4as,8as)-n-tert-butyl-2-[(2r,3s)-2-hydroxy-3-[[(2r)-3-methyl-3-methylsulfonyl-2-[(2-pyridin-3-yloxyacetyl)amino]butanoyl]amino]-4-phenylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-3-carboxamide Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@@H](NC(=O)COC=1C=NC=CC=1)C(C)(C)S(C)(=O)=O)C1=CC=CC=C1 QRBIFAKBTSNLCS-ZTFBILFISA-N 0.000 description 1
- CWVMWSZEMZOUPC-JUAXIXHSSA-N (3s,5s,8r,9s,10s,13s,14s,16r)-16-bromo-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](Br)C4)=O)[C@@H]4[C@@H]3CC[C@H]21 CWVMWSZEMZOUPC-JUAXIXHSSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 description 1
- CNPVJJQCETWNEU-CYFREDJKSA-N (4,6-dimethyl-5-pyrimidinyl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone Chemical compound N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C CNPVJJQCETWNEU-CYFREDJKSA-N 0.000 description 1
- ONKCBKDTKZIWHZ-MRWFHJSOSA-N (4r)-4-[[(2r)-6-amino-2-[[(2r)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2r)-1-amino-6-[bis[2-[[4-[2-(1h-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxope Chemical compound C([C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN(C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(N)=O)NC(=O)C=1C=CC(NC(=S)NN)=CC=1)C1=CC=C(O)C=C1 ONKCBKDTKZIWHZ-MRWFHJSOSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- QCNJQJJFXFJVCX-ZDUSSCGKSA-N (4s)-4-(2-cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C([C@@]1(NC(=O)NC2=CC=C(C(=C21)F)F)C(F)(F)F)#CC1CC1 QCNJQJJFXFJVCX-ZDUSSCGKSA-N 0.000 description 1
- JJWJSIAJLBEMEN-ZDUSSCGKSA-N (4s)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)N1)C(F)(F)F)#CC1CC1 JJWJSIAJLBEMEN-ZDUSSCGKSA-N 0.000 description 1
- UXDWYQAXEGVSPS-GFUIURDCSA-N (4s)-6-chloro-4-[(e)-2-cyclopropylethenyl]-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C(/[C@]1(C2=CC(Cl)=CC=C2NC(=O)N1)C(F)(F)F)=C\C1CC1 UXDWYQAXEGVSPS-GFUIURDCSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- QDITZBLZQQZVEE-YBEGLDIGSA-N (5z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=C2C=3C=CN=CC=3)C2=C1 QDITZBLZQQZVEE-YBEGLDIGSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000006653 (C1-C20) heteroaryl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006654 (C3-C12) heteroaryl group Chemical group 0.000 description 1
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006655 (C3-C8) heteroaryl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- LCFFREMLXLZNHE-GBOLQPHISA-N (e)-2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound C12=C(N)N=CN=C2N([C@@H]2CCCN(C2)C(=O)C(/C#N)=C/C(C)(C)N2CCN(CC2)C2COC2)N=C1C(C(=C1)F)=CC=C1OC1=CC=CC=C1 LCFFREMLXLZNHE-GBOLQPHISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- WSTAITCRSVOCTK-UHFFFAOYSA-N 1,4-diazabicyclo[2.2.2]octane;trimethylalumane Chemical compound C[Al](C)C.C[Al](C)C.C1CN2CCN1CC2 WSTAITCRSVOCTK-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- DBPMWRYLTBNCCE-UHFFFAOYSA-N 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CN=C(OC)C=2NC=C1C(=O)C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 DBPMWRYLTBNCCE-UHFFFAOYSA-N 0.000 description 1
- NKPHEWJJTGPRSL-OCCSQVGLSA-N 1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea Chemical compound CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O NKPHEWJJTGPRSL-OCCSQVGLSA-N 0.000 description 1
- SOJJMSYMCLIQCZ-CYBMUJFWSA-N 1-[(2r)-4-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)purin-8-yl]-2-methylpiperazin-1-yl]ethanone Chemical compound C1CN(C(C)=O)[C@H](C)CN1C1=NC2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N1CC(F)(F)F SOJJMSYMCLIQCZ-CYBMUJFWSA-N 0.000 description 1
- QLAVHTXREMEJLM-DYTVHUQLSA-N 1-[(2r,4s,5r)-5-[[[(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-sulfanylphosphoryl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-di Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)CO)[C@@H](OP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 QLAVHTXREMEJLM-DYTVHUQLSA-N 0.000 description 1
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000004486 1-methylpiperidin-3-yl group Chemical group CN1CC(CCC1)* 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BEMBRAMZGVDPMH-UHFFFAOYSA-N 11-ethyl-5-methyl-8-[2-(1-oxidoquinolin-1-ium-4-yl)oxyethyl]dipyrido[2,3-d:2',3'-h][1,4]diazepin-6-one Chemical compound CN1C(=O)C2=CC(CCOC=3C4=CC=CC=C4[N+]([O-])=CC=3)=CN=C2N(CC)C2=NC=CC=C21 BEMBRAMZGVDPMH-UHFFFAOYSA-N 0.000 description 1
- ZOAIEFWMQLYMTF-UHFFFAOYSA-N 18-(4-iodophenyl)octadecyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OCCCCCCCCCCCCCCCCCCC1=CC=C(I)C=C1 ZOAIEFWMQLYMTF-UHFFFAOYSA-N 0.000 description 1
- VVQNAFBGAWCMLU-UHFFFAOYSA-N 1h-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- VNIWZCGZPBJWBI-UHFFFAOYSA-N 2-(1,1-dioxothiazinan-2-yl)-n-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide Chemical compound OC=1C(=O)N(C)C(N2S(CCCC2)(=O)=O)=NC=1C(=O)NCC1=CC=C(F)C=C1 VNIWZCGZPBJWBI-UHFFFAOYSA-N 0.000 description 1
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
- YNSKTNDHCWUYHU-UHFFFAOYSA-N 2-(4-bromo-2-cyanophenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(Br)C=C1C#N YNSKTNDHCWUYHU-UHFFFAOYSA-N 0.000 description 1
- DBXGGXLBTWZXBB-MRXNPFEDSA-N 2-(6-fluorobenzimidazol-1-yl)-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-7h-purin-8-one Chemical compound C1COC2=C(F)C=CC=C2[C@@H]1N(C1=N2)C(=O)NC1=CN=C2N1C=NC2=CC=C(F)C=C21 DBXGGXLBTWZXBB-MRXNPFEDSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- UAXHPOBBKRWJGA-ZDUSSCGKSA-N 2-[2-[(2s)-2-methyl-2,3-dihydroindol-1-yl]-2-oxoethyl]-6-morpholin-4-yl-1h-pyrimidin-4-one Chemical compound C([C@@H]1C)C2=CC=CC=C2N1C(=O)CC(NC(=O)C=1)=NC=1N1CCOCC1 UAXHPOBBKRWJGA-ZDUSSCGKSA-N 0.000 description 1
- ZVAGBRFUYHSUHA-UHFFFAOYSA-N 2-[5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole;methanesulfonic acid Chemical compound CS(O)(=O)=O.COC1=CC(=C2N=C3C=CC=CC3=C2)NC1=CC=1NC(C)=CC=1C ZVAGBRFUYHSUHA-UHFFFAOYSA-N 0.000 description 1
- MCIDWGZGWVSZMK-UHFFFAOYSA-N 2-[6-(1h-indol-4-yl)-1h-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole Chemical compound C1CN(C(C)C)CCN1CC1=CN=C(C=2C=3C=NNC=3C=C(C=2)C=2C=3C=CNC=3C=CC=2)O1 MCIDWGZGWVSZMK-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- AQLUWRRQWYYZBA-UHFFFAOYSA-N 2-amino-5-methyl-5-sulfanylhexanoic acid Chemical compound CC(C)(S)CCC(N)C(O)=O AQLUWRRQWYYZBA-UHFFFAOYSA-N 0.000 description 1
- RTJUXLYUUDBAJN-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](F)[C@@H](CO)O1 RTJUXLYUUDBAJN-KVQBGUIXSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical compound NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical compound NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 1
- NYPGBHKJFKQTIY-TYYBGVCCSA-N 2-cyanoethylazanium;(e)-4-hydroxy-4-oxobut-2-enoate Chemical compound NCCC#N.OC(=O)\C=C\C(O)=O NYPGBHKJFKQTIY-TYYBGVCCSA-N 0.000 description 1
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 description 1
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 1
- VZUKEVFHSPMCSH-UHFFFAOYSA-N 2-nitroethanamine Chemical compound NCC[N+]([O-])=O VZUKEVFHSPMCSH-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 description 1
- DGTRDHAJCIKUSV-UHFFFAOYSA-N 3,5-difluoro-4-methylbenzoic acid Chemical compound CC1=C(F)C=C(C(O)=O)C=C1F DGTRDHAJCIKUSV-UHFFFAOYSA-N 0.000 description 1
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-n-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KOWPUNQBGWIERF-UHFFFAOYSA-N 3-bromo-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Br)=C1 KOWPUNQBGWIERF-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- ZTGQZSKPSJUEBU-UHFFFAOYSA-N 3-bromopropan-1-amine Chemical compound NCCCBr ZTGQZSKPSJUEBU-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- SDNSCXCXVQHBGH-UHFFFAOYSA-N 4-(2-isothiocyanatoethyl)morpholine Chemical compound S=C=NCCN1CCOCC1 SDNSCXCXVQHBGH-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-trimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 1
- GWNOTCOIYUNTQP-FQLXRVMXSA-N 4-[4-[[(3r)-1-butyl-3-[(r)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid Chemical compound N([C@@H](C(=O)N1CCCC)[C@H](O)C2CCCCC2)C(=O)C1(CC1)CCN1CC(C=C1)=CC=C1OC1=CC=C(C(O)=O)C=C1 GWNOTCOIYUNTQP-FQLXRVMXSA-N 0.000 description 1
- VFOKSTCIRGDTBR-UHFFFAOYSA-N 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one Chemical compound C12=NC(OCCCC)=NC(N)=C2NC(=O)CN1CC(C=1)=CC=CC=1CN1CCCC1 VFOKSTCIRGDTBR-UHFFFAOYSA-N 0.000 description 1
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- PGFQDLOMDIBAPY-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C(C(F)(F)F)=C1 PGFQDLOMDIBAPY-UHFFFAOYSA-N 0.000 description 1
- BOCATKBAKISRLA-UHFFFAOYSA-N 4-propyl-5-pyridin-4-yl-3h-1,3-oxazol-2-one Chemical compound N1C(=O)OC(C=2C=CN=CC=2)=C1CCC BOCATKBAKISRLA-UHFFFAOYSA-N 0.000 description 1
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 description 1
- LGWACEZVCMBSKW-UHFFFAOYSA-N 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine Chemical compound CC1(C)OCCN(C2=N3)C1=NC2=C(N1CCOCC1)N=C3C1=CN=C(N)N=C1 LGWACEZVCMBSKW-UHFFFAOYSA-N 0.000 description 1
- BBLXLHYPDOMJMO-UHFFFAOYSA-N 5-(butan-2-ylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound CCC(C)NS(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(F)C(F)=CC=2)=C1 BBLXLHYPDOMJMO-UHFFFAOYSA-N 0.000 description 1
- AKKCGLXULFRAET-UHFFFAOYSA-N 5-[7-methyl-6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]pyrimidin-2-amine Chemical compound S1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2C(C)=C1CN1CCN(S(C)(=O)=O)CC1 AKKCGLXULFRAET-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- MNWOBDDXRRBONM-UHFFFAOYSA-N 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]triazole-4-carboxamide;2,4-dioxo-1h-pyrimidine-6-carboxylic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1.NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 MNWOBDDXRRBONM-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- TZDZANYHAKEIKU-UHFFFAOYSA-N 5-fluoro-1h-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=C(F)C=CC2=C1N=CN2 TZDZANYHAKEIKU-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- XWHARLVGMNPKNZ-UHFFFAOYSA-N 6-N-cyclopropyl-2-N-quinolin-6-yl-7H-purine-2,6-diamine methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C1CC1Nc1nc(Nc2ccc3ncccc3c2)nc2nc[nH]c12 XWHARLVGMNPKNZ-UHFFFAOYSA-N 0.000 description 1
- UBLOHCIYTDRGJH-UHFFFAOYSA-N 6-[2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-4-oxoquinazolin-5-yl]-n,n-bis(2-methoxyethyl)hex-5-ynamide Chemical compound C=1C=CC=C(Cl)C=1CN1C(=O)C=2C(C#CCCCC(=O)N(CCOC)CCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC=CC(O)=C1 UBLOHCIYTDRGJH-UHFFFAOYSA-N 0.000 description 1
- SSZHESNDOMBSRV-UHFFFAOYSA-N 6-amino-2-(butylamino)-9-[[6-[2-(dimethylamino)ethoxy]pyridin-3-yl]methyl]-7h-purin-8-one Chemical compound C12=NC(NCCCC)=NC(N)=C2NC(=O)N1CC1=CC=C(OCCN(C)C)N=C1 SSZHESNDOMBSRV-UHFFFAOYSA-N 0.000 description 1
- LFMPVTVPXHNXOT-HNNXBMFYSA-N 6-amino-2-[(2s)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7h-purin-8-one Chemical compound C12=NC(O[C@@H](C)CCC)=NC(N)=C2NC(=O)N1CCCCCN1CCCCC1 LFMPVTVPXHNXOT-HNNXBMFYSA-N 0.000 description 1
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- QYORNABIQXMJPL-UHFFFAOYSA-N 6-fluoro-1h-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC(F)=CC2=C1N=CN2 QYORNABIQXMJPL-UHFFFAOYSA-N 0.000 description 1
- BRBZPYDLUUWBCD-UHFFFAOYSA-N 7-(2-chloro-6-fluorophenyl)-5-(4-chlorophenyl)-1,5,6,7-tetrahydrotetrazolo[1,5-a]pyrimidine Chemical compound FC1=CC=CC(Cl)=C1C1N2NN=NC2=NC(C=2C=CC(Cl)=CC=2)C1 BRBZPYDLUUWBCD-UHFFFAOYSA-N 0.000 description 1
- NKTOUOPYSOOYCV-UHFFFAOYSA-N 7-(trifluoromethyl)-3H-benzimidazole-4-carboxylic acid Chemical compound FC(C1=CC=C(C=2NC=NC=21)C(=O)O)(F)F NKTOUOPYSOOYCV-UHFFFAOYSA-N 0.000 description 1
- KUWZSNDZDDLPCS-UHFFFAOYSA-N 7-chloro-3H-benzimidazole-4-carboxylic acid Chemical compound ClC1=CC=C(C=2NC=NC=21)C(=O)O KUWZSNDZDDLPCS-UHFFFAOYSA-N 0.000 description 1
- FATBAZTVZWUQEB-UHFFFAOYSA-N 7-fluoro-3H-benzimidazole-4-carboxylic acid Chemical compound FC1=CC=C(C=2NC=NC=21)C(=O)O FATBAZTVZWUQEB-UHFFFAOYSA-N 0.000 description 1
- YEAHTLOYHVWAKW-UHFFFAOYSA-N 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one Chemical compound C1=CC(OC)=CC=C1COC(C(=C1)OC)=CC2=C1C1=CC=C(C(C)O)C=C1C(=O)O2 YEAHTLOYHVWAKW-UHFFFAOYSA-N 0.000 description 1
- LMJFJIDLEAWOQJ-CQSZACIVSA-N 8-[(1r)-1-(3,5-difluoroanilino)ethyl]-n,n-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide Chemical compound N([C@H](C)C=1C2=C(C(C=C(O2)N2CCOCC2)=O)C=C(C=1)C(=O)N(C)C)C1=CC(F)=CC(F)=C1 LMJFJIDLEAWOQJ-CQSZACIVSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ACCFLVVUVBJNGT-AWEZNQCLSA-N 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2s)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN1C(=O)N(C[C@H](C)OC)C(C2=C3)=C1C=NC2=CC=C3C1=CN=CC(C(C)(C)O)=C1 ACCFLVVUVBJNGT-AWEZNQCLSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- JXQUAHHUSMJUFV-HZPZRMRQSA-N 9-[2-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1([C@@H]2CCO[P@](O2)(=O)COCCN2C=3N=CN=C(C=3N=C2)N)=CC=CC(Cl)=C1 JXQUAHHUSMJUFV-HZPZRMRQSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 1
- 229960005531 AMG 319 Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 1
- 108010083528 Adenylate Cyclase Toxin Proteins 0.000 description 1
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 description 1
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 208000015338 Autoimmune hepatitis type 1 Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229940124527 BI 224436 Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- PKWRMUKBEYJEIX-DXXQBUJASA-N Birinapant Chemical compound CN[C@@H](C)C(=O)N[C@@H](CC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(C2=C(C3=CC=C(F)C=C3N2)C[C@H]2N(C[C@@H](O)C2)C(=O)[C@H](CC)NC(=O)[C@H](C)NC)NC2=CC(F)=CC=C12 PKWRMUKBEYJEIX-DXXQBUJASA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910014263 BrF3 Inorganic materials 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- TYWQVEFAASFDMO-UHFFFAOYSA-O CC(NCCC(CNC(C)=O)S)=O.O[S+]=O Chemical compound CC(NCCC(CNC(C)=O)S)=O.O[S+]=O TYWQVEFAASFDMO-UHFFFAOYSA-O 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 241001200905 Carpilius corallinus Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108010040512 Clupeine Proteins 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940124901 Comvax Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 229940124721 DTP-Hib-HBV vaccine Drugs 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- ZINBFGBAIFRYSH-UHFFFAOYSA-N Demethoxyviridin Natural products CC12C(O)C(O)C(=O)c3coc(C(=O)c4c5CCC(=O)c5ccc14)c23 ZINBFGBAIFRYSH-UHFFFAOYSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- 101100223822 Dictyostelium discoideum zfaA gene Proteins 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- ZPLVYYNMRMBNGE-UHFFFAOYSA-N Eponemycin Natural products CC(C)CCCCC(=O)NC(CO)C(=O)NC(CC(C)=C)C(=O)C1(CO)CO1 ZPLVYYNMRMBNGE-UHFFFAOYSA-N 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108700038635 Euvax-B Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101000588031 Heliothis armigera entomopoxvirus Spindolin Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000848255 Homo sapiens Acyl-CoA 6-desaturase Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- GNWHRHGTIBRNSM-UHFFFAOYSA-N IC-87114 Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)C=CC=C2N=C1CN1C2=NC=NC(N)=C2N=C1 GNWHRHGTIBRNSM-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 1
- 101710205775 Inducible T-cell costimulator Proteins 0.000 description 1
- 229940124915 Infanrix Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- MCPUZZJBAHRIPO-UHFFFAOYSA-N Lersivirine Chemical compound CCC1=NN(CCO)C(CC)=C1OC1=CC(C#N)=CC(C#N)=C1 MCPUZZJBAHRIPO-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- PSPFQEBFYXJZEV-UHFFFAOYSA-N N'-(1,8-dimethyl-4-imidazo[1,2-a]quinoxalinyl)ethane-1,2-diamine Chemical compound C1=C(C)C=C2N3C(C)=CN=C3C(NCCN)=NC2=C1 PSPFQEBFYXJZEV-UHFFFAOYSA-N 0.000 description 1
- LQVZVAUEYQBXFV-ZDUSSCGKSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-2-[(2S)-pyrrolidin-2-yl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ClC=1C=C(C=CC=1F)NC(=NO)C1=C2C(=NC=C1)N=C(N2)[C@H]1NCCC1 LQVZVAUEYQBXFV-ZDUSSCGKSA-N 0.000 description 1
- FKRNSKFRDNVLRO-UHFFFAOYSA-N N'-(3-chlorophenyl)-2-[(cyclopropylmethylamino)methyl]-6,7-difluoro-N-hydroxy-3H-benzimidazole-4-carboximidamide Chemical compound ClC=1C=C(C=CC=1)NC(=NO)C1=CC(=C(C2=C1NC(=N2)CNCC1CC1)F)F FKRNSKFRDNVLRO-UHFFFAOYSA-N 0.000 description 1
- IAGGEPKQKNWHFJ-UHFFFAOYSA-N N'-(3-ethynylphenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound C(#C)C=1C=C(C=CC=1)NC(=NO)C1=C2C(=NC=C1)N=CN2 IAGGEPKQKNWHFJ-UHFFFAOYSA-N 0.000 description 1
- RFDADYIXKFYXKX-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-6,7-difluoro-2-(2-morpholin-4-ylethylamino)-3H-benzimidazole-4-carboxamide Chemical compound ClC=1C=C(C=CC=1F)NC(=O)C1=CC(=C(C2=C1NC(=N2)NCCN1CCOCC1)F)F RFDADYIXKFYXKX-UHFFFAOYSA-N 0.000 description 1
- PXRQDOLEHFGTKM-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-6,7-difluoro-3H-benzimidazole-4-carboxamide Chemical compound ClC=1C=C(C=CC=1F)NC(=O)C1=CC(=C(C2=C1NC=N2)F)F PXRQDOLEHFGTKM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- QJTLLKKDFGPDPF-QGZVFWFLSA-N N-[8-[(2R)-2-hydroxy-3-morpholin-4-ylpropoxy]-7-methoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]-2-methylpyridine-3-carboxamide Chemical compound CC1=C(C=CC=N1)C(=O)N=C2N=C3C(=C4N2CCN4)C=CC(=C3OC)OC[C@@H](CN5CCOCC5)O QJTLLKKDFGPDPF-QGZVFWFLSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- IAEFDUKKCAAVKA-UHFFFAOYSA-N N-hydroxy-N'-[3-(trifluoromethoxy)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC(=CC=C1)OC(F)(F)F)C1=C2C(=NC=C1)N=CN2 IAEFDUKKCAAVKA-UHFFFAOYSA-N 0.000 description 1
- VQOIBGMVZHSQIP-UHFFFAOYSA-N N-hydroxy-N'-naphthalen-2-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC2=CC=CC=C2C=C1)C1=C2C(=NC=C1)N=CN2 VQOIBGMVZHSQIP-UHFFFAOYSA-N 0.000 description 1
- IGNQGHGGSKLCSA-UHFFFAOYSA-N N-hydroxy-N'-phenyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide Chemical compound ON=C(NC1=CC=CC=C1)C1=C2C(=NC=C1)N=CN2 IGNQGHGGSKLCSA-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- RCOVTDPDGVXQIK-UHFFFAOYSA-M O.O.O.[Na+].[O-]S(=O)CCCCS Chemical compound O.O.O.[Na+].[O-]S(=O)CCCCS RCOVTDPDGVXQIK-UHFFFAOYSA-M 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- TUVCWJQQGGETHL-UHFFFAOYSA-N PI-103 Chemical compound OC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 TUVCWJQQGGETHL-UHFFFAOYSA-N 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 239000012648 POLY-ICLC Substances 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 108700033496 Recombivax HB Proteins 0.000 description 1
- 229940124942 Recombivax HB Drugs 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
- 108010090287 SCY-635 Proteins 0.000 description 1
- 108010040181 SF 1126 Proteins 0.000 description 1
- 101150036449 SIRPA gene Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010084296 T2635 peptide Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- MSLJYSGFUMYUDX-UHFFFAOYSA-N Trimidox Chemical compound ON=C(N)C1=CC(O)=C(O)C(O)=C1 MSLJYSGFUMYUDX-UHFFFAOYSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 229940124922 Twinrix Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
- SCTJKHUUZLXJIP-RUZDIDTESA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OCCCOCCCCCCCCCCCCCCCC)C=NC2=C1N SCTJKHUUZLXJIP-RUZDIDTESA-N 0.000 description 1
- JHXLLEDIXXOJQD-VBWFMVIDSA-N [(2r)-2-decoxy-3-dodecylsulfanylpropyl] [(2r,3s,5r)-3-fluoro-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate Chemical compound C1[C@H](F)[C@@H](COP(O)(=O)OC[C@H](CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 JHXLLEDIXXOJQD-VBWFMVIDSA-N 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- MPSGQQOHTJUJKB-QUBYGPBYSA-N [(2r,5r)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethylphosphonic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](OCP(O)(O)=O)C=C1F MPSGQQOHTJUJKB-QUBYGPBYSA-N 0.000 description 1
- WXJFKKQWPMNTIM-VWLOTQADSA-N [(2s)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid Chemical compound CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O WXJFKKQWPMNTIM-VWLOTQADSA-N 0.000 description 1
- IBHARWXWOCPXCR-WELGVCPWSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](COP(O)(=O)OCC(CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 IBHARWXWOCPXCR-WELGVCPWSA-N 0.000 description 1
- FJAOCNGVPLTSLD-NKWVEPMBSA-N [(2s,5r)-5-(2-amino-6-methoxypurin-9-yl)oxolan-2-yl]methanol Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@H]1CC[C@@H](CO)O1 FJAOCNGVPLTSLD-NKWVEPMBSA-N 0.000 description 1
- BINXAIIXOUQUKC-UIPNDDLNSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 BINXAIIXOUQUKC-UIPNDDLNSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- KDNSSKPZBDNJDF-UHFFFAOYSA-N [1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid Chemical compound C12=NC(N)=NC=C2N=CN1CC1(OCP(O)(O)=O)CC1 KDNSSKPZBDNJDF-UHFFFAOYSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- VJLRLTSXTLICIR-UHFFFAOYSA-N [8-[6-amino-5-(trifluoromethyl)pyridin-3-yl]-1-[6-(2-cyanopropan-2-yl)pyridin-3-yl]-3-methylimidazo[4,5-c]quinolin-2-ylidene]cyanamide Chemical compound N#CN=C1N(C)C2=CN=C3C=CC(C=4C=C(C(N)=NC=4)C(F)(F)F)=CC3=C2N1C1=CC=C(C(C)(C)C#N)N=C1 VJLRLTSXTLICIR-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000030002 adult glioblastoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- QNWVQSLLLTZQPH-VIIPOJRNSA-N albuvirtide Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN1C(C=CC1=O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 QNWVQSLLLTZQPH-VIIPOJRNSA-N 0.000 description 1
- 108010011303 albuvirtide Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 108010058359 alisporivir Proteins 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 229950004424 alovudine Drugs 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 229950005846 amdoxovir Drugs 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000002095 anti-migrative effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229950006356 aplaviroc Drugs 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 229950003870 astodrimer Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 208000018093 autoimmune cholangitis Diseases 0.000 description 1
- 208000027841 autoimmune hepatitis type 2 Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- 229950003269 bectumomab Drugs 0.000 description 1
- ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229950002782 besifovir Drugs 0.000 description 1
- YJEJKUQEXFSVCJ-WRFMNRASSA-N bevirimat Chemical compound C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C YJEJKUQEXFSVCJ-WRFMNRASSA-N 0.000 description 1
- 229950002892 bevirimat Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 108010063132 birinapant Proteins 0.000 description 1
- 229950004237 birinapant Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229950002903 bivatuzumab Drugs 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229950009079 brecanavir Drugs 0.000 description 1
- JORVRJNILJXMMG-OLNQLETPSA-N brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- 229960005539 bryostatin 1 Drugs 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 1
- NIDRYBLTWYFCFV-UHFFFAOYSA-N calanolide F Natural products C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 1
- 229950008230 capravirine Drugs 0.000 description 1
- 229940124765 capsid inhibitor Drugs 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 229960000730 caspofungin acetate Drugs 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 description 1
- 229950011033 cenicriviroc Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- QETUKYDWZIRTEI-QUMGSSFMSA-N chembl1649931 Chemical compound C1([C@@H](NC(C)=O)CCN2[C@@H]3CC[C@H]2C[C@H](C3)N2C(C)=NC3=C2CCN(C3)C(=O)C(C)C)=CC=CC(F)=C1 QETUKYDWZIRTEI-QUMGSSFMSA-N 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 description 1
- 229960002402 cobicistat Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229950002550 copanlisib Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010089438 cryptophycin 1 Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- AMHIJMKZPBMCKI-PKLGAXGESA-N ctds Chemical compound O[C@@H]1[C@@H](OS(O)(=O)=O)[C@@H]2O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@H](CO)[C@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O[C@@H](O[C@@H]1CO)[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O2 AMHIJMKZPBMCKI-PKLGAXGESA-N 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- SWJBYJJNDIXFSA-KUHUBIRLSA-N demethoxyviridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@]2(C)C3=C1OC=C3C(=O)C[C@H]2O SWJBYJJNDIXFSA-KUHUBIRLSA-N 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 229950008962 detumomab Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000004427 diamine group Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- PFWDHRASWSUTIA-KAFJHEIMSA-L disodium;(2s)-5-amino-5-oxo-2-[(2-phenylacetyl)amino]pentanoate;2-phenylacetate Chemical compound [Na+].[Na+].[O-]C(=O)CC1=CC=CC=C1.NC(=O)CC[C@@H](C([O-])=O)NC(=O)CC1=CC=CC=C1 PFWDHRASWSUTIA-KAFJHEIMSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 229960002542 dolutegravir Drugs 0.000 description 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229950009964 drozitumab Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229950011453 dusigitumab Drugs 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229960003586 elvitegravir Drugs 0.000 description 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 description 1
- 229950006528 elvucitabine Drugs 0.000 description 1
- MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
- 229950002002 emivirine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229950010640 ensituximab Drugs 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229950002189 enzastaurin Drugs 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- ZPLVYYNMRMBNGE-TWOQFEAHSA-N eponemycin Chemical compound CC(C)CCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)=C)C(=O)[C@@]1(CO)CO1 ZPLVYYNMRMBNGE-TWOQFEAHSA-N 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- 208000019091 erythema multiforme major Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- SQGRDKSRFFUBBU-UHFFFAOYSA-N ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholin-4-ylmethyl)-2-(1,3-thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate Chemical compound N1C(C=2SC=CN=2)=NC(C=2C(=CC(F)=CC=2)Br)C(C(=O)OCC)=C1CN1CCOCC1 SQGRDKSRFFUBBU-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- QUIWHXQETADMGN-UHFFFAOYSA-N evobrutinib Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C=1C(N)=NC=NC=1NCC1CCN(C(=O)C=C)CC1 QUIWHXQETADMGN-UHFFFAOYSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229950002846 ficlatuzumab Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229950010320 flanvotumab Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229950003232 fosalvudine tidoxil Drugs 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 229950011117 fozivudine tidoxil Drugs 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229950002140 futuximab Drugs 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229950008209 gedatolisib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229950002026 girentuximab Drugs 0.000 description 1
- 229950000918 glembatumumab Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010085930 heberbiovac-HB Proteins 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 229940065376 hepagam b Drugs 0.000 description 1
- 108010050151 hepatitis B hyperimmune globulin Proteins 0.000 description 1
- 108700025184 hepatitis B virus X Proteins 0.000 description 1
- 229940036107 hepatitis b immunoglobulin Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 108010034964 igantibe Proteins 0.000 description 1
- 229950002200 igovomab Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108700043043 inosine glycyl-cysteinyl-glutamate disodium Proteins 0.000 description 1
- 229950000038 interferon alfa Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000009384 kangtai Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 108010075606 kynostatin 272 Proteins 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 229940035824 lymphoma vaccine Drugs 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 229950002475 mesilate Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- FVNJBPMQWSIGJK-HNNXBMFYSA-N methyl (4r)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate Chemical compound C1([C@@H]2N=C(NC(C)=C2C(=O)OC)C=2C(=CC(F)=CN=2)F)=CC=C(F)C=C1Cl FVNJBPMQWSIGJK-HNNXBMFYSA-N 0.000 description 1
- QRMNENFZDDYDEF-GOSISDBHSA-N methyl (8s)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-1-carboxylate Chemical compound C1([C@H](CBr)CN(C1=C1)C(=O)C=2NC3=C(OC)C(OC)=C(OC)C=C3C=2)=C2C(C(=O)OC)=C(C)NC2=C1OC(=O)N1CCN(C)CC1 QRMNENFZDDYDEF-GOSISDBHSA-N 0.000 description 1
- FEFIBEHSXLKJGI-UHFFFAOYSA-N methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7h-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate Chemical compound C12=NC(OCCCC)=NC(N)=C2NC(=O)N1CCCN(CC=1C=C(CC(=O)OC)C=CC=1)CCCN1CCOCC1 FEFIBEHSXLKJGI-UHFFFAOYSA-N 0.000 description 1
- ULABTQKXRQJVDY-UHFFFAOYSA-N methyl 2-formamido-4-(trifluoromethoxy)benzoate Chemical compound C(=O)NC1=C(C(=O)OC)C=CC(=C1)OC(F)(F)F ULABTQKXRQJVDY-UHFFFAOYSA-N 0.000 description 1
- WZXHBDXBEANBCB-UHFFFAOYSA-N methyl 3-amino-4,5-difluoro-2-nitrobenzoate Chemical compound NC=1C(=C(C(=O)OC)C=C(C=1F)F)[N+](=O)[O-] WZXHBDXBEANBCB-UHFFFAOYSA-N 0.000 description 1
- GPMSTDWXXKAKCT-UHFFFAOYSA-N methyl 3-amino-4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C(N)=C1 GPMSTDWXXKAKCT-UHFFFAOYSA-N 0.000 description 1
- KHGLCBLRFVACBI-UHFFFAOYSA-N methyl 3-amino-4-fluoro-2-nitrobenzoate Chemical compound NC=1C(=C(C(=O)OC)C=CC=1F)[N+](=O)[O-] KHGLCBLRFVACBI-UHFFFAOYSA-N 0.000 description 1
- VWAXPEIKSDVOLN-UHFFFAOYSA-N methyl 3-amino-5-chloro-2-nitrobenzoate Chemical compound COC(=O)C1=CC(Cl)=CC(N)=C1[N+]([O-])=O VWAXPEIKSDVOLN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- KHASNRBNVBIREH-IZEXYCQBSA-N methyl n-[(2s)-1-[[(5s)-5-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-6-phosphonooxyhexyl]amino]-1-oxo-3,3-diphenylpropan-2-yl]carbamate Chemical compound C=1C=CC=CC=1C([C@H](NC(=O)OC)C(=O)NCCCC[C@@H](COP(O)(O)=O)N(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)C1=CC=CC=C1 KHASNRBNVBIREH-IZEXYCQBSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- WOUUWUGULFOVHG-UHFFFAOYSA-N mivotilate Chemical compound S1CSC1=C(C(=O)OC(C)C)C(=O)NC1=NC(C)=CS1 WOUUWUGULFOVHG-UHFFFAOYSA-N 0.000 description 1
- 229950008403 mivotilate Drugs 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- 229950008798 mozenavir Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000001538 myasthenic effect Effects 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- LNLJHGXOFYUARS-OAQYLSRUSA-N n-[(1r)-1-[8-chloro-2-(1-oxidopyridin-1-ium-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl]pyrido[3,2-d]pyrimidin-4-amine Chemical compound [O-][N+]1=CC=CC(C=2C(=CC3=CC=CC(Cl)=C3N=2)[C@@H](NC=2C3=NC=CC=C3N=CN=2)C(F)(F)F)=C1 LNLJHGXOFYUARS-OAQYLSRUSA-N 0.000 description 1
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 description 1
- OQGRFQCUGLKSAV-JTQLQIEISA-N n-[(3s)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide Chemical compound N([C@@H]1C(NC(=O)CC1)=O)C(=O)CC1=CC=CC=C1 OQGRFQCUGLKSAV-JTQLQIEISA-N 0.000 description 1
- DPHPCLGZSLZAGL-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-(2-methylpropyl)-2-(1,3-thiazol-2-yl)-1,3-thiazole-4-carboxamide Chemical compound CC(C)CC=1SC(C=2SC=CN=2)=NC=1C(=O)NCC1=CC=C(F)C=C1 DPHPCLGZSLZAGL-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GDCJHDUWWAKBIW-UHFFFAOYSA-N n-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1C1=CC=C(NS(=O)(=O)CCN(C)C)C=C1 GDCJHDUWWAKBIW-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940060932 nabi-hb Drugs 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229950008353 narnatumab Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229940109551 nipent Drugs 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 208000028780 ocular motility disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229950004852 panulisib Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229950004260 parsatuzumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950010966 patritumab Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 229930195126 picroside Natural products 0.000 description 1
- KEUKDVIGAVVGLF-RUYHYXBRSA-N picroside I Natural products OC[C@]12O[C@H]1[C@@H]3O[C@@H](O[C@@H]4O[C@H](COC(=O)C=Cc5ccccc5)[C@@H](O)[C@H](O)[C@H]4O)C=C[C@@H]3[C@H]2O KEUKDVIGAVVGLF-RUYHYXBRSA-N 0.000 description 1
- AKNILCMFRRDTEY-UHFFFAOYSA-N picroside II Natural products C1=C(O)C(OC)=CC(C(=O)OC2C3C(C(OC=C3)OC3C(C(O)C(O)C(CO)O3)O)C3(CO)OC32)=C1 AKNILCMFRRDTEY-UHFFFAOYSA-N 0.000 description 1
- 229950004941 pictilisib Drugs 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229950005769 pilaralisib Drugs 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229940072689 plaquenil Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 108700002563 poly ICLC Proteins 0.000 description 1
- 229940115270 poly iclc Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- ZVIWEYTXPYNLGB-UHFFFAOYSA-M potassium;4-[[2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]-3-chlorobenzoate Chemical compound [K+].ClC1=CC(C(=O)[O-])=CC=C1NC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 ZVIWEYTXPYNLGB-UHFFFAOYSA-M 0.000 description 1
- 229950001452 pradefovir Drugs 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XEABSBMNTNXEJM-UHFFFAOYSA-N propagermanium Chemical compound OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O XEABSBMNTNXEJM-UHFFFAOYSA-N 0.000 description 1
- 229950002828 propagermanium Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 150000003243 quercetin Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 229950011613 racotumomab Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 229950011639 radretumab Drugs 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108700018720 recombinant interferon alpha 2b-like Proteins 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 229950006764 rigosertib Drugs 0.000 description 1
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 description 1
- VLQLUZFVFXYXQE-USRGLUTNSA-M rigosertib sodium Chemical compound [Na+].COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC([O-])=O)=C1 VLQLUZFVFXYXQE-USRGLUTNSA-M 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
- OCJRRXHWPBXZSU-BNCZGPJRSA-N rovafovir etalafenamide Chemical compound O([P@@](=O)(CO[C@@H]1C=C(F)[C@@H](O1)N1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OCC)C1=CC=CC=C1 OCJRRXHWPBXZSU-BNCZGPJRSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 108010048106 sifuvirtide Proteins 0.000 description 1
- WIOOVJJJJQAZGJ-ISHQQBGZSA-N sifuvirtide Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CO)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 WIOOVJJJJQAZGJ-ISHQQBGZSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 229950011267 solitomab Drugs 0.000 description 1
- 229950007865 sonolisib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229950002089 spebrutinib Drugs 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950001269 taselisib Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- 229950010259 teprotumumab Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 229950001139 timonacic Drugs 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229950009860 vicriviroc Drugs 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 229950006959 vorsetuzumab Drugs 0.000 description 1
- 229950003511 votumumab Drugs 0.000 description 1
- OGUJBRYAAJYXQP-IJFZAWIJSA-N vuw370o5qe Chemical compound CC(O)=O.CC(O)=O.C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OGUJBRYAAJYXQP-IJFZAWIJSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present disclosure relates generally to inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) activity and their use and manufacture thereof.
- IDO1 indoleamine 2,3-dioxygenase 1
- IDO1 indoleamine 2,3-dioxygenase 1
- IDO1 catalyzes the degradation of tryptophan to kynurenine, and its effects on immune suppression are due to decreased tryptophan availability and the generation of tryptophan metabolites resulting in multipronged negative effects on cytotoxic T lymphocytes, as well as expansion of immunosuppressive regulatory T cells.
- IDO1 is elevated in multiple cancers, is induced by chemotherapy, targeted therapy, or immunotherapy. IDO1 expression in the tumor microenvironment is correlated with poor prognosis in a variety of cancers.
- IDO1 inhibitors are positioned to potentiate the efficacy of multiple oncology therapeutics including immunotherapies, targeted agents, and chemotherapies. Indeed, epacadostat (INCB24360), a potent and selective IDO1 inhibitor, entered clinical trials and is demonstrating activity in combination with ipilimumab (anti-CTLA4) in melanoma.
- epacadostat ICCB24360
- anti-CTLA4 ipilimumab
- IDO1 has been shown to play a role in chronic infections, HIV and AIDS, autoimmune diseases or disorders (e.g., rheumatoid arthritis), and immunologic tolerance, prevention of fetal rejection in utero. Inhibition of IDO1 may also be an important treatment strategy for patients with neurological or neuropsychiatric diseases or disorders, such as depression.
- WO2015/002918 and WO2014/159248 disclose heteroaryl compounds having activity as inhibitors of indoleamine 2,3-dioxygenase.
- the present disclosure provides compounds that function as inhibitors of IDO1.
- the disclosure also provides compositions, including pharmaceutical compositions, kits that include the compounds, and methods of making the compounds.
- the compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated by IDO1.
- the disclosure also provides compounds for use in therapy.
- the disclosure further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated by IDO1.
- the disclosure provides uses of the compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by IDO1.
- Some embodiments provide the compounds of formula I for use in the treatment of a disease or condition in a mammal, particularly a human, that is amenable to treatment by an IDO1 inhibitor.
- the disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of the disclosure (e.g. a compound of Formula I), and at least one pharmaceutically acceptable excipient.
- a compound of the disclosure e.g. a compound of Formula I
- at least one pharmaceutically acceptable excipient e.g. a compound of Formula I
- a dash (“-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH 2 is attached through the carbon atom.
- a dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning.
- a wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.
- C u-v indicates that the following group has from u to v carbon atoms.
- C 1-6 alkyl indicates that the alkyl group has from 1 to 6 carbon atoms.
- references to "about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
- the term “about” includes the indicated amount ⁇ 10%.
- the term “about” includes the indicated amount ⁇ 5%.
- the term “about” includes the indicated amount ⁇ 1%.
- to the term “about X” includes description of "X”.
- the singular forms "a” and “the” include plural references unless the context clearly dictates otherwise.
- reference to “the compound” includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art.
- alkyl refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms ( i.e., C 1-20 alkyl), 1 to 8 carbon atoms ( i.e ., C 1-8 alkyl), 1 to 6 carbon atoms ( i.e ., C 1-6 alkyl), or 1 to 4 carbon atoms ( i.e ., C 1-4 alkyl).
- alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl.
- alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, "butyl” includes n-butyl (i.e.
- Alkenyl refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms ( i.e ., C 2-20 alkenyl), 2 to 8 carbon atoms ( i.e ., C 2-8 alkenyl), 2 to 6 carbon atoms ( i.e ., C 2-6 alkenyl), or 2 to 4 carbon atoms ( i.e ., C 2-4 alkenyl).
- alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).
- Alkynyl refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms ( i.e ., C 2-20 alkynyl), 2 to 8 carbon atoms ( i.e ., C 2-8 alkynyl), 2 to 6 carbon atoms ( i.e ., C 2-6 alkynyl), or 2 to 4 carbon atoms ( i.e ., C 2-4 alkynyl).
- alkynyl also includes those groups having one triple bond and one double bond.
- Alkoxy refers to the group “alkyl-O-”. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.
- Hydroalkoxy refers to an alkoxy group as defined above, wherein one or more hydrogen atoms are replaced by a halogen.
- R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
- Examples of acyl include formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.
- Amino refers to the group -NR y R z wherein R y and R z are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, or heteroaryl; each of which may be optionally substituted.
- Aryl refers to an aromatic carbocyclic group having a single ring (e.g. monocyclic) or multiple rings (e.g. bicyclic or tricyclic) including fused systems.
- aryl has 6 to 20 ring carbon atoms ( i.e ., C 6-20 aryl), 6 to 12 carbon ring atoms ( i.e ., C 6-2 aryl), or 6 to 10 carbon ring atoms ( i.e ., C 6-10 aryl).
- Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl.
- Aryl does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl.
- Cycloalkyl refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems.
- cycloalkyl includes cycloalkenyl groups (i.e. the cyclic group having at least one double bond).
- cycloalkyl has from 3 to 20 ring carbon atoms ( i.e ., C 3-20 cycloalkyl), 3 to 12 ring carbon atoms ( i.e ., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms ( i.e ., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms ( i.e ., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms ( i.e ., C 3-6 cycloalkyl).
- Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- Halogen or “halo” includes fluoro, chloro, bromo, and iodo.
- Haloalkyl refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached.
- Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two ("di") or three (“tri") halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (-CHF 2 ) and trifluoromethyl (-CF 3 ).
- Heteroalkyl refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group.
- the term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group.
- Heteroatomic groups include, but are not limited to, -NR-, -O-, -S-, -S(O)-, - S(O) 2 -, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted.
- heteroalkyl groups include -OCH 3 , -CH 2 OCH 3 , -SCH 3 , -CH 2 SCH 3 , -NRCH 3 , and -CH 2 NRCH 3 , where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted.
- heteroalkyl include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
- Heteroaryl refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- heteroaryl include 1 to 20 ring carbon atoms ( i.e ., C 1-20 heteroaryl), 3 to 12 ring carbon atoms ( i.e ., C 3-12 heteroaryl), or 3 to 8 carbon ring atoms ( i.e ., C 3-8 heteroaryl); and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur.
- heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl.
- Heteroaryl does not encompass or overlap with aryl as defined above.
- Heterocyclyl or “heterocyclic ring” refers to an unsaturated non-aromatic cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur.
- heterocyclyl or “heterocyclic ring” refers to rings that are saturated or partially saturated unless otherwise indicated, e.g., in some embodiments “heterocyclyl” or “heterocyclic ring” refers to rings that are partially saturated where specified.
- the term “heterocyclyl” or “heterocyclic ring” includes heterocycloalkenyl groups ( i.e ., the heterocyclyl group having at least one double bond).
- a heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro.
- heterocyclyl has 2 to 20 ring carbon atoms ( i.e., C 2-20 heterocyclyl), 2 to 12 ring carbon atoms ( i.e ., C 2-12 heterocyclyl), 2 to 10 ring carbon atoms ( i.e ., C 2-10 heterocyclyl), 2 to 8 ring carbon atoms ( i.e ., C 2-8 heterocyclyl), 3 to 12 ring carbon atoms ( i.e ., C 3-12 heterocyclyl), 3 to 8 ring carbon atoms ( i.e ., C 3-8 heterocyclyl), or 3 to 6 ring carbon atoms ( i.e ., C 3-6 heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, 1
- heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl.
- bridged- heterocyclyl refers to a four- to ten-membered cyclic moiety connected at two non-adjacent atoms of the heterocyclyl with one or more ( e.g ., 1 or 2) four- to ten-membered cyclic moiety having at least one heteroatom where each heteroatom is independently selected from nitrogen, oxygen, and sulfur.
- bridged-heterocyclyl includes bicyclic and tricyclic ring systems.
- spiro-heterocyclyl refers to a ring system in which a three- to ten-membered heterocyclyl has one or more additional ring, wherein the one or more additional ring is three- to ten-membered cycloalkyl or three- to ten-membered heterocyclyl, where a single atom of the one or more additional ring is also an atom of the three- to ten-membered heterocyclyl.
- spiro-heterocyclyl examples include bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl.
- Sulfonyl refers to the group -S(O) 2 R, where R is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
- a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc.
- a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc.
- combinations of groups are referred to herein as one moiety, e.g . arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
- substituted means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded.
- the one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof.
- impermissible substitution patterns e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms.
- impermissible substitution patterns are well known to the skilled artisan.
- substituted may describe other chemical groups defined herein.
- substituted aryl includes, but is not limited to, "alkylaryl.” Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.
- substituted alkyl refers to an alkyl group having one or more substituents including hydroxyl, halo, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
- substituted cycloalkyl refers to a cycloalkyl group having one or more substituents including alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl
- substituted heterocyclyl refers to a heterocyclyl group having one or more substituents including alkyl, haloalkyl, heterocyclyl, cycloalkyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl
- substituted aryl refers to an aryl group having one or more substituents including halo, alkyl, haloalkyl, cycloalkyl, heterocyclyl, heteroaryl, alkoxy, and cyano
- substituted heteroaryl refers to an heteroaryl group having one or more substituents including alkyl, haloalkyl, cycloalkyl, hetero
- the one or more substituents may be further substituted with halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted.
- the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.
- Tautomeric isomers are in equilibrium with one another.
- amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.
- any formula or structure given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
- Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I.
- isotopically labeled compounds of the present disclosure for example those into which radioactive isotopes such as 3 H, 13 C and 14 C are incorporated.
- isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- the disclosure also included compounds of Formula I in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule.
- Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound of Formula I when administered to a mammal, particularly a human. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12):524-527 (1984 ).
- Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
- Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index.
- An 18 F labeled compound may be useful for PET or SPECT studies.
- Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compound of Formula I.
- the concentration of such a heavier isotope, specifically deuterium may be defined by an isotopic enrichment factor.
- any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
- a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition.
- any atom specifically designated as a deuterium (D) is meant to represent deuterium.
- the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- pharmaceutically acceptable salt of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable.
- Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, mono, di or tri cycloalkyl amines, mono, di or tri arylamines or mixed amines, etc.
- primary, secondary and tertiary amines such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri
- Suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
- Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
- pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- Treatment is an approach for obtaining beneficial or desired results including clinical results.
- beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g ., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g ., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread ( e.g ., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g ., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
- a) inhibiting the disease or condition e.g ., decreasing one or more symptoms
- Prevention means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop.
- Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
- Subject refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications.
- the subject is a mammal. In one embodiment, the subject is a human.
- terapéuticaally effective amount or “effective amount” of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression.
- a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of IDO1 activity.
- the therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.
- inhibitors indicates a decrease in the baseline activity of a biological activity or process.
- Inhibition of activity of IDO1 or variants thereof refers to a decrease in activity in IDO1 as a direct or indirect response to the presence of a compound of the present application relative to the activity IDO1 in the absence of the compound of the present application.
- Inhibition of IDO1 refers to a decrease in IDO1 activity as a direct or indirect response to the presence of a compound described herein relative to the activity of IDO1 in the absence of the compound described herein.
- the inhibition of IDO1 activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment.
- R 1 is bicyclic aryl or heteroaryl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1 - 6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl, wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; and wherein each C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, -N(R 20 )(R 22 ), and C 3-6 cycloalkyl.
- R 1 is bicyclic aryl or heteroaryl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl.
- the compound is selected from the group consisting of:
- R 1 is phenyl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1 - 6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl, wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; and wherein each C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, -N(R 20 )(R 22 ), and C 3-6 cycloalkyl.
- R 1 is phenyl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, -CHF 2 , -O-CHF 2 , -CF 3 , -O-CF 3 , C 1 - 4 alkoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, and C 3-6 cycloalkyl, and wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring.
- R 2a , R 2b , and, when present, R 2c are not hydrogen.
- R 2a is not hydrogen.
- R 2b is not hydrogen.
- R 2c is not hydrogen.
- the compound is selected from the group consisting of:
- L is a bond
- R t is C 1-6 alkyl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO 2 , C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, -CN, and C 1-6 alkoxy.
- the compound is selected from the group consisting of:
- R t is C 3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein said cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO 2 , C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, -CN, C 1-6 alkoxy and C 1-6 alkyl.
- the compound is selected from the group consisting of:
- R t is hydrogen
- the compound is selected from the group consisting of:
- L is -NR 3 .
- R t is C 1-6 optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO 2 , C 1-6 haloalkyl, C 1-6 haloalkoxy, -N(R 20 )(R 22 ), -SO 2 R 20 , C 3-6 cycloalkyl, -CN, and C 1-6 alkoxy.
- the compound is selected from the group consisting of:
- L is -NR 3 and R t is C 3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein said cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO 2 , C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, -CN, and C 1-6 alkoxy.
- the compound is selected from the group consisting of:
- L is -NR 3 and R t is hydrogen.
- the compound is selected from the group consisting of:
- L is -SO 2 NR 3 -.
- the compound is selected from the group consisting of:
- X is -N-.
- X is -CR 2c -.
- the compound is selected from the group consisting of:
- L is -C(O)-NR 3 -.
- the compound is selected from the group consisting of:
- L is N, m is 1, and n is 0.
- L is N, m is 2, and n is 0.
- L is N, m is 3, and n is 0.
- the compound of Formula I is represented by Formula IA or IB:
- R 1 is selected from the group consiting of and
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of Formula I is represented by Formula II:
- the compound of Formula I is represented by Formula IIA or IIB:
- the compound of Formula I is represented by Formula III:
- the compound of Formula I is represented by Formula IV:
- the group of any Formula described herein is selected from the group consisting of hydrogen, (1-methylpiperidin-2-yl)methylamino, (1-methylpyrrolidin-3-yl)amino, (2-pyrimidin-2-ylethylamino)methyl, (2S)-pyrrolidin-2-yl, (isopropyloxycarbonyl)amino, (1,3-thiazol-2-ylmethylamino)methyl, 1H-imidazol-2-yl, 1H-pyrazol-5-yl, 1H-pyrrol-2-yl, 1-hydroxyethyl, 2-(2-methoxyethylamino)ethyl, 2-(diethylamino)ethyl, 2-(diethylamino)ethylamino, 2-(dimethylamino)-1-hydroxyethyl, 2-(dimethylamino)ethyl, 2-(dimethylamino)ethylamino, [2-(2-(2-
- the group of any Formula described herein is selected from the group consisting of: -H,
- the group of any Formula described herein is selected from the group consisting of: -H, -NH 2 ,
- the group of any Formula described herein is selected from the group consisting of: -NH 2 ,
- the compound of Formula I is represented by Formula IIA or IIB:
- each R 1a is independently hydroxyl, halo, -CN, C 1 - 6 haloalkoxy, or C 1-6 haloalkyl. In some embodiments, each R 1a is independently halo or - CF 3 . In some embodiments, each R 1a is independently halo. In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3.
- Example 10 the compound of Example 10 (shown below) may be referred to as N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide or N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide, where both names provide the structure below.
- Tautomeric isomers are in equilibrium with one another. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both.
- Non-limiting examples of benzimidazole and imidazo[4,5-b]pyridine tautomers are shown below:
- n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule.
- the deuterium atom is a non-radioactive isotope of the hydrogen atom.
- Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. See, e.g ., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984 ).
- Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
- “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
- “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid.
- the free base can be obtained by basifying a solution of the acid salt.
- an addition salt particularly a pharmaceutically acceptable addition salt
- a suitable organic solvent may be used to prepare nontoxic pharmaceutically acceptable addition salts.
- a “solvate” is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
- a “prodrug” is a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
- optical isomers, racemates, or other mixtures thereof of the compounds described herein or pharmaceutically acceptable salts or a mixture thereof can be obtained by asymmetric synthesis or by resolution of the racemate. Resolution of racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column.
- Z- and E- forms or cis- and trans- forms of the hydroxyamidine compounds described herein. Specifically, Z- and E- forms are included even if only one designation is named for both carbon-carbon double bonds as well as the hydroxyamidine bond.
- compositions provided herein that include a compound described herein or pharmaceutically acceptable salts, or a mixture thereof may include racemic mixtures, or mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein the same as if each and every isomeric form were specifically and individually listed.
- provided herein are also crystalline and amorphous forms of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof.
- chelates are also chelates, non-covalent complexes, and mixtures thereof, of the compounds described herein or pharmaceutically acceptable salts, or a mixture thereof.
- a "chelate” is formed by the coordination of a compound to a metal ion at two (or more) points.
- a “non-covalent complex” is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
- the methods described herein may be applied to cell populations in vivo or ex vivo.
- In vivo means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual.
- Ex vivo means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the invention may be used for a variety of purposes, including therapeutic and experimental purposes.
- the invention may be used ex vivo to determine the optimal schedule and/or dosing of administration of an IDOl inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the invention may be suited are described below or will become apparent to those skilled in the art.
- the selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.
- the compounds described herein may be used to treat subjects who have or are suspected of having disease states, disorders, and conditions (also collectively referred to as "indications") responsive or believed to be responsive to the inhibition of IDO1 activity.
- the compounds described herein may be used to inhibit the activity of an IDOl polypeptide.
- the compounds described herein may be used to inhibit excessive or destructive immune reactions or growth or a proliferation of a cell, such as a cancer cell, or inhibit immunosuppression.
- Example indications suitable for treatment with compounds described here include, without limitation cancer, viral infection such as HIV infection, HBV infection, HCV infection, other infections (e.g., skin infections, GI infection, urinary tract infections, genito-urinary infections, and systemic infections), depression, neurodegenerative disorders such as Alzheimer's disease and Huntington's disease, trauma, age-related cataracts, organ transplantation ( e.g ., organ transplant rejection), and autoimmune diseases.
- viral infection such as HIV infection, HBV infection, HCV infection
- other infections e.g., skin infections, GI infection, urinary tract infections, genito-urinary infections, and systemic infections
- depression e.g., neurodegenerative disorders such as Alzheimer's disease and Huntington's disease, trauma, age-related cataracts, organ transplantation (e.g ., organ transplant rejection), and autoimmune diseases.
- autoimmune diseases include, but are not limited to, asthma, collagen diseases such as rheumatoid arthritis, systemic lupus erythematosus. Sharp's syndrome, CREST syndrome (calcinosis, Raynaud's syndrome, esophageal dysmotility, sclerodactyly, telangiectasia), dermatomyositis, vasculitis (Morbus Wegener's) and Sjögren's syndrome, renal diseases such as Goodpasture's syndrome, rapidly- progressing glomerulonephritis and membrano-proliferative glomerulonephritis type II, endocrine diseases such as type-I diabetes, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), autoimmune parathyroidism, pernicious anemia, gonad insufficiency, idiopathic Morbus Addison's, hyperthyreosis, Hashimoto
- the compounds described herein may be used for treating cancer, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disease.
- the disease to be treated is a solid tumor.
- the solid tumor is from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma.
- the solid tumor is from non-small cell lung cancer, small-cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, or breast cancer..
- the disease is an autoimmune disease.
- the autoimmune disease is systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), psoriasis, Sjoegren's syndrome, psoriasis, autoimmune hemolytic anemia, asthma, or chronic obstructive pulmonary disease (COPD).
- the disease is inflammation.
- the disease is excessive or destructive immune reactions, such as asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), and lupus.
- a compound of formula I for use in a method for treating a subject, who has or is suspected of having a disease or condition responsive or believed to be responsive to the inhibition of IDO1 activity by administering to the subject the compound described herein or pharmaceutically acceptable salts, or a mixture thereof.
- a method of inhibiting kinase activity of a IDO1 polypeptide by contacting the polypeptide with the compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof.
- a compound of formula I for use in a method of inhibiting a growth or a proliferation of cancer cells of hematopoietic origin comprising contacting the cancer cells with an effective amount of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof.
- the compounds of the present application may be used in combination with one or more additional therapeutic agent that are being used and/or developed to treat cancers or inflammatory disorders.
- the one or more additional therapeutic agent may be a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti-proliferation agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof.
- the one or more additional therapeutic agent may be an inhibitor to PI3K such as PI3K ⁇ , PI3K ⁇ , PI3K ⁇ , and/or PI3K ⁇ , Janus kinase (JAK) such as JAK1, JAK2 and/or JAK3 , spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), bromodomain containing protein inhibitor (BRD) such as BRD4, a lysyl oxidase protein (LOX), lysyl oxidase-like protein (LOXL) such as LOXL1-5, matrix metalloprotease (MMP) such as MMP 1-10, adenosine A2B receptor (A2B), isocitrate dehydrogenase (IDH) such as IDH1, apoptosis signal-regulating kinase (ASK) such as ASK1, serine/threonine
- a phosphoinositide 3-kinase inhibitor functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, including but not limited to PI3K ⁇ , PI3K ⁇ , PI3K ⁇ , and PI3K ⁇ .
- Non-limiting examples of PI3K inhibitors include wortmannin, demethoxyviridin, LY294002, idelalisib, perifosine, PX-866, IPI-145, BAY 80-6946, BEZ235, RP6530, TGR 1202, INK1117, GDC-0941, BKM120, XL147 (also known as SAR245408), XL765 (also known as SAR245409), Palomid 529, GSK1059615, ZSTK474, PWT33597, IC87114, CAL263, RP6503, PI-103, GNE-477, CUDC-907 and AEZS-136.
- the PI3K inhibitor is a PI3K ⁇ inhibitors, such as idelalisib, IPI-145, RP6530, and RP6503, as well as those disclosed in U.S. Patent No. 8,569,296 , and PCT publications WO 2014/006572 and WO 2015/001491 .
- the one or more additional therapeutic agent may be an MMP9 inhibitor, or an agent that inhibits the expression and/or activity of MMP9.
- a representative protein sequence for MMP9 is GenBank Accession No. NP_004985.
- the inhibitor can be small molecule or biologic.
- SB-3CT CAS 292605-14-2 .
- siRNA, antisense RNA and antibodies have also been demonstrated to inhibit the expression or activity of MMP9 and are within the scope of the present disclosure.
- an MMP9 inhibitor is a monoclonal anti-MMP9 antibody.
- the one or more additional therapeutic agent includes an MMP9 inhibitor and a nucleoside analog such as gemcitabine.
- One, two, three, or more of the therapeutic agents may be further used or combined with a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof.
- a chemotherapeutic agent an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof.
- Chemotherapeutic agents may be categorized by their mechanism of action into, for example, the following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (floxuridine, capecitabine, and cytarabine); purine analogs, folate antagonists and related inhibitors, antiproliferative/antimitotic agents including natural products such as vinca alkaloid (vinblastine, vincristine) and microtubule such as taxane (paclitaxel, docetaxel), vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide); DNA damaging agents (actinomycin, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, iphosphamide,
- chemotherapeutic agent or “chemotherapeutic” (or “chemotherapy,” in the case of treatment with a chemotherapeutic agent) is meant to encompass any non-proteinaceous (i.e., non-peptidic) chemical compound useful in the treatment of cancer.
- chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; emylerumines and memylamelamines including alfretamine, triemylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimemylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (articularly cryptophycin 1 and cryptophycin 8); dolastatin; duocar
- dynemicin including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carrninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, es
- One or more chemotherapeutic agent are used or included in the present application.
- gemcitabine, nab-paclitaxel, and gemcitabine/nab-paclitaxel are used with the JAK inhibitor and/or PI3K ⁇ inhibitor for treating hyperproliferative disorders.
- chemotherapeutic agent anti-hormonal agents that act to regulate or inhibit hormone action on tumors
- antiestrogens and selective estrogen receptor modulators SERMs
- SERMs selective estrogen receptor modulators
- tamoxifen including NolvadexTM
- raloxifene including NolvadexTM
- droloxifene 4-hydroxytamoxifen
- trioxifene keoxifene
- LY117018 onapristone
- toremifene Fareston(r)
- inhibitors of the enzyme aromatase which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate (Megace(r)), exemestane, formestane, fadrozole, vorozole (Rivisor(r)), letrozole (Femara(r)), and anastrozole (Arimidex(r).
- anti-androgens
- the anti-angiogenic agents include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN(r), ENDOSTATIN(r), suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproternase-2, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulfated chitin derivatives (prepared from queen crab shells), sulfated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((1-azetidine-2-carboxylic acid (LACA), cishydroxyproline, D,L-3,4-dehydroproline, thiaproline, .alpha.-
- anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and Ang-1/Ang-2. See Ferrara N. and Alitalo, K. "Clinical application of angiogenic growth factors and their inhibitors" (1999) Nature Medicine 5:1359-1364 .
- the anti-fibrotic agents include, but are not limited to, the compounds such as beta-aminoproprionitrile (BAPN), as well as the compounds disclosed in U.S. Pat. No. 4,965,288 to Palfreyman, et al., issued Oct. 23, 1990 , entitled "Inhibitors of lysyl oxidase,” relating to inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen; U.S. Pat. No. 4,997,854 to Kagan, et al., issued Mar.
- BAPN beta-aminoproprionitrile
- Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product stabilized by resonance, such as the following primary amines: emylenemamine, hydrazine, phenylhydrazine, and their derivatives, semicarbazide, and urea derivatives, aminonitriles, such as beta-aminopropionitrile (BAPN), or 2-nitroethylamine, unsaturated or saturated haloamines, such as 2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine, 3-bromopropylamine, p-halobenzylamines, selenohomocysteine lactone.
- primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce
- the anti-fibrotic agents are copper chelating agents, penetrating or not penetrating the cells.
- Exemplary compounds include indirect inhibitors such compounds blocking the aldehyde derivatives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases, such as the thiolamines, in particular D-penicillamine, or its analogues such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetamidoethyl)dithio)butanoic acid, p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid, sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2-acetamid
- the immunotherapeutic agents include and are not limited to therapeutic antibodies suitable for treating patients; such as abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab
- the application also provides a compound of formula I for use in a method for treating a subject who is undergoing one or more standard therapies, such as chemotherapy, radiotherapy, immunotherapy, surgery, or combination thereof. Accordingly, one or more therapeutic agent or inhibitors may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, surgery or combination thereof.
- the subject may be a human who is (i) substantially refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii). In some of embodiments, the subject is refractory to at least two, at least three, or at least four chemotherapy treatments (including standard or experimental chemotherapies).
- the subject is refractory to at least one, at least two, at least three, or at least four chemotherapy treatment (including standard or experimental chemotherapy) selected from fludarabine, rituximab, obinutuzumab, alkylating agents, alemtuzumab and other chemotherapy treatments such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone); R-CHOP (rituximab-CHOP); hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine); R-hyperCVAD (rituximab-hyperCVAD); FCM (fludarabine, cyclophosphamide, mitoxantrone); R-FCM (rituximab, fludarabine, cyclophosphamide, mitoxantrone); bortezom
- chemotherapy treatment
- lymphomas Treatment of certain lymphomas is reviewed in Cheson, B.D., Leonard, J.P., “Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma” The New England Journal of Medicine 2008, 359(6), p. 613-626 ; and Wierda, W.G., "Current and Investigational Therapies for Patients with CLL” Hematology 2006, p. 285-294 . Lymphoma incidence patterns in the United States is profiled in Morton, L.M., et al. "Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992-2001” Blood 2006, 107(1), p. 265-276 .
- immunotherapeutic agents treating lymphoma or leukemia include, but are not limited to, rituximab (such as Rituxan), alemtuzumab (such as Campath, MabCampath), anti-CD 19 antibodies, anti-CD20 antibodies, anti-MN-14 antibodies, anti-TRAIL, Anti-TRAIL DR4 and DR5 antibodies, anti-CD74 antibodies, apolizumab, bevacizumab, CHIR-12.12, epratuzumab (hLL2- anti-CD22 humanized antibody), galiximab, ha20, ibritumomab tiuxetan, lumiliximab, milatuzumab, ofatumumab, PRO131921, SGN-40, WT-1 analog peptide vaccine, WT1 126-134 peptide vaccine, tositumomab, autologous human tumor-derived HSPPC-96, and veltuzumab.
- Additional immunotherapy agents includes using cancer vaccines
- chemotherapy agents for treating lymphoma or leukemia include aldesleukin, alvocidib, antineoplaston AS2-1, antineoplaston A10, anti-thymocyte globulin, amifostine trihydrate, aminocamptothecin, arsenic trioxide, beta alethine, Bcl-2 family protein inhibitor ABT-263, BMS-345541, bortezomib (Velcade®), bryostatin 1, busulfan, carboplatin, campath-1H, CC-5103, carmustine, caspofungin acetate, clofarabine, cisplatin, Cladribine (Leustarin), Chlorambucil (Leukeran), Curcumin, cyclosporine, Cyclophosphamide (Cyloxan, Endoxan, Endoxana, Cyclostin), cytarabine, denileukin diftitox, dexamethasone, DT PACE
- the cancer is melanoma.
- Suitable agents for use in combination with the compounds described herein include, without limitation, dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen", which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC, temozolomide or YERVOYTM.
- Compounds according to the invention may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in the treatment of melanoma.
- cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF)
- Anti-melanoma vaccines are, in some ways, similar to the anti-virus vaccines which are used to prevent diseases caused by viruses such as polio, measles, and mumps.
- Weakened melanoma cells or parts of melanoma cells called antigens may be injected into a patient to stimulate the body's immune system to destroy melanoma cells.
- Melanomas that are confined to the arms or legs may also be treated with a combination of agents including one or more compounds described herein, using a hyperthermic isolated limb perfusion technique.
- This treatment protocol temporarily separates the circulation of the involved limb from the rest of the body and injects high doses of chemotherapy into the artery feeding the limb, thus providing high doses to the area of the tumor without exposing internal organs to these doses that might otherwise cause severe side effects.
- the fluid is warmed to 102° to 104° F.
- Melphalan is the drug most often used in this chemotherapy procedure. This can be given with another agent called tumor necrosis factor (TNF).
- TNF tumor necrosis factor
- the therapeutic treatments can be supplemented or combined with any of the abovementioned therapies with stem cell transplantation or treatment.
- One example of modified approach is radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as indium In 111, yttrium Y 90, iodine 1-131.
- combination therapies include, but are not limited to, Iodine-131 tositumomab (Bexxar®), Yttrium-90 ibritumomab tiuxetan (Zevalin®), Bexxar® with CHOP.
- peripheral blood stem cell transplantation autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro -treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, pharmacological study, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
- a compound of formula I for use in a method for treating or preventing an HBV infection in a human having or at risk of having the infection comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- a compound of formula I for use in a method for treating an HBV infection in a human having or at risk of having the infection comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- the present disclosure provides a compound of formula I for use in a method for treating an HBV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents which are suitable for treating an HBV infection.
- compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent or excipient are provided.
- kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents are provided.
- the additional therapeutic agent may be an anti-HBV agent.
- the additional therapeutic agent is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B core antigen (HbcAg), cyclophilin inhibitors , HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP (Na+-taurocholate cotransporting polypeptide)
- the additional therapeutic is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha receptor ligands, HBsAg inhibitors, compounds targeting HbcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimul
- a compound disclosed herein is formulated as a tablet, which may optionally contain one or more other compounds useful for treating HBV.
- the tablet can contain another active ingredient for treating HBV, such as HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), modulators of tlr7, modulators of tlr8, modulators of tlr7 and tlr8, interferon alpha receptor ligands, hyaluronidase inhibitors, hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B core antigen (HbcAg), cyclophilin inhibitors , HBV viral entry inhibitors, NTCP
- such tablets are suitable for once daily dosing.
- the additional therapeutic agent is selected from one or more of:
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with one, two, three, four or more additional therapeutic agents. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents.
- the one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HBV DNA polymerase inhibitor.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HBV DNA polymerase inhibitor and at least one additional therapeutic agent selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, HBsAg inhibitors, compounds targeting HbcAg, cyclophilin inhibitors , HBV therapeutic vaccines, HBV prophylactic vaccines HBV viral entry inhibitors, NTCP inhibitors, antisense oligonu
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HBV DNA polymerase inhibitor and at least a second additional therapeutic agent selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1 inhibitors
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HBV DNA polymerase inhibitor and at least a second additional therapeutic agent selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
- a second additional therapeutic agent selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HBV DNA polymerase inhibitor, one or two additional therapeutic agents selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1 inhibitors, Ar
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with one, two, three, four or more additional therapeutic agents selected from adefovir (Hepsera®), tenofovir disoproxil fumarate + emtricitabine (TRUVADA®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®), Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha 1b (Hapgen®), inter
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®).
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®).
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a second additional therapeutic agent selected from the group consisting of immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10,
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a second additional therapeutic agent selected from the group consisting of peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha 1b (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a second additional therapeutic agent selected from the group consisting of immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10,
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a second additional therapeutic agent selected from the group consisting of HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®), one or two additional therapeutic agents selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, t
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with 5-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 5-10; 5-15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with 10 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 25 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide.
- a compound as disclosed herein may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with 100-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with 100-150; 100-200, 100-250; 100-300; 100-350; 150-200; 150-250; 150-300; 150-350; 150-400; 200-250; 200-300; 200-350; 200-400; 250-350; 250-400; 350-400 or 300-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with 300 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 250 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with 150 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil.
- a compound as disclosed herein e.g., a compound of formula (I)
- the components of the composition are administered as a simultaneous or sequential regimen.
- the combination may be administered in two or more administrations.
- a compound disclosed herein is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
- a compound disclosed herein is administered with one or more additional therapeutic agents.
- Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and one or more additional therapeutic agents are both present in the body of the patient.
- Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents.
- a unit dose of a compound disclosed herein is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents.
- a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound disclosed herein within seconds or minutes.
- a unit dose of a compound disclosed herein is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents.
- a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound disclosed herein.
- a compound of formula I for use in a method for treating or preventing an HIV infection in a human having or at risk of having the infection comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- a compound of formula I for use in a method for treating an HIV infection in a human having or at risk of having the infection comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- the present disclosure provides a compound of formula I for use in a method for treating an HIV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents which are suitable for treating an HIV infection.
- compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent or excipient are provided.
- kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents are provided.
- the additional therapeutic agent may be an anti- HIV agent.
- the additional therapeutic agent is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, entry inhibitors (e.g., CCR5 inhibitors, gp41 inhibitors (i.e., fusion inhibitors) and CD4 attachment inhibitors), CXCR4 inhibitors, gpl20 inhibitors, G6PD and NADH-oxidase inhibitors, compounds that target the HIV capsid ("capsid inhibitors"; e.g., capsid polymerization inhibitors or capsid disrupting compounds such as those disclosed in WO 2013/006738 (Gilead Sciences), US 2013/0165489 (University of Pennsylvania), and WO
- the additional therapeutic agent is selected from one or more of:
- the additional therapeutic agent is a Toll-like receptor 8 modulator selected from the group consisting of motolimod, resiquimod, 3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463 and those disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma),
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with one, two, three, four or more additional therapeutic agents. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents.
- the two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, or they can be selected from different classes of therapeutic agents.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and an HIV protease inhibiting compound.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with two HIV nucleoside or nucleotide inhibitor of reverse transcriptase.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, or tenofovir alafenamide hemifumarate.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, or tenofovir alafenamide hemifumarate.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with a first additional therapeutic agent selected from the group consisting of: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent selected from the group consisting of emtricitibine and lamivudine.
- a first additional therapeutic agent selected from the group consisting of: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate
- a second additional therapeutic agent selected from the group consisting of emtricitibine and lamivudine.
- a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with a first additional therapeutic agent selected from the group consisting of: tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent, wherein the second additional therapeutic agent is emtricitibine.
- the components of the composition are administered as a simultaneous or sequential regimen.
- the combination may be administered in two or more administrations.
- a compound disclosed herein is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
- a compound disclosed herein is administered with one or more additional therapeutic agents.
- Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and one or more additional therapeutic agents are both present in the body of the patient.
- Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents.
- a unit dose of a compound disclosed herein is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents.
- a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound disclosed herein within seconds or minutes.
- a unit dose of a compound disclosed herein is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents.
- a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound disclosed herein.
- kits that include a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, and suitable packaging.
- a kit further includes instructions for use.
- a kit includes a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, and a label and/or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.
- articles of manufacture that include a compound described herein or pharmaceutically acceptable salts, or a mixture thereof in a suitable container.
- the container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.
- compositions that contain one or more of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients.
- Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g ., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985 ); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds .).
- the pharmaceutical compositions may be administered in either single or multiple doses.
- the pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes.
- the pharmaceutical composition may be administered by intraarterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
- Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets.
- the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.
- the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
- excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
- the formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
- compositions that include at least one compound described herein or pharmaceutically acceptable salts, or a mixture thereof can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art.
- Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos. 3,845,770 ; 4,326,525 ; 4,902,514 ; and 5,616,345 .
- Another formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds described herein in controlled amounts.
- transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g. , U.S. Patent Nos. 5,023,252 , 4,992,445 and 5,001,139 . Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein or pharmaceutically acceptable salts, or a mixture thereof.
- a pharmaceutical excipient When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- the tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
- the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
- a dosage may be expressed as a number of milligrams of a compound described herein per kilogram of the subject's body weight (mg/kg). Dosages of between about 0.1 and 150 mg/kg may be appropriate. In some embodiments, about 0.1 and 100 mg/kg may be appropriate. In other embodiments a dosage of between 0.5 and 60 mg/kg may be appropriate.
- Normalizing according to the subject's body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.
- the daily dosage may also be described as a total amount of a compound described herein administered per dose or per day.
- Daily dosage of a compound of Formula I may be between about 1 mg and 4,000 mg, between about 2,000 to 4,000 mg/day, between about 1 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 10 to 500 mg/day, between about 20 to 500 mg/day, between about 50 to 300 mg/day, between about 75 to 200 mg/day, or between about 15 to 150 mg/day.
- the total daily dosage for a human subject may be between 1 mg and 1,000 mg, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day.
- the compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are well known in cancer chemotherapy, and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.
- the method comprises administering to the subject an initial daily dose of about 1 to 500 mg of a compound described herein and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week.
- the compounds may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g., from Sigma Aldrich or other chemical suppliers.
- Typical embodiments of compounds described herein may be synthesized using the general reaction schemes described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing compounds which are embodiments described in the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. In general, compounds described herein are typically stable and isolatable at room temperature and pressure.
- the compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
- protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
- Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York , and references cited therein.
- the compounds of this disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
- the starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof.
- many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA).
- solvent refers to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, and the like).
- solvents used in the reactions of the present invention are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
- q.s means adding a quantity sufficient to achieve a stated function, e.g. , to bring a solution to the desired volume (i.e. , 100%).
- the compounds of Formula I may prepared by first providing the substituted imidazo[4,5-b]pyridine or benzimidazole core, and optionally further modifying the core as desired to provide the substituents disclosed herein.
- Scheme 1 shows the preparation of compounds of Formula I, where m, n, L, R 1 , R 2a , R 2b , and X are as defined herein, and R 4 is as defined herein, or a functional group that is converted thereto using standard reaction conditions and protection/deprotection steps as required.
- Suitable solvent e.g., formic acid, ethanol, etc.
- an elevated temperature typically about 80-100 °C
- 1-c is then converted to the corresponding thioamide 1-d using Lawesson's reagent (i.e., 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide) under standard conditions.
- 1-e is obtained by cyclization of the thioamide 1-d using hydroxylamine.
- Scheme 2 shows the synthesis of compounds of Formula I where R t is hydrogen, and R 1 , R 2a , R 2b , and X are as defined herein.
- 2-a is nitrated using fuming nitric acid to provide 2-b , which is then cyclized to provide C-2 unsubstituted imidazo[4,5-b]pyridine or benzimidazole 2-c under reducing conditions (e.g., zinc, iron, etc.).
- Amide 2-e is provided by reacting the corresponding ester 2-c with a suitable amine 2-d under standard amide bond forming reaction conditions, and is then converted to compounds of Formula I using the methods shown above in Scheme 1.
- Scheme 3 shows the synthesis of compounds of Formula I where R t is - NH 2 , and R 1 , R 2a , R 2b , and X are as defined herein.
- 3-b is obtained by reaction of 3-a with cyanogen bromide.
- Amide 3-d is provided by reacting the corresponding ester 3-b with a suitable amine 3-c under standard amide bond forming reaction conditions, and is then converted to compounds of Formula I using the methods shown above in Scheme 1.
- the process may comprise protection and deprotection/further modification of R 4 (Scheme 1) to provide the desired group in the compound of Formula I.
- Scheme 4 shows an exemplary protection/deprotection or further modification to provide compounds of Formula I, where R t , R m , m, L, R 1 , R 2a , R 2b , and X are as defined herein.
- suitably substituted 4-a can be protected to provide 4-b using a suitable proecting group PG, such as a silyl ether (see, e.g., T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York , and references cited therein).
- PG a suitable proecting group
- 4-b is then converted to the corresponding thioamide 4-c and cyclized using hydroxylamine as shown above in Scheme 1 to provide 4-d .
- 4-d can then be coverted to compound 4-e by deprotectiona and optional further modification.
- 4-d can be deprotected and converted to a suitable leaving group (e.g., a TMS-O- group) and then reacted with a suitable amine to provide compounds of formula 4-e where L is -NR 3 -. 4-e is then converted to compounds of Formula I using the methods shown above in Scheme 1.
- a suitable leaving group e.g., a TMS-O- group
- 4-e is then converted to compounds of Formula I using the methods shown above in Scheme 1.
- TFA Trifluoroacetic acid
- THF Tetrahydrofuran TIGIT
- T cell immunoreceptor with Ig and ITIM domains TIM T-cell immunoglobulin and mucin domain
- TKM-HBV TKM-HepB
- Tlr Toll-like receptor modulators TNF Tumor necrosis factor
- TPL2 Serine/threonine kinase Vac Vacuum w/v Weight/volume w/w Weight/weight YPEG-rhIFNalpha-2a PEG-interferon alfa-2a YPEG-rhIFNalpha-2b Ypeginterferon alfa-2b ⁇ Chemical shift (ppm) ⁇ g Microgram ⁇ L/ ⁇ l Microliter ⁇ M Micromolar ⁇ m Micrometer ⁇ mol Micromole
- Methyl 3-formamido-4-methyl-2-nitrobenzoate Methyl 3-formamido-4-methylbenzoate (5.3 g, 27 mmol) was added to fuming nitric acid at 0 °C portion wise over 45 min. The reaction mixture was stirred at 0 °C for an additional 1 h, and then ice was added and the mixture stirred for 1.5 h at room temperature. The precipitated solid was filtered, and washed with water. The solid was purified by silica gel to give the desired product. C 10 H 10 N 2 O 5 . 239.0 (M+1).
- Methyl 4-methyl-1H-benzo[d]imidazole-7-carboxylate A mixture of methyl 3-formamido-4-methyl-2-nitrobenzoate (1.0 g, 4.2 mmol) and iron (1.2 g, 21 mmol) in methanol (10 mL) and acetic acid (5 mL) was stirred at 70 °C for 3 hr. To the cooled reaction mixture was added ethyl acetate and water and the mixture was filtered and the solid was washed with ethyl acetate. The aqueous layer was washed two times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the desired product. C 10 H 10 N 2 O 2 . 191.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide.
- 3-chloro-4-fluoroanilinein 253 mg, 1.74 mmol
- dichloroethane at 0 °C under nitrogen was added trimethylaluminum (2 M in heptane, 1.74 mL, 3.47 mmol) dropwise over 5 min.
- the solution was allowed to warm to room temperature and stirred for 30 min.
- the solution was cooled to 0 °C and to this solution was added methyl 4-methyl-1H-benzo[d]imidazole-7-carboxylate (220 mg, 1.16 mmol).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-methyl-1H-benzo[d]imidazole-7-carboximidamide A mixture of N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide (154 mg, 0.507 mmol), phosphorous pentachloride (158 mg, 0.761 mmol) in phosphoryl chloride (1.5 mL) and 1,2-dichloroethane (1.5 mL) were stirred at 80 °C for 2.5 hr.
- Methyl 2-formamido-3-nitro-4-(trifluoromethoxy)benzoate (2.2 g, 7.0 mmol) was dissolved in ethanol (15 mL) and water (5 mL). Ammonium chloride (0.108 mol) was added in one portion and the reaction was allowed to stir at room temperature. Zinc powder (0.108 mol) was added portion-wise over 5 minutes and the reaction was allowed to stir 5 minutes after completion of addition. The zinc was then removed by vacuum filtration and the filtrate was concentrated in vacuo. The crude was dissolved in water (20 mL) and extracted with EtOAc (4 x 10 mL). Combined organic layers were washed with brine (1 x 50 mL), dried over sodium sulfate, and concentrated in vacuo to give methyl 3-amino-2-formamido-4-(trifluoromethoxy)benzoate.
- Methyl 3-amino-2-formamido-4-(trifluoromethoxy)benzoate (1.32 g, 5.0 mmol) was dissolved in formic acid (15 mL) and heated to 80 °C for 1 hour. The reaction was cooled to rt, concentrated in vacuo, and quenched with saturated sodium bicarbonate solution (10 mL). The mixture was extracted with EtOAc (4x5 mL) and combined organic layers were washed with brine (1x15 mL) and concentrated in vacuo. Crude material was purified by column chromatography to give methyl 4-(trifluoromethoxy)-1H-benzo[d]imidazole-7-carboxylate.
- Example 2 was made analogously to Example 10 using methyl 4-(trifluoromethoxy)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 4,5-difluoro-1 H -benzo[d]imidazole-7-carboxylate.
- Example 3 (N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide) was made analogously to Example 59 using 6-fluoro-1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid.
- Example 4 was made analogously to Example 59 using 5-fluoro-1H-benzo[d]imidazole-7-carboxylic in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid.
- Example 5 was made analogously to Example 59 using 4-fluoro-1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid.
- Example 6 was made analogously to Example 59 using 4-chloro-1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid.
- Example 7 was made analogously to Example 59 using 4-(trifluoromethyl)-1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid. C 15 H 9 ClF 4 N 4 O. 373.1 (M+1).
- Example 8 was made analogously to Example 59 using 1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid. C 14 H 10 ClFN 4 O. 305.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-5-fluoro-4-methyl-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 1 using N-(3-chloro-4-fluorophenyl)-5-fluoro-3-formamido-4-methyl-2-nitrobenzamide in place of methyl 3-formamido-4-methyl-2-nitrobenzoate.
- N-(3-Chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide was made analogously to Example 1 using N-(3-chloro-4-fluorophenyl)-5-fluoro-4-methyl-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide.
- Methyl 2,3-diamino-4,5-difluorobenzoate (60 mg, 0.30 mmol) was dissolved in formic acid (2 mL) and heated to 100 °C in a sealed tube for 10 minutes. The reaction was allowed to cool to room temperature and concentrated in vacuo. The residue was dissolved in sat. sodium bicarbonate (2 mL) and extracted with EtOAc (3 x 3 mL). Combined organic layers were washed with water (1 x 5 mL) and concentrated in vacuo to give methyl 4,5-difluoro-1 H -benzo[d]imidazole-7-carboxylate as a brown solid which was used without further purification.
- Methyl 4,5-difluoro-1 H -benzo[d]imidazole-7-carboxylate (12 mg, 0.056 mmol) was dissolved in DCE (1 mL) under an inert atmosphere. Trimethylaluminum (0.085 mL, 2.0 M in toluene) was added dropwise to the reaction followed by 3-chloro-4-fluoroaniline (0.085 mmol). The reaction was allowed to stir at rt overnight under inert atmosphere. The reaction was quenched with sat. sodium bicarb (3 mL) and extracted with EtOAc (3 x 2mL).
- Methyl 5-chloro-3-formamido-2-nitrobenzoate was made analogously to Example 1 using methyl 3-amino-5-chloro-2-nitrobenzoate in place of methyl 3-amino-4-methylbenzoate.
- Methyl 6-chloro-1H-benzo[d]imidazole-4-carboxylate was made analogously to Example 1 using methyl 5-chloro-3-formamido-2-nitrobenzoate in place of methyl 3-formamido-4-methyl-2-nitrobenzoate.
- 6-chloro-N-(3-chloro-4-fluorophenyl)-1H-benzo[d]imidazole-4-carboxamide was made analogously to Example 1 using methyl 6-chloro-1H-benzo[d]imidazole-4-carboxylate in place of methyl 4-methyl-1H-benzo[d]imidazole-7-carboxylate.
- 6-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide was made analogously to Example 1 using 6-chloro-N-(3-chloro-4-fluorophenyl)-1H-benzo[d]imidazole-4-carboxamide in place of N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide.
- Methyl 4-bromo-3-formamidobenzoate was prepared analogously to Example 9, using methyl 3-amino-4-bromobenzoate in place of 3-amino- N -(3-chloro-4-fluorophenyl)-5-fluoro-4-methyl-2-nitrobenzamide.
- Methyl 4-bromo-1 H -benzo[ d ]imidazole-7-carboxylate was prepared analogously to Example 1, using methyl 4-bromo-3-formamido-2-nitrobenzoate in place of methyl 3-formamido-4-methyl-2-nitrobenzoate.
- Methyl 2-amino-4,5-difluoro-1 H -benzo[ d ]imidazole-7-carboxylate (75 mg, 0.33 mmol) was dissolved in DCE (4 mL) under inert atmosphere and cooled to 0 °C. Trimethylaluminium (1.2 mL, 2M hexanes) was added dropwise followed by 3-chloro-4-fluoroaniline (1.0 mmol) and the reaction was then heated to 70 °C for 2 days. The reaction was cooled to rt and quenched with saturated bicarbonate solution. The reaction was extracted with EtOAc (3x3 mL) and combined organic layers were washed with brine (1x6 mL) and concentrated in vacuo.
- Example 14 was made analogously to Example 13 using 3-bromo-4-fluoroaniline in place of 3-chloro-4-fluoroaniline.
- Example 15 was made analogously to Example 13 using 3-bromoaniline in place of 3-chloro-4-fluoroaniline.
- Example 16 was made analogously to Example 13 using 3-chloroaniline in place of 3-chloro-4-fluoroaniline.
- 1 H NMR (400 MHz, Methanol- d 4 ) ⁇ 8.69 - 8.59 (m, 2H), 8.51 - 8.45 (m, 1H), 8.39 (t, J 2.1 Hz, 1H), 8.21 - 8.15 (m, 1H).
- Example 17 was made analogously to Example 13 using 4-fluoro-3-(trifluoromethyl)aniline in place of 3-chloro-4-fluoroaniline.
- 1 H NMR (400 MHz, DMSO- d 6 ) ⁇ 11.04 (s, 1H), 8.93 (s, 1H), 8.16 (s, 2H), 7.24 - 7.10 (m, 3H), 6.83 (dt, J 7.9, 3.5 Hz, 1H).
- Example 18 was made analogously to Example 15 using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1 H -benzo[ d ]imidazole-7-carboxylate.
- Example 19 was made analogously to Example 14 using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1 H- benzo[ d ]imidazole-7-carboxylate.
- Example 20 was made analogously to Example 16 using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1 H- benzo[ d ]imidazole-7-carboxylate.
- Example 21 was made analogously to Example 17 using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1 H- benzo[ d ]imidazole-7-carboxylate.
- 1 H NMR (400 MHz, DMSO- d 6 ) ⁇ 10.95 (s, 1H), 8.93 (s, 1H), 8.32 (s, 2H), 7.24 - 7.05 (m, 4H), 6.83 (dd, J 8.5, 4.2 Hz, 1H).
- Example 22 was made analogously to Example 13 (using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1 H- benzo[ d ]imidazole-7-carboxylate.
- Methyl 4,5-difluoro-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboxylate Dissolved methyl 2,3-diamino-4,5-difluorobenzoate (50 mg, 0.25 mmol) in THF (3 ml), to the solution was added 4-(2-isothiocyanatoethyl)morpholine (0.43 g, 0.002 mmol) and triethylamine (0.36 g, 0.003 mol).
- reaction mixture was heated at 80°C overnight, then to the reaction mixture was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.47 g, 0.002 mol), heated at 80°C for 1h.
- the reaction mixture was diluted with EtOAc, and washed with NaHCO 3 saturated solution, organic layer was evaporated and the residue was purified with Combi-Flash column chromatography to afford 84mg desired product.
- Example 23 was made analogously to Example 107 using the general procedure for hydroxy amidine formation. C 20 H 20 ClF 3 N 6 O 2 . 469.1 (M+1).
- Example 24 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1 H- benzo[ d ]midazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4 H )-one in place of 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one.
- Example 25 was prepared analogously to Example 45 , using 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4 H )-one and cyclopropylmethanamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 3-methoxypropylamine, respectively.
- Example 26 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4 H )-one and dimethylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 3-methoxypropylamine, respectively.
- Example 27 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4 H )-one and isopropylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 3-methoxypropylamine, respectively.
- Example 28 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4 H )-one and ethylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1 H- benzo[ d ]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 3-methoxypropylamine, respectively.
- Example 29 was prepared analogously to Example 46, using 4-(3-chlorophenyl)-3-(4,5-difluoro-2-(hydroxymethyl)-1 H -benzo[ d ]imidazol-7-yl)-1,2,4-oxadiazol-5(4 H )-one in place of 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(hydroxymethyl)-1 H -benzo[ d ]imidazol-7-yl)-1,2,4-oxadiazol-5(4 H )-one.
- Example 30 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4 H )-one and methylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1 H- benzo[ d ]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 3-methoxypropylamine, respectively.
- Example 31 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4 H )-one and ammonia (0.5 M solution in dioxane) in place of 3-(2-(bromomethyl)-4,5-difluoro-1 H -benzo[ d ]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 3-methoxypropylamine, respectively.
- N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-2-morpholino-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 13 using methyl 4,5-difluoro-2-morpholino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate and 3-chloro-4-fluoroaniline in place of methyl 2-amino-4,5-difluoro-1 H- benzo[ d ]imidazole-7-carboxylate.
- Example 32 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-morpholino-1H-benzo[d]imidazole-7-carboxamide in place of N -(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- Example 33 was made analogously to Example 22 using methyl 4-fluoro-2-((2-(methylsulfoyl)ethyl)amino)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate.
- Example 34 was made analogously to Example 33 using 4-(2-isothiocyanatoethyl)morpholine in place of 1-isothiocyanato-2-(methylsulfonyl)ethane.
- Example 35 was made analogously to Example 39 using 2-(methylsulfonyl)ethanamine in place of N 1 ,N 1 -dimethylpropane-1,3-diamine with an addition of triethylamine (1.2 eq) in the cyclization reaction.
- Example 36 N -(3-Chloro-4-fluorophenyl)-2-((2-(4,4-difluoropiperidin-1-yl)ethyl)amino)-4,5-difluoro- N '-hydroxy-1 H -benzo[d]imidazole-7-carboximidamide
- Example 36 was made analogously to Example 39 using 2-(4,4-difluoropiperidin-1-yl)ethanamine in place of N 1 ,N 1 -dimethylpropane-1,3-diamine.
- Example 37 was made analogously to Example 39 using 1-morpholinopropan-2-amine in place of N1,N 1 -dimethylpropane-1,3-diamine.
- N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-2-(methylamino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 13 using methyl 4,5-difluoro-2-(methylamino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate and 3-chloro-4-fluoroaniline in place of methyl 2-amino-4,5-difluoro-1 H -benzo[ d ]imidazole-7-carboxylate and stirring overnight at room temperature.
- Example 38 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(methylamino)-1H-benzo[d]imidazole-7-carboxamide in place of N -(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- the TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(methylamino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid. C 15 H 11 ClF 3 N 5 O. 370.05/371.98 (M+1).
- Example 39 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N -(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- Methyl 4,5-difluoro-2-((2-methoxyethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate was made analogously to Example 39 using 2-methoxyethanamine and triethylamine (1 equiv) in place of N , N -dimethylpropane-1,3-diamine.
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-methoxyethyl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((2-methoxyethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H- benzo[ d ]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H- benzo[ d ]imidazole-7-carboxylate.
- Example 40 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-methoxyethyl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N -(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide .
- the TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-methoxyethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid.
- Methyl 4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate was made analogously to Example 39 using 2-(pyrrolidin-1-yl)ethanamine in place of N,N- dimethylpropane-1,3-diamine.
- N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate.
- Example 41 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N -(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- Methyl 2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate was made analogously to Example 39 using N , N -diethylethane-1,2-diamine in place of N,N- dimethylpropane-1,3-diamine.
- N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate.
- Example 42 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N -(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide .
- Methyl 2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate was made analogously to Example 39 using N , N -dimethylethane-1,2-diamine in place of N,N- dimethylpropane-1,3-diamine.
- N-(3-Chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H -benzo[ d ]imidazole-7-carboxylate.
- Example 43 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N -(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide .
- Example 44 was made analogously to Example 53 using 1-methylpiperidine-3-carboxylic acid in place of 3-(dimethylamino)propanoic acid.
- the TFA salt of 4,5-difluoro-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole-7-carboxylic acid was isolated as a colorless oil.
- Example 44 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole-7-carboxamide in place of N -(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide .
- the TFA salt of N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid.
- Methyl 4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxylate A mixture of methyl 2,3-diamino-4,5-difluorobenzoate (2.0 g, 9.9 mmol) in methoxyacetic acid (23 mL) was stirred at 120 °C for 3 hr. To the mixture was added saturated sodium bicarbonate and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, absorbed onto silica and purified by silica gel chromatography to give the desired product. C 11 H 10 F 2 N 2 O 3 . 257.3 (M+1).
- Example 47 was made analogously to Example 45 using 0.5 M ammonia in dioxane in place of 3-methoxypropylamine. C 15 H 11 ClF 3 N 5 O. 370.1 (M+1).
- Example 48 was made analogously to Example 45 using 2 M methylamine in tetrahydrofuran in place of 3-methoxypropylamine.
- Example 49 was made analogously to Example 45 using cyclopropylmethylamine in place of 3-methoxypropylamine. C 19 H 17 ClF 3 N 5 O.424.0 (M+1).
- Example 50 was made analogously to Example 45 using 2 M ethylamine in tetrahydrofuran in place of 3-methoxypropylamine. C 17 H 15 ClF 3 N 5 O. 398.0 (M+1).
- Example 51 was made analogously to Example using isopropylamine in place of 3-methoxypropylamine. C 18 H 17 ClF 3 N 5 O. 412.1 (M+1).
- Example 52 was made analogously to Example 45 using dimethylamine in place of 3-methoxypropylamine. C 17 H 15 ClF 3 N 5 O. 398.1 (M+1).
- Example 53 was made analogously to Example 95 C 18 H 17 ClF 3 N 5 O. 411.11 (M+1).
- N-(3-bromo-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-1H-benzo[d]imidazole-4-carboxamide was made analogously to Example 53 using 3-bromo-4-fluoroaniline in place of 3-chloro-4-fluoroaniline.
- Example 54 was made analogously to Example 95. C 18 H 17 BrF 3 N 5 O. 456.1 (M+1).
- N-(3-bromophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-1H-benzo[d]imidazole-4-carboxamide was made analogously to Example 53 using 3-bromoaniline in place of 3-chloro-4-fluoroaniline.
- Example 55 was made analogously to Example 95. C 18 H 18 BrF 2 N 5 O. 438.10.
- N-(3-chlorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-1H-benzo[d]imidazole-4-carboxamide was made analogously to Example 53 using 3-chloroaniline in place of 3-chloro-4-fluoroaniline.
- Example 56 was made analogously to Example 95 C 18 H 18 ClF 2 N 5 O. 394.12 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-hydroxyethyl)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 183 using Ethyl 2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)acetate.
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-hydroxyethyl)-1H-benzo[d]imidazole-7-carboxamide.
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-benzo[d]imidazole-7-carbothioamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-benzo[d]imidazole-7-carboxamide.
- Example 57 was made analogously to Example 112 using 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4,5-difluoro-1-(methylsulfonyl)-1H-benzo[d]imidazol-2-yl)ethyl methanesulfonate in place of 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-3-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate.
- Example 58 was made analogously to Example 57 using 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4,5-difluoro-1-(methylsulfonyl)-1H-benzo[d]imidazol-2-yl)ethyl methanesulfonate and diethylamine in place of 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-3-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate and methylamine.
- N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide 122 mg, 0.42 mmol
- PCl 5 (0.63 mmol
- the reaction was cooled to rt and concentrated in vacuo.
- the residue was dissolved in a pre-mixed solution of hydroxylamine (50% aqueous solution, 4.0 mmol) and ethanol (2 mL) and the reaction was allowed to stir at rt for 10 minutes.
- Example 60 was made analogously to Example 59 using 5-chloro-2-fluoroaniline in place of 3-chloro-4-fluoroaniline.
- Example 61 was made analogously to Example 59 using 5-bromo-2,4-difluoroaniline in place of 3-chloro-4-fluoroaniline.
- 1 H NMR (400 MHz, DMSO- d 6 ) ⁇ 11.03 (s, 1H), 8.71 (s, 1H), 8.59 (s, 1H), 8.36 (d, J 4.8 Hz, 1H), 7.34 - 7.21 (m, 3H).
- Example 62 was made analogously to Example 59 using 5-chloro-2,4-difluoroaniline in place of 3-chloro-4-fluoroaniline.
- Example 63 was made analogously to Example 59 using 3,5-dichloro-4-fluoroaniline in place of 3-chloro-4-fluoroaniline.
- Example 64 was made analogously to Example 59 using 3-chloro-2,4-difluoroaniline in place of 3-chloro-4-fluoroaniline.
- Example 65 was made analogously to Example 59 using 3-cyclopropyl-4-fluoroaniline in place of 3-chloro-4-fluoroaniline. C 16 H 14 FN 5 O. 312.1 (M+1).
- Example 66 was made analogously to Example 59 using 4-(trifluoromethoxy)aniline in place of 3-chloro-4-fluoroaniline. C 14 H 10 F 3 N 5 O 2 . 338.1 (M+1).
- Example 69 was made analogously to Example 59 using benzofuran-7-amine in place of 3-chloro-4-fluoroaniline. C 15 H 11 N 5 O 2 . 294.1 (M+1).
- Example 70 was made analogously to Example 59 using benzofuran-5-amine in place of 3-chloro-4-fluoroaniline. C 15 H 11 N 5 O 2 . 294.1 (M+1).
- Example 71 was made analogously to Example 59 using acid and 5-bromo-2-fluoroaniline in place of 3-chloro-4-fluoroaniline.
- 1 H NMR (400 MHz, DMSO- d 6 ) ⁇ 11.16 (s, 1H), 10.06 (s, 1H), 8.74 (s, 1H), 8.57 (s, 1H), 8.35 (d, J 5.1 H, 1H), 7.25 (s, 1H), 7.14 - 6.92 (m, 3H).
- Example 72 was made analogously to Example 59 using 5-bromo-3-fluoroaniline in place of 3-chloro-4-fluoroaniline. C 13 H 9 BrFN 5 O. 350.1/352.1 (M+1).
- Example 73 was made analogously to Example 59 using 3-(trifluoromethyl)aniline in place of 3-chloro-4-fluoroaniline.
- Example 74 was made analogously to Example 59 using 2,2-difluorobenzo[d][1,3]dioxol-5-amine in place of 3-chloro-4-fluoroaniline.
- Example 75 was made analogously to Example 59 using 3-fluoro-5-(trifluoromethyl)aniline in place of 3-chloro-4-fluoroaniline. C 14 H 9 F 4 N 5 O. 340.1 (M+1).
- N-(2,5-dichlorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (40 mg, 0.13 mmol) was dissolved in POCl 3 (2 mL) and PCl 5 (0.195 mmol) was added. The reaction was heated to 80 °C overnight, allowed to cool to rt, and concentrated in vacuo. The crude was dissolved in a pre-mixed solution of hydroxylamine (50% in water, 1.0 mmol) and ethanol (2 mL) and allowed to stir at rt for 10 mins then concentrated in vacuo.
- N-(3-bromo-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide 150 mg, 0.448 mmol
- phenyl boronic acid 2.0 mmol
- degassed THF 2.0 mL
- water 0.50 mL
- PdCl 2 (dppf) 0.090 mmol
- K 2 CO 3 2.0 mmol
- N-(6-fluoro-[1,1'-biphenyl]-3-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (100 mg, 0.301 mmol) was dissolved in POCl 3 , PCl 5 (2.0 mmol) was added, and the reaction was heated to 80 °C overnight. The reaction was allowed to cool to rt and concentrated in vacuo. The crude was dissolved in a pre-mixed solution of hydroxylamine (50% in water, 3.0 mmol) and ethanol (2 mL) and allowed to stir at rt for 10 mins.
- N-(3-bromo-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide 100 mg, 0.298 mmol
- PdCl 2 (PPh 3 ) 2 0.015 mmol
- CuI 0.0298 mmol
- N-(3-(but-1-yn-1-yl)-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (56 mg, 0.182 mmol) was dissolved in POCl 3 (2 mL) and PCl 5 (0.272 mmol) was added and the reaction was heated to 80 °C for 45 mins. The reaction was allowed to cool to rt and concentrated in vacuo. The material was dissolved in a pre-mixed solution of hydroxylamine (50% in water, 2.0 mmol) and ethanol (2 mL) and allowed to stir at rt for 10 mins.
- Example 79 was made analogously to Example 78 using ethynylcyclopropane (5 eq) in place of but-1-yne. C 18 H 14 FN 5 O. 336.1 (M+1).
- N -(3-bromophenyl)- N' -hydroxy-1 H -imidazo[4,5- b ]pyridine-7-carboximidamide N -(3-bromophenyl)- N' -hydroxy-1 H -imidazo[4,5- b ]pyridine-7-carboximidamide.
- N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide 0.062 g, 0.195 mmol
- phosphoryl chloride 0.18 mL, 1.95 mmol
- DCE 2 mL
- phosphorus pentachloride 0.061 g, 0.293 mmol
- Example 81 was synthesized analogously to Example 80, using N-(3-bromo-4-fluorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide. (C 13 H 9 BrFN 5 O. 350.0/352.0 [M+1] + .
- N -(3-chlorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 80 using 3-chloroaniline in place of 3-bromoaniline.
- Example 82 was synthesized analogously to Example 80, using N-(3-chlorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(4-fluoro-3-(trifluoromethyl)phenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 80 using 4-fluoro-3-(trifluoromethyl)aniline in place of 3-bromoaniline.
- Example 83 was synthesized analogously to Example 80, using N- (4-fluoro-3-(trifluoromethyl)phenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- Example 84 was synthesized analogously to Example 80, using N -(4-fluoro-3-(prop-1-yn-1-yl)phenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(3-bromo-4-chlorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 80, using 3-bromo-4-chloroaniline in place of 4-fluoro-3-(prop-1-yn-1-yl)aniline.
- Example 85 was synthesized analogously to Example 80 using N-(3-bromo-4-chlorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N- (3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- Example 86 was synthesized analogously to Example 80, using 3,4-dichloroaniline in place of 3-bromoaniline. C 13 H 8 Cl 2 N 4 O. 307.0 [M+1] + .
- Example 86 was synthesized analogously to Example 80, using N- (3,4-dichlorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- Example 87 was synthesized analogously to Example 80, using N -(4-chlorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(4-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 80, using 4-bromoaniline in place of 3-bromoaniline.
- Example 88 was synthesized analogously to Example 80, using N -(4-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(4-fluorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 80 using 5-fluoroaniline in place of 3-bromoaniline. C 13 H 9 FN 4 O. 257.0 [M+1] + .
- Example 89 was synthesized analogously to Example 80, using N -(4-fluorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(3-cyano-4-fluorophenyl)-1 H -imidazo[4,5-b]pyridine-7-carboxamide was synthesized analogously to Example 80, using 3-cyano-4-fluoroaniline in place of 3-bromoaniline.
- Example 90 was synthesized analogously to Example 80, using N -(3-cyano-4-fluorophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(4-(trifluoromethyl)phenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 84, using 4-(trifluoromethyl)aniline in place of 4-fluoro-3-(prop-1-yn-1-yl)aniline.
- Example 91 was synthesized analogously to Example 80 using N -(4-(trifluoromethyl)phenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(3-methoxyphenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 80, using 3-methoxyaniline in place of 3-bromoaniline.
- Example 92 was synthesized analogously to Example 80, using N -(3-methoxyphenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(4-fluoro-3-isopropylphenyl)-1 H -imidazo[4,5-b]pyridine-7-carboxamide was synthesized analogously to Example 80, using 4-fluoro-3-isopropylaniline in place of 3-bromoaniline.
- Example 93 was synthesized analogously to Example 80, using N -(4-fluoro-3-isopropylphenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -( p -tolyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 84, using p -toluidine in place of 4-fluoro-3-(prop-1-yn-1-yl)aniline. C 14 H 12 N 4 O. 253.1 [M+1] + .
- Example 94 was synthesized analogously to Example 80, using N- ( p -tolyl)-1 H- imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N-(3-ethynylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide A mixture of N-(3-ethynylphenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (41 mg, 0.155 mmol), phosphorous pentachloride (48 mg, 0.233 mmol) in phosphoryl chloride (0.3mL) and 1,2-dichloroethane (0.3 mL) were stirred at 80 °C for 2 hr. The reaction mixture was concentrated and suspended in ethanol (2 mL) and to this mixture was added 50% hydroxylamine in water (0.265 mL, 4.33 mmol).
- N-(3-ethylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was prepared as described in Example 95.
- N-(3-ethynyl-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 95 using 3-ethynyl-4-fluoroaniline in place of 3-ethynylaniline.
- Example 97 was made analogously to Example 95 C 15 H 10 FN 5 O. 295.09 (M+1).
- N-(3-(difluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 95 using 3-(difluoromethyl)aniline in place of 3-ethynylaniline. C14H10F2N4O. 289.10 (M+1).
- Example 98 was made analogously to Example 95 using N-(3-(difluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide.
- N-(3-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 95 using 3-(trifluoromethoxy)aniline in place of 3-ethynylaniline.
- Example 99 was made analogously to Example 95 using N-(3-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N-phenyl-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 95 using aniline in place of 3-ethynylaniline. C13H10N4O. 239.10 (M+1).
- Example 100 was made analogously to Example 95 using N-phenyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C 13 H 11 N 5 O.
- N-(4-fluoro-3-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 95 using 4-fluoro-3-(trifluoromethoxy)aniline in place of 3-ethynylaniline.
- Example 101 was made analogously to Example 95 using N-(4-fluoro-3-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N-(naphthalen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 95 using naphthalen-2-amine in place of 3-ethynylaniline. C 17 H 12 N 4 O. 289.10 (M+1).
- N-Hydroxy-N-(naphthalen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide (Example 102) and N-(3-chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide (Example 103) were made analogously to Example 95 using N-(naphthalen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide give two products (N-hydroxy-N-(naphthalen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide and N-(3-chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide).
- N-(3-Chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was prepared according to Example 102. C 17 H 12 ClN 5 O. 338.11(M+1).
- N-(naphthalen-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 95 using naphthalen-1-amine in place of 3-ethynylaniline. C 17 H 12 N 4 O. 289.10 (M+1).
- N'-hydroxy-N-(naphthalen-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide (Example 104) and N-(4-chloronaphthalen-1-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide (Example 105) were made analogously to Example 95 using N-(naphthalen-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide give two products (N'-hydroxy-N-(naphthalen-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide and N-(4-chloronaphthalen-1-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide).
- Example 105 was made analogously to Example 104. C 17 H 12 ClN 5 O. 338.11(M+1).
- N-(4-fluoro-3-methoxyphenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 95 using 4-fluoro-3-methoxyanilinein place of 3-ethynylaniline. C 14 H 11 FN 4 O 2 . 286.09 (M+1).
- Example 106 was made analogously to Example 95 using 4-fluoro-3-methoxyphenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C 14 H 12 FN 5 O 2 . 302.10 (M+1).
- N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide A mixture of 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (1.06 g, 3.77 mmol) in acetic acid (11 mL) was stirred at 180 °C for 1 hr in a microwave. Water was added and the resulting precipitate was filtered and dried on high vac to give the desired product. C 14 H 10 ClFN 4 O. 305.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide A mixture of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide (132 mg, 0.433 mmol), phosphorous pentachloride (135 mg, 0.650 mmol) in phosphoryl chloride (2 mL) and 1,2-dichloroethane (2 mL) were stirred at 80 °C for 2.5 hr.
- N-(3-chloro-4-fluorophenyl)-2-ethyl-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 107 using propionic acid in place of acetic acid.
- Example 108 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-ethyl-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N-(3-chloro-4-fluorophenyl)-2-cyclopropyl-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 107 using cyclopropanecarboxylic acid in place of acetic acid.
- Example 109 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-cyclopropyl-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- Example 110 N -(3-Chloro-4-fluorophenyl)- N' -hydroxy-2-(methoxymethyl)-1 H- imidazo[4,5-b]pyridine-7-carboximidamide
- N-(3-chloro-4-fluorophenyl)-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 107 using methoxyacetic acid in place of acetic acid. C 15 H 12 ClFN 4 O 2 . 334.9 (M+1).
- the reaction mixture was concentrated and suspended in ethanol (20 mL) and to this mixture was added 50% hydroxylamine in water (4.8 mL, 78 mmol). The reaction mixture stirred for 1 hr and was concentrated. Water and aqueous saturated sodium bicarbonate were added and the solid was filtered and dried on high vac. The solid was suspended in ethyl acetate (100 mL) and to this mixture was added carbonyldiimidazole (1.90 g, 11.7 mmol). The mixture was stirred for 18 hr and concentrated. The residue was purified by silica gel chromatography to give the desired product (871 mg). C 16 H 11 ClFN 5 O 3 . 376.3 (M+1).
- Example 110 was made analogously to Example 95 using N-(3-chloro-4-fluorophenyl)-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- Example 111 4-(3-Chloro-4-fluorophenyl)-3-(2-(hydroxymethyl)-1H-imidazo [4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4 H )-one
- N-(3-chloro-4-fluorophenyl)-2-((dimethylamino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide A solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (30 mg, 0.065 mmol) and dimethylamine (2 M in THF, 0.655 mL, 1.3 mmol) in acetonitrile (1 mL) was stirred at 65 °C for 3 hr min.
- Example 114 was made analogously to Example 112 using 2 M ethylamine in THF in place of morpholine. C 16 H 16 ClFN 6 O. 363.1 (M+1).
- Example 115 was made analogously to Example 112 using benzylamine in place of morpholine. C 21 H 18 ClFN 6 O. 425.1 (M+1).
- Example 116 was made analogously to Example 112 using isopropylamine in place of morpholine. C 17 H 18 ClFN 6 O. 377.1 (M+1).
- Example 117 was made analogously to Example 112 using cyclopropylmethylamine in place of morpholine. C 18 H 18 ClFN 6 O. 388.9 (M+1).
- Example 118 was made analogously to Example 112 using 2,2,2-trifluoroethylamine in place of morpholine. C 16 H 13 ClF 4 N 6 O. 416.7 (M+1).
- Example 119 was made analogously to Example 112 using cyclopropylamine in place of morpholine. C 17 H 16 ClFN 6 O. 374.9 (M+1).
- Example 120 N -(3-Chloro-4-fluorophenyl)- N' -hydroxy-2-(((3-methoxypropyl)amino)methyl)-1 H- imidazo[4,5-b]pyridine-7-carboximidamide
- Example 120 was made analogously to Example 112 using 3-methoxypropylamine in place of morpholine. C 18 H 20 ClFN 6 O 2 . 407.1 (M+1).
- Example 121 was made analogously to Example 112 using pyridin-2-ylmethanamine in place of morpholine. C 20 H 17 ClFN 7 O. 426.1 (M+1).
- Example 122 N -(3-Chloro-4-fluorophenyl)- N' -hydroxy-2-(((3-methoxypropyl)(methyl)amino)methyl)-1 H -imidazo[4,5-b]pyridine-7-carboximidamide
- Example 122 was made analogously to Example 112 using 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxy-N-methylpropan-1-amine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine.
- Example 123 was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and 2-methoxybenzylamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine.
- Example 124 was made analogously to Example 112 using 2-methoxyethylamine in place of morpholine.C 17 H 18 ClFN 6 O 2 . 393.1(M+1).
- Example 125 was made analogously to Example 112 using 2-(pyridin-2-yl)ethanamine in place of morpholine. C 21 H 19 ClFN 7 O. 440.1 (M+1).
- Example 126 was made analogously to Example 112 using 3-picolylamine in place of morpholine. C 20 H 17 ClFN 7 O. 426.1 (M+1).
- Example 127 was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and (tetrahydro-2H-pyran-2-yl)methanamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine.
- Example 129 N -(3-Chloro-4-fluorophenyl)- N' -hydroxy-2-((((tetrahydro-2 H -pyran-3-yl)methyl)amino)methyl)-1 H -imidazo[4,5-b]pyridine-7-carboximidamide
- Example 129 was made analogously to Example 112 using (tetrahydro-2H-pyran-3-yl)methanamine in place of morpholine. C 20 H 22 ClFN 6 O 2 . 433.1 (M+1).
- Example 130 was made analogously to Example 112 using pyrimidin-2-ylmethanamine in place of morpholine. C 19 H 16 ClFN 8 O. 427.1 (M+1).
- Example 131 was made analogously to Example 112 using 3-morpholinopropan-1-amine in place of morpholine. C 21 H 25 ClFN 7 O 2 . 462.2 (M+1).
- Example 132 was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and tetrahydro-2H-pyran-4-amine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine.
- Example 133 was made analogously to Example 112 using 4-picolylamine in place of morpholine. C 20 H 17 ClFN 7 O. 426.1 (M+1).
- Example 134 was made analogously to Example 112 using pyrazin-2-ylmethanamine in place of morpholine. C 19 H 16 ClFN 8 O. 427.1 (M+1).
- Example 135 N -(3-Chloro-4-fluorophenyl)- N' -hydroxy-2-((((tetrahydrofuran-3-yl)methyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide
- Example 135 was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and (tetrahydrofuran-3-yl)methanamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine.
- Example 136 was made analogously to Example 112 using N,N-dimethylethane-l,2-diamine in place of morpholine. C 18 H 21 ClFN 7 O. 406.1 (M+1).
- Example 137 was made analogously to Example 112 using 2-(pyrimidin-2-yl)ethanamine in place of morpholine. C 20 H 18 ClFN 8 O. 441.1 (M+1).
- Example 138 N -(3-Chloro-4-fluorophenyl)- N' -hydroxy-2-(((3-hydroxypropyl)amino)methyl)-1 H -imidazo[4,5-b]pyridine-7-carboximidamide
- Example 138 was made analogously to Example 112 using 3-aminopropanol in place of morpholine. C 17 H 18 ClFN 6 O 2 . 393.1 (M+1).
- Example 139 was synthesized analogously to Example 112 using pyrrolidine in place of morpholine. C 18 H 18 ClFN 6 O. 389.1 [M+1] + .
- Example 140 N -(3-Chloro-4-fluorophenyl)- N '-hydroxy-2-(piperidin-1-ylmethyl)-1 H -imidazo[4,5- b ]pyridine-7-carboximidamide
- Example 140 was synthesized analogously to Example 112 using piperidine in place of morpholine. C 19 H 20 ClFN 6 O. 403.1 [M+1] + .
- Example 141 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1 H -imidazo[4,5- b ]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 2,2-dimethylpropan-1-amine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1 H- imidazo[4,5- b ]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively.
- Example 142 N -(3-Chloro-4-fluorophenyl)-2-(((2,2-difluoroethyl)amino)methyl)- N' -hydroxy-1 H -imidazo[4,5- b ]pyridine-7-carboximidamide
- Example 142 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1 H -imidazo[4,5- b ]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 2,2-difluoroethylamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1 H- imidazo[4,5- b ]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively.
- Example 143 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1 H -imidazo[4,5- b ]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and 3-amino-2,2-dimethylpropan-1-ol in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1 H- imidazo[4,5- b ]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively.
- Example 144 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1 H -imidazo[4,5- b ]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4 H )-one and thiazol-2-ylmethanamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1 H- imidazo[4,5- b ]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively.
- N-(3-chloro-4-fluorophenyl)-2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide To a soln of the 3-chloro-4-fluoroanilinein (239 mg, 1.64 mmol) dichloroethane at 0 °C under nitrogen was added trimethylaluminum (2 M in heptane, 1.57, 3.15 mmol) dropwise over 5 min. The solution was allowed to warm to room temperature and stirred for 30 min.
- Example 146 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N -(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide A mixture of 2,3-diamino- N -(3-chloro-4-fluorophenyl)isonicotinamide (0.150 g, 0.534 mmol) and nicotinaldehyde (0.50 mL, 5.34 mmol) in DMSO was stirred at 100 °C under air atmosphere for 16 h. Mixture was cooled to rt and diluted with water.
- Example 147 was synthesized analogously to Example 80, using N -(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(3-chloro-4-fluorophenyl)-2-(1 H -pyrrol-2-yl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 147 using 1 H -pyrrole-2-carbaldehyde in place of nicotinaldehyde. C 17 H 11 ClFN 5 O. 356.1 [M+1] + .
- Example 148 was synthesized analogously to Example 80, using N -(3-chloro-4-fluorophenyl)-2-(1 H -pyrrol-2-yl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- Methyl 2,3-diaminoisonicotinate A mixture of 2,3-diaminoisonicotinic acid (2.0 g, 13 mmol) in sulfuric acid (2.5 mL) and methanol (25 mL) was stirred at 120 °C in a microwave for 1 hr. To the reaction mixture was added aqueous saturated sodium bicarbonate until basic and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the desired product. C 7 H 9 N 3 O 2 . 168.1 (M+1).
- Methyl 2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate was made analogously to Example 147 using methyl 2,3-diaminoisonicotinate and 1H-imidazole-2-carbaldehyde. C 11 H 9 N 5 O 2 . 244.0 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 146 using methyl 2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate in place of methyl 2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate.
- Example 149 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- Example 150 N -(3-Chloro-4-fluorophenyl)- N' -hydroxy-2-(1 H -pyrazol-5-yl)-1 H- imidazo[4,5- b ]pyridine-7-carboximidamide
- N -(3-chloro-4-fluorophenyl)-2-(1 H -pyrazol-5-yl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide was synthesized analogously to Example 147 using 1H-pyrazole-5-carbaldehyde in place of nicotinaldehyde.
- Example 150 was synthesized analogously to Example 80, using N -(3-chloro-4-fluorophenyl)-2-(1 H -pyrazol-5-yl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide in place of N -(3-bromophenyl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide.
- N -(3-chloro-4-fluorophenyl)- N' -hydroxy-2-(4-methyl-1 H -imidazol-2-yl)-1 H- imidazo[4,5- b ]pyridine-7-carboximidamide To a mixture of N -(3-chloro-4-fluorophenyl)-2-(4-methyl-1 H -imidazol-2-yl)-1 H -imidazo[4,5- b ]pyridine-7-carboxamide (0.009 g, 0.024 mmol) in DCE (0.5 mL) and phosphoryl chloride (0.5 mL) was added phosphorus pentachloride (0.008 g, 0.036 mmol).
- N-(3-chloro-4-fluorophenyl)-2-cyanamido-3-nitroisonicotinamide A mixture of 2-chloro-N-(3-chloro-4-fluorophenyl)-3-nitroisonicotinamide (1.02 g, 3.09 mmol), cyanamide (260 mg, 6.18 mmol), and potassium carbonate (1.28 g, 9.27 mmol) in dimethylformamide (10 mL) was stirred at 80 °C for 2 hr. The reaction mixture was absorbed onto silica gel and purified by silica gel chromatography to give the desired product (1.03 g). C 13 H 7 ClFN 5 O 3 . 336.0 (M+1).
- Example 153 was made analogously to Example 107 using 2-amino-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N-(3-chloro-4-fluorophenyl)-2-(cyclopropylamino)-1H-imidazo[4,5-b]pyridine-7-carboxamide Dissolved 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (0.54g, 0.002 mol) in THF (5 ml), to the solution was added cyclopropyl isothiocyanate (0.23g, 0.002 mmol) and triethylamine (1.95g, 0.02 mol).
- Example 154 was made analogously to Example 107 using the general procedure for hydroxyamidine formation. C 16 H 14 ClFN 6 O. 361.1 (M+1).
- Example 155 was made analogously to Example 154 using phenyl isothiocyanate.
- Example 156 was made analogously to Example 154 using (2-isothiocyanatoethyl)benzene. C 21 H 18 ClFN 6 O. 425.1 (M+1).
- Example 157 was made analogously to Example 154 using 1,1,1-trifluoro-2-isothiocyanatoethane.
- Example 158 was made analogously to Example 154 using methyl isothiocyanate. C 14 H 12 ClFN 6 O. 335.1 (M+1).
- Example 159 Isopropyl (7-( N -(3-chloro-4-fluorophenyl)- N'- hydroxycarbamimidoyl)-1 H -imidazo[4,5-b]pyridin-2-yl)carbamate
- Example 159 was made analogously to Example 107 using isopropyl (7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)carbamate in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- Example 160 Ethyl (7-( N -(3-chloro-4-fluorophenyl)- N' -hydroxycarbamimidoyl)-1 H -imidazo[4,5-b]pyridin-2-yl)carbamate
- Example 160 was made analogously to Example 154 using O-ethyl carbonisothiocyanatidate. C 16 H 14 ClFN 6 O 3 . 393.1 (M+1).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
- The present disclosure relates generally to inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) activity and their use and manufacture thereof.
- Catabolism of the essential amino acid tryptophan by the inducible heme-containing enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a central pathway maintaining the immunosuppressive microenvironment in many cancers. IDO1 catalyzes the degradation of tryptophan to kynurenine, and its effects on immune suppression are due to decreased tryptophan availability and the generation of tryptophan metabolites resulting in multipronged negative effects on cytotoxic T lymphocytes, as well as expansion of immunosuppressive regulatory T cells. IDO1 is elevated in multiple cancers, is induced by chemotherapy, targeted therapy, or immunotherapy. IDO1 expression in the tumor microenvironment is correlated with poor prognosis in a variety of cancers. IDO1 inhibitors are positioned to potentiate the efficacy of multiple oncology therapeutics including immunotherapies, targeted agents, and chemotherapies. Indeed, epacadostat (INCB24360), a potent and selective IDO1 inhibitor, entered clinical trials and is demonstrating activity in combination with ipilimumab (anti-CTLA4) in melanoma.
- In addition to the above, IDO1 has been shown to play a role in chronic infections, HIV and AIDS, autoimmune diseases or disorders (e.g., rheumatoid arthritis), and immunologic tolerance, prevention of fetal rejection in utero. Inhibition of IDO1 may also be an important treatment strategy for patients with neurological or neuropsychiatric diseases or disorders, such as depression.
-
WO2015/002918 andWO2014/159248 disclose heteroaryl compounds having activity as inhibitors of indoleamine 2,3-dioxygenase. - A need remains for additional therapeutic agents useful to treat proliferative disorders or diseases that are mediated by IDO1.
- The present disclosure provides compounds that function as inhibitors of IDO1. The disclosure also provides compositions, including pharmaceutical compositions, kits that include the compounds, and methods of making the compounds. The compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated by IDO1. The disclosure also provides compounds for use in therapy. The disclosure further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated by IDO1. Moreover, the disclosure provides uses of the compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by IDO1.
-
- R1 is mono or bicyclic aryl or heteroaryl, wherein each mono or bicyclic aryl or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; and
wherein each C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, - N(R20)(R22) and C3-6 cycloalkyl; - X is N or CR2c;
- R2a, R2b, and R2c are independently hydrogen, hydroxyl, halo, CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, or C1-6 alkyl;
- R2d and R2e are independently hydrogen, C1-6 haloalkyl, C1-6 haloalkoxy, or C1-6 alkyl;
- n and m are independently 0, 1, 2, or 3;
- each Rn and Rm are independently hydrogen, hydroxyl, halo, C1-6 alkoxy, C1-6 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl; or two Rn or Rm join to form a C3-6 cycloalkyl; and
wherein each C1-6 alkoxy, C1-6 alkyl, C3-6 cycloalkyl aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, - N(R20)(R22), C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, and C3-6 cycloalkyl; - L is a bond, -NR3-, -C(O)-NR3-, -NR3-C(O)-, -NR3SO2-, -NR3SO2-NR3-,-SO2NR3-, -O-, -S-, or -S(O)t-, where t is 0, 1 or 2;
- each R3 is independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl; and
- Rt is hydrogen, C1-6 alkyl, C1-6 alkoxy, -C(O)R20, -C(O)OR20, -NC(O)OR20,-N(R20)(R22), -C(O)N(R20)(R22), -SO2R20, -N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), -SO2N(R20)(R22), C3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, provided that when Rt is C1-6 alkoxy, -NC(O)OR20,-N(R20)(R22), -N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), or - SO2N(R20)(R22), and m is 0, then L is a bond;
wherein said C1-6 alkyl, C1-6 alkoxy, C3-15 cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, -C(O)R20, -N(R20)(R22), -SO2R20,-N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), -SO2N(R20)(R22), C3-6 cycloalkyl, -CN, C1-6 alkoxy, C1-6 alkyl, and heterocyclyl; and wherein said heterocyclyl is optionally substituted with one or two oxo;
wherein said C3-6 cycloalkyl, C1-6 alkyl or C1-6 alkoxy is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, - N(R20)(R22), -SO2R20, -N(R20)SO2(R22), -N(R20)SO2-N(R21)(R22)-, and -SO2N(R20)(R22); and said C1-6 alkyl is optionally substituted with aryl; - R20, R21, and R22 are independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, aryl, heterocyclyl, and heteroaryl; wherein said aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three halogen;
- Some embodiments provide the compounds of formula I for use in the treatment of a disease or condition in a mammal, particularly a human, that is amenable to treatment by an IDO1 inhibitor.
- In certain embodiments, the disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of the disclosure (e.g. a compound of Formula I), and at least one pharmaceutically acceptable excipient.
- The inventions of this disclosure are described throughout. In addition, specific embodiments of the invention are as disclosed herein.
- The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.
- As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
- A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.
- The prefix "Cu-v" indicates that the following group has from u to v carbon atoms. For example, "C1-6 alkyl" indicates that the alkyl group has from 1 to 6 carbon atoms.
- Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term "about" includes the indicated amount ± 10%. In other embodiments, the term "about" includes the indicated amount ± 5%. In certain other embodiments, the term "about" includes the indicated amount ± 1%. Also, to the term "about X" includes description of "X". Also, the singular forms "a" and "the" include plural references unless the context clearly dictates otherwise. Thus, e.g., reference to "the compound" includes a plurality of such compounds and reference to "the assay" includes reference to one or more assays and equivalents thereof known to those skilled in the art.
- "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C1-20 alkyl), 1 to 8 carbon atoms (i.e., C1-8 alkyl), 1 to 6 carbon atoms (i.e., C1-6 alkyl), or 1 to 4 carbon atoms (i.e., C1-4 alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, "butyl" includes n-butyl (i.e. -(CH2)3CH3), sec-butyl (i.e. -CH(CH3)CH2CH3), isobutyl (i.e.-CH2CH(CH3)2) and tert-butyl (i.e. -C(CH3)3); and "propyl" includes n-propyl (i.e.-(CH2)2CH3) and isopropyl (i.e. -CH(CH3)2).
- "Alkenyl" refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkenyl), 2 to 8 carbon atoms (i.e., C2-8 alkenyl), 2 to 6 carbon atoms (i.e., C2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-4 alkenyl). Examples of alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).
- "Alkynyl" refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkynyl), 2 to 8 carbon atoms (i.e., C2-8 alkynyl), 2 to 6 carbon atoms (i.e., C2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C2-4 alkynyl). The term "alkynyl" also includes those groups having one triple bond and one double bond.
- "Alkoxy" refers to the group "alkyl-O-". Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. "Haloalkoxy" refers to an alkoxy group as defined above, wherein one or more hydrogen atoms are replaced by a halogen.
- "Acyl" refers to a group -C(=O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.
- "Amido" refers to both a "C-amido" group which refers to the group - C(=O)NRyRz and an "N-amido" group which refers to the group -NRyC(=O)Rz, wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
- "Amino" refers to the group -NRyRz wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, or heteroaryl; each of which may be optionally substituted.
- "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g. monocyclic) or multiple rings (e.g. bicyclic or tricyclic) including fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., C6-20 aryl), 6 to 12 carbon ring atoms (i.e., C6-2 aryl), or 6 to 10 carbon ring atoms (i.e., C6-10 aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl.
- "Cyano" or "carbonitrile" refers to the group -CN.
- "Cycloalkyl" refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term "cycloalkyl" includes cycloalkenyl groups (i.e. the cyclic group having at least one double bond). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-6 cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- "Halogen" or "halo" includes fluoro, chloro, bromo, and iodo. "Haloalkyl" refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two ("di") or three ("tri") halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (-CHF2) and trifluoromethyl (-CF3).
- "Heteroalkyl" refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. The term "heteroalkyl" includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NR-, -O-, -S-, -S(O)-, - S(O)2-, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted. Examples of heteroalkyl groups include -OCH3, -CH2OCH3, -SCH3, -CH2SCH3, -NRCH3, and -CH2NRCH3, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. As used herein, heteroalkyl include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
- "Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl include 1 to 20 ring carbon atoms (i.e., C1-20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C3-12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C3-8 heteroaryl); and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass or overlap with aryl as defined above.
- "Heterocyclyl" or "heterocyclic ring" refers to an unsaturated non-aromatic cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. As used herein, "heterocyclyl" or "heterocyclic ring" refers to rings that are saturated or partially saturated unless otherwise indicated, e.g., in some embodiments "heterocyclyl" or "heterocyclic ring" refers to rings that are partially saturated where specified. The term "heterocyclyl" or "heterocyclic ring" includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond). A heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro. As used herein, heterocyclyl has 2 to 20 ring carbon atoms (i.e., C2-20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C2-12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C2-10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C2-8 heterocyclyl), 3 to 12 ring carbon atoms (i.e., C3-12 heterocyclyl), 3 to 8 ring carbon atoms (i.e., C3-8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C3-6 heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen. Examples of heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl. As used herein, the term "bridged- heterocyclyl" refers to a four- to ten-membered cyclic moiety connected at two non-adjacent atoms of the heterocyclyl with one or more (e.g., 1 or 2) four- to ten-membered cyclic moiety having at least one heteroatom where each heteroatom is independently selected from nitrogen, oxygen, and sulfur. As used herein, "bridged-heterocyclyl" includes bicyclic and tricyclic ring systems. Also as used herein, the term "spiro-heterocyclyl" refers to a ring system in which a three- to ten-membered heterocyclyl has one or more additional ring, wherein the one or more additional ring is three- to ten-membered cycloalkyl or three- to ten-membered heterocyclyl, where a single atom of the one or more additional ring is also an atom of the three- to ten-membered heterocyclyl. Examples of the spiro-heterocyclyl include bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl.
- "Hydroxy" or "hydroxyl" refers to the group -OH.
- "Oxo" refers to the group (=O) or (O).
- "Sulfonyl" refers to the group -S(O)2R, where R is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
- Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent "alkyl" group, a divalent "aryl" group, etc., may also be referred to as an "alkylene" group or an "alkylenyl" group, an "arylene" group or an "arylenyl" group, respectively. Also, unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, e.g. arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
- The terms "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term "optionally substituted" refers to any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.
- The term "substituted" means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof. Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term "substituted" may describe other chemical groups defined herein. For example, the term "substituted aryl" includes, but is not limited to, "alkylaryl." Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.
- In some embodiments, the term "substituted alkyl" refers to an alkyl group having one or more substituents including hydroxyl, halo, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl. In additional embodiments, "substituted cycloalkyl" refers to a cycloalkyl group having one or more substituents including alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl; "substituted heterocyclyl" refers to a heterocyclyl group having one or more substituents including alkyl, haloalkyl, heterocyclyl, cycloalkyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl; "substituted aryl" refers to an aryl group having one or more substituents including halo, alkyl, haloalkyl, cycloalkyl, heterocyclyl, heteroaryl, alkoxy, and cyano; "substituted heteroaryl" refers to an heteroaryl group having one or more substituents including halo, alkyl, haloalkyl, heterocyclyl, heteroaryl, alkoxy, and cyano and "substituted sulfonyl" refers to a group -S(O)2R, in which R is substituted with one or more substituents including alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl. In other embodiments, the one or more substituents may be further substituted with halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted. In other embodiments, the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.
- Some of the compounds exist as tautomeric isomers. Tautomeric isomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.
- Any formula or structure given herein, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18 F, 31P, 32P, 35S, 36Cl and 125I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as 3H, 13C and 14C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
- The disclosure also included compounds of Formula I in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound of Formula I when administered to a mammal, particularly a human. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
- Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index. An 18F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compound of Formula I.
- The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as "H" or "hydrogen", the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.
- In many cases, the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- The term "pharmaceutically acceptable salt" of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, mono, di or tri cycloalkyl amines, mono, di or tri arylamines or mixed amines, etc. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
- Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
- As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- "Treatment" or "treating" is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
- "Prevention" or "preventing" means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
- "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.
- The term "therapeutically effective amount" or "effective amount" of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of IDO1 activity. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.
- The term "inhibition" indicates a decrease in the baseline activity of a biological activity or process. "Inhibition of activity of IDO1" or variants thereof refers to a decrease in activity in IDO1 as a direct or indirect response to the presence of a compound of the present application relative to the activity IDO1 in the absence of the compound of the present application. "Inhibition of IDO1" refers to a decrease in IDO1 activity as a direct or indirect response to the presence of a compound described herein relative to the activity of IDO1 in the absence of the compound described herein. In some embodiments, the inhibition of IDO1 activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment.
-
- R1 is mono or bicyclic aryl or heteroaryl, wherein each mono or bicyclic aryl or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; and
wherein each C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN,-N(R20)(R22) and C3-6 cycloalkyl; - X is N or CR2c;
- R2a, R2b, and R2c are independently hydrogen, hydroxyl, halo, CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, or C1-6 alkyl;
- R2d and R2e are independently hydrogen, C1-6 haloalkyl, C1-6 haloalkoxy, or C1-6 alkyl;
- n and m are independently 0, 1, 2, or 3;
- each Rn and Rm are independently hydrogen, hydroxyl, halo, C1-6 alkoxy, C1-6 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl; or two Rn or Rm join to form a C3-6 cycloalkyl; and
wherein each C1-6 alkoxy, C1-6 alkyl, C3-6 cycloalkyl aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN,-N(R20)(R22), C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, and C3-6 cycloalkyl; - L is a bond, -NR3-, -C(O)-NR3-, -NR3-C(O)-, -NR3SO2-, -NR3SO2-NR3-,-SO2NR3-, -O-, -S-, or -S(O)t-, where t is 0, 1 or 2;
- each R3 is independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl; and
- Rt is hydrogen, C1-6 alkyl, C1-6 alkoxy, -C(O)R20, -C(O)OR20, -NC(O)OR20,-N(R20)(R22), -C(O)N(R20)(R22), -SO2R20, -N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), -SO2N(R20)(R22), C3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, provided that when Rt is C1-6 alkoxy, -NC(O)OR20,-N(R20)(R22), -N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), or-SO2N(R20)(R22), and m is 0, then L is a bond;
wherein said C1-6 alkyl, C1-6 alkoxy, C3-15 cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, -C(O)R20, -N(R20)(R22), -SO2R20,-N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), -SO2N(R20)(R22), C3-6 cycloalkyl, -CN, C1-6 alkoxy, C1-6 alkyl, and heterocyclyl; and wherein said heterocyclyl is optionally substituted with one or two oxo;
wherein said C3-6 cycloalkyl, C1-6 alkyl or C1-6 alkoxy is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy,-N(R20)(R22), -SO2R21, -N(R20)SO2(R22), -N(R20)SO2-N(R21)(R22)-, and -SO2N(R20)(R22); and said C1-6 alkyl is optionally substituted with aryl; - R20, R21, and R22 are independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, aryl, heterocyclyl, and heteroaryl; wherein said aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three halogen;
- In some embodiments, R1 is bicyclic aryl or heteroaryl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; and wherein each C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, -N(R20)(R22), and C3-6 cycloalkyl.
- In some embodiments, R1 is bicyclic aryl or heteroaryl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl.
- In some embodiments, the compound is selected from the group consisting of:
- N'-hydroxy-N-naphthalen-2-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N'-hydroxy-N-naphthalen-1-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(4-chloronaphthalen-1-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(1-benzofuran-4-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(1-benzofuran-6-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(1-benzofuran-7-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide; and
- N-(1-benzofuran-5-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide.
- In some embodiments, R1 is phenyl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; and wherein each C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, -N(R20)(R22), and C3-6 cycloalkyl.
- In some embodiments, R1 is phenyl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, -CHF2, -O-CHF2, -CF3, -O-CF3, C1-4 alkoxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, and C3-6 cycloalkyl, and wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring.
- In some embodiments, at least one of R2a, R2b, and, when present, R2c are not hydrogen. In some embodiments, R2a is not hydrogen. In some embodiments, R2b is not hydrogen. In some embodiments, R2c is not hydrogen.
- In some embodiments, the compound is selected from the group consisting of:
- N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 7-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-(trifluoromethyl)-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-morpholin-4-ylethylamino)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(methylaminomethyl)-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-(trifluoromethoxy)-3H-benzimidazole-4-carboximidamide; and
- N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide.
- In some embodiments, L is a bond.
- In some embodiments, Rt is C1-6 alkyl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, -CN, and C1-6 alkoxy.
- In some embodiments, the compound is selected from the group consisting of:
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- 2-(chloromethyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2,2,2-trifluoro-1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[cyclopropyl(hydroxy)methyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-hydroxypropan-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide; and
- 2-(aminomethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide.
- In some embodiments, Rt is C3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein said cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, -CN, C1-6 alkoxy and C1-6 alkyl.
- In some embodiments, the compound is selected from the group consisting of:
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-morpholin-4-ylethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(pyrrolidin-1-ylmethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(piperidin-1-ylmethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-pyridin-3-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-pyrrol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2S)-pyrrolidin-2-yl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-pyrazol-5-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-cyclopropyl-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-thiophen-2-yl-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(morpholin-4-ylmethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[hydroxy(phenyl)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-ethyl-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-piperidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-pyrrolidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide; and
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(5-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide.
- In some embodiments, Rt is hydrogen.
- In some embodiments, the compound is selected from the group consisting of:
- N-(3-ethynylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-ethynyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-[3-(difluoromethyl)phenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N'-hydroxy-N-[3-(trifluoromethoxy)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N'-hydroxy-N-phenyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-ethylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-[4-fluoro-3-(trifluoromethoxy)phenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(4-fluoro-3-methoxyphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(5-bromo-2-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-bromo-5-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N'-hydroxy-N-[3-(trifluoromethyl)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-[3-fluoro-5-(trifluoromethyl)phenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-bromophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-bromo-4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chlorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(4-fluoro-3-prop-1-ynylphenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-bromo-4-chlorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3,4-dichlorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(4-chlorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(4-bromophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-cyano-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N'-hydroxy-N-[4-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N'-hydroxy-N-(3-methoxyphenyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(4-fluoro-3-propan-2-ylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N'-hydroxy-N-(4-methylphenyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(5-chloro-2-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(5-bromo-2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(5-chloro-2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(2,5-dichlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3,5-dichloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chlor2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-cyclopropyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(4-fluoro-3-phenylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-but-1-ynyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-[3-(2-cyclopropylethynyl)-4-fluorophenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide; and
- N'-hydroxy-N-[4-(trifluoromethoxy)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide.
- In some embodiments, L is -NR3.
- In some embodiments, Rt is C1-6 optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, -N(R20)(R22), -SO2R20, C3-6 cycloalkyl, -CN, and C1-6 alkoxy.
- In some embodiments,, the compound is selected from the group consisting of:
- N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[2-(methylamino)ethyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-((2-methoxyethyl)amino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide
- N-(3-chloro-4-fluorophenyl)-2-[(2,2-dimethylpropylamino)methyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[2-(2-methoxyethylamino)ethyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- ethyl N-[7-[(Z)-N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]carbamate;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2,2,2-trifluoroethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-(dimethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)-1-hydroxyethyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2-methylpropylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methylaminomethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-[2,2-difluoroethyl(methyl)amino]ethyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(propan-2-ylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[(2,2-difluoroethylamino)methyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[[(3-hydroxy-2,2-dimethylpropyl)amino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(propan-2-ylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-(ethylaminomethyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-(ethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(3-methoxypropylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[(dimethylamino)methyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[[3-methoxypropyl(methyl)amino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2-methoxyethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2,2,2-trifluoroethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[[2-(dimethylamino)ethylamino]methyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(3-hydroxypropylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-[[7-[(Z)-N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl] acetamide;
- N-(3-chlorophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[2-[2-methoxyethyl(methyl)amino]ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethylamino]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide; and
- N-(3-chlorophenyl)-2-((dimethylamino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide.
- In some embodiments, L is -NR3 and Rt is C3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein said cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, -CN, and C1-6 alkoxy.
- In some embodiments, the compound is selected from the group consisting of:
- N-(3-chloro-4-fluorophenyl)-2-(cyclopropylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-(cyclopropylmethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-phenylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- 2-anilino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyrimidin-2-ylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-(cyclobutylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(1,3-thiazol-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[(cyclopropylmethylamino)methyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyridin-2-ylmethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- 2-[(benzylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[[(2-methoxyphenyl)methylamino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2-pyridin-2-ylethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[(cyclopropylamino)methyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyridin-3-ylmethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(oxan-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- 2-(anilinomethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(oxan-3-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyrimidin-2-ylmethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(3-morpholin-4-ylpropylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(oxan-4-ylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyridin-4-ylmethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyrazin-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(oxolan-3-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2-pyrimidin-2-ylethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-[cyclopropylmethyl(methyl)amino]ethyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-morpholin-4-ylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(1-methylpiperidin-2-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide; and
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(1-methylpyrrolidin-3-yl)amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide.
- In some embodiments, L is -NR3 and Rt is hydrogen.
- In some embodiments, the compound is selected from the group consisting of:
- 2-(2-aminoethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide; and
- 2-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide.
- In some embodiments, L is -SO2NR3-.
- In some embodiments, the compound is selected from the group consisting of:
- 2-(benzenesulfonamidomethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide, and
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methanesulfonamidomethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide.
- In some embodiments, X is -N-.
- In some embodiments, X is -CR2c-.
- In some embodiments, the compound is selected from the group consisting of:
- N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 7-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-(trifluoromethyl)-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-morpholin-4-ylethylamino)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(methylaminomethyl)-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-(trifluoromethoxy)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(hydroxymethyl)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-morpholin-4-yl-3H-benzimidazole-4-carboximidamide;
- N-(3-chlorophenyl)-6,7-difluoro-N'-hydroxy-2-(1-methylpiperidin-3-yl)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 6-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 7-bromo-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-[(3-methoxypropylamino)methyl]-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propyl]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(methylamino)-3H-benzimidazole-4-carboximidamide;
- N-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-bromophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chlorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propylamino]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-methoxyethylamino)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethylamino]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-[(propan-2-ylamino)methyl]-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[(dimethylamino)methyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-(ethylaminomethyl)-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-[2-(methylamino)ethyl]-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-2-(2-methylsulfonylethylamino)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-methylsulfonylethylamino)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[(cyclopropylmethylamino)methyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-2-(3-morpholin-4-ylpropylamino)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-2-[2-(4,4-difluoropiperidin-1-yl)ethylamino]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(1-morpholin-4-ylpropan-2-ylamino)-3H-benzimidazole-4-carboximidamide;
- 2-(aminomethyl)-N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide;
- 2-amino-N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-N-(3-bromo-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-N-(3-bromophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-N-(3-chlorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-N-(3-bromophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-N-(3-bromo-4-fluorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-N-(3-chlorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-6,7-difluoro-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- 2-amino-7-fluoro-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-3H-benzimidazole-4-carboximidamide;
- N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3-methoxypropyl)amino)methyl)-1H-benzo[d]imidazole-7-carboximidamide;
- N-(3-chlorophenyl)-2-(((cyclopropylmethyl)amino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide;
- N-(3-chlorophenyl)-2-((dimethylamino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide;
- N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((isopropylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide;
- N-(3-chlorophenyl)-2-((ethylamino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide;
- N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(hydroxymethyl)-1H-benzo[d]imidazole-7-carboximidamide;
- N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((methylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide;
- 2-(aminomethyl)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide; and
- N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide.
- In some embodiments, L is -C(O)-NR3-.
- In some embodiments, the compound is selected from the group consisting of:
- ethyl N-[7-[(Z)-N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]carbamate;
- N-[[7-[(Z)-N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]acetamide; and
- propan-2-yl N-[7-[(Z)-N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]carbamate.
- In some embodiments, L is N, m is 1, and n is 0.
- In some embodiments, L is N, m is 2, and n is 0.
- In some embodiments, L is N, m is 3, and n is 0.
-
-
-
-
-
-
-
- In one embodiment, the group
-
-
-
-
- wherein R2a, R2b, X, Rm, Rn, m, n, and Rt are as defined herein and each R1a is independently hydroxyl, halo, -CN, C1-6 haloalkoxy, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, or two of the optional substituents can join to form an additional partially saturated heterocyclic ring, and
- s is 0, 1, 2 or 3.
- In some embodiments, each R1a is independently hydroxyl, halo, -CN, C1-6 haloalkoxy, or C1-6 haloalkyl. In some embodiments, each R1a is independently halo or - CF3. In some embodiments, each R1a is independently halo. In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3.
- In general, the specific compounds exemplified herein are named using ChemBioDraw Ultra. However, it is understood that other names may be used to identify compounds of the same structure. In particular, the compounds may also be named using other nomenclature systems and symbols that are commonly recognized in the art of chemistry including, for example, Chemical Abstract Service (CAS) and International Union of Pure and Applied Chemistry (IUPAC). Other compounds or radicals may be named with common names, or systematic or non-systematic names.
- For example, the compound of Example 10 (shown below) may be referred to as N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide or N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide, where both names provide the structure below.
- Provided are also all tautomeric forms of the compounds of any Formula described herein. Tautomeric isomers are in equilibrium with one another. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both. Non-limiting examples of benzimidazole and imidazo[4,5-b]pyridine tautomers are shown below:
- Provided are also compounds described herein or pharmaceutically acceptable salts, or a mixture thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. As known in the art, the deuterium atom is a non-radioactive isotope of the hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
- Provided are also pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein. "Pharmaceutically acceptable" or "physiologically acceptable" refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use. "Pharmaceutically acceptable salts" or "physiologically acceptable salts" include, for example, salts with inorganic acids and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts.
- A "solvate" is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
- A "prodrug" is a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
- In certain embodiments, provided are optical isomers, racemates, or other mixtures thereof of the compounds described herein or pharmaceutically acceptable salts or a mixture thereof. In those situations, the single enantiomer or diastereomer, i.e., optically active form, can be obtained by asymmetric synthesis or by resolution of the racemate. Resolution of racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column. In addition, provided are also Z- and E- forms (or cis- and trans- forms) of the hydroxyamidine compounds described herein. Specifically, Z- and E- forms are included even if only one designation is named for both carbon-carbon double bonds as well as the hydroxyamidine bond.
- Compositions provided herein that include a compound described herein or pharmaceutically acceptable salts, or a mixture thereof may include racemic mixtures, or mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein the same as if each and every isomeric form were specifically and individually listed.
- In certain embodiments, provided herein are also crystalline and amorphous forms of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof.
- In certain embodiments, provided are also chelates, non-covalent complexes, and mixtures thereof, of the compounds described herein or pharmaceutically acceptable salts, or a mixture thereof. A "chelate" is formed by the coordination of a compound to a metal ion at two (or more) points. A "non-covalent complex" is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
- The methods described herein may be applied to cell populations in vivo or ex vivo. "In vivo" means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual. "Ex vivo" means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the invention may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the invention may be used ex vivo to determine the optimal schedule and/or dosing of administration of an IDOl inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the invention may be suited are described below or will become apparent to those skilled in the art. The selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.
- In some embodiments, the compounds described herein may be used to treat subjects who have or are suspected of having disease states, disorders, and conditions (also collectively referred to as "indications") responsive or believed to be responsive to the inhibition of IDO1 activity. In some embodiments, the compounds described herein may be used to inhibit the activity of an IDOl polypeptide. In some embodiments, the compounds described herein may be used to inhibit excessive or destructive immune reactions or growth or a proliferation of a cell, such as a cancer cell, or inhibit immunosuppression.
- Example indications suitable for treatment with compounds described here include, without limitation cancer, viral infection such as HIV infection, HBV infection, HCV infection, other infections (e.g., skin infections, GI infection, urinary tract infections, genito-urinary infections, and systemic infections), depression, neurodegenerative disorders such as Alzheimer's disease and Huntington's disease, trauma, age-related cataracts, organ transplantation (e.g., organ transplant rejection), and autoimmune diseases.
- Examples of autoimmune diseases include, but are not limited to, asthma, collagen diseases such as rheumatoid arthritis, systemic lupus erythematosus. Sharp's syndrome, CREST syndrome (calcinosis, Raynaud's syndrome, esophageal dysmotility, sclerodactyly, telangiectasia), dermatomyositis, vasculitis (Morbus Wegener's) and Sjögren's syndrome, renal diseases such as Goodpasture's syndrome, rapidly- progressing glomerulonephritis and membrano-proliferative glomerulonephritis type II, endocrine diseases such as type-I diabetes, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), autoimmune parathyroidism, pernicious anemia, gonad insufficiency, idiopathic Morbus Addison's, hyperthyreosis, Hashimoto's thyroiditis and primary myxedema, skin diseases such as pemphigus vulgaris, bullous pemphigoid, herpes gestationis, epidermolysis bullosa and erythema multiforme major, liver diseases such as primary biliary cirrhosis, autoimmune cholangitis, autoimmune hepatitis type-1, autoimmune hepatitis type-2, primary sclerosing cholangitis, neuronal diseases such as multiple sclerosis, myasthenia gravis, myasthenic Lambert-Eaton syndrome, acquired neuromyotomy, Guillain-Barre syndrome (Muller-Fischer syndrome), stiff-man syndrome, cerebellar degeneration, ataxia, opsoclonus, sensoric neuropathy and achalasia, blood diseases such as autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (Morbus Werlhof), infectious diseases with associated autoimmune reactions such as AIDS, allergic inflammation, inflammatory bowel disease, psoriasis and systemic lupus erythematosusor, malaria and Chagas disease.
- In some embodiments, the compounds described herein may be used for treating cancer, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disease.
- In other embodiments, the disease to be treated is a solid tumor. In particular embodiments, the solid tumor is from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma. In some embodiments, the solid tumor is from non-small cell lung cancer, small-cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, or breast cancer..
- In some embodiments, the disease is an autoimmune disease. In particular embodiments, the autoimmune disease is systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), psoriasis, Sjoegren's syndrome, psoriasis, autoimmune hemolytic anemia, asthma, or chronic obstructive pulmonary disease (COPD). In other embodiments, the disease is inflammation. In yet other embodiments, the disease is excessive or destructive immune reactions, such as asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), and lupus.
- Provided is a compound of formula I for use in a method for treating a subject, who has or is suspected of having a disease or condition responsive or believed to be responsive to the inhibition of IDO1 activity by administering to the subject the compound described herein or pharmaceutically acceptable salts, or a mixture thereof. Provided is also a method of inhibiting kinase activity of a IDO1 polypeptide by contacting the polypeptide with the compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof. Provided is also a compound of formula I for use in a method of inhibiting a growth or a proliferation of cancer cells of hematopoietic origin comprising contacting the cancer cells with an effective amount of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof.
- In one embodiment, the compounds of the present application may be used in combination with one or more additional therapeutic agent that are being used and/or developed to treat cancers or inflammatory disorders. The one or more additional therapeutic agent may be a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti-proliferation agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof.
- The one or more additional therapeutic agent may be an inhibitor to PI3K such as PI3Kγ, PI3Kβ, PI3Kδ, and/or PI3Kα, Janus kinase (JAK) such as JAK1, JAK2 and/or JAK3 , spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), bromodomain containing protein inhibitor (BRD) such as BRD4, a lysyl oxidase protein (LOX), lysyl oxidase-like protein (LOXL) such as LOXL1-5, matrix metalloprotease (MMP) such as MMP 1-10, adenosine A2B receptor (A2B), isocitrate dehydrogenase (IDH) such as IDH1, apoptosis signal-regulating kinase (ASK) such as ASK1, serine/threonine kinase TPL2, discoidin domain receptor (DDR) such as DDR1 and DDR2, histone deacetylase (HDAC), protein kinase C (PKC), or any combination thereof.
- A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, including but not limited to PI3Kγ, PI3Kβ, PI3Kδ, and PI3Kα. Non-limiting examples of PI3K inhibitors include wortmannin, demethoxyviridin, LY294002, idelalisib, perifosine, PX-866, IPI-145, BAY 80-6946, BEZ235, RP6530, TGR 1202, INK1117, GDC-0941, BKM120, XL147 (also known as SAR245408), XL765 (also known as SAR245409), Palomid 529, GSK1059615, ZSTK474, PWT33597, IC87114, CAL263, RP6503, PI-103, GNE-477, CUDC-907 and AEZS-136. In some embodiments, the PI3K inhibitor is a PI3Kδ inhibitors, such as idelalisib, IPI-145, RP6530, and RP6503, as well as those disclosed in
U.S. Patent No. 8,569,296 , andPCT publications WO 2014/006572 andWO 2015/001491 - In some embodiments, the one or more additional therapeutic agent may be an MMP9 inhibitor, or an agent that inhibits the expression and/or activity of MMP9. A representative protein sequence for MMP9 is GenBank Accession No. NP_004985. The inhibitor can be small molecule or biologic. For instance, Gu et al., The Journal of Neuroscience, 25(27): 6401-6408 (2005) discloses a specific MMP9 inhibitor, SB-3CT (CAS 292605-14-2). Further, siRNA, antisense RNA and antibodies have also been demonstrated to inhibit the expression or activity of MMP9 and are within the scope of the present disclosure. In one embodiment, an MMP9 inhibitor is a monoclonal anti-MMP9 antibody. In some embodiment, the one or more additional therapeutic agent includes an MMP9 inhibitor and a nucleoside analog such as gemcitabine.
- One, two, three, or more of the therapeutic agents (e.g. a PI3K inhibitor, a JAK inhibitor, a SYK inhibitor, a BTK inhibitor, a BRD4 inhibitor, a LOXL2 inhibitor, a MMP9 inhibitor, a A2B inhibitor, an IDH inhibitor, an ASK inhibitor, a TPL2 inhibitor, a DDR1 inhibitor, a TBK inhibitor, a HDAC inhibitor, a PKC inhibitor) may be further used or combined with a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof.
- Chemotherapeutic agents may be categorized by their mechanism of action into, for example, the following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (floxuridine, capecitabine, and cytarabine); purine analogs, folate antagonists and related inhibitors, antiproliferative/antimitotic agents including natural products such as vinca alkaloid (vinblastine, vincristine) and microtubule such as taxane (paclitaxel, docetaxel), vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide); DNA damaging agents (actinomycin, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, iphosphamide, melphalan, merchlorehtamine, mitomycin, mitoxantrone, nitrosourea, procarbazine, taxol, taxotere, teniposide, etoposide, triethylenethiophosphoramide); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/ antimitotic alkylating agents such as nitrogen mustards cyclophosphamide and analogs, melphalan, chlorambucil), and (hexamethylmelamine and thiotepa), alkyl nitrosoureas (BCNU) and analogs, streptozocin), trazenes-dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, oxiloplatinim, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel; antimigratory agents; antisecretory agents (breveldin); immunosuppressives tacrolimus sirolimus azathioprine, mycophenolate; compounds (TNP-470, genistein) and growth factor inhibitors (vascular endothelial growth factor inhibitors, fibroblast growth factor inhibitors); angiotensin receptor blocker, nitric oxide donors; anti-sense oligonucleotides; antibodies (trastuzumab, rituximab); cell cycle inhibitors and differentiation inducers (tretinoin); inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan and mitoxantrone, topotecan, irinotecan, camptothesin), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylpednisolone, prednisone, and prenisolone); growth factor signal transduction kinase inhibitors; dysfunction inducers, toxins such as Cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, or diphtheria toxin, and caspase activators; and chromatin.
- As used herein the term "chemotherapeutic agent" or "chemotherapeutic" (or "chemotherapy," in the case of treatment with a chemotherapeutic agent) is meant to encompass any non-proteinaceous (i.e., non-peptidic) chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; emylerumines and memylamelamines including alfretamine, triemylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimemylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (articularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, foremustine, lomustine, nimustine, ranimustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammaII and calicheamicin phiI1, see, e.g., Agnew, Chem. Intl. Ed. Engl, 33:183-186 (1994); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carrninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as demopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replinisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformthine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; leucovorin; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; losoxantrone; fluoropyrimidine; folinic acid; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK(r); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-tricUorotriemylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiopeta; taxoids, e.g., paclitaxel (TAXOL(r) and docetaxel (TAXOTERE(r)); chlorambucil; gemcitabine (Gemzar(r)); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitroxantrone; vancristine; vinorelbine (Navelbine(r)); novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeoloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoids such as retinoic acid; capecitabine; FOLFIRI (fluorouracil, leucovorin, and irinotecan) and pharmaceutically acceptable salts, acids or derivatives of any of the above. One or more chemotherapeutic agent are used or included in the present application. For example, gemcitabine, nab-paclitaxel, and gemcitabine/nab-paclitaxel are used with the JAK inhibitor and/or PI3Kδ inhibitor for treating hyperproliferative disorders.
- Also included in the definition of "chemotherapeutic agent" are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as antiestrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including Nolvadex™), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston(r)); inhibitors of the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate (Megace(r)), exemestane, formestane, fadrozole, vorozole (Rivisor(r)), letrozole (Femara(r)), and anastrozole (Arimidex(r).); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprohde, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
- The anti-angiogenic agents include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN(r), ENDOSTATIN(r), suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproternase-2, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulfated chitin derivatives (prepared from queen crab shells), sulfated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((1-azetidine-2-carboxylic acid (LACA), cishydroxyproline, D,L-3,4-dehydroproline, thiaproline, .alpha.-dipyridyl, beta-aminopropionitrile fumarate, 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; methotrexate, mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chimp-3, chymostatin, beta-cyclodextrin tetradecasulfate, eponemycin; fumagillin, gold sodium thiomalate, d-penicillamine (CDPT), beta-1-anticollagenase-serum, alpba-2-antiplasmin, bisantrene, lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA", thalidomide; angiostatic steroid, cargboxynaminolmidazole; metalloproteinase inhibitors such as BB94. Other anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and Ang-1/Ang-2. See Ferrara N. and Alitalo, K. "Clinical application of angiogenic growth factors and their inhibitors" (1999) Nature Medicine 5:1359-1364.
- The anti-fibrotic agents include, but are not limited to, the compounds such as beta-aminoproprionitrile (BAPN), as well as the compounds disclosed in
U.S. Pat. No. 4,965,288 to Palfreyman, et al., issued Oct. 23, 1990 , entitled "Inhibitors of lysyl oxidase," relating to inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen;U.S. Pat. No. 4,997,854 to Kagan, et al., issued Mar. 5, 1991 , entitled "Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in situ using adjacently positioned diamine analogue substrate," relating to compounds which inhibit LOX for the treatment of various pathological fibrotic states, which are herein incorporated by reference. Further exemplary inhibitors are described inU.S. Pat. No. 4,943,593 to Palfreyman, et al., issued Jul. 24, 1990 , entitled "Inhibitors of lysyl oxidase," relating to compounds such as 2-isobutyl-3-fluoro-, chloro-, or bromo-allylamine; as well as, e.g.,U.S. Pat. No. 5,021,456 ;U.S. Pat. No. 5,5059,714 U.S. Pat. No. 5,120,764 ;U.S. Pat. No. 5,182,297 ;U.S. Pat. No. 5,252,608 (relating to 2-(1-naphthyloxymemyl)-3-fluoroallylamine); andU.S. Patent Application No. 2004/0248871 , which are herein incorporated by reference. Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product stabilized by resonance, such as the following primary amines: emylenemamine, hydrazine, phenylhydrazine, and their derivatives, semicarbazide, and urea derivatives, aminonitriles, such as beta-aminopropionitrile (BAPN), or 2-nitroethylamine, unsaturated or saturated haloamines, such as 2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine, 3-bromopropylamine, p-halobenzylamines, selenohomocysteine lactone. Also, the anti-fibrotic agents are copper chelating agents, penetrating or not penetrating the cells. Exemplary compounds include indirect inhibitors such compounds blocking the aldehyde derivatives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases, such as the thiolamines, in particular D-penicillamine, or its analogues such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetamidoethyl)dithio)butanoic acid, p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid, sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sulphanate, sodium-4-mercaptobutanesulphinate trihydrate. - The immunotherapeutic agents include and are not limited to therapeutic antibodies suitable for treating patients; such as abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farietuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, narnatumab, naptumomab, necitumumab, , nimotuzumab, nofetumomabn, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, simtuzumab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, CC49 and 3F8. The exemplified therapeutic antibodies may be further labeled or combined with a radioisotope particle, such as indium In 111, yttrium Y 90, iodine 1-131.
- The application also provides a compound of formula I for use in a method for treating a subject who is undergoing one or more standard therapies, such as chemotherapy, radiotherapy, immunotherapy, surgery, or combination thereof. Accordingly, one or more therapeutic agent or inhibitors may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, surgery or combination thereof.
- In certain embodiments, the subject may be a human who is (i) substantially refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii). In some of embodiments, the subject is refractory to at least two, at least three, or at least four chemotherapy treatments (including standard or experimental chemotherapies).
- In certain embodiments, the subject is refractory to at least one, at least two, at least three, or at least four chemotherapy treatment (including standard or experimental chemotherapy) selected from fludarabine, rituximab, obinutuzumab, alkylating agents, alemtuzumab and other chemotherapy treatments such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone); R-CHOP (rituximab-CHOP); hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine); R-hyperCVAD (rituximab-hyperCVAD); FCM (fludarabine, cyclophosphamide, mitoxantrone); R-FCM (rituximab, fludarabine, cyclophosphamide, mitoxantrone); bortezomib and rituximab; temsirolimus and rituximab; temsirolimus and Velcade®; Iodine-131 tositumomab (Bexxar®) and CHOP; CVP (cyclophosphamide, vincristine, prednisone); R-CVP (rituximab-CVP); ICE (iphosphamide, carboplatin, etoposide); R-ICE (rituximab-ICE); FCR (fludarabine, cyclophosphamide, rituximab); FR (fludarabine, rituximab); and D.T. PACE (dexamethasone, thalidomide, cisplatin, Adriamycin®, cyclophosphamide, etoposide).
- Other examples of chemotherapy treatments (including standard or experimental chemotherapies) are described below. In addition, treatment of certain lymphomas is reviewed in Cheson, B.D., Leonard, J.P., "Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma" The New England Journal of Medicine 2008, 359(6), p. 613-626; and Wierda, W.G., "Current and Investigational Therapies for Patients with CLL" Hematology 2006, p. 285-294. Lymphoma incidence patterns in the United States is profiled in Morton, L.M., et al. "Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992-2001" Blood 2006, 107(1), p. 265-276.
- Examples of immunotherapeutic agents treating lymphoma or leukemia include, but are not limited to, rituximab (such as Rituxan), alemtuzumab (such as Campath, MabCampath), anti-CD 19 antibodies, anti-CD20 antibodies, anti-MN-14 antibodies, anti-TRAIL, Anti-TRAIL DR4 and DR5 antibodies, anti-CD74 antibodies, apolizumab, bevacizumab, CHIR-12.12, epratuzumab (hLL2- anti-CD22 humanized antibody), galiximab, ha20, ibritumomab tiuxetan, lumiliximab, milatuzumab, ofatumumab, PRO131921, SGN-40, WT-1 analog peptide vaccine, WT1 126-134 peptide vaccine, tositumomab, autologous human tumor-derived HSPPC-96, and veltuzumab. Additional immunotherapy agents includes using cancer vaccines based upon the genetic makeup of an individual patient's tumor, such as lymphoma vaccine example is GTOP-99 (MyVax®).
- Examples of chemotherapy agents for treating lymphoma or leukemia include aldesleukin, alvocidib, antineoplaston AS2-1, antineoplaston A10, anti-thymocyte globulin, amifostine trihydrate, aminocamptothecin, arsenic trioxide, beta alethine, Bcl-2 family protein inhibitor ABT-263, BMS-345541, bortezomib (Velcade®), bryostatin 1, busulfan, carboplatin, campath-1H, CC-5103, carmustine, caspofungin acetate, clofarabine, cisplatin, Cladribine (Leustarin), Chlorambucil (Leukeran), Curcumin, cyclosporine, Cyclophosphamide (Cyloxan, Endoxan, Endoxana, Cyclostin), cytarabine, denileukin diftitox, dexamethasone, DT PACE, docetaxel, dolastatin 10, Doxorubicin (Adriamycin®, Adriblastine), doxorubicin hydrochloride, enzastaurin, epoetin alfa, etoposide, Everolimus (RAD001), fenretinide, filgrastim, melphalan, mesna, Flavopiridol, Fludarabine (Fludara), Geldanamycin (17-AAG), ifosfamide, irinotecan hydrochloride, ixabepilone, Lenalidomide (Revlimid®, CC-5013), lymphokine-activated killer cells, melphalan, methotrexate, mitoxantrone hydrochloride, motexafin gadolinium, mycophenolate mofetil, nelarabine, oblimersen (Genasense) Obatoclax (GX15-070), oblimersen, octreotide acetate, omega-3 fatty acids, oxaliplatin, paclitaxel, PD0332991, PEGylated liposomal doxorubicin hydrochloride, pegfilgrastim, Pentstatin (Nipent), perifosine, Prednisolone, Prednisone, R-roscovitine (Selicilib, CYC202), recombinant interferon alfa, recombinant interleukin-12, recombinant interleukin-11, recombinant flt3 ligand, recombinant human thrombopoietin, rituximab, sargramostim, sildenafil citrate, simvastatin, sirolimus, Styryl sulphones, tacrolimus, tanespimycin, Temsirolimus (CCl-779), Thalidomide, therapeutic allogeneic lymphocytes, thiotepa, tipifarnib, Velcade® (bortezomib or PS-341), Vincristine (Oncovin), vincristine sulfate, vinorelbine ditartrate, Vorinostat (SAHA), vorinostat, and FR (fludarabine, rituximab), CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CVP (cyclophosphamide, vincristine and prednisone), FCM (fludarabine, cyclophosphamide, mitoxantrone), FCR (fludarabine, cyclophosphamide, rituximab), hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), ICE (iphosphamide, carboplatin and etoposide), MCP (mitoxantrone, chlorambucil, and prednisolone), R-CHOP (rituximab plus CHOP), R-CVP (rituximab plus CVP), R-FCM (rituximab plus FCM), R-ICE (rituximab-ICE), and R-MCP (Rituximab-MCP).
- In some embodiments, the cancer is melanoma. Suitable agents for use in combination with the compounds described herein include, without limitation, dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen", which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC, temozolomide or YERVOY™. Compounds according to the invention may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in the treatment of melanoma.
- Compounds described here may also be used in combination with vaccine therapy in the treatment of melanoma. Anti-melanoma vaccines are, in some ways, similar to the anti-virus vaccines which are used to prevent diseases caused by viruses such as polio, measles, and mumps. Weakened melanoma cells or parts of melanoma cells called antigens may be injected into a patient to stimulate the body's immune system to destroy melanoma cells.
- Melanomas that are confined to the arms or legs may also be treated with a combination of agents including one or more compounds described herein, using a hyperthermic isolated limb perfusion technique. This treatment protocol temporarily separates the circulation of the involved limb from the rest of the body and injects high doses of chemotherapy into the artery feeding the limb, thus providing high doses to the area of the tumor without exposing internal organs to these doses that might otherwise cause severe side effects. Usually the fluid is warmed to 102° to 104° F. Melphalan is the drug most often used in this chemotherapy procedure. This can be given with another agent called tumor necrosis factor (TNF).
- The therapeutic treatments can be supplemented or combined with any of the abovementioned therapies with stem cell transplantation or treatment. One example of modified approach is radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as indium In 111, yttrium Y 90, iodine 1-131. Examples of combination therapies include, but are not limited to, Iodine-131 tositumomab (Bexxar®), Yttrium-90 ibritumomab tiuxetan (Zevalin®), Bexxar® with CHOP.
- Other therapeutic procedures include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, pharmacological study, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
- In certain embodiments, a compound of formula I for use in a method for treating or preventing an HBV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents. In one embodiment, a compound of formula I for use in a method for treating an HBV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.
- In certain embodiments, the present disclosure provides a compound of formula I for use in a method for treating an HBV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents which are suitable for treating an HBV infection.
- In one embodiment, pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent or excipient are provided.
- In one embodiment, kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents are provided.
- In the above embodiments, the additional therapeutic agent may be an anti-HBV agent. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B core antigen (HbcAg), cyclophilin inhibitors , HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP (Na+-taurocholate cotransporting polypeptide) inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, hepatitis B virus E antigen inhibitors, recombinant scavenger receptor A (SRA) proteins, Src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NOD1, Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, Natural Killer Cell Receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PEG-Interferon Lambda, recombinant thymosin alpha-1, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha, modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), Hepatitis B virus replication inhibitors compounds such as those disclosed in
US20100143301 (Gilead Sciences),US20110098248 (Gilead Sciences),US20090047249 (Gilead Sciences),US8722054 (Gilead Sciences),US20140045849 (Janssen),US20140073642 (Janssen),WO2014/056953 (Janssen),WO2014/076221 (Janssen),WO2014/128189 (Janssen),US20140350031 (Janssen),WO2014/023813 (Janssen),US20080234251 (Array Biopharma),US20080306050 (Array Biopharma),US20100029585 (Ventirx Pharma),US20110092485 (Ventirx Pharma),US20110118235 (Ventirx Pharma),US20120082658 (Ventirx Pharma),US20120219615 (Ventirx Pharma),US20140066432 (Ventirx Pharma),US20140088085 (VentirxPharma),US20140275167 (Novira therapeutics),US20130251673 (Novira therapeutics),US8513184 (Gilead Sciences),US20140030221 (Gilead Sciences),US20130344030 (Gilead Sciences),US20130344029 (Gilead Sciences),US20140343032 (Roche),WO2014037480 (Roche),US20130267517 (Roche),WO2014131847 (Janssen),WO2014033176 (Janssen),WO2014033170 (Janssen),WO2014033167 (Janssen),US20140330015 (Ono pharmaceutical),US20130079327 (Ono pharmaceutical),US20130217880 (Ono pharmaceutical), and other drugs for treating HBV, and combinations thereof. - In certain embodiments, the additional therapeutic is selected from the group consisting of HBV combination drugs, HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, Toll-like receptor 7 and 8 modulators, Toll-like receptor 3 modulators, interferon alpha receptor ligands, HBsAg inhibitors, compounds targeting HbcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NOD1, recombinant thymosin alpha-1, BTK inhibitors, and hepatitis B virus replication inhibitors, and combinations thereof.
- In certain embodiments a compound disclosed herein is formulated as a tablet, which may optionally contain one or more other compounds useful for treating HBV. In certain embodiments, the tablet can contain another active ingredient for treating HBV, such as HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), modulators of tlr7, modulators of tlr8, modulators of tlr7 and tlr8, interferon alpha receptor ligands, hyaluronidase inhibitors, hepatitis B surface antigen (HBsAg) inhibitors, compounds targeting hepatitis B core antigen (HbcAg), cyclophilin inhibitors , HBV viral entry inhibitors, NTCP (Na+-taurocholate cotransporting polypeptide) inhibitors, endonuclease modulators, inhibitors of ribonucleotide reductase, hepatitis B virus E antigen inhibitors, Src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, CCR2 chemokine antagonists, thymosin agonists, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NOD1, Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, Natural Killer Cell Receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRP alpha, modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, and Hepatitis B virus replication inhibitors, and combinations thereof.
- In certain embodiments, such tablets are suitable for once daily dosing.
- In certain embodiments, the additional therapeutic agent is selected from one or more of:
- (1) Combination drugs selected from the group consisting of tenofovir disoproxil fumarate + emtricitabine (TRUVADA®); adefovir + clevudine, ABX-203+lamivudine+PEG-IFNalpha, ABX-203+adefovir+PEG-IFNalpha and GBV-015;
- (2) HBV DNA polymerase inhibitors selected from the group consisting of besifovir, entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir dipivoxil , tenofovir dipivoxil fumarate, tenofovir octadecyloxyethyl ester, telbivudine (Tyzeka®), pradefovir, Clevudine, emtricitabine (Emtriva®), ribavirin, lamivudine (Epivir-HBV®), phosphazide, famciclovir, SNC-019754, FMCA, fusolin, AGX-1009 and metacavir;
- (3) Immunomodulators selected from the group consisting of rintatolimod, imidol hydrochloride, ingaron, dermaVir, plaquenil (hydroxychloroquine), proleukin, hydroxyurea, mycophenolate mofetil (MPA) and its ester derivative mycophenolate mofetil (MMF), WF-10, ribavirin, IL-12, polymer polyethyleneimine (PEI), Gepon, VGV-1, MOR-22, BMS-936559 and IR-103;
- (4) Toll-like receptor 7 modulators selected from the group consisting of GS-9620, GSK-2245035, imiquimod, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202 RG-7863 and RG-7795;
- (5) Toll-like receptor 8 modulators selected from the group consisting of motolimod, resiquimod, 3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463;
- (6) Toll-like receptor 3 modulators selected from the group consisting of rintatolimod, poly-ICLC, MCT-465, MCT-475, Riboxxon, Riboxxim and ND-1.1;
- (7) Interferon alpha receptor ligands selected from the group consisting of interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alpha 1b (Hapgen®), Veldona, Infradure, Roferon-A, YPEG-interferon alfa-2a (YPEG-rhIFNalpha-2a), P-1101, Algeron, Alfarona, Ingaron (interferon gamma), rSIFN-co (recombinant super compound interferon), Ypeginterferon alfa-2b (YPEG-rhIFNalpha-2b), MOR-22, peginterferon alfa-2b (PEG-Intron®), Bioferon, Novaferon, Inmutag (Inferon), Multiferon®, interferon alfa-n1(Humoferon®), interferon beta-la (Avonex®), Shaferon, interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b (BioGeneric Pharma), interferon-alpha 2 (CJ), Laferonum, VIPEG, BLAUFERON-B, BLAUFERON-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, Layfferon, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai, Pegstat, rHSA-IFN alpha-2b and Interapo (Interapa);
- (8) Hyaluronidase inhibitors selected from the group consisting of astodrimer;
- (9) Modulators of IL-10;
- (10) HBsAg inhibitors selected from the group consisting of HBF-0259, PBHBV-001, PBHBV-2-15, PBHBV-2-1, REP 9AC, REP-9C and REP 9AC';
- (11) Toll like receptor 9 modulators selected from CYT003;
- (12) Cyclophilin inhibitors selected from the group consisting of OCB-030, SCY-635 and NVP-018;
- (13) HBV Prophylactic vaccines selected from the group consisting of Hexaxim, Heplisav, Mosquirix, DTwP-HBV vaccine, Bio-Hep-B, D/T/P/HBV/M (LBVP-0101; LBVW-0101), DTwP-Hepb-Hib-IPV vaccine, Heberpenta L, DTwP-HepB-Hib, V-419, CVI-HBV-001, Tetrabhay, hepatitis B prophylactic vaccine (Advax Super D), Hepatrol-07, GSK-223192A, Engerix B®, recombinant hepatitis B vaccine (intramuscular, Kangtai Biological Products), recombinant hepatitis B vaccine (Hansenual polymorpha yeast, intramuscular, Hualan Biological Engineering), Bimmugen, Euforavac, Eutravac, anrix-DTaP-IPV-Hep B, Infanrix-DTaP-IPV-Hep B-Hib, Pentabio Vaksin DTP-HB-Hib, Comvac 4, Twinrix, Euvax-B, Tritanrix HB, Infanrix Hep B, Comvax, DTP-Hib-HBV vaccine, DTP-HBV vaccine, Yi Tai, Heberbiovac HB, Trivac HB, GerVax, DTwP-Hep B-Hib vaccine, Bilive, Hepavax-Gene, SUPERVAX, Comvac5, Shanvac-B, Hebsulin, Recombivax HB, Revac B mcf, Revac B+, Fendrix, DTwP-HepB-Hib, DNA-001, Shan6, rhHBsAG vaccine, and DTaP-rHB-Hib vaccine;
- (14) HBV Therapeutic vaccines selected from the group consisting of HBsAG-HBIG complex, Bio-Hep-B, NASVAC, abi-HB (intravenous), ABX-203, Tetrabhay, GX-110E, GS-4774, peptide vaccine (epsilonPA-44), Hepatrol-07, NASVAC (NASTERAP), IMP-321, BEVAC, Revac B mcf, Revac B+, MGN-1333, KW-2, CVI-HBV-002, AltraHepB, VGX-6200, FP-02, TG-1050, NU-500, HBVax, im/TriGrid/antigen vaccine, Mega-CD40L-adjuvanted vaccine, HepB-v, NO-1800, recombinant VLP-based therapeutic vaccine (HBV infection, VLP Biotech), AdTG-17909, AdTG-17910 AdTG-18202, ChronVac-B, and Lm HBV;
- (15) HBV viral entry inhibitor selected from the group consisting of Myrcludex B;
- (16) Antisense oligonucleotide targeting viral mRNA selected from the group consisting of ISIS-HBVRx;
- (17) Short interfering RNAs (siRNA) selected from the group consisting of TKM-HBV (TKM-HepB), ALN-HBV, SR-008, ddRNAi and ARC-520;
- (18) Endonuclease modulators selected from the group consisting of PGN-514;
- (19) Inhibitors of ribonucleotide reductase selected from the group consisting of Trimidox;
- (20) Hepatitis B virus E antigen inhibitors selected from the group consisting of wogonin;
- (21) HBV antibodies targeting the surface antigens of the hepatitis B virus selected from the group consisting of GC-1102, XTL-17, XTL-19, XTL-001, KN-003 and fully human monoclonal antibody therapy (hepatitis B virus infection, Humabs BioMed);
- (22) HBV antibodies including monoclonal antibodies and polyclonal antibodies selected from the group consisting of Zutectra, Shang Sheng Gan Di, Uman Big (Hepatitis B Hyperimmune), Omri-Hep-B, Nabi-HB, Hepatect CP, HepaGam B, igantibe, Niuliva, CT-P24, hepatitis B immunoglobulin (intravenous, pH4, HBV infection, Shanghai RAAS Blood Products) and Fovepta (BT-088);
- (23) CCR2 chemokine antagonists selected from the group consisting of propagermanium;
- (24) Thymosin agonists selected from the group consisting of Thymalfasin;
- (25) Cytokines selected from the group consisting of recombinant IL-7, CYT-107, interleukin-2 (IL-2, Immunex); recombinant human interleukin-2 (Shenzhen Neptunus) and celmoleukin;
- (26) Nucleoprotein inhibitors (HBV core or capsid protein inhibitors) selected from the group consisting ofNVR-1221, NVR-3778, BAY 41-4109, morphothiadine mesilate and DVR-23;
- (27) Stimulators of retinoic acid-inducible gene 1 selected from the group consisting of SB-9200, SB-40, SB-44, ORI-7246, ORI-9350, ORI-7537, ORI-9020, ORI-9198 and ORI-7170;
- (28) Stimulators of NOD2 selected from the group consisting of SB-9200;
- (29) Recombinant thymosin alpha-1 selected from the group consisting of NL-004 and PEGylated thymosin alpha 1;
- (30) Hepatitis B virus replication inhibitors selected from the group consisting of isothiafludine, IQP-HBV, RM-5038 and Xingantie;
- (31) PI3K inhibitors selected from the group consisting of idelalisib, AZD-8186, buparlisib, CLR-457, pictilisib, neratinib, rigosertib, rigosertib sodium, EN-3342, TGR-1202, alpelisib, duvelisib, UCB-5857, taselisib, XL-765, gedatolisib, VS-5584, copanlisib, CAI orotate, perifosine, RG-7666, GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458, CUDC-907, PQR-309, INCB-040093, pilaralisib, BAY-1082439, puquitinib mesylate, SAR-245409, AMG-319, RP-6530, ZSTK-474, MLN-1117, SF-1126, RV-1729, sonolisib, LY-3023414, SAR-260301 and CLR-1401;
- (32) cccDNA inhibitors selected from the group consisting of BSBI-25;
- (33) PD-L1 inhibitors selected from the group consisting of MEDI-0680, RG-7446, durvalumab, KY-1003, KD-033, MSB-0010718C, TSR-042, ALN-PDL, STI-A1014 and BMS-936559;
- (34) PD-1 inhibitors selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, BGB-108 and mDX-400;
- (35) BTK inhibitors selected from the group consisting of ACP-196, dasatinib, ibrutinib, PRN-1008, SNS-062, ONO-4059, BGB-3111, MSC-2364447, X-022, spebrutinib, TP-4207, HM-71224, KBP-7536 and AC-0025;
- (36) Other drugs for treating HBV selected from the group consisting of gentiopicrin (gentiopicroside), nitazoxanide, birinapant, NOV-205 (Molixan; BAM-205), Oligotide, Mivotilate, Feron, levamisole, Ka Shu Ning, Alloferon, WS-007, Y-101 (Ti Fen Tai), rSIFN-co, PEG-IIFNm, KW-3, BP-Inter-014, oleanolic acid, HepB-nRNA, cTP-5 (rTP-5), HSK-II-2, HEISCO-106-1, HEISCO-106, Hepbarna, IBPB-006IA, Hepuyinfen, DasKloster 0014-01, Jiangantai (Ganxikang), picroside, GA5 NM-HBV, DasKloster-0039, hepulantai, IMB-2613, TCM-800B, reduced glutathione and ZH-2N; and
- (37) The compounds disclosed in
US20100143301 (Gilead Sciences),US20110098248 (Gilead Sciences),US20090047249 (Gilead Sciences),US8722054 (Gilead Sciences),US20140045849 (Janssen),US20140073642 (Janssen),WO2014/056953 (Janssen),WO2014/076221 (Janssen),WO2014/128189 (Janssen),US20140350031 (Janssen),WO2014/023813 (Janssen),US20080234251 (Array Biopharma),US20080306050 (Array Biopharma),US20100029585 (Ventirx Pharma),US20110092485 (Ventirx Pharma),US20110118235 (Ventirx Pharma),US20120082658 (Ventirx Pharma),US20120219615 (Ventirx Pharma),US20140066432 (Ventirx Pharma),US20140088085 (VentirxPharma),US20140275167 (Novira therapeutics),US20130251673 (Novira therapeutics),US8513184 (Gilead Sciences),US20140030221 (Gilead Sciences),US20130344030 (Gilead Sciences),US20130344029 (Gilead Sciences),US20140343032 (Roche),WO2014037480 (Roche),US20130267517 (Roche),WO2014131847 (Janssen),WO2014033176 (Janssen),WO2014033170 (Janssen),WO2014033167 (Janssen),US20140330015 (Ono pharmaceutical),US20130079327 (Ono pharmaceutical), andUS20130217880 (Ono pharmaceutical). - In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents. The one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.
- In a specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor. In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor and at least one additional therapeutic agent selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, HBsAg inhibitors, compounds targeting HbcAg, cyclophilin inhibitors , HBV therapeutic vaccines, HBV prophylactic vaccines HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, Hepatitis B virus E antigen inhibitors, recombinant scavenger receptor A (SRA) proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NOD1, Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, Natural Killer Cell Receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PEG-Interferon Lambda, recombinant thymosin alpha-1, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha, modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), and Hepatitis B virus replication inhibitors.
- In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor and at least a second additional therapeutic agent selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1 inhibitors, Arginase-1 inhibitors, PI3K inhibitors and stimulators of NOD2.
- In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor and at least a second additional therapeutic agent selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
- In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor, one or two additional therapeutic agents selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1 inhibitors, Arginase-1 inhibitors, PI3K inhibitors and stimulators of NOD2, and one or two additional therapeutic agents selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents selected from adefovir (Hepsera®), tenofovir disoproxil fumarate + emtricitabine (TRUVADA®), tenofovir disoproxil fumarate (Viread®), entecavir (Baraclude®), lamivudine (Epivir-HBV®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®), Clevudine®, emtricitabine (Emtriva®), peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha 1b (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-n1(Humoferon®), ribavirin, interferon beta-la (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), BEVAC, Laferonum, VIPEG, BLAUFERON-B, BLAUFERON-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2, Immunex), recombinant human interleukin-2 (Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai, Alloferon and celmoleukin;
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®).
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®).
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a second additional therapeutic agent selected from the group consisting of immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, HBsAg inhibitors, compounds targeting HbcAg, cyclophilin inhibitors , HBV Therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, Hepatitis B virus E antigen inhibitors, recombinant scavenger receptor A (SRA) proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, short synthetic hairpin RNAs (sshRNAs), HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein inhibitors (HBV core or capsid protein inhibitors), stimulators of retinoic acid-inducible gene 1, stimulators of NOD2, stimulators of NOD1, recombinant thymosin alpha-1, Arginase-1 inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, Natural Killer Cell Receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors, CD137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PEG-Interferon Lambd, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha, modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), a and Hepatitis B virus replication inhibitors.
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a second additional therapeutic agent selected from the group consisting of peginterferon alfa-2b (PEG-Intron®), Multiferon®, interferon alpha 1b (Hapgen®), interferon alpha-2b (Intron A®), pegylated interferon alpha-2a (Pegasys®), interferon alfa-n1(Humoferon®), ribavirin, interferon beta-1a (Avonex®), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), BEVAC, Laferonum, VIPEG, BLAUFERON-B, BLAUFERON-A, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon alfa-2b (Virchow), peginterferon alfa-2b (Amega), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2, Immunex), recombinant human interleukin-2 (Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai, Alloferon and celmoleukin;
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a second additional therapeutic agent selected from the group consisting of immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, Arginase-1 inhibitors, PI3K inhibitors, PD-1 inhibitors, PD-L1 inhibitors and stimulators of NOD2.
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®) and at least a second additional therapeutic agent selected from the group consisting of HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: entecavir (Baraclude®), adefovir (Hepsera®), tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine (Tyzeka®) or lamivudine (Epivir-HBV®), one or two additional therapeutic agents selected from the group consisting of: immunomodulators, toll-like receptor modulators (modulators of tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12 and tlr13), HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and "antibody-like" therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs ®, Fab derivatives), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, PD-1 inhibitors, PD-L1 inhibitors, Arginase-1 inhibitors, PI3K inhibitors and stimulators of NOD2, and one or two additional therapeutic agents selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, short interfering RNAs (siRNA), miRNA gene therapy agents, short synthetic hairpin RNAs (sshRNAs), and nucleoprotein inhibitors (HBV core or capsid protein inhibitors).
- In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 5-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 5-10; 5-15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 10 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 25 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. A compound as disclosed herein (e.g., a compound of formula (I)) may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.
- In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 100-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 100-150; 100-200, 100-250; 100-300; 100-350; 150-200; 150-250; 150-300; 150-350; 150-400; 200-250; 200-300; 200-350; 200-400; 250-350; 250-400; 350-400 or 300-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 300 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 250 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 150 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. A compound as disclosed herein (e.g., a compound of formula (I)) may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.
- In certain embodiments, when a compound disclosed herein is combined with one or more additional therapeutic agents as described above, the components of the composition are administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.
- In certain embodiments, a compound disclosed herein is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
- In certain embodiments, a compound disclosed herein is administered with one or more additional therapeutic agents. Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and one or more additional therapeutic agents are both present in the body of the patient.
- Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound disclosed herein is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound disclosed herein within seconds or minutes. In some embodiments, a unit dose of a compound disclosed herein is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound disclosed herein.
- In certain embodiments, a compound of formula I for use in a method for treating or preventing an HIV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents. In one embodiment, a
compound of formula I for use in a method for treating an HIV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents. - In certain embodiments, the present disclosure provides a compound of formula I for use in a method for treating an HIV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents which are suitable for treating an HIV infection.
- In one embodiment, pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent or excipient are provided.
- In one embodiment, kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents are provided.
- In the above embodiments, the additional therapeutic agent may be an anti- HIV agent. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, entry inhibitors (e.g., CCR5 inhibitors, gp41 inhibitors (i.e., fusion inhibitors) and CD4 attachment inhibitors), CXCR4 inhibitors, gpl20 inhibitors, G6PD and NADH-oxidase inhibitors, compounds that target the HIV capsid ("capsid inhibitors"; e.g., capsid polymerization inhibitors or capsid disrupting compounds such as those disclosed in
WO 2013/006738 (Gilead Sciences),US 2013/0165489 (University of Pennsylvania), andWO 2013/006792 (Pharma Resources), pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof. - In further embodiments, the additional therapeutic agent is selected from one or more of:
- (1) HIV protease inhibitors selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfmavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L- 756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100, DG35, and AG 1859;
- (2) HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-120, rilpivirene, BILR 355 BS, VRX 840773, lersivirine (UK-453061), RDEA806, KM023 and MK-1439;
- (3) HIV nucleoside or nucleotide inhibitors of reverse transcriptase selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, abavavir sulfate, amdoxovir, elvucitabine, alovudine, MIV-210, ±- FTC, D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), KP-1461, GS-9131 (Gilead Sciences) and fosalvudine tidoxil (formerly HDP 99.0003), tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide (Gilead Sciences), tenofovir alafenamide hemifumarate (Gilead Sciences), GS-9148 (Gilead Sciences), adefovir, adefovir dipivoxil, CMX-001 (Chimerix) or CMX-157 (Chimerix);
- (4) HIV integrase inhibitors selected from the group consisting of curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, AR- 177, L-870812, and L-870810, raltegravir, BMS-538158, GSK364735C, BMS-707035, MK- 2048, BA 011, elvitegravir, dolutegravir and GSK-744;
- (5) HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) including, but not limited to, BI-224436, CX0516, CX05045, CX14442, compounds disclosed in
WO 2009/062285 (Boehringer Ingelheim),WO 2010/130034 (Boehringer Ingelheim),WO 2013/159064 (Gilead Sciences),WO 2012/145728 (Gilead Sciences),WO 2012/003497 (Gilead Sciences),WO 2012/003498 (Gilead Sciences) each of which is incorporated by references in its entirety herein; - (6) gp41 inhibitors selected from the group consisting of enfuvirtide, sifuvirtide, albuvirtide, FB006M, and TRI-1144;
- (7) the CXCR4 inhibitor AMD-070;
- (8) the entry inhibitor SP01A;
- (9) the gpl20 inhibitor BMS-488043;
- (10) the G6PD and NADH-oxidase inhibitor immunitin;
- (11) CCR5 inhibitors selected from the group consisting of aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO-140, INCB15050, PF-232798 (Pfizer), and CCR5mAb004;
- (12) CD4 attachment inhibitors selected from the group consisting of ibalizumab (TMB-355) and BMS-068 (BMS-663068);
- (13) pharmacokinetic enhancers selected from the group consisting of cobicistat and SPI-452; and
- (14) other drugs for treating HIV selected from the group consisting of BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA-457 (bevirimat), HRG214, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889, and PA- 1050040 (PA-040), and combinations thereof.
- In certain embodiments, the additional therapeutic agent is a Toll-like receptor 8 modulator selected from the group consisting of motolimod, resiquimod, 3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463 and those disclosed in
US20140045849 (Janssen),US20140073642 (Janssen),WO2014/056953 (Janssen),WO2014/076221 (Janssen),WO2014/128189 (Janssen),US20140350031 (Janssen),WO2014/023813 (Janssen),US20080234251 (Array Biopharma),US20080306050 (Array Biopharma),US20100029585 (Ventirx Pharma),US20110092485 (Ventirx Pharma),US20110118235 (Ventirx Pharma),US20120082658 (Ventirx Pharma), -
US20120219615 (Ventirx Pharma),US20140066432 (Ventirx Pharma),US20140088085 (VentirxPharma),US20140275167 (Novira therapeutics),US20130251673 (Novira therapeutics). - In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents. The two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, or they can be selected from different classes of therapeutic agents. In a specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase. In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound. In a further embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and an HIV protease inhibiting compound. In an additional embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer. In another embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two HIV nucleoside or nucleotide inhibitor of reverse transcriptase.
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, or tenofovir alafenamide hemifumarate.
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, or tenofovir alafenamide hemifumarate.
- In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent selected from the group consisting of emtricitibine and lamivudine. In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of: tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent, wherein the second additional therapeutic agent is emtricitibine.
- In certain embodiments, when a compound disclosed herein is combined with one or more additional therapeutic agents as described above, the components of the composition are administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.
- In certain embdoiments, a compound disclosed herein is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
- In certain embodiments, a compound disclosed herein is administered with one or more additional therapeutic agents. Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and one or more additional therapeutic agents are both present in the body of the patient.
- Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound disclosed herein is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound disclosed herein within seconds or minutes. In some embodiments, a unit dose of a compound disclosed herein is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound disclosed herein.
- Provided herein are also kits that include a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, and suitable packaging. In one embodiment, a kit further includes instructions for use. In one aspect, a kit includes a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, and a label and/or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.
- Provided herein are also articles of manufacture that include a compound described herein or pharmaceutically acceptable salts, or a mixture thereof in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.
- Compounds provided herein are usually administered in the form of pharmaceutical compositions. Thus, provides herein are also pharmaceutical compositions that contain one or more of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients. Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).
- The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes. In certain embodiments, the pharmaceutical composition may be administered by intraarterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
- One mode for administration is parenteral, for example, by injection. The forms in which the pharmaceutical compositions described herein may be incorporated for administration by injection include, for example, aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.
- Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets. In making the pharmaceutical compositions that include at least one compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof, the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
- Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
- The compositions that include at least one compound described herein or pharmaceutically acceptable salts, or a mixture thereof can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in
U.S. Patent Nos. 3,845,770 ;4,326,525 ;4,902,514 ; and5,616,345 . Another formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds described herein in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g.,U.S. Patent Nos. 5,023,252 ,4,992,445 and5,001,139 . Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. - For preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein or pharmaceutically acceptable salts, or a mixture thereof. When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- The tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- Compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In other embodiments, compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
- The specific dose level of a compound of the present application for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the subject undergoing therapy. For example, a dosage may be expressed as a number of milligrams of a compound described herein per kilogram of the subject's body weight (mg/kg). Dosages of between about 0.1 and 150 mg/kg may be appropriate. In some embodiments, about 0.1 and 100 mg/kg may be appropriate. In other embodiments a dosage of between 0.5 and 60 mg/kg may be appropriate. Normalizing according to the subject's body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.
- The daily dosage may also be described as a total amount of a compound described herein administered per dose or per day. Daily dosage of a compound of Formula I may be between about 1 mg and 4,000 mg, between about 2,000 to 4,000 mg/day, between about 1 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 10 to 500 mg/day, between about 20 to 500 mg/day, between about 50 to 300 mg/day, between about 75 to 200 mg/day, or between about 15 to 150 mg/day.
- When administered orally, the total daily dosage for a human subject may be between 1 mg and 1,000 mg, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day.
- The compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are well known in cancer chemotherapy, and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.
- In a particular embodiment of a compound of formula I for use in a method, the method comprises administering to the
subject an initial daily dose of about 1 to 500 mg of a compound described herein and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week. - The compounds may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g., from Sigma Aldrich or other chemical suppliers.
- Typical embodiments of compounds described herein may be synthesized using the general reaction schemes described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing compounds which are embodiments described in the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. In general, compounds described herein are typically stable and isolatable at room temperature and pressure.
- The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
- Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein.
- Furthermore, the compounds of this disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
- The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989) organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- The terms "solvent", "inert organic solvent", or "inert solvent" refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, and the like). Unless specified to the contrary, the solvents used in the reactions of the present invention are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
- The term "q.s." means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
- The compounds of Formula I may prepared by first providing the substituted imidazo[4,5-b]pyridine or benzimidazole core, and optionally further modifying the core as desired to provide the substituents disclosed herein.
-
- In Scheme 1, suitably substituted 1-a and 1-b are coupled and cyclized in a suitable solvent (e.g., formic acid, ethanol, etc.) at an elevated temperature (typically about 80-100 °C) to provide the imidazo[4,5-b]pyridine or benzimidazole core 1-c. 1-c is then converted to the corresponding thioamide 1-d using Lawesson's reagent (i.e., 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide) under standard conditions. 1-e is obtained by cyclization of the thioamide 1-d using hydroxylamine. Hydrolysis of 1-e to obtain compound 1-f is achieved by reaction with a suitable base (e.g., NaOH). Alternately, 1-c is transformed to compound 1-f using phosphorous pentachloride, followed by treatment with aqueous hydroxylamine.
-
- In Scheme 2, 2-a is nitrated using fuming nitric acid to provide 2-b, which is then cyclized to provide C-2 unsubstituted imidazo[4,5-b]pyridine or benzimidazole 2-c under reducing conditions (e.g., zinc, iron, etc.). Amide 2-e is provided by reacting the corresponding ester 2-c with a suitable amine 2-d under standard amide bond forming reaction conditions, and is then converted to compounds of Formula I using the methods shown above in Scheme 1.
-
- In Scheme 3, 3-b is obtained by reaction of 3-a with cyanogen bromide. Amide 3-d is provided by reacting the corresponding ester 3-b with a suitable amine 3-c under standard amide bond forming reaction conditions, and is then converted to compounds of Formula I using the methods shown above in Scheme 1.
- In certain embodiments, the process may comprise protection and deprotection/further modification of R4 (Scheme 1) to provide the desired
- In Scheme 4, suitably substituted 4-a can be protected to provide 4-b using a suitable proecting group PG, such as a silyl ether (see, e.g., T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein). 4-b is then converted to the corresponding thioamide 4-c and cyclized using hydroxylamine as shown above in Scheme 1 to provide 4-d. 4-d can then be coverted to compound 4-e by deprotectiona and optional further modification. For example, 4-d can be deprotected and converted to a suitable leaving group (e.g., a TMS-O- group) and then reacted with a suitable amine to provide compounds of formula 4-e where L is -NR3-. 4-e is then converted to compounds of Formula I using the methods shown above in Scheme 1.
- Each of the intermediates in the above schemes may be isolated and/or purified prior to the subsequent step, or used in the next step without purification and/or isolation. It will also be appreciated that the addition of any substituent may result in the production of a number of isomeric products any or all of which may be isolated and purified using conventional techniques.
- The following examples are included to demonstrate specific embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the disclosure, and thus can be considered to constitute specific modes for its practice.
List of Abbreviations and Acronyms Abbreviation Meaning % Percent °C Degree Celsius A2B Adenosine A2B receptor Ac Acetyl ACN/CH3CN/MeCN Acetonitrile ADME Absorption, distribution, metabolism and excretion AlMe3 Trimethylaluminum APECED Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy ASK Apoptosis signal-regulating kinase BAPN Beta-aminoproprionitrile BCNU Carmustine bicarb Bicarbonate br Broad BRD Bromodomain containing protein inhibitor BTK Bruton's tyrosine kinase BTK Bruton's tyrosine kinase CAS Chemical Abstract Service cccDNA Covalently closed circular DNA CCR C-C chemokine receptor CD Cluster of differentiation CHOP Cyclophosphamide CNS Central nervous system COPD Chronic obstructive pulmonary disease CREST Calcinosis, Raynaud's syndrome, esophageal dysmotility, sclerodactyly and telangiectasia CRISPR Clustered regularly interspaced short palindromic repeats CVP Cyclophosphamide, vincristine, prednisone d Doublet D Deuterium D.T. PACE Dexamethasone, thalidomide, cisplatin, Adriamycin®, cyclophosphamide, etoposide D/d Deuterium DABAL-Me3 Bis(trimethylaluminum)-DABCO® adduct DABCO® 1,4-Diazabicyclo[2.2.2]octane DCE Dichloroethane DCM/CH2Cl2 Dichloromethane/methylene chloride dd Doublet of doublets DDR Discoidin domain receptor DIPEA/DIEA N,N-Diisopropylethylamine DMF Dimethylformamide DMFO Difluoromethylornithine DMPK Drug metabolism and pharmacokinetics DMSO Dimethylsulfoxide DTIC Dacarbazine EC50 The half maximal effective concentration EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide equiv/eq Equivalents Et Ethyl Et3N Triethylamine EtOAc/AcOEt Ethylacetate EtOH Ethanol F Fahrenheit Fab Fragment antigen-binding FBS Fetal bovine serum FCM Fludarabine, cyclophosphamide, mitoxantrone FCR Fludarabine, cyclophosphamide, rituximab FOLFIRI Fluorouracil, leucovorin, and irinotecan FR Fludarabine, rituximab g Grams GITR Glucocorticoid-induced TNFR-related protein Gp Glycoprotein h/hr Hours HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) HbcAg Hepatitis B core antigen HBsAg Hepatitis B surface antigen HBV Hepatitis B virus HBx Hepatitis B viral protein HDAC Histone deacetylase hex Hexanes HOBt Hydroxybenzotriazole HPLC High pressure liquid chromatography hyperCVAD Hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine Hz Hertz ICE Iphosphamide, carboplatin, etoposide ICOS Inducible T-cell COStimulator IDH Isocitrate dehydrogenase IDO1 Indoleamine 2,3-dioxygenase 1 IL Interleukin INCB24360 Epacadostat IUPAC International Union of Pure and Applied Chemistry J Coupling constant (MHz) JAK Janus kinase Kg/kg Kilogram LACA 1-Azetidine-2-carboxylic acid LCMS/LC-MS Liquid chromatography-mass spectrometry LET Linear energy transfer LOX Lysyl oxidase protein LOXL Lysyl oxidase-like protein M Molar m multiplet M+ Mass peak M+H Mass peak plus hydrogen MCP Mitoxantrone, chlorambucil, and prednisolone Me Methyl mg Milligram MHz Megahertz min/m Minute miRNA MicroRNA ml/mL Milliliter mM Millimolar MMF Ester derivative mycophenolate mofetil mmol Millimole MMP Matrix metalloprotease mol Mole MPA Mycophenolate mofetil MS Mass spectroscopy MS Multiple sclerosis N Normal NADH Nicotinamide adenine dinucleotide in reduced form NCINI Non-catalytic site, or allosteric, integrase inhibitors NCS N-Chlorosuccinimide ng Nanograms nM NanoMolar NMR Nuclear magnetic resonance NOD Nucleotide-binding oligomerization domain-containing protein NTCP Na+-taurocholate cotransporting polypeptide PD Programmed cell death PdCl2(dppf) [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), PdCl2(PPh3)2 Bis(triphenylphosphine)palladium(II) dichloride PD-L Programmed death-ligand PEG Polyethylene glycol PEI Polymer polyethyleneimine PET Positron emission tomography Ph Phenyl PI3K Phosphoinositide 3-kinase PKC Protein kinase C prep Preparative q.s. Quantity sufficient to achieve a stated function RA Rheumatoid arthritis R-CHOP Rituximab-CHOP (Rituximab plus CHOP) R-CVP Rituximab-CVP (Rituximab plus CVP) Rf Retention factor R-FCM Rituximab plus FCM R-hyperCVAD Rituximab-hyperCVAD R-ICE Rituximab-ICE R-MCP Rituximab-MCP RPM Revolutions per minute rSIFN-co Recombinant super compound interferon RT/rt Room temperature s Second s Singlet SAHA Vorinostat sat. Saturated SEM 2-(Trimethylsilyl)ethoxymethyl SERMs Selective estrogen receptor modulators siRNA Short interfering RNAs SIRP Signal-regulatory protein SLE Systemic lupus erythematosus SPECT Single-photon emission computed tomography SRA Scavenger receptor A Src Proto-oncogene tyrosine-protein kinase sshRNAs Short synthetic hairpin RNAs STING Sequence To and withIN Graphics SYK Spleen tyrosine kinase t Triplet TALENs Transcription activator-like effector nucleases TBAF Tetra-n-butylammonium fluoride TCA Trichloroacetic acid TEA Triethylamine temp. Temperature TFA Trifluoroacetic acid THF Tetrahydrofuran TIGIT T cell immunoreceptor with Ig and ITIM domains TIM T-cell immunoglobulin and mucin domain TKM-HBV TKM-HepB Tlr Toll-like receptor modulators TNF Tumor necrosis factor TPL2 Serine/threonine kinase Vac Vacuum w/v Weight/volume w/w Weight/weight YPEG-rhIFNalpha-2a PEG-interferon alfa-2a YPEG-rhIFNalpha-2b Ypeginterferon alfa-2b δ Chemical shift (ppm) µg Microgram µL/ µl Microliter µM Micromolar µm Micrometer µmol Micromole -
- Methyl 3-formamido-4-methylbenzoate. A solution of methyl -3-amino-4-methylbenzoate (5.1 g, 31 mmol) in formic acid (42 mL) was stirred at 110 °C for 4 hr. The reaction mixture was allowed to cool to room temp. Water was added and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the desired product. C10H11NO3. 194.0 (M+1).
- Methyl 3-formamido-4-methyl-2-nitrobenzoate. Methyl 3-formamido-4-methylbenzoate (5.3 g, 27 mmol) was added to fuming nitric acid at 0 °C portion wise over 45 min. The reaction mixture was stirred at 0 °C for an additional 1 h, and then ice was added and the mixture stirred for 1.5 h at room temperature. The precipitated solid was filtered, and washed with water. The solid was purified by silica gel to give the desired product. C10H10N2O5. 239.0 (M+1).
- Methyl 4-methyl-1H-benzo[d]imidazole-7-carboxylate. A mixture of methyl 3-formamido-4-methyl-2-nitrobenzoate (1.0 g, 4.2 mmol) and iron (1.2 g, 21 mmol) in methanol (10 mL) and acetic acid (5 mL) was stirred at 70 °C for 3 hr. To the cooled reaction mixture was added ethyl acetate and water and the mixture was filtered and the solid was washed with ethyl acetate. The aqueous layer was washed two times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the desired product. C10H10N2O2. 191.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide. To a solution of the 3-chloro-4-fluoroanilinein (253 mg, 1.74 mmol) dichloroethane at 0 °C under nitrogen was added trimethylaluminum (2 M in heptane, 1.74 mL, 3.47 mmol) dropwise over 5 min. The solution was allowed to warm to room temperature and stirred for 30 min. The solution was cooled to 0 °C and to this solution was added methyl 4-methyl-1H-benzo[d]imidazole-7-carboxylate (220 mg, 1.16 mmol). The solution was stirred at 85 °C for 6 hr and, then, cooled to room temperature. To the mixture was added ethyl acetate and 10% citric acid and the resulting precipitate was filtered and dried on high vac to give the desired product. C15H11ClFN3O. 304.4 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-methyl-1H-benzo[d]imidazole-7-carboximidamide. A mixture of N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide (154 mg, 0.507 mmol), phosphorous pentachloride (158 mg, 0.761 mmol) in phosphoryl chloride (1.5 mL) and 1,2-dichloroethane (1.5 mL) were stirred at 80 °C for 2.5 hr. The reaction mixture was concentrated and suspended in ethanol (1.5 mL) and to this mixture was added 50% hydroxylamine in water (0.311 mL, 5.07 mmol). The reaction mixture stirred for 1 hr and was concentrated. The residue was purified by preparative HPLC to give the desired product. C15H12ClFN4O. 319.1 (M+1).
-
- Nitric acid (18 mL) was cooled to -10 °C in a dry ice/acetone bath and methyl 2-formamido-4-(trifluoromethoxy)benzoate (1.97 g, 7.0 mol) was added and the reaction was allowed to stir for 4 hours at -10 °C. The reaction was slowly quenched with water (20 mL) and extracted with EtOAc (3x 10 mL). Combined organic layers were washed with brine (1 x 30 mL) and concentrated in vacuo to give methyl 2-formamido-3-nitro-4-(trifluoromethoxy)benzoate as a mixture of isomers.
- Methyl 2-formamido-3-nitro-4-(trifluoromethoxy)benzoate (2.2 g, 7.0 mmol) was dissolved in ethanol (15 mL) and water (5 mL). Ammonium chloride (0.108 mol) was added in one portion and the reaction was allowed to stir at room temperature. Zinc powder (0.108 mol) was added portion-wise over 5 minutes and the reaction was allowed to stir 5 minutes after completion of addition. The zinc was then removed by vacuum filtration and the filtrate was concentrated in vacuo. The crude was dissolved in water (20 mL) and extracted with EtOAc (4 x 10 mL). Combined organic layers were washed with brine (1 x 50 mL), dried over sodium sulfate, and concentrated in vacuo to give methyl 3-amino-2-formamido-4-(trifluoromethoxy)benzoate.
- Methyl 3-amino-2-formamido-4-(trifluoromethoxy)benzoate (1.32 g, 5.0 mmol) was dissolved in formic acid (15 mL) and heated to 80 °C for 1 hour. The reaction was cooled to rt, concentrated in vacuo, and quenched with saturated sodium bicarbonate solution (10 mL). The mixture was extracted with EtOAc (4x5 mL) and combined organic layers were washed with brine (1x15 mL) and concentrated in vacuo. Crude material was purified by column chromatography to give methyl 4-(trifluoromethoxy)-1H-benzo[d]imidazole-7-carboxylate.
- N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(trifluoromethoxy)-1H-benzo[d]imidazole-7-carboximidamide. Example 2 was made analogously to Example 10 using methyl 4-(trifluoromethoxy)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate. C15H9ClF4N4O2. 389.0/391.1 (M+1).
-
- Example 3 (N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide) was made analogously to Example 59 using 6-fluoro-1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid. C14H9ClF2N4O. 323.1/325.0 (M+1).
-
- Example 4 was made analogously to Example 59 using 5-fluoro-1H-benzo[d]imidazole-7-carboxylic in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid. C14H9ClF2N4O. 323.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.01 (s, 1H), 8.87 (d, J = 15.9 Hz, 2H), 7.60 (dd, J = 8.7, 2.4 Hz, 1H), 7.20 (dd, J = 10.2, 2.4 Hz, 1H), 7.02 (t, J = 9.1 Hz, 1H), 6.95 (dd, J = 6.6, 2.7 Hz, 1H), 6.52 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H).
-
- Example 5 was made analogously to Example 59 using 4-fluoro-1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid. C14H9ClF2N4O. 323.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 10.75 (s, 1H), 8.75 (s, 1H), 8.27 (s, 1H), 7.16 (dd, J = 8.4, 4.6 Hz, 1H), 7.09 - 6.94 (m, 2H), 6.90 (dd, J = 6.6, 2.7 Hz, 1H), 6.47 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H).
-
- Example 6 was made analogously to Example 59 using 4-chloro-1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid. C14H9Cl2FN4O. 339.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.85 (s, 1H), 8.81 (s, 1H), 8.39 (s, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 8.1 Hz, 1H), 7.01 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.6, 2.7 Hz, 1H), 6.47 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H).
-
- Example 7 was made analogously to Example 59 using 4-(trifluoromethyl)-1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid. C15H9ClF4N4O. 373.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.97 (d, J = 5.0 Hz, 1H), 8.83 (s, 1H), 8.35 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.01 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.6, 2.7 Hz, 1H), 6.46 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H).
-
- Example 8 was made analogously to Example 59 using 1H-benzo[d]imidazole-7-carboxylic acid in place of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid. C14H10ClFN4O. 305.1 (M+1).
-
- 3,5-difluoro-4-methyl-2-nitrobenzoic acid. To a solution of concentrated nitric acid (65% in water, 7.5 mL) and sulfuric acid (15 mL) at 0 °C was added 3,5-difluoro-4-methylbenzoic acid (5.0 g, 29 mmol) in portions over 1 hr. The solution was allowed to warm to room temperature and stirred for 18 hr. The reaction mixture was poured onto ice and the resulting precipitate was filtered and dried on high vac to give the desired product (6.3 g). C8H5F2NO4. 217.9 (M+1).
- N-(3-chloro-4-fluorophenyl)-3,5-difluoro-4-methyl-2-nitrobenzamide. To a solution of 3-chloro-4-fluoroaniline (670 mg, 4.6 mmol), 3,5-difluoro-4-methyl-2-nitrobenzoic acid (1.0 g, 4.6 mmol), and triethylamine (1.9 mL, 14 mmol) in dichlromethane (40 mL) at 0 °C was added phosphoryl chloride (0.64 mL, 6.9 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 1 hr. To the reaction mixture was added saturated sodium bicarbonate and the aqueous layer was washed three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, adsorbed onto silica and purified by silica gel chromatography to give the desired product (1.6 g). C14H8ClF3N2O3. 345.0 (M+1).
- 3-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-4-methyl-2-nitrobenzamide. A solution of N-(3-chloro-4-fluorophenyl)-3,5-difluoro-4-methyl-2-nitrobenzamide (674 mg, 1.96 mmol) and 28% aqueous ammonium hydroxide in ethanol (2 mL) was stirred at 80 °C for 18 hr. To this solution was added water and the resulting precipitate was filtered and dried on high vac to give the desired product (583 mg). C14H10ClF2N3O3. 364.0 (M+23).
- N-(3-chloro-4-fluorophenyl)-5-fluoro-3-formamido-4-methyl-2-nitrobenzamide. A mixture of acetic anhydride (0.4 mL, 4.3 mmol) in formic acid (4 mL) was stirred for 5 min. To this solution was added 3-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-4-methyl-2-nitrobenzamide (583 mg, 1.7 mmol). The reaction mixture stirred for 2 hr and was poured onto cold water and the resulting precipitate was filtered and dried on high vac to give the desired product (562 mg). C15H10ClF2N3O4. 370.0 (M+1).
-
- N-(3-Chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide was made analogously to Example 1 using N-(3-chloro-4-fluorophenyl)-5-fluoro-4-methyl-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide. C15H11ClF2N4O. 337.0 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 10.97 (s, 1H), 8.96 (s, 1H), 8.86 (s, 1H), 7.20-7.11 (m, 1H), 7.01 (t, J = 9.2 Hz, 1H), 6.97 (dd, J = 6.5, 2.6 Hz, 1H), 2.44 (d, J = 1.6 Hz, 3H).
-
- 3-Amino-4,5-difluoro-2-nitrobenzoic acid (15g, 68.8 mmol) was dissolved in methanol (200 mL) and sulfuric acid (20 mL) was added dropwise to the solution over 5 minutes. A reflux condenser was attached and the reaction was heated to 71 °C overnight. The reaction was then cooled to room temperature and concentrated in vacuo to approximately 50 mL of solvent. The reaction was neutralized to pH=7 with saturated potassium carbonate and then extracted with EtOAc (5 x 40 mL). Combined organic layers were washed with brine (1 x 60 mL) and concentrated in vacuo to give methyl 3-amino-4,5-difluoro-2-nitrobenzoate as a yellow solid which was used without further purification.
- 3-Amino-4,5-difluoro-2-nitrobenzoate (14.5 g, 62 mmol) was dissolved in ethanol (150 mL) and water (50 mL). Ammonium chloride (0.934 mol) was added in one portion and the reaction was allowed to stir at room temperature. Zinc powder (0.934 mol) was added portion-wise over 5 minutes and the reaction was allowed to stir 5 minutes after completion of addition. The zinc was then removed by vacuum filtration and the filtrate was concentrated in vacuo. The crude was dissolved in water (60 mL) and extracted with EtOAc (4 x 40 mL). Combined organic layers were washed with brine (1 x 50 mL), dried over sodium sulfate, and concentrated in vacuo to give methyl 2,3-diamino-4,5-difluorobenzoate as a brown powder.
- Methyl 2,3-diamino-4,5-difluorobenzoate (60 mg, 0.30 mmol) was dissolved in formic acid (2 mL) and heated to 100 °C in a sealed tube for 10 minutes. The reaction was allowed to cool to room temperature and concentrated in vacuo. The residue was dissolved in sat. sodium bicarbonate (2 mL) and extracted with EtOAc (3 x 3 mL). Combined organic layers were washed with water (1 x 5 mL) and concentrated in vacuo to give methyl 4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate as a brown solid which was used without further purification.
- Methyl 4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate (12 mg, 0.056 mmol) was dissolved in DCE (1 mL) under an inert atmosphere. Trimethylaluminum (0.085 mL, 2.0 M in toluene) was added dropwise to the reaction followed by 3-chloro-4-fluoroaniline (0.085 mmol). The reaction was allowed to stir at rt overnight under inert atmosphere. The reaction was quenched with sat. sodium bicarb (3 mL) and extracted with EtOAc (3 x 2mL). Combined organic layers were washed with water (1 x 4 mL) and concentrated in vacuo to give N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide which was used directly in the next reaction. The crude material was dissolved in POCl3 (2 mL) and PCl5 (0.083 mmol) was added. The reaction was heated to 85 °C in a sealed tube for 12 hours. The reaction was allowed to cool to room temperature and concentrated in vacuo. The residue was dissolved in a premixed solution of ethanol (2 mL) and hydroxylamine (0.55 mmol, 50% in water) and the reaction was allowed to stir at room temperature for 5 minutes. The reaction was concentrated in vacuo and purified by reverse-phase HPLC to afford N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide as a white solid. C14H8ClF3N4O. 341.1/343.2 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 10.87 (s, 1H), 8.77 (s, 1H), 8.28 (s, 1H), 7.25 (d, J = 5.5 Hz, 1H), 7.03 (t, J = 9.0 Hz, 1H), 6.96 (dd, J = 6.5, 2.8 Hz, 1H), 6.48 (d, J = 9.1 Hz, 1H).
-
-
-
-
- 6-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide was made analogously to Example 1 using 6-chloro-N-(3-chloro-4-fluorophenyl)-1H-benzo[d]imidazole-4-carboxamide in place of N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide. C14H9Cl2FN4O. 339.0 (M+1).
-
-
- Methyl 4-bromo-3-formamido-2-nitrobenzoate. To fuming nitric acid (14 mL) at -10 °C was added methyl 4-bromo-3-formamidobenzoate (5.1 g, 20 mmol), portionwise over 90 min. The mixture was stirred at 0 °C for 1 h and then poured over ice and allowed to stir and warm to rt over 1.5 h. The solid was isolated via filtration and the filter pad was washed with water. The solid was taken up in EtOAc, washed with brine, concentrated onto silica gel, and purified via column chromatography on silica gel to yield a mixture of the desired product and its regioisomer (3.5 g). C9H7BrN2O5. 324.9/326.9 [M+23]+.
-
-
- 4-bromo-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was prepared analogously to Example 1, using 4-bromo-N-(3-chloro-4-fluorophenyl)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-4-methyl-1H-benzo[d]imidazole-7-carboxamide. C14H9BrClFN4O. 382.9/384.9 [M+1]+.
-
- Methyl 2,3-diamino-4,5-difluorobenzoate (0.5 g, 2.0 mmol) was dissolved in methanol (7.0 mL) and water (2.50 mL). Cyanogen bromide (3.0 mmol) was added and the reaction was refluxed in a sealed tube for 45 mins. The reaction was allowed to cool to rt and diluted with water (4 mL) and EtOAc (4 mL). The water layer was isolated and neutralized to pH=8 with sat. sodium carbonate. The neutralized aqueous layer was extracted with EtOAc (3x4 mL) and combined organic layers were washed with brine (1x5 mL), dried over sodium sulfate, and concentrated in vacuo to give methyl 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate as a brown solid.
- Methyl 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate (75 mg, 0.33 mmol) was dissolved in DCE (4 mL) under inert atmosphere and cooled to 0 °C. Trimethylaluminium (1.2 mL, 2M hexanes) was added dropwise followed by 3-chloro-4-fluoroaniline (1.0 mmol) and the reaction was then heated to 70 °C for 2 days. The reaction was cooled to rt and quenched with saturated bicarbonate solution. The reaction was extracted with EtOAc (3x3 mL) and combined organic layers were washed with brine (1x6 mL) and concentrated in vacuo. The crude material was dried loaded on to silica gel and purified by column chromatography (EtOAc/hex) to give 2-amino-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide as a white powder.
- 2-Amino-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide (20 mg, 0.0587 mmol) and Lawesson's reagent (0.176 mmol) was dissolved in toluene (2mL) and heated to 90°C overnight. The reaction was allowed to cool to rt and precipitates were removed by vacuum filtration and the filtrate was concentrated. The crude material was purified by column chromatography (EtOAc/hex) to give 2-amino-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carbothioamide as a yellow oil.
- 2-Amino-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carbothioamide (20 mg, 0.0561 mmol) was dissolved in ethanol (2 mL) and hydroxylamine (50% in aqueous solution, 0.561 mmol) was added and the reaction was allowed to stir overnight at rt. The reaction was concentrated in vacuo and purified by reverse-phase HPLC to give 2-amino-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide as a white solid. C14H9ClF3N5O. 356.0/357.9 (M+1). 1H NMR (400 MHz, Methanol-d 4) δ 7.27 (dd, J = 5.8, 2.7 Hz, 1H), 7.15 (t, J = 8.6 Hz, 1H), 7.03 - 6.98 (m, 2H), 6.94 (s, 1H), 6.67 (d, J = 3.8 Hz, 1H).
-
- Example 14 was made analogously to Example 13 using 3-bromo-4-fluoroaniline in place of 3-chloro-4-fluoroaniline. C14H9BrF3N5O. 400.0/402.0 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 10.94 (s, 1H), 8.76 (s, 1H), 7.12 (dd, J = 6.1, 2.6 Hz, 1H), 7.06 (t, J = 8.8 Hz, 2H), 6.61 - 6.51 (m, 1H).
-
- Example 15 was made analogously to Example 13 using 3-bromoaniline in place of 3-chloro-4-fluoroaniline. C12H10BrF2N5O. 382.0/384.1 (M+1). 1H NMR (400 MHz, Methanol-d 4) δ 7.11 - 6.96 (m, 4H), 6.69 - 6.63 (m, 1H).
-
- Example 16 was made analogously to Example 13 using 3-chloroaniline in place of 3-chloro-4-fluoroaniline. C14H10ClF2N5O. 338.0/340.1 (M+1). 1H NMR (400 MHz, Methanol-d 4) δ 8.69 - 8.59 (m, 2H), 8.51 - 8.45 (m, 1H), 8.39 (t, J = 2.1 Hz, 1H), 8.21 - 8.15 (m, 1H).
-
- Example 17 was made analogously to Example 13 using 4-fluoro-3-(trifluoromethyl)aniline in place of 3-chloro-4-fluoroaniline. C15H9F6N5O. 390.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.04 (s, 1H), 8.93 (s, 1H), 8.16 (s, 2H), 7.24 - 7.10 (m, 3H), 6.83 (dt, J = 7.9, 3.5 Hz, 1H).
-
- Example 18 was made analogously to Example 15 using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate. C14H11BrFN5O. 364.0/366.0 (M+1). 1H NMR (400 MHz, Methanol-d 4) δ 7.16 (dd, J = 8.8, 4.5 Hz, 1H), 7.09 - 6.92 (m, 4H), 6.65 (d, J = 8.1 Hz, 1H).
-
- Example 19 was made analogously to Example 14 using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate. C14H10BrF2N5O. 382.0/384.0 (M+1). 1H NMR (400 MHz, Methanol-d 4) δ 7.15 (dd, J = 8.8, 4.6 Hz, 1H), 7.10 - 6.99 (m, 2H), 6.95 (t, J = 8.6 Hz, 1H), 6.69 (dt, J = 8.8, 3.5 Hz, 1H).
-
- Example 20 was made analogously to Example 16 using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate. C14H11ClFN5O. 320.1/322.1 (M+1). 1H NMR (400 MHz, Methanol-d 4) δ 7.16 (dd, J = 8.8, 4.6 Hz, 1H), 7.10 - 6.99 (m, 2H), 6.89 (ddd, J = 8.0, 2.0, 0.9 Hz, 1H), 6.79 (t, J = 2.0 Hz, 1H), 6.64 - 6.58 (m, 1H).
-
- Example 21 was made analogously to Example 17 using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate. C15H10F5N5O. 372.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 10.95 (s, 1H), 8.93 (s, 1H), 8.32 (s, 2H), 7.24 - 7.05 (m, 4H), 6.83 (dd, J = 8.5, 4.2 Hz, 1H).
-
- 3-Amino-4-fluoro-2-nitrobenzoic acid (5g, 25 mmol) was dissolved in methanol (120 mL) and sulfuric acid (2.5 mL) was added dropwise to the solution over 5 minutes. A reflux condenser was attached and the reaction was heated to 71 °C overnight. The reaction was then cooled to room temperature and concentrated in vacuo to approximately 50 mL of solvent. The reaction was neutralized to pH=7 with saturated potassium carbonate and then extracted with EtOAc (5 x 40 mL). Combined organic layers were washed with brine (1 x 60 mL) and concentrated in vacuo to give methyl 3-amino-4-fluoro-2-nitrobenzoate as a yellow solid which was used without further purification.
- 3-Amino-4-fluoro-2-nitrobenzoate (2.32 g, 11.0 mmol) was dissolved in ethanol (100 mL) and water (35 mL). Ammonium chloride (0.163 mol) was added in one portion and the reaction was allowed to stir at room temperature. Zinc powder (0.163 mol) was added portion-wise over 5 minutes and the reaction was allowed to stir 5 minutes after completion of addition. The zinc was then removed by vacuum filtration and the filtrate was concentrated in vacuo. The crude was dissolved in water (20 mL) and extracted with EtOAc (4 x 10 mL). Combined organic layers were washed with brine (1 x 50 mL), dried over sodium sulfate, and concentrated in vacuo to give methyl 2,3-diamino-4-fluorobenzoate as a brown powder.
- Methyl 2,3-diamino-4-fluorobenzoate (0.1g, 0.54 mmol) was dissolved in methanol (2.0 mL) and water (1.0 mL). Cyanogen bromide (0.54 mmol) was added and the reaction was refluxed in a sealed tube for 45 mins. The reaction was allowed to cool to rt and diluted with water (4 mL) and EtOAc (4 mL). The water layer was isolated and neutralized to pH=8 with sat. sodium carbonate. The neutralized aqueous layer was extracted with EtOAc (3x4 mL) and combined organic layers were washed with brine (1x5 mL), dried over sodium sulfate, and concentrated in vacuo to give methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate as a brown solid.
- Example 22 was made analogously to Example 13 (using methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate in place of 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate. C14H10ClF2N5O. 338.1/339.2 (M+1). 1H NMR (400 MHz, Methanol-d 4) δ 7.14 (dd, J = 8.8, 4.6 Hz, 1H), 7.00 (dt, J = 23.9, 9.2 Hz, 2H), 6.91 (dd, J = 6.4, 2.7 Hz, 1H), 6.64 (dt, J = 8.8, 3.4 Hz, 1H).
-
- Methyl 4,5-difluoro-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboxylate. Dissolved methyl 2,3-diamino-4,5-difluorobenzoate (50 mg, 0.25 mmol) in THF (3 ml), to the solution was added 4-(2-isothiocyanatoethyl)morpholine (0.43 g, 0.002 mmol) and triethylamine (0.36 g, 0.003 mol). The reaction mixture was heated at 80°C overnight, then to the reaction mixture was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.47 g, 0.002 mol), heated at 80°C for 1h. The reaction mixture was diluted with EtOAc, and washed with NaHCO3 saturated solution, organic layer was evaporated and the residue was purified with Combi-Flash column chromatography to afford 84mg desired product. C15H18F2N4O3. 341.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboxamide. Dissolved 3-chloro-4-fluoroaniline (12.8mg, 0.088 mmol) in dichloroethane (2 ml), to the solution was added trimethylamine (0.088 ml, 2M in toluene) and triethylamine (0.36 g, 0.003 mol). Then to the raction mixture was added methyl 4,5-difluoro-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboxylate (20 mg, 0.06 mmol). The reaction mixture was stirred at room temperature for 2h, then the reaction mixture was diluted with EtOAc, and washed with NaHCO3 saturated solution, organic layer was evaporated and the residue was purified with Combi-Flash column chromatography to afford 27mg desired product. C20H19ClF3N5O2. 454.4 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide. Example 23 was made analogously to Example 107 using the general procedure for hydroxy amidine formation. C20H20ClF3N6O2. 469.1 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.01 - 6.85 (m, 3H), 6.67 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 4.00 (t, J = 4.8 Hz, 4H), 3.81 - 3.73 (m, 2H), 3.49 - 3.36 (m, 6H).
-
-
- 4-(3-chlorophenyl)-3-(4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one was prepared analogously to Example 45, using N-(3-chlorophenyl)-4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxamide. C17H11ClF2N4O3. 393.0 [M+1]+.
- 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one and 4-(3-chlorophenyl)-3-(4,5-difluoro-2-(hydroxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one were prepared analogously to Example 45, using 4-(3-chlorophenyl)-3-(4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one in place of 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one. C16H8BrClF2N4O2. 440.9/442.9 [M+1]+. C16H9ClF2N4O3. 379.0 [M+1]+.
- N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3-methoxypropyl)amino)methyl)-1H-benzo[d]imidazole-7-carboximidamide. Example 24 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]midazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. C19H20ClF2N5O2. 424.1 [M+1]+.
-
- Example 25 was prepared analogously to Example 45 , using 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one and cyclopropylmethanamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C19H18ClF2N5O. 406.1 [M+1]+.
-
- Example 26 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one and dimethylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C17H16ClF2N5O. 380.1 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 12.93 (br s, 1H), 11.00 (br s, 1H), 10.27 (br s, 1H), 8.86 (s, 1H), 7.38 - 7.23 (m, 1H), 7.06 - 6.96 (m, 1H), 6.85 (t, J = 2.1 Hz, 1H), 6.81 (d, J = 7.8 Hz, 1H), 6.47 (dd, J = 8.2, 1.8 Hz, 1H), 4.58 (s, 2H), 2.85 (s, 6H).
-
- Example 27 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one and isopropylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C18H18ClF2N5O. 394.1 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 12.88 (br s, 1H), 11.03 (br s, 1H), 9.27 (br s, 3H), 8.85 (s, 1H), 7.31 - 7.20 (m, 1H), 7.04 (t, J = 8.1 Hz, 1H), 6.83 (d, J = 8.1 Hz, 1H), 6.80 (t, J = 2.1 Hz, 1H), 6.49 (dd, J = 8.3, 1.8 Hz, 1H), 4.51 - 4.43 (m, 2H), 3.54 - 3.35 (m, 1H), 1.28 (d, J = 6.3 Hz, 6H).
-
- Example 28 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one and ethylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C17H16ClF2N5O. 380.1 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 12.87 (br s, 1H), 11.01 (br s, 1H), 9.27 (br s, 2H), 8.85 (s, 1H), 7.30 - 7.21 (m, 1H), 7.03 (t, J = 8.0 Hz, 1H), 6.87 - 6.78 (m, 2H), 6.52 - 6.45 (m, 1H), 4.54 - 4.38 (m, 2H), 3.17 - 2.98 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H).
-
- Example 29 was prepared analogously to Example 46, using 4-(3-chlorophenyl)-3-(4,5-difluoro-2-(hydroxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one in place of 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(hydroxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one. C15H11ClF2N4O2. 353.0 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 11.00 (br s, 1H), 8.79 (s, 1H), 7.16 (dd, J = 12.0, 7.0 Hz, 1H), 7.07 - 7.00 (m, 1H), 6.85 - 6.79 (m, 2H), 6.53 - 6.47 (m, 1H), 4.67 (s, 2H).
-
- Example 30 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one and methylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C16H14ClF2N5O. 366.0 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 12.86 (br s, 1H), 11.00 (br s, 1H), 9.24 (br s, 2H), 8.84 (s, 1H), 7.30 - 7.19 (m, 1H), 7.03 (t, J = 8.0 Hz, 1H), 6.88 - 6.75 (m, 2H), 6.53 - 6.45 (m, 1H), 4.45 (t, J = 5.6 Hz, 2H), 2.74 - 2.64 (m, 3H).
-
- Example 31 was prepared analogously to Example 45, using 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one and ammonia (0.5 M solution in dioxane) in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C15H12ClF2N5O. 352.0 [M+1]+ 1H NMR (400 MHz, DMSO-d6 ) δ 12.77 (br s, 1H), 11.00 (br s, 1H), 8.83 (s, 1H), 8.52 (br s, 3H), 7.21 (dd, J = 12.0, 6.9 Hz, 1H), 7.04 (t, J = 8.1 Hz, 1H), 6.83 (dd, J = 7.8, 2.0 Hz, 1H), 6.80 (t, J = 2.1 Hz, 1H), 6.49 (dd, J = 8.2, 2.1 Hz, 1H), 4.34 (q, J = 5.4 Hz, 2H).
-
- Methyl 2,3-diamino-4,5-difluorobenzoate (5.0 g, 25 mmol, 1 equiv) was dissolved in formic acid (120 mL) and stirred at 80 °C for 3 hours. Formic acid was subsequently removed in vacuo and methyl 4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate was obtained as a brown solid. C9H6F2N2O2, 213.0 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 8.43 (s, 1H), 7.83 (dd, J = 11.5, 7.2 Hz, 1H), 3.95 (s, 3H). 19F NMR (377 MHz, DMSO-d 6) δ -146.16 (dd, J = 21.8, 7.2 Hz, 1F), -149.09 (dd, J = 21.8, 11.6 Hz, IF).
- To a suspension of methyl 4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate (6.0 g, 28 mmol, 1 equiv) in THF (60 mL) was added a 60 wt% dispersion of NaH (1.7 g, 42 mmol, 1.5 equiv) in three portions. Once gas evolution ceased, the reaction mixture was cooled to 0 °C and SEM-Cl (6.0 mL, 34 mmol, 1.2 equiv) was added. The ice bath was subsequently removed and the reaction was stirred at room temperature for 3 hours before being quenched with saturated aqueous NH4Cl. The reaction mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by silica gel chromatography (0-5% MeOH/CH2Cl2 over 20 minutes). Methyl 4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow solid. C15H20F2N2O3Si, 342.9 (M+1). 1H NMR (400 MHz, Chloroform-d) δ 8.17 (s, 1H), 7.91 (dd, J = 11.5, 7.5 Hz, 1H), 5.68 (s, 2H), 4.06 (s, 3H), 3.64 - 3.45 (m, 2H), 0.98 - 0.85 (m, 2H), -0.04 (d, J = 0.6 Hz, 9H). 19F NMR (377 MHz, Chloroform-d) δ -144.34 (m, 1F), -150.20 (m, 1F).
- To a solution of methyl 4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate (2.2 g, 6 mmol, 1 equiv) in acetonitrile (46.2 mL) was added NCS (1.29 g, 10 mmol, 1.5 equiv). The reaction mixture was stirred at 100 °C in a sealed vessel for 12 hours. Acetonitrile was subsequently removed in vacuo and the crude product purified by silica gel chromatography (0-5% MeOH/CH2Cl2 over 20 minutes). Methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was obtained as a crystalline yellow solid. C15H19ClF2N2O3Si, 376.9/378.9 (M+1).
- To a solution of Methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate (0.29 g, 0.46 mmol, 1 equiv) in DMSO (2 mL) was added morpholine (0.14 mL, 1.6 mmol, 3.5 equiv). The reaction was stirred at 60 °C for 3 hours before being diluted with DMF/H2O and purified by reverse phase HPLC (10-90% CH3CN/H2O over 20 mins). The TFA salt of methyl 4,5-difluoro-2-morpholino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was obtained as a white solid. C19H27F2N3O4Si, 428.1 (M+1).
- N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-2-morpholino-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 13 using methyl 4,5-difluoro-2-morpholino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate and 3-chloro-4-fluoroaniline in place of methyl 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate. C18H14ClF3N4O2, 411.1/413.0 (M+1).
- Example 32 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-morpholino-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C18H15ClF3N5O2. 426.1/428.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 10.78 (br. s, 1H), 8.82 (s, 1H), 7.04 (t, J = 9.1 Hz, 1H), 7.00 (dd, J = 6.6, 2.7 Hz, 1H), 6.93 (dd, J = 12.1, 6.9 Hz, 1H), 6.51 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.69 - 3.62 (m, 4H), 3.53 - 3.44 (m, 4H).
-
- Methyl 2,3-diamino-4-fluorobenzoate (150 mg, 0.814 mmol) and 1-isothiocyanato-2-(methylsulfonyl)ethane (5.0 mmol) were dissolved in THF (4.5 mL) and triethylamine (7.0 mmol) was added and the reaction was heated to reflux overnight. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (5.0 mmol) was added and the reaction was allowed to heat at reflux for an additional 1 hour. The reaction was allowed to cool to room temperature, quenched with water, and extracted with EtOAc (3x 3 mL). The combined organic layers were washed with brine (1x4mL), concentrated, and purified by silica gel column chromatography to give methyl 4-fluoro-2-((2-(methylsulfonyl)ethyl)amino)-1H-benzo[d]imidazole-7-carboxylate.
- Example 33 was made analogously to Example 22 using methyl 4-fluoro-2-((2-(methylsulfoyl)ethyl)amino)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-amino-4-fluoro-1H-benzo[d]imidazole-7-carboxylate. C17H16ClF2N5O3S. 444.1/446/1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.89 (s, 1H), 8.85 (s, 1H), 7.12 - 6.98 (m, 3H), 6.95 (dd, J = 6.5, 2.7 Hz, 1H), 6.55 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.89 (d, J = 6.3 Hz, 2H), 3.51 (t, J = 6.1 Hz, 2H), 3.08 (s, 3H).
-
- Example 34 was made analogously to Example 33 using 4-(2-isothiocyanatoethyl)morpholine in place of 1-isothiocyanato-2-(methylsulfonyl)ethane.
-
- Example 35 was made analogously to Example 39 using 2-(methylsulfonyl)ethanamine in place of N1,N1-dimethylpropane-1,3-diamine with an addition of triethylamine (1.2 eq) in the cyclization reaction. C17H15ClF3N5O3S. 462.1/464.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.94 (s, 1H), 8.82 (d, J = 4.0 Hz, 1H), 7.65 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.03 - 6.91 (m, 2H), 6.55 (dt, J = 9.0, 3.5 Hz, 1H), 3.84 (d, J = 5.9 Hz, 2H), 3.48 (t, J = 6.4 Hz, 2H), 3.06 (s, 3H).
-
- Example 36 was made analogously to Example 39 using 2-(4,4-difluoropiperidin-1-yl)ethanamine in place of N1,N1-dimethylpropane-1,3-diamine. C21H20ClF5N6O. 503.2/505/2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.81 (s, 1H), 8.71 (s, 1H), 6.94 (dd, J = 6.5, 2.8 Hz, 1H), 6.87 (dd, J = 12.2, 6.9 Hz, 1H), 6.76 (s, 1H), 6.59 (s, 1H), 6.53 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.78 - 3.67 (m, 2H), 3.50 (s, 4H), 3.41 (t, J = 5.7 Hz, 2H), 2.34 (dt, J = 13.6, 7.8 Hz, 4H).
-
- Example 37 was made analogously to Example 39 using 1-morpholinopropan-2-amine in place of N1,N1-dimethylpropane-1,3-diamine. C21H22ClF3N6O2. 483.1/485.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.82 (s, 1H), 8.69 (s, 1H), 7.14 - 6.97 (m, 2H), 6.93 (dd, J = 6.6, 2.8 Hz, 1H), 6.87 (dd, J = 12.3, 7.1 Hz, 1H), 6.58 - 6.49 (m, 1H), 4.41 - 4.26 (m, 1H), 3.85 (s, 4H), 3.49 (s, 2H), 3.32 (d, J = 6.3 Hz, 4H), 1.26 (d, J = 6.7 Hz, 3H).
-
- To a solution of methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate (0.16 g, 0.43 mmol, 1 equiv) in DMSO (1 mL) was added a 2 M solution of methylamine in methanol (0.76 mL, 1.51 mmol, 3.5 equiv) and triethylamine (0.06 mL, 0.43 mmol, 1 equiv). The reaction was stirred at 60 °C for 2 hours before being diluted with water and extracted with EtOAc. The combined organics were dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by silica gel chromatography (0-3% MeOH/CH2Cl2). Methyl 4,5-difluoro-2-(methylamino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was obtained as a yellow oil. C16H23F2N3O3Si. 372.05 (M+1).
- N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-2-(methylamino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 13 using methyl 4,5-difluoro-2-(methylamino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate and 3-chloro-4-fluoroaniline in place of methyl 2-amino-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate and stirring overnight at room temperature. The crude product was purified by reverse phase HPLC (10-90% CH3CN/H2O over 20 mins) and the TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(methylamino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C15H10ClF3N4O. 355.06/356.98 (M+1).
- Example 38 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(methylamino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(methylamino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid. C15H11ClF3N5O. 370.05/371.98 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.94 (s, 1H), 8.79 (s, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.06 - 7.01 (m, 1H), 6.99 (dd, J = 6.6, 2.7 Hz, 1H), 6.53 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 2.98 (d, J = 3.7 Hz, 3H). 19F NMR (377 MHz, DMSO-d 6) δ -73.7, - 126.8 , -147.4 , -155.1 (TFA salt).
-
- To a solution of methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate (0.25 g, 0.66 mmol, 1 equiv) in DMSO (1.25 mL) was added N,N-dimethylpropane-1,3-diamine (0.10 mL, 0.81 mmol, 1.2 equiv). The reaction was stirred at 60 °C for 6 hours before being diluted with DMF/water and purified by reverse phase HPLC (10-90% CH3CN/H2O over 15 mins). The TFA salt of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was obtained as a yellow oil. C20H32F2N4O3Si. 443.18 (M+1).
- To a solution of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate (TFA salt, 159 mg, 0.36 mmol, 1 equiv) and 3-chloro-4-fluoroaniline (209 mg, 1 mmol, 4 equiv) in DCE (7.5 mL) was added a 2 M solution of AlMe3 in toluene (1.26 mL, 3 mmol, 7 equiv) at room temperature. The reaction was stirred overnight before quenching with 2 M aqueous NaOH and extracting with ethyl acetate. The combined organics were dried over MgSO4, filtered and concentrated in vacuo. The crude product was dissolved in CH2Cl2 (2 mL) and TFA (2 mL) was added. The SEM-deprotection was stirred overnight before being concentrated in vacuo. The crude product was purified by reverse phase HPLC (10-90% CH3CN/H2O over 15 mins). The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1H-benzo[d]-imidazole-7-carboxamide was obtained as an off-white solid. C19H19ClF3N5O. 426.18/428.13 (M+1).
- Example 39 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid. C19H20ClF3N6O. 441.12/443.09 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.85 (s, 1H), 9.72 (s, 1H), 8.74 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 7.00 - 6.85 (m, 2H), 6.55 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.42 (m, 2H), 3.10 (m, 2H), 2.80 (s, 6H), 1.93 (m, 2H). 19F NMR (377 MHz, DMSO-d 6) δ -73.7, -127.1, - 149.4, -156.5.
-
- Methyl 4,5-difluoro-2-((2-methoxyethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 2-methoxyethanamine and triethylamine (1 equiv) in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-((2-methoxyethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C18H27F2N3O4Si. 416.09/417.07 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-methoxyethyl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((2-methoxyethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-methoxyethyl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C17H14ClF3N4O2. 399.09/401.02 (M+1).
- Example 40 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-methoxyethyl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide . The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-methoxyethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid. C17H15ClF3N5O2. 414.09/416.01 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.98 (s, 1H), 8.79 (s, 1H), 8.11 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 7.04 (dd, J = 12.1, 7.0 Hz, 1H), 6.99 (dd, J = 6.6, 2.7 Hz, 1H), 6.55 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 3.56 (t, J = 5.1 Hz, 2H), 3.51 (t, J = 4.7 Hz, 2H), 3.29 (s, 3H). 19F NMR (377 MHz, DMSO-d 6) δ - 75.18 (6F), -126.96 (1F), -147.44 (1F), -155.18 (1F).
-
- Methyl 4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 2-(pyrrolidin-1-yl)ethanamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C21H32F2N4O3Si. 455.21 (M+1).
- N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C20H19ClF3N5O. 438.21/440.12 (M+1).
- Example 41 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid. C20H20ClF3N6O. 453.14/455.11 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.78 (s, 1H), 9.84 (s, 1H), 8.70 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 7.02 (s, 1H), 6.93 (dd, J = 6.6, 2.7 Hz, 1H), 6.84 (dd, J = 12.3, 6.9 Hz, 1H), 6.53 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 4.00 (dq, J = 8.3, 7.1 Hz, 1H), 3.75-3.60 (m, 3H), 3.45-3.35 (m, 3H), 2.05-1.80 (m, 4H), 1.24 (td, J = 7.0, 0.9 Hz, 1H). 19F NMR (377 MHz, DMSO-d 6) δ - 74.94 (9F), -127.34 (1F), -150.32 (1F), -157.02 (1F).
-
- Methyl 2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using N,N-diethylethane-1,2-diamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C21H34F2N4O3Si. 457.22 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C20H21ClF3N5O. 440.21/442/11 (M+1).
- Example 42 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide . The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid. C20H22ClF3N6O. 455.18/457.11 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.77 (s, 1H), 9.73 (s, 1H), 8.70 (s, 1H), 7.08 (t, J = 9.1 Hz, 1H), 6.97 (s, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.85 (dd, J = 12.2, 6.9 Hz, 1H), 6.53 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.68 (m, 2H), 3.31 (m, 2H), 3.26 - 3.13 (m, 4H), 1.20 (t, J = 7.2 Hz, 6H). 19F NMR (376 MHz, DMSO-d 6) δ -74.9, -127.3, -150.3, -157.1.
-
- Methyl 2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using N,N-dimethylethane-1,2-diamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C19H30F2N4O3Si. 429.17 (M+1).
- N-(3-Chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C18H17ClF3N5O. 412.19/414.09 (M+1).
- Example 43 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide . The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid. C18H18ClF3N6O. 427.14/429.09 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.78 (s, 1H), 9.74 (s, 1H), 8.71 (s, 1H), 7.09 (t, J = 10.7 Hz, 1H), 7.04 (br s, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.84 (dd, J = 12.2, 7.0 Hz, 1H), 6.53 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.69 (q, J = 5.9 Hz, 2H), 3.31 (t, J = 5.8 Hz, 2H), 2.86 (s, 6H). 19F NMR (376 MHz, DMSO-d 6) δ -74.99 (9F), -127.32 (1F), -150.28 (1F), -156.83 (1F).
-
-
- To a solution of 4,5-difluoro-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole-7-carboxylic acid (TFA salt, 63 mg, 0.19 mmol, 1 equiv), 3-chloroaniline (0.05 mL, 0.48 mmol, 2.5 equiv), and DIPEA (0.16 mL, 0.95 mmol, 5 equiv) in DMF (1 mL) was added HATU (87 mg, 0.23 mmol, 1.2 equiv) and the reaction was stirred overnight at room temperature. The crude product was purified by reverse phase HPLC (10-90% CH3CN/H2O) and the TFA salt of N-(3-chlorophenyl)-4,5-difluoro-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole-7-carboxamide was obtained as a white solid. C20H19ClF2N4O. 405.19/407.12 (M+1).
- Example 44 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide . The TFA salt of N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole-7-carboximidamide was isolated as a white solid. C20H20ClF2N5O. 420.22/422.17 (M+1).
-
- Methyl 4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxylate. A mixture of methyl 2,3-diamino-4,5-difluorobenzoate (2.0 g, 9.9 mmol) in methoxyacetic acid (23 mL) was stirred at 120 °C for 3 hr. To the mixture was added saturated sodium bicarbonate and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, absorbed onto silica and purified by silica gel chromatography to give the desired product. C11H10F2N2O3. 257.3 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxamide. To a solution of the 3-chloro-4-fluoroaniline in (1.30 g, 8.90 mmol) in dichloroethane (60 mL) at 0 °C under nitrogen was added trimethylaluminum (2 M in heptane, 8.90 mL, 17.8 mmol) dropwise over 5 min. The solution was allowed to warm to room temperature and stirred for 30 min. The solution was cooled to 0 °C and to this solution was added methyl 4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxylate (1.52 g, 5.93 mmol). The solution was stirred at 85 °C for 3 hr and, then, cooled to room temperature. Water and 10% citric acid were added and the resulting precipitate was filtered and dried on high vac to give the desired product. C16H11ClF3N3O2. 370.1 (M+1).
- 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one. A mixture of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxamide (1.80 g, 4.86 mmol), phosphorous pentachloride (1.52 g, 7.29 mmol) in phosphoryl chloride (14 mL) and 1,2-dichloroethane (14 mL) was stirred at 80 °C for 2.5 hr. The reaction mixture was concentrated and suspended in ethanol (14 mL) and to this mixture was added 50% hydroxylamine in water (3.0 mL, 49 mmol). The reaction mixture stirred for 1.5 hr. Water was added to the reaction mixture and the resulting precipitate was collected by filtration and dried on high vac. The dried solid and carbonyl diimidazole (1.6 g, 9.7 mmol) was suspended in ethyl acetate (50 mL) and the reaction mixture stirred for 18 hr. The resulting solution was absorbed onto silica gel and purified by silica gel chromatography to give the desired product. C17H10ClF3N4O3. 411.0 (M+1).
- 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(hydroxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one. To a mixture of 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one (937 mg, 2.28 mmol) in dichloromethane (16 mL) at 0 °C was added a solution of 1 M boron tribromide in dichloromethane (3.42 mL, 3.42 mmol). The reaction was allowed to warm to room temperature and stirred for 18 hr. The reaction mixture was diluted with dichloromethane and saturated sodium bicarbonate and the aqueous layer was washed three times with dichlromethane. The combined organic layers contained a precipitate that was filtered off to give 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(hydroxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one (203 mg) as a white solid. The filtrate was dried over sodium sulfate, filtered, loaded onto silica gel column and purified by silica gel chromatography to give 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. C16H7BrClF3N4O2. 459.0 (M+1). C16H8ClF3N4O3. 397.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(((3-methoxypropyl)amino)methyl)-1H-benzo[d]imidazole-4-carboximidamide. A solution of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (12 mg, 0.026 mmol) and 3-methoxypropylamine (0.027 mL, 0.26 mmol) in acetonitrile (1 mL) was stirred at 65 °C for 10 min. The reaction was concentrated. The residue was brought up in tetrahydrofuran (0.3 mL) and water (0.3 mL). To this solution was added 2 N sodium hydroxide (0.19 mL, 0.34 mmol) and the reaction mixture stirred for 10 min. To the mixture was added acetic acid (0.05 mL) and the solution was loaded directly onto a prep HPLC for purification to give the desired product. C19H19ClF3N5O2. 442.1 (M+1).
-
- To a solution of 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(hydroxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one (20 mg, 0.050 mmol) in tetrahydrofuran (0.4 mL) and water (0.4 mL) was added 2 N sodium hydroxide (0.38 mL, 0.76 mmol) and the reaction mixture stirred for 10 min. To the mixture was added acetic acid (0.06 mL) and the solution was loaded directly onto a prep HPLC for purification to give the desired product. C15H10ClF3N4O2. 371.0 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.93 (s, 1H), 8.80 (s, 1H), 7.16 (dd, J = 12.0, 7.0 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.49 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 4.63 (s, 2H).
-
- Example 47 was made analogously to Example 45 using 0.5 M ammonia in dioxane in place of 3-methoxypropylamine. C15H11ClF3N5O. 370.1 (M+1).
-
- Example 48 was made analogously to Example 45 using 2 M methylamine in tetrahydrofuran in place of 3-methoxypropylamine. C16H13ClF3N5O. 384.0 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 12.84 (s, 1H), 10.92 (s, 1H), 9.21 (s, 2H), 8.82 (s, 1H), 7.34 - 7.17 (m, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.90 (dd, J= 6.6, 2.7 Hz, 1H), 6.48 (dt, J = 9.0, 3.5 Hz, 1H), 4.40 (t, J = 5.8 Hz, 2H), 2.65 (s, 3H).
-
- Example 49 was made analogously to Example 45 using cyclopropylmethylamine in place of 3-methoxypropylamine. C19H17ClF3N5O.424.0 (M+1).
-
- Example 50 was made analogously to Example 45 using 2 M ethylamine in tetrahydrofuran in place of 3-methoxypropylamine. C17H15ClF3N5O. 398.0 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 12.85 (s, 1H), 10.92 (s, 1H), 9.25 (s, 2H), 8.82 (s, 1H), 7.33 - 7.20 (m, 1H), 7.05 (t, J = 9.0 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.50 (dt, J = 9.0, 3.6 Hz, 1H), 4.43 (t, J = 5.9 Hz, 2H), 3.11 - 2.95 (m, 2H), 1.21 (t, J = 7.2 Hz, 3H).
-
- Example 51 was made analogously to Example using isopropylamine in place of 3-methoxypropylamine. C18H17ClF3N5O. 412.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 12.85 (s, 1H), 10.94 (s, 1H), 9.25 (s, 2H), 8.82 (s, 1H), 7.33 - 7.20 (m, 1H), 7.06 (t, J = 9.0 Hz, 1H), 6.90 (dd, J = 6.5, 2.7 Hz, 1H), 6.50 (dt, J = 9.1, 3.5 Hz, 1H), 4.49 - 4.37 (m, 2H), 3.48 - 3.33 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H).
-
- Example 52 was made analogously to Example 45 using dimethylamine in place of 3-methoxypropylamine. C17H15ClF3N5O. 398.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ12.93 (s, 1H), 10.93 (s, 1H), 10.28 (s, 1H), 8.83 (s, 1H), 7.40 - 7.23 (m, 1H), 7.03 (t, J = 9.1 Hz, 1H), 6.95 (dd, J = 6.6, 2.7 Hz, 1H), 6.49 (dt, J = 9.0, 3.5 Hz, 1H), 4.56 (s, 2H), 2.83 (s, 6H).
-
- 2-(2-(dimethylamino)ethyl)-6,7-difluoro-1H-benzo[d]imidazole-4-carboxylic acid. A mixture of methyl 2,3-diamino-4,5-difluorobenzoate (2.0g, 9.89mmol) and 3-(dimethylamino)propanoic acid (6.08g, 39.6mmol) in concentrated hydrochloric acid was stirred at 120°C overnight in a sealed screw-top flask. The reaction was concentrated under reduced pressure. Cured product was used as is in next step without purification. C12H13F2N3O2. 270.10 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-1H-benzo[d]imidazole-4-carboxamide. A mixture of 2-(2-(dimethylamino)ethyl)-6,7-difluoro-1H-benzo[d]imidazole-4-carboxylic acid (300 mg, 1.114mmol), 3-chloro-4-fluoroaniline (300 mg, 1.114mmol), bis(2-oxo-3-oxazolidinyl)phosphinic chloride (567mg, 2.23mmol) and diisopropylethylamine (1.94mL, 11.1 mmol) in dichloromethane (8 mL) was stirred for 2hr. The reaction mixture was filtered and absorbed onto silica gel and purified by silica gel chromatography to give the desired product. C18H16ClF3N4O.
- N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide. Example 53 was made analogously to Example 95 C18H17ClF3N5O. 411.11 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.92 (s, 1H), 8.78 (s, 1H), 7.17 (dd, J = 12.0, 7.0 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.6, 2.7 Hz, 1H), 6.50 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.53 (t, J = 7.5 Hz, 2H), 3.26 (t, J = 7.6 Hz, 2H), 2.83 (s, 6H)
-
-
- N-(3-bromo-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide. Example 54 was made analogously to Example 95. C18H17BrF3N5O. 456.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.89 (s, 1H), 8.76 (s, 1H), 7.17 (dd, J = 11.9, 7.0 Hz, 1H), 7.07 (dd, J = 6.1, 2.7 Hz, 1H), 7.00 (t, J= 8.8 Hz, 1H), 6.53 (ddd, J = 8.9, 4.1, 2.7 Hz, 1H), 3.53 (t, J = 7.5 Hz, 2H), 3.26 (t, J = 7.5 Hz, 2H), 2.83 (s, 6H).
-
-
- N-(3-bromophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide. Example 55 was made analogously to Example 95. C18H18BrF2N5O. 438.10. 1H NMR (400 MHz, DMSO-d 6) δ 10.98 (s, 1H), 8.78 (s, 1H), 7.22 - 7.07 (m, 1H), 7.00 - 6.85 (m, 3H), 6.55 - 6.40 (m, 1H), 3.54 (t, J = 7.5 Hz, 2H), 3.35 - 3.20 (m, 2H), 2.84 (s, 6H).
-
-
- N-(3-chlorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide. Example 56 was made analogously to Example 95 C18H18ClF2N5O. 394.12 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.94 (s, 1H), 8.78 (s, 1H), 7.14 (dd, J = 12.0, 7.0 Hz, 1H), 7.00 (t, J = 8.0 Hz, 1H), 6.86 - 6.74 (m, 2H), 6.51 - 6.38 (m, 1H), 3.54 (t, J = 7.5 Hz, 2H), 3.27 (t, J = 7.5 Hz, 2H), 2.83 (s, 6H).
-
-
-
-
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-benzo[d]imidazole-7-carbothioamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-benzo[d]imidazole-7-carboxamide. C25H31ClF3N3OSSi. 542.16 (M+1).
- 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-benzo[d]imidazole-7-carbothioamide. C26H30ClF3N4O3Si. 567.17 (M+1).
- 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4,5-difluoro-1-(methylsulfonyl)-1H-benzo[d]imidazol-2-yl)ethyl methanesulfonate was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one. C19H14ClF3N4O7S2. 567.00 (M+1).
- N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-(methylamino)ethyl)-1H-benzo[d]imidazole-4-carboximidamide. Example 57 was made analogously to Example 112 using 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4,5-difluoro-1-(methylsulfonyl)-1H-benzo[d]imidazol-2-yl)ethyl methanesulfonate in place of 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-3-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate. C16H16ClFN6O. 363.11 (M+1).
-
- Example 58 was made analogously to Example 57 using 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4,5-difluoro-1-(methylsulfonyl)-1H-benzo[d]imidazol-2-yl)ethyl methanesulfonate and diethylamine in place of 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-3-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate and methylamine. C20H21ClF3N5O. 440.14 1H NMR (400 MHz, DMSO-d 6) δ 10.85 (s, 1H), 8.78 (s, 1H), 7.18 (dd, J = 11.9, 6.9 Hz, 1H), 7.03 (t, J = 9.0 Hz, 1H), 6.94 (dd, J = 6.6, 2.7 Hz, 1H), 6.48 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.50 (t, J = 7.6 Hz, 2H), 3.24 (t, J = 7.7 Hz, 2H), 3.19 (q, J = 8.3, 7.3 Hz, 4H), 1.20 (t, J = 7.3 Hz, 6H).
-
- 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (300 mg, 2.0 mmol), 3-chloro-4-fluoroaniline (2.0 mmol), and HATU (2.4 mmol) were dissolved in DMF (5 mL) and DIPEA (6 mmol) was added. The reaction was allowed to stir at rt overnight. The reaction was quenched with saturated sodium bicarbonate solution (5 mL) and the reaction was extracted with EtOAc (3x5 mL). Combined organic layers were washed with brine (1x8 mL) and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc/hex) to give N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (122 mg, 0.42 mmol) and PCl5 (0.63 mmol) was dissolved in POCl3 (2 mL) and heated to 85 °C for 12 hours. The reaction was cooled to rt and concentrated in vacuo. The residue was dissolved in a pre-mixed solution of hydroxylamine (50% aqueous solution, 4.0 mmol) and ethanol (2 mL) and the reaction was allowed to stir at rt for 10 minutes. The reaction was concentrated in vacuo and purified by reverse-phase HPLC to give N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide as a white solid. C13H9ClFN5O. 306.0/308.0 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.14 (s, 1H), 8.92 (d, J = 1.9 Hz, 1H), 8.64 (s, 1H), 8.43 - 8.39 (m, 1H), 7.28 - 7.23 (m, 1H), 7.03 (t, J = 9.1 Hz, 1H), 6.98 - 6.92 (m, 1H), 6.51 (dt, J = 8.9, 3.4 Hz, 1H).
-
- Example 60 was made analogously to Example 59 using 5-chloro-2-fluoroaniline in place of 3-chloro-4-fluoroaniline. C13H9ClFN5O. 306.1/308.2 (M+1). 1H NMR (400 MHz, Methanol-d 4) δ 8.88 (s, 1H), 8.46 (d, J = 5.3 Hz, 1H), 7.35 (d, J = 5.3 Hz, 1H), 7.01 - 6.95 (m, 2H), 6.92 - 6.85 (m, 1H).
-
- Example 61 was made analogously to Example 59 using 5-bromo-2,4-difluoroaniline in place of 3-chloro-4-fluoroaniline. C13H8BrF2N5O. 368.0/370.0 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.03 (s, 1H), 8.71 (s, 1H), 8.59 (s, 1H), 8.36 (d, J = 4.8 Hz, 1H), 7.34 - 7.21 (m, 3H).
-
- Example 62 was made analogously to Example 59 using 5-chloro-2,4-difluoroaniline in place of 3-chloro-4-fluoroaniline. C13H8ClF2N5O. 324.0/326.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.08 (s, 1H), 8.71 (d, J = 17.2 Hz, 2H), 8.42 - 8.34 (m, 1H), 7.34 (dd, J = 10.7, 9.3 Hz, 1H), 7.28 (d, J = 5.0 Hz, 1H), 7.15 (t, J = 8.2 Hz, 1H).
-
- Example 63 was made analogously to Example 59 using 3,5-dichloro-4-fluoroaniline in place of 3-chloro-4-fluoroaniline. C13H8Cl2FN5O. 340.1/342.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.26 (s, 1H), 10.10 (s, 1H), 9.07 (d, J = 1.1 Hz, 1H), 8.53 (s, 1H), 8.45 - 8.37 (m, 1H), 7.31 (d, J = 5.2 Hz, 1H), 6.81 - 6.73 (m, 2H).
-
- Example 64 was made analogously to Example 59 using 3-chloro-2,4-difluoroaniline in place of 3-chloro-4-fluoroaniline. C13H8ClF2N5O. 324.1/326.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 10.99 (s, 0H), 8.67 (s, 1H), 8.51 (s, 1H), 8.34 (dd, J = 5.0, 2.3 Hz, 1H), 7.22 (s, 1H), 7.04 (t, J = 9.0 Hz, 1H), 6.84 (s, 1H).
-
- Example 65 was made analogously to Example 59 using 3-cyclopropyl-4-fluoroaniline in place of 3-chloro-4-fluoroaniline. C16H14FN5O. 312.1 (M+1).
-
- Example 66 was made analogously to Example 59 using 4-(trifluoromethoxy)aniline in place of 3-chloro-4-fluoroaniline. C14H10F3N5O2. 338.1 (M+1).
-
- Example 67 was made analogously to Example 59 using benzofuran-4-amine in place of 3-chloro-4-fluoroaniline. C15H11N5O2. 294.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.32 (s, 1H), 8.92 (s, 1H), 8.86 (s, 1H), 8.34 (dd, J = 5.2, 2.7 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.16 - 7.09 (m, 2H), 7.06 (dd, J = 2.3, 1.0 Hz, 1H), 6.95 (t, J = 8.0 Hz, 1H), 6.36 (d, J = 7.8 Hz, 1H).
-
- Example 68 was made analogously to Example 59 using benzofuran-6-amine in place of 3-chloro-4-fluoroaniline. C15H11N5O2. 294.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.17 (s, 1H), 8.89 (d, J = 33.4 Hz, 2H), 8.40 (d, J = 6.1 Hz, 1H), 7.79 - 7.74 (m, 1H), 7.30 (dd, J = 8.6, 2.0 Hz, 1H), 7.24 (t, J = 5.9 Hz, 1H), 6.90 (t, J = 2.5 Hz, 1H), 6.76 (dd, J = 2.2, 1.1 Hz, 1H), 6.69 (dt, J = 8.4, 1.9 Hz, 1H).
-
- Example 69 was made analogously to Example 59 using benzofuran-7-amine in place of 3-chloro-4-fluoroaniline. C15H11N5O2. 294.1 (M+1).
-
- Example 70 was made analogously to Example 59 using benzofuran-5-amine in place of 3-chloro-4-fluoroaniline. C15H11N5O2. 294.1 (M+1).
-
- Example 71 was made analogously to Example 59 using acid and 5-bromo-2-fluoroaniline in place of 3-chloro-4-fluoroaniline. C13H9BrFN5O. 350.1/352.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.16 (s, 1H), 10.06 (s, 1H), 8.74 (s, 1H), 8.57 (s, 1H), 8.35 (d, J = 5.1 H, 1H), 7.25 (s, 1H), 7.14 - 6.92 (m, 3H).
-
- Example 72 was made analogously to Example 59 using 5-bromo-3-fluoroaniline in place of 3-chloro-4-fluoroaniline. C13H9BrFN5O. 350.1/352.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.32 (s, 1H), 9.08 (s, 1H), 8.55 (s, 1H), 8.37 (d, J = 5.1 Hz, 1H), 7.23 (d, J = 5.1 Hz, 1H), 6.84 - 6.75 (m, 1H), 6.66 (t, J = 1.9 Hz, 1H), 6.30 (dt, J = 11.3, 2.1 Hz, 1H).
-
- Example 73 was made analogously to Example 59 using 3-(trifluoromethyl)aniline in place of 3-chloro-4-fluoroaniline. C14H10F3N5O. 322.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.34 (s, 1H), 9.13 (s, 1H), 8.77 (s, 1H), 8.43 (d, J = 5.1 Hz, 1H), 7.29 (d, J = 5.1 Hz, 1H), 7.27 - 7.13 (m, 1H), 7.13 - 7.02 (m, 2H), 6.90 - 6.71 (m, 1H).
-
- Example 74 was made analogously to Example 59 using 2,2-difluorobenzo[d][1,3]dioxol-5-amine in place of 3-chloro-4-fluoroaniline.
- N-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. C14H9F2N5O3. 334.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.00 (d, J = 13.0 Hz, 1H), 8.86 (s, 1H), 8.46 (s, 1H), 8.34 (d, J = 5.0 Hz, 1H), 7.22 (d, J = 31.8 Hz, 1H), 7.00 (d, J = 8.7 Hz, 1H), 6.78 (d, J = 2.2 Hz, 1H), 6.34 (dd, J = 8.7, 2.3 Hz, 1H).
-
- Example 75 was made analogously to Example 59 using 3-fluoro-5-(trifluoromethyl)aniline in place of 3-chloro-4-fluoroaniline. C14H9F4N5O. 340.1 (M+1).
-
- 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (200 mg, 1.0 mmol) and 2,5-dichloroaniline (2.0 mmol) were dissolved in DCM (3 mL) and cooled to 0 °C. Triethylamine (4.0 mmol) was added dropwise followed by POCl3 (2.0 mmol) and the reaction was allowed to slowly come to rt and stir for 15 mins. The reaction was quenched with saturated sodium bicarbonate solution and extracted with EtOAc (3x5 mL). Combined organic layers were washed with brine (1x7 mL) and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc/hex) to give N-(2,5-dichlorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N-(2,5-dichlorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (40 mg, 0.13 mmol) was dissolved in POCl3 (2 mL) and PCl5 (0.195 mmol) was added. The reaction was heated to 80 °C overnight, allowed to cool to rt, and concentrated in vacuo. The crude was dissolved in a pre-mixed solution of hydroxylamine (50% in water, 1.0 mmol) and ethanol (2 mL) and allowed to stir at rt for 10 mins then concentrated in vacuo. The crude was purified by reverse-phase HPLC to give N-(2,5-dichlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. C13H9Cl2N5O. 322.0/324.0 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.50 (s, 1H), 8.80 (s, 1H), 8.71 (s, 1H), 8.48 - 8.39 (m, 1H), 7.43 - 7.34 (m, 2H), 6.98 (dd, J = 8.6, 2.4 Hz, 1H), 6.69 (d, J = 3.2 Hz, 1H).
-
- 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (1.5g, 9.0 mmol), 3-bromo-4-fluoroaniline (11.0 mmol), and HATU (12.0 mmol) were dissolved in DMF (15.0 mL) and DIPEA (28.0 mmol) was added and the reaction was allowed to stir overnight at rt. The reaction was quenched with saturated sodium bicarb solution and the precipitate was isolated by vacuum filtration. The precipitate was washed with water followed by diethyl ether to give N-(3-bromo-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide as a yellow powder.
- N-(3-bromo-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (150 mg, 0.448 mmol) and phenyl boronic acid (2.0 mmol) was dissolved in degassed THF (2.0 mL) and water (0.50 mL). PdCl2(dppf) (0.090 mmol) and K2CO3 (2.0 mmol) were added and the reaction was heated to 65 °C overnight. The reaction was allowed to cool to rt and quenched with saturated bicarb solution. The solution was extracted with EtOAc (3 x 4 mL) and combined organic layers were washed with brine (1x 5 ((EtOAc/hex) to give N-(6-fluoro-[1,1'-biphenyl]-3-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N-(6-fluoro-[1,1'-biphenyl]-3-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (100 mg, 0.301 mmol) was dissolved in POCl3, PCl5 (2.0 mmol) was added, and the reaction was heated to 80 °C overnight. The reaction was allowed to cool to rt and concentrated in vacuo. The crude was dissolved in a pre-mixed solution of hydroxylamine (50% in water, 3.0 mmol) and ethanol (2 mL) and allowed to stir at rt for 10 mins. The reaction was purified by reverse-phase HPLC to give N-(6-fluoro-[1,1'-biphenyl]-3-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. C19H14FN5O. 348.2 (M+1).
-
- N-(3-bromo-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (100 mg, 0.298 mmol), PdCl2(PPh3)2 (0.015 mmol), and CuI (0.0298 mmol) were dissolved in degassed DMF (0.75 mL) and DIPEA (3.0 mmol) was added. But-1-yne was bubbled through the reaction for 5 mins and then removed. The reaction was allowed to stir overnight under an atmosphere of but-1-yne. The reaction was quenched with water and extracted with EtOAc (3x 3 mL). The combined organic layers were washed with brine (1x5 mL) and concentrated in vacuo. The crude was purified by column chromatography (EtOAc/hex) to give N-(3-(but-1-yn-1-yl)-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (57 mg, 62%).
- N-(3-(but-1-yn-1-yl)-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (56 mg, 0.182 mmol) was dissolved in POCl3 (2 mL) and PCl5 (0.272 mmol) was added and the reaction was heated to 80 °C for 45 mins. The reaction was allowed to cool to rt and concentrated in vacuo. The material was dissolved in a pre-mixed solution of hydroxylamine (50% in water, 2.0 mmol) and ethanol (2 mL) and allowed to stir at rt for 10 mins. The reaction was purified by reverse-phase HPLC to giveN-(3-(but-1-yn-1-yl)-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. C17H14FN5O. 324.2 (M+1).
-
- Example 79 was made analogously to Example 78 using ethynylcyclopropane (5 eq) in place of but-1-yne. C18H14FN5O. 336.1 (M+1).
-
- N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. To a solution of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (0.102 g, 0.625 mmol), 3-bromoaniline (0.07 mL, 0.625 mmol), HOBt (0.101 g, 0.750 mmol) and DIEA (0.27 mL, 1.56 mmol) in DMF (3 mL) was added EDC (0.16 mL, 0.75 mmol). The mixture stirred at room temperature for 16 h. The mixture was diluted with sat. bicarb solution and the solid was isolated via filtration. The solid was suspended in 10% citric acid solution and then isolated via filtration. The filter cake was rinsed with water and dried under vacuum to yield the desired product. C13H9BrN4O. 317.0/319.0 [M+1]+.
- N-(3-bromophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. To a mixture of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (0.062 g, 0.195 mmol) and phosphoryl chloride (0.18 mL, 1.95 mmol) in DCE (2 mL) was added phosphorus pentachloride (0.061 g, 0.293 mmol). The mixture was stirred at 80 °C for 2 h. The mixture was cooled to rt and concentrated under reduced pressure. The residue was taken up in EtOH (3 mL) and hydroxylamine (0.12 mL of a 50 w/w% solution in water, 1.96 mmol) was added. The mixture stirred 2 h at rt. The mixture was concentrated and the residue was dissolved in DMSO/water and purified via preparative HPLC to yield the desired product. C13H10BrN5O. 332.0/334.0 [M+1]+. 1H NMR (400 MHz, DMSO-d 6) δ 11.25 (br s, 1H), 8.94 (br s, 1H), 8.71 (br s, 1H), 8.42 (dd, J = 5.0, 2.5 Hz, 1H), 7.26 (dd, J = 5.2, 2.2 Hz, 1H), 7.01 - 6.98 (m, 1H), 6.96 - 6.91 (m, 2H), 6.51 (ddd, J = 4.9, 3.8, 2.2 Hz, 1H).
-
- N-(3-bromo-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. To a solution of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (0.097 g, 0.595 mmol), 3-bromo-4-fluoroaniline (0.114 g, 0.597 mmol), HOBt (0.099 g, 0.729 mmol) and DIEA (0.26 mL, 1.49 mmol) in DMF (3 mL) was added EDC (0.15 mL, 0.71 mmol). The mixture stirred at room temperature for 16 h. The mixture was diluted with sat. bicarb solution and the solid was isolated via filtration. The solid was taken up in DCM/MeCN, concentrated onto silica gel, and purified via flash chromatography on silica gel to give the desired product. C13H8BrFN4O. 335.0/337.0 [M+1]+.
- N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 81 was synthesized analogously to Example 80, using N-(3-bromo-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. (C13H9BrFN5O. 350.0/352.0 [M+1]+. 1H NMR (400 MHz, DMSO-d 6) δ 11.18 (br s, 1H), 8.94 (br s, 1H), 8.69 (br s, 1H), 8.42 (d, J = 5.1 Hz, 1H), 7.26 (d, J = 5.1 Hz, 1H), 7.09 (dd, J = 6.1, 2.7 Hz, 1H), 7.00 (t, J = 8.8 Hz, 1H), 6.54 (ddd, J = 8.9, 4.1, 2.7 Hz, 1H).
-
-
- N-(3-chlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 82 was synthesized analogously to Example 80, using N-(3-chlorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C13H10ClN5O. 288.0 [M+1]+. 1H NMR (400 MHz, DMSO-d 6) δ 11.28 (br s, 1H), 8.98 (s, 1H), 8.75 (br s, 1H), 8.43 (dd, J = 4.9, 1.5 Hz, 1H), 7.26 (dd, J = 5.1, 1.5 Hz, 1H), 6.99 (t, J = 8.1 Hz, 1H), 6.87 - 6.78 (m, 2H), 6.47 (ddd, J = 8.3, 2.2, 0.9 Hz, 1H).
-
-
- N-(4-fluoro-3-(trifluoromethyl)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 83 was synthesized analogously to Example 80, using N-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H9F4N5O. 340.1 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 11.18 (br s, 1H), 9.09 (s, 1H), 8.55 (br s, 1H), 8.40 (dd, J = 5.0, 1.8 Hz, 1H), 7.29 (d, J = 5.0 Hz, 1H), 7.16 - 7.07 (m, 2H), 6.85 - 6.79 (m, 1H).
-
- 4-fluoro-3-(prop-1-yn-1-yl)aniline. A solution of 3-bromo-4-fluoroaniline (0.254 g, 1.337 mmol) and trimethyl(prop-1-yn-1-yl)silane (0.59 mL, 4.010 mmol) in DMF (1.5 mL) was degassed by bubbling N2 for approx. 5 min. CuI (0.025 g, 0.134 mmol), Pd(PPh3)2Cl2 (0.094 g, 0.134 mmol) and TBAF (4.68 mL of a 1 M solution in THF, 4.68 mmol) were added and the mixture was heated at 65 °C for 16 h. The mixture was diluted with water and extracted 3× with DCM. The combined organic layers were washed with sat. bicarb solution and brine, dried (Na2SO4), filtered and concentrated. The residue was purified via flash chromatography on silica gel to yield the desired product. C9H8FN. 150.0 [M+1]+.
- N-(4-fluoro-3-(prop-1-yn-1-yl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. To a solution of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (0.030 g, 0.184 mmol), 4-fluoro-3-(prop-1-yn-1-yl)aniline (0.028 g, 0.134 mmol), HOBt (0.030 g, 0.221 mmol) and DIEA (0.08 mL, 0.46 mmol) in DMF (2 mL) was added EDC (0.05 mL, 0.22 mmol). The mixture stirred at room temperature for 16 h. The mixture was diluted with sat. bicarb solution and was extracted 3× with EtOAc. The combined organic layers were washed with 10% citric acid solution and brine, dried (Na2SO4), filtered, concentrated onto silica gel, and purified via flash chromatography on silica gel to yield the desired product. C16H11FN4O. 295.1 [M+1]+.
- N-(4-fluoro-3-(prop-1-yn-1-yl)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 84 was synthesized analogously to Example 80, using N-(4-fluoro-3-(prop-1-yn-1-yl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C16H12FN5O. 310.1 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 11.02 (br s, 1H), 8.75 (s, 1H), 8.60 (brs, 1H), 8.36 (d, J = 4.9 Hz, 1H), 7.18 (d, J = 5.0 Hz, 1H), 6.85 (t, J = 9.1 Hz, 1H), 6.78 (dd, J = 6.3, 2.8 Hz, 1H), 6.52 (ddd, J = 8.
8, 4.4, 2.9 Hz, 1H), 1.98 (s, 3H). -
-
- N-(3-bromo-4-chlorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 85 was synthesized analogously to Example 80 using N-(3-bromo-4-chlorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C13H9BrClN5O. 366.0/368.0 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 11.27 (br s, 1H), 9.01 (s, 1H), 8.65 (br s, 1H), 8.40 (dd, J = 5.1, 1.7 Hz, 1H), 7.25 (dd, J = 5.0, 1.5 Hz, 1H), 7.17 (d, J = 8.7 Hz, 1H), 7.11 (dd, J = 2.7, 0.8 Hz, 1H), 6.49 (dd, J = 8.7, 2.6 Hz, 1H).
-
-
- N-(3,4-dichlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 86 was synthesized analogously to Example 80, using N-(3,4-dichlorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C13H9Cl2N50. 322.0 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 11.33 (br s, 1H), 9.09 (s, 1H), 8.71 (br s, 1H), 8.44 (dd, J = 5.2, 1.8 Hz, 1H), 7.29 (dd, J = 5.0, 1.6 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 7.00 (d, J = 2.7 Hz, 1H), 6.49 (dd, J = 8.8, 2.6 Hz, 1H).
-
- N-(4-chlorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. To a solution of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (0.110 g, 0.674 mmol), 4-chloroaniline (0.088 g, 0.689 mmol), HOBt (0.109 g, 0.807 mmol) and DIEA (0.30 mL, 1.72 mmol) in DMF (3 mL) was added EDC (0.18 mL, 0.809 mmol). The mixture stirred at room temperature for 16 h. The mixture was diluted with sat. bicarb solution and the solid was isolated via filtration. The solid was suspended in approx. 3 mL THF. The solid was removed via filtration and the filter cake was washed with THF. The filtrate was dried (Na2SO4), filtered and concentrated under reduced pressure to yield the desired product. C13H9ClN4O. 273.0 [M+1]+.
- N-(4-chlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 87 was synthesized analogously to Example 80, using N-(4-chlorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C13H10ClN5O. 288.0 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 11.19 (br s, 1H), 8.92 (s, 1H), 8.75 (br s, 1H), 8.41 (d, J = 5.1 Hz, 1H), 7.21 (d, J = 5.1 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.68 (d, J = 8.8 Hz, 2H).
-
-
- N-(4-bromophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 88 was synthesized analogously to Example 80, using N-(4-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C13H10BrN5O. 332.0/334.0 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 11.19 (br s, 1H), 8.89 (s, 1H), 8.72 (br s, 1H), 8.41 (d, J = 5.0 Hz, 1H), 7.21 (d, J = 5.3 Hz, 1H), 7.19 (d, J = 8.7 Hz, 2H), 6.62 (d, J = 8.8 Hz, 2H).
-
-
- N-(4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 89 was synthesized analogously to Example 80, using N-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C13H10FN5O. 272.1 [M+1]+. 1H NMR (400 MHz, DMSO-d6 ) δ 11.05 (br s, 1H), 8.80 (s, 1H), 8.72 (br s, 1H), 8.39 (dd, J = 5.1, 1.3 Hz, 1H), 7.18 (d, J = 5.1 Hz, 1H), 6.88 (t, J = 8.8 Hz, 2H), 6.71 (dd, J = 9.0, 4.8 Hz, 2H).
-
-
- N-(3-cyano-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 90 was synthesized analogously to Example 80, using N-(3-cyano-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H9FN6O. 297.1 [M+1]+.
-
-
- N'-hydroxy-N-(4-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 91 was synthesized analogously to Example 80 using N-(4-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H10F3N5O. 322.1 [M+1]+.
-
-
- N'-hydroxy-N-(3-methoxyphenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 92 was synthesized analogously to Example 80, using N-(3-methoxyphenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H13N5O2. 284.1 [M+1]+.
-
-
- N-(4-fluoro-3-isopropylphenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 93 was synthesized analogously to Example 80, using N-(4-fluoro-3-isopropylphenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C16H16FN5O. 314.1 [M+1]+.
-
-
- N'-hydroxy-N-(p-tolyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 94 was synthesized analogously to Example 80, using N-(p-tolyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H13N5O. 268.1 [M+1]+.
-
- N-(3-ethynylphenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A solution of 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (100 mg, 0.613 mmol), bis(2-oxo-3-oxazolidinyl)phosphinic chloride (312mg, 1.23mmol) and diisopropylethylamine (0.534 mL, 3.06 mmol) in dichloromethane (10 mL). was stirred for 16hr. The reaction mixture was filtered and absorbed onto silica gel and purified by silica gel chromatography to give the desired product (140 mg). C15H10N4O. 263.1 (M+1).
- N-(3-ethynylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. A mixture of N-(3-ethynylphenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (41 mg, 0.155 mmol), phosphorous pentachloride (48 mg, 0.233 mmol) in phosphoryl chloride (0.3mL) and 1,2-dichloroethane (0.3 mL) were stirred at 80 °C for 2 hr. The reaction mixture was concentrated and suspended in ethanol (2 mL) and to this mixture was added 50% hydroxylamine in water (0.265 mL, 4.33 mmol). The reaction mixture stirred for 1 hr and was concentrated. The residue was purified by preparative HPLC to give two products (Example 95 and Example 96). N-(3-ethynylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. C15H11N5O. 278.07 (M+1) 1H NMR (400 MHz, DMSO-d 6) δ 11.23 (s, 1H), 8.90 (s, 1H), 8.78 (s, 1H), 8.43 (d, J = 5.1 Hz, 1H), 7.24 (d, J = 5.1 Hz, 1H), 7.00 (t, J = 8.1 Hz, 1H), 6.93 - 6.85 (m, 2H), 6.59 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H), 4.07 (s, 1H).
-
- N-(3-ethylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was prepared as described in Example 95. C15H15N5O. 281.10 (M+1) 1H NMR (400 MHz, DMSO-d6 ) δ 11.09 (s, 1H), 8.74 (d, J = 15.8 Hz, 2H), 8.39 (d, J = 5.1 Hz, 1H), 7.19 (d, J = 5.1 Hz, 1H), 6.98 - 6.87 (m, 1H), 6.64 (ddd, J = 7.5, 1.6, 0.9 Hz, 1H), 6.55 - 6.43 (m, 2H), 2.34 (q, J = 7.6 Hz, 2H), 0.89 (t, J = 7.6 Hz, 3H).
-
-
- N-(3-ethynyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 97 was made analogously to Example 95 C15H10FN5O. 295.09 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.17 (s, 1H), 8.90 (s, 1H), 8.78 (s, 1H), 8.43 (d, J = 5.1 Hz, 1H), 7.26 (d, J = 5.1 Hz, 1H), 6.98 - 6.89 (m, 2H), 6.62 (ddd, J = 9.0, 4.4, 2.9 Hz, 1H), 4.39 (d, J = 0.6 Hz, 1H).
-
-
- N-(3-(difluoromethyl)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 98 was made analogously to Example 95 using N-(3-(difluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H11F2N5O. 304.10 (M+1) 1H NMR (400 MHz, DMSO-d 6) δ, 12.51 (s, 1H), 11.17 (s, 1H), 8.92 (d, J = 25.4 Hz, 1H), 8.41 (s, 1H), 8.33 (d, J = 5. 0 Hz, 1H), 7.41-7.23 (m, 1H), 7.19 - 7.02 (m, 1H), 7.02 - 6.80 (m, 2H), 6.73 (d, J = 8.2 Hz, 1H).
-
-
- N-hydroxy-N-(3-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 99 was made analogously to Example 95 using N-(3-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H10F3N5O2. 338.10 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 9.54 (s, 1H), 9.22 (s, 1H), 8.58 (d, J = 5.3 Hz, 1H), 7.40 (d, J = 5.3 Hz, 1H), 7.12 (td, J = 8.1, 0.5 Hz, 1H), 6.74 (ddt, J = 8.2, 2.1, 1.0 Hz, 1H), 6.69-6.61 (m, 3H).
-
-
- N-hydroxy-N-phenyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 100 was made analogously to Example 95 using N-phenyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C13H11N5O. 254.10 1H NMR (400 MHz, DMSO-d 6) δ 12.51 (s, 1H), 11.01 (s, 1H), 8.63 (s, 1H), 8.40 (d, J = 1.1 Hz, 1H), 8.34 - 8.26 (m, 1H), 7.08 - 6.99 (m, 2H), 6.95 (dd, J = 8.5, 7.3 Hz, 1H), 6.82 - 6.76 (m, 1H), 6.73 - 6.58 (m, 2H).
-
-
- N-(4-fluoro-3-(trifluoromethoxy)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 101 was made analogously to Example 95 using N-(4-fluoro-3-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H9F4N5O2. 355.07 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.26 (s, 1H), 9.10 (s, 1H), 8.77 (s, 1H), 8.45 (d, J = 5.1 Hz, 1H), 7.30 (d, J = 5.1 Hz, 1H), 7.24-7.10 (m, 1H), 6.76 - 6.70 (m, 2H).
-
-
- N-Hydroxy-N-(naphthalen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide (Example 102) and N-(3-chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide (Example 103) were made analogously to Example 95 using N-(naphthalen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide give two products (N-hydroxy-N-(naphthalen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide and N-(3-chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide). C17H13N5O. 304.11 (M+1) and C17H12ClN5O. 338.11(M+1).
-
- N-(3-Chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was prepared according to Example 102. C17H12ClN5O. 338.11(M+1).
-
-
- N'-hydroxy-N-(naphthalen-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide (Example 104) and N-(4-chloronaphthalen-1-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide (Example 105) were made analogously to Example 95 using N-(naphthalen-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide give two products (N'-hydroxy-N-(naphthalen-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide and N-(4-chloronaphthalen-1-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide). C17H13N5O. 304.11 (M+1)
-
- N-(4-Chloronaphthalen-1-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 105 was made analogously to Example 104. C17H12ClN5O. 338.11(M+1).
-
-
- N-(4-fluoro-3-methoxyphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 106 was made analogously to Example 95 using 4-fluoro-3-methoxyphenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H12FN5O2. 302.10 (M+1).
-
- 2-Chloro-3-nitroisonicotinic acid. To a solution of 2-chloro-4-methyl-3-nitropyridine (5.0 g, 29 mmol) in sulfuric acid (40 mL) was added potassium dichromate (11.3 g, 38.5 mmol) in portions over 20 min. The reaction was stirred at 60 °C overnight and poured onto ice. The water was washed with ethyl acetate three times and the combined organic layers were dried over sodium sulfate, filtered and concentrated to give the desired product. C6H3ClN2O4. 203.1 (M+1).
- 2-Chloro-N-(3-chloro-4-fluorophenyl)-3-nitroisonicotinamide. To a solution of 3-chloro-4-fluoroaniline (3.84 g, 26.4 mmol), 2-chloro-3-nitroisonicotinic acid (5.34 g, 26.4 mmol) and triethylamine (11 mL, 79 mmol) in dichlromethane (100 mL) in an ice bath was added phosphoryl chloride (3.69 mL, 39.6 mmol). The ice bath was removed and the reaction stirred for 1 hr. Saturated sodium bicarbonate was added and the aqueous layer was washed three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and concentrated onto silica gel and purified by silica gel chromatography (0->100% ethyl acetate in dichloromethane) to give the desired product. C12H6C12FN3O3. 330.0 (M+1).
- 2-Amino-N-(3-chloro-4-fluorophenyl)-3-nitroisonicotinamide. A mixture of 2-chloro-N-(3-chloro-4-fluorophenyl)-3-nitroisonicotinamide (4.78 g, 14.5 mmol) in ethanol (15 mL) and 28% ammonium hydroxide in water (14.1 mL, 101.4 mmol) was stirred in a closed vessel at 90 °C for 1.5 hr. The reaction mixture was cooled in an ice bath and the resulting precipitate filtered and washed with cold ethanol. Dried the solid on high vac to give desired product. C12H8ClFN4O3. 311.1 (M+1).
- 2,3-Diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide. A mixture of 2-amino-N-(3-chloro-4-fluorophenyl)-3-nitroisonicotinamide (3.43 g, 11.0 mmol) and 10 % Palladium on carbon (250 mg) in methanol (100 mL) was mixed in a Parr shaker at 40 psi hydrogen for 2 hr. Reaction was filtered and concentrated to give the desired product. C12H10ClFN4O. 281.1 (M+1).
- N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. A mixture of 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (1.06 g, 3.77 mmol) in acetic acid (11 mL) was stirred at 180 °C for 1 hr in a microwave. Water was added and the resulting precipitate was filtered and dried on high vac to give the desired product. C14H10ClFN4O. 305.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide. A mixture of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide (132 mg, 0.433 mmol), phosphorous pentachloride (135 mg, 0.650 mmol) in phosphoryl chloride (2 mL) and 1,2-dichloroethane (2 mL) were stirred at 80 °C for 2.5 hr. The reaction mixture was concentrated and suspended in ethanol (2 mL) and to this mixture was added 50% hydroxylamine in water (0.265 mL, 4.33 mmol). The reaction mixture stirred for 1 hr and was concentrated. The residue was purified by preparative HPLC to give the desired product. C14H11ClFN5O. 320.0 (M+1).
-
-
- N-(3-chloro-4-fluorophenyl)-2-ethyl-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 108 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-ethyl-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C15H13ClFN5O. 334.1 (M+1).
-
-
- N-(3-chloro-4-fluorophenyl)-2-cyclopropyl-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 109 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-cyclopropyl-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C16H13ClFN5O. 346.1 (M+1).
-
-
- 4-(3-chloro-4-fluorophenyl)-3-(2-(methoxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one. A mixture of N-(3-chloro-4-fluorophenyl)-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (2.62 g, 7.82 mmol), phosphorous pentachloride (2.44 g, 11.7 mmol) in phosphoryl chloride (22 mL) and 1,2-dichloroethane (22 mL) were stirred at 80 °C for 2.5 hr. The reaction mixture was concentrated and suspended in ethanol (20 mL) and to this mixture was added 50% hydroxylamine in water (4.8 mL, 78 mmol). The reaction mixture stirred for 1 hr and was concentrated. Water and aqueous saturated sodium bicarbonate were added and the solid was filtered and dried on high vac. The solid was suspended in ethyl acetate (100 mL) and to this mixture was added carbonyldiimidazole (1.90 g, 11.7 mmol). The mixture was stirred for 18 hr and concentrated. The residue was purified by silica gel chromatography to give the desired product (871 mg). C16H11ClFN5O3. 376.3 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 110 was made analogously to Example 95 using N-(3-chloro-4-fluorophenyl)-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C15H13ClFN5O2. 350.1 (M+1).
-
- To a mixture of 4-(3-chloro-4-fluorophenyl)-3-(2-(methoxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (400 mg, 1.07 mmol) in dichloromethane (8 mL) at 0 °C was added a solution of 1 M boron tribromide in dichloromethane (1.60 mL, 1.60 mmol). The reaction was allowed to warm to room temperature and stirred for 18 hr. The reaction mixture was diluted with dichloromethane and saturated sodium bicarbonate and the aqueous layer was washed three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, loaded onto silica gel column and purified by silica gel chromatography to give two product: 4-(3-chloro-4-fluorophenyl)-3-(2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (385 mg) and 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. C15H9ClFN5O3. 362.0 (M+1).
- 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. C15H8BrClFN5O2. 425.9 (M+1).
-
- (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate. To a solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (510 mg, 1.41 mmol) and triethylamine (1.97 mL, 14.1 mmol) in dichlromethane (20 mL) at -78 °C was added methanesulfonyl chloride (0.548 mL, 7.05 mmol) dropwise over 10 min. The reaction mixture was warmed to 0 °C and stirred for 10 min. Water was added and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography to give two product: (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate (440 mg) and 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one. C17H13ClFN5O7S2. 518.2 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(morpholinomethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. A solution of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate (27 mg, 0.052 mmol) and morpholine (0.10 mL, 1.1 mmol) in acetonitrile (1 mL) was stirred at 65 °C for 10 min. The reaction was concentrated. The residue was brought up in tetrahydrofuran (0.5 mL) and water (0.5 mL). To this solution was added 2 N sodium hydroxide (0.39 mL, 0.78 mmol) and the reaction mixture stirred for 10 min. To the mixture was added acetic acid (0.05 mL) and the solution was loaded directly onto a prep HPLC for purification to give the desired product. C18H18ClFN6O2. 405.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-2-((dimethylamino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. A solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (30 mg, 0.065 mmol) and dimethylamine (2 M in THF, 0.655 mL, 1.3 mmol) in acetonitrile (1 mL) was stirred at 65 °C for 3 hr min. The reaction was concentrated. The residue was brought up in tetrahydrofuran (0.5 mL) and water (0.5 mL). To this solution was added 2 N sodium hydroxide (0.39 mL, 0.78 mmol) and the reaction mixture stirred for 10 min. To the mixture was added acetic acid (0.05 mL) and the solution was loaded directly onto a prep HPLC for purification to give the desired product (12 mg). C16H16ClFN6O. 363.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-2-((ethylamino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 114 was made analogously to Example 112 using 2 M ethylamine in THF in place of morpholine. C16H16ClFN6O. 363.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 12.76 (s, 1H), 11.16 (s, 1H), 9.29 (s, 2H), 8.96 (s, 1H), 8.38 (d, J = 5.0 Hz, 1H), 7.41 - 6.99 (m, 2H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.51 (d, J = 8.7 Hz, 1H), 4.47 (s, 2H), 3.08 (s, 2H), 1.23 (t, J = 7.3 Hz, 3H).
-
- 2-((benzylamino)methyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 115 was made analogously to Example 112 using benzylamine in place of morpholine. C21H18ClFN6O. 425.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((isopropylamino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 116 was made analogously to Example 112 using isopropylamine in place of morpholine. C17H18ClFN6O. 377.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.18 (s, 1H), 9.28 (s, 2H), 8.96 (s, 1H), 8.38 (d, J = 5.0 Hz, 1H), 7.24 - 6.96 (m, 2H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.51 (s, 1H), 4.48 (s, 2H), 3.56 - 3.28 (m, 1H), 1.37 - 1.15 (m, 6H).
-
- N-(3-chloro-4-fluorophenyl)-2-(((cyclopropylmethyl)amino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 117 was made analogously to Example 112 using cyclopropylmethylamine in place of morpholine. C18H18ClFN6O. 388.9 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.14 (s, 1H), 9.41 (s, 2H), 8.95 (s, 1H), 8.38 (d, J = 5.0 Hz, 1H), 7.28 - 6.98 (m, 2H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.52 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 4.50 (s, 2H), 2.96 (s, 2H), 1.17 - 0.92 (m, 1H), 0.68 - 0.48 (m, 2H), 0.42 - 0.24 (m, 2H).
-
- N-(3-chloro-4-fluorophenyl)-2-(((cyclopropylmethyl)amino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 118 was made analogously to Example 112 using 2,2,2-trifluoroethylamine in place of morpholine. C16H13ClF4N6O. 416.7 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-2-((cyclopropylamino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 119 was made analogously to Example 112 using cyclopropylamine in place of morpholine. C17H16ClFN6O. 374.9 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((3-methoxypropyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 120 was made analogously to Example 112 using 3-methoxypropylamine in place of morpholine. C18H20ClFN6O2. 407.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((pyridin-2-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 121 was made analogously to Example 112 using pyridin-2-ylmethanamine in place of morpholine. C20H17ClFN7O. 426.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((3-methoxypropyl)(methyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 122 was made analogously to Example 112 using 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxy-N-methylpropan-1-amine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine. C19H22ClFN6O2. 421.2 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((2-methoxybenzyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 123 was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and 2-methoxybenzylamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine. C22H20ClFN6O2. 455.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((2-methoxyethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 124 was made analogously to Example 112 using 2-methoxyethylamine in place of morpholine.C17H18ClFN6O2. 393.1(M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((2-(pyridin-2-yl)ethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 125 was made analogously to Example 112 using 2-(pyridin-2-yl)ethanamine in place of morpholine. C21H19ClFN7O. 440.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((pyridin-3-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 126 was made analogously to Example 112 using 3-picolylamine in place of morpholine. C20H17ClFN7O. 426.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((((tetrahydro-2H-pyran-2-yl)methyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 127 was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and (tetrahydro-2H-pyran-2-yl)methanamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine. C20H22ClFN6O2. 433.1 (M+1).
-
- A solution of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate (14 mg, 0.027 mmol) and aniline (0.025 mL, 0.27 mmol) in acetonitrile (1 mL) was stirred at 65 °C for 18 hr. To the solution was added isopropylamine (0.1 mL) and the reaction stirred at 65 °C for 5 min. The reaction was concentrated. The residue was brought up in tetrahydrofuran (0.3 mL) and water (0.3 mL). To this solution was added 2 N sodium hydroxide (0.2 mL, 0.41 mmol) and the reaction mixture stirred for 10 min. To the mixture was added acetic acid (0.05 mL) and the solution was loaded directly onto a prep HPLC for purification to give the desired product. C20H16ClFN6O. 411.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((((tetrahydro-2H-pyran-3-yl)methyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 129 was made analogously to Example 112 using (tetrahydro-2H-pyran-3-yl)methanamine in place of morpholine. C20H22ClFN6O2. 433.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((pyrimidin-2-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 130 was made analogously to Example 112 using pyrimidin-2-ylmethanamine in place of morpholine. C19H16ClFN8O. 427.1 (M+1).
-
- Example 131 was made analogously to Example 112 using 3-morpholinopropan-1-amine in place of morpholine. C21H25ClFN7O2. 462.2 (M+1).
-
- Example 132 was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and tetrahydro-2H-pyran-4-amine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine. C19H20ClFN6O2. 419.1 (M+1).
-
- Example 133 was made analogously to Example 112 using 4-picolylamine in place of morpholine. C20H17ClFN7O. 426.1 (M+1).
-
- Example 134 was made analogously to Example 112 using pyrazin-2-ylmethanamine in place of morpholine. C19H16ClFN8O. 427.1 (M+1).
-
- Example 135 was made analogously to Example 112 using 4-(3-chloro-4-fluorophenyl)-3-(2-(chloromethyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and (tetrahydrofuran-3-yl)methanamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine. C19H20ClFN6O2. 419.1 (M+1).
-
- Example 136 was made analogously to Example 112 using N,N-dimethylethane-l,2-diamine in place of morpholine. C18H21ClFN7O. 406.1 (M+1).
-
- Example 137 was made analogously to Example 112 using 2-(pyrimidin-2-yl)ethanamine in place of morpholine. C20H18ClFN8O. 441.1 (M+1).
-
- Example 138 was made analogously to Example 112 using 3-aminopropanol in place of morpholine. C17H18ClFN6O2. 393.1 (M+1).
-
- Example 139 was synthesized analogously to Example 112 using pyrrolidine in place of morpholine. C18H18ClFN6O. 389.1 [M+1]+.
-
- Example 140 was synthesized analogously to Example 112 using piperidine in place of morpholine. C19H20ClFN6O. 403.1 [M+1]+.
-
- Example 141 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2,2-dimethylpropan-1-amine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively. C19H22ClFN6O. 405.2 [M+1]+.
-
- Example 142 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2,2-difluoroethylamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively. C16H14ClF3N6O. 399.1 [M+1]+.
-
- Example 143 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-amino-2,2-dimethylpropan-1-ol in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively. C19H22ClFN6O2. 421.2 [M+1]+.
-
- Example 144 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and thiazol-2-ylmethanamine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively. C18H15ClFN7OS. 432.1 [M+1]+.
-
- A solution of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate (17 mg, 0.033 mmol) and 0.5 M ammonia in dioxane (1.44 mL, 0.722 mmol) in acetonitrile (1 mL) was stirred at 65 °C for 30 min. The reaction was concentrated. The residue was brought up in tetrahydrofuran (0.5 mL) and to this solution was added triethylamine (0.021 mL, 0.15 mmol) and acetyl chloride (0.003 mL, 0.045 mmol. The reaction stirred for 3 hr and, then, more acetyl chloride (0.003 mL, 0.045 mmol) was added. The reaction stirred for 2 hr and was concentrated. The residue was brought up in tetrahydrofuran (0.3 mL) and water (0.3 mL). To this solution was added 2 N sodium hydroxide (0.22 mL, 0.44 mmol) and the reaction mixture stirred for 10 min. To the mixture was added acetic acid (0.05 mL) and the solution was loaded directly onto a prep HPLC for purification to give the desired product. C16H14ClFN6O2. 377.1 (M+1).
-
- Methyl-2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine. A solution of 4-methyl-3-nitropyridin-2-amine (400 mg, 2.61 mmol), thiophene-2-carbaldehyde (449 mg, 3.92 mmol) and sodium hydrosulfite (1.61 g, 7.84 mmol) in dimethyl sulfoxide (5 mL) and ethanol (5 mL) were stirred at 90 °C for 18 hr. The mixture was allowed to cool to room temperature and to this mixture was added water and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, absorbed onto silica gel and purified by silica gel chromatography to give the desired product. C11H9N3S. 216.1 (M+1).
- Methyl 2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate. A solution of 7-methyl-2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine (234 mg, 1.09 mmol) and selenium dioxide (482, 4.35 mmol) in pyridine (2.5 mL) was stirred at 120 °C for 24 hours. The reaction mixture was filtered through a pad of celite and the celite pad was washed with hot water and methanol. The filtrate was concentrated and the resulting residue was dried on high vac. The residue was brought up in methanol (10 mL) and to this solution was added thionyl chloride (0.55 mL, 7.6 mmol). The solution was stirred at 70 °C for 4 hours. The resulting mixture was concentrated to give the desired product. C12H9N3O2S. 260.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. To a soln of the 3-chloro-4-fluoroanilinein (239 mg, 1.64 mmol) dichloroethane at 0 °C under nitrogen was added trimethylaluminum (2 M in heptane, 1.57, 3.15 mmol) dropwise over 5 min. The solution was allowed to warm to room temperature and stirred for 30 min. The solution was cooled to 0 °C and to this solution was added methyl 2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate (272 mg, 1.05 mmol). The solution was stirred at 85 °C for 18 hr and, then, cooled to room temperature. Saturated sodium bicarbonate was carefully added to the solution and the aqueous layer was washed three times with dichloromethane. The aqueous layer was acidified with 10% citric acid and the resulting precipitate was filtered and dried on high vac to give the desired product. C17H10ClFN4OS. 373.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 146 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17H11ClFN5OS. 388.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A mixture of 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (0.150 g, 0.534 mmol) and nicotinaldehyde (0.50 mL, 5.34 mmol) in DMSO was stirred at 100 °C under air atmosphere for 16 h. Mixture was cooled to rt and diluted with water. The aqueous layer was extracted 3 × with EtOAc and the combined organic layers were washed with brine, dried (Na2SO4), filtered, concentrated onto silica gel, and purified via column chromatography on silica gel to yield the final product. C18H11ClFN5O. 368.1 [M+1]+.
- Example 147 was synthesized analogously to Example 80, using N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C18H12ClFN6O. 383.1 [M+1]+.
-
-
- Example 148 was synthesized analogously to Example 80, using N-(3-chloro-4-fluorophenyl)-2-(1H-pyrrol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17H12ClFN6O. 371.1 [M+1]+.
-
- Methyl 2,3-diaminoisonicotinate. A mixture of 2,3-diaminoisonicotinic acid (2.0 g, 13 mmol) in sulfuric acid (2.5 mL) and methanol (25 mL) was stirred at 120 °C in a microwave for 1 hr. To the reaction mixture was added aqueous saturated sodium bicarbonate until basic and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the desired product. C7H9N3O2. 168.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 146 using methyl 2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate in place of methyl 2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate. C16H10ClFN6O. 357.2 (M+1).
- Example 149 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C16H11ClFN7O. 372.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.07 (s, 1H), 8.92 (s, 1H), 8.33 (d, J = 5.1 Hz, 1H), 7.44 (s, 2H), 7.18 (d, J = 5.1 Hz, 1H), 7.02 (t, J = 9.1 Hz, 1H), 6.96 (dd, J = 6.5, 2.7 Hz, 1H), 6.56 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H).
-
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-pyrazol-5-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 150 was synthesized analogously to Example 80, using N-(3-chloro-4-fluorophenyl)-2-(1H-pyrazol-5-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-bromophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C16H11ClFN7O. 372.1 [M+1]+.
-
- Methyl 2-(4-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate. A mixture of methyl 2,3-diaminoisonicotinate (0.102 g, 0.610 mmol) and 4-methyl-1H-imidazole-2-carbaldehyde (0.319 g, 2.90 mmol) in DMSO (5 mL) stirred at 100 °C under air atmosphere for 16 h. The mixture was diluted with water and the solid was isolated via filtration. The filter cake was washed with water and then cooled over dry ice and dried on the lyophilizer to give the desired product, which was taken on without purification. C12H11N5O2. 258.1 [M+1]+.
- N-(3-chloro-4-fluorophenyl)-2-(4-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. To DABAL-Me3 (0.128 g, 0.499 mmol) in THF (2 mL) was added 3-chloro-4-fluoroaniline (0.073 g, 0.499 mmol). The mixture stirred at 40 °C for 1 h. A slurry of methyl 2-(4-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxylate (0.080 g, 0.311 mmol) in THF (2.5 mL) was added and the mixture stirred at 65 °C for 16 h. The mixture was quenched by the addition of 1 N HCl (1 mL) and then was diluted with water/EtOAc. The aqueous layer was extracted 3× with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4), filtered, concentrated onto silica gel, and purified via column chromatography on silica gel to yield the desired product. C17H12ClFN6O. 371.1 [M+1]+.
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(4-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. To a mixture of N-(3-chloro-4-fluorophenyl)-2-(4-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (0.009 g, 0.024 mmol) in DCE (0.5 mL) and phosphoryl chloride (0.5 mL) was added phosphorus pentachloride (0.008 g, 0.036 mmol). The mixture stirred at 90 °C for 4 h. Additional phosphorus pentachloride (0.008 g, 0.036 mmol) was added and the mixture stirred at 90 °C for 72 h. The mixture was cooled to rt and concentrated. The residue was diluted with EtOH (3 mL) and hydroxylamine (0.05 mL of a 50 w/w% solution in water, 0.82 mmol) was added. The mixture was concentrated and the residue was diluted with DMSO/water and purified via preparative HPLC to yield the desired product. C17H13ClFN7O. 386.0 [M+1]+.
-
- (S)-tert-butyl 2-((2-amino-4-((3-chloro-4-fluorophenyl)carbamoyl)pyridin-3-yl)carbamoyl)pyrrolidine-1-carboxylate. To N-Boc-L-proline (0.429 g, 1.991 mmol) in DCM (20 mL) at 0 °C was added isobutyl chloroformate (0.57 mL, 4.38 mmol) dropwise, followed by TEA (0.69 mL, 4.98 mmol). 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (0.559 g, 1.991 mmol) was added and the mixture was allowed to warm to rt and stirred 16 h. The mixture was diluted with water and the aqueous phase was extracted 3× with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4), filtered, concentrated onto silica gel, and purified via column chromatography on silica gel to yield the desired product. C22H25ClFN5O4. 478.2 [M+1]+.
- tert-butyl 2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidine-1-carboxylate. A solution of (S)-tert-butyl 2-((2-amino-4-((3-chloro-4-fluorophenyl)carbamoyl)pyridin-3-yl)carbamoyl)pyrrolidine-1-carboxylate (0.094 g, 0.197 mmol) in AcOH (4 mL) was heated to 65 °C for 4 h and to 80 °C for 2 h. The mixture was cooled to rt and concentrated. The residue was partitioned between sat. bicarb solution and EtOAc and the aqueous layer was extracted 3× with EtOAc. The combined organic layers were concentrated onto silica gel and purified via column chromatography on silica gel to yield the desired product. C22H23ClFN5O3. 460.1 [M+1]+.
- tert-butyl 2-(7-((3-chloro-4-fluorophenyl)carbamothioyl)-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidine-1-carboxylate. A mixture of tert-butyl 2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidine-1-carboxylate (0.043 g, 0.093 mmol) and Lawesson's reagent (0.076 g, 0.187 mmol) in toluene (2 mL) was stirred at 95 °C for 16 h. The mixture was cooled to rt, concentrated onto silica gel, and purified via column chromatography on silica gel to yield the desired product. C22H23ClFN5O2S. 476.1 [M+1]+.
- tert-butyl 2-(7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidine-1-carboxylate. To a mixture of tert-butyl 2-(7-((3-chloro-4-fluorophenyl)carbamothioyl)-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidine-1-carboxylate (0.019 g, 0.040 mmol) in MeOH (2 mL) was added hydroxylamine (0.12 mL of a 50 w/w% solution in water, 2.00 mmol). The mixture was stirred at 70 °C for 45 min. The mixture was cooled to rt and diluted with brine and EtOAc. The aqueous layer was extracted 4× with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated to yield the desired product. C22H24ClFN6O3. 475.2 [M+1]+.
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(pyrrolidin-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. To a solution of tert-butyl 2-(7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidine-1-carboxylate (0.018 g, 0.038 mmol) in DCM (1 mL) was added TFA (1 mL). The mixture stirred at rt for 10 min and was then concentrated. The residue was dissolved in DMSO/water and purified via preparative HPLC to yield the desired product. C17H16ClFN6O. 375.1 [M+1]+.
-
- N-(3-chloro-4-fluorophenyl)-2-cyanamido-3-nitroisonicotinamide. A mixture of 2-chloro-N-(3-chloro-4-fluorophenyl)-3-nitroisonicotinamide (1.02 g, 3.09 mmol), cyanamide (260 mg, 6.18 mmol), and potassium carbonate (1.28 g, 9.27 mmol) in dimethylformamide (10 mL) was stirred at 80 °C for 2 hr. The reaction mixture was absorbed onto silica gel and purified by silica gel chromatography to give the desired product (1.03 g). C13H7ClFN5O3. 336.0 (M+1).
- 2-amino-N-(3 -chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A mixture of N-(3-chloro-4-fluorophenyl)-2-cyanamido-3-nitroisonicotinamide (1.07 g, 3.20 mmol) and sodium hydrosulfite (1.96 g, 9.59 mmol) in ethanol (10 mL) and dimethyl sulfoxide (10 mL) was stirred at 70 °C for 24 hr. Water was added and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and absorbed onto silica gel and purified by silica gel chromatography to give the desired product. C13H9ClFN5O. 306.1 (M+1).
- 2-Amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 153 was made analogously to Example 107 using 2-amino-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C13H10ClFN6O. 321.0 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 8.84 (s, 1H), 8.15 - 8.10 (m, 1H), 7.94-7.89 (m, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.00 - 6.92 (m, 1H), 6.91 - 6.79 (m, 1H), 6.63 - 6.54 (m, 1H).
-
- N-(3-chloro-4-fluorophenyl)-2-(cyclopropylamino)-1H-imidazo[4,5-b]pyridine-7-carboxamide. Dissolved 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (0.54g, 0.002 mol) in THF (5 ml), to the solution was added cyclopropyl isothiocyanate (0.23g, 0.002 mmol) and triethylamine (1.95g, 0.02 mol). The reaction mixture was heated at 80°C overnight, then to the reaction mixture was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.44 g, 0.002 mol), heated at 80°C for 1h. The reaction mixture was diluted with EtOAc, and then water was added. Product crashed out to afford 200mg desired product. C16H13ClFN5O. 346.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(cyclopropylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 154 was made analogously to Example 107 using the general procedure for hydroxyamidine formation. C16H14ClFN6O. 361.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.93 (s, 1H), 8.80 (s, 1H), 8.01 (d, J = 6.1 Hz, 1H), 7.13 - 7.00 (m, 2H), 6.97 (d, J = 6.1 Hz, 1H), 6.55 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 2.81 (dq, J = 6.9, 3.4 Hz, 1H), 0.83 (td, J = 7.1, 5.0 Hz, 2H), 0.59 (p, J = 4.7 Hz, 2H).
-
- Example 155 was made analogously to Example 154 using phenyl isothiocyanate. C19H14ClFN6O 397.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.37 (s, 1H), 10.09 (s, 1H), 8.92 (s, 1H), 8.05 (d, J = 6.1 Hz, 1H), 7.66 (d, J = 8.1 Hz, 2H), 7.39 (t, J = 7.7 Hz, 2H), 7.14 - 7.04 (m, 2H), 7.02 (dt, J = 5.6, 2.6 Hz, 2H), 6.60 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H).
-
- Example 156 was made analogously to Example 154 using (2-isothiocyanatoethyl)benzene. C21H18ClFN6O. 425.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.92 (s, 1H), 7.95 (d, J = 6.3 Hz, 1H), 7.37 - 7.16 (m, 6H), 7.13 - 7.05 (m, 1H), 7.02 (dd, J = 6.5, 2.8 Hz, 1H), 6.96 - 6.85 (m, 1H), 6.57 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 3.73 - 3.62 (m, 2H), 2.89 (t, J = 7.3 Hz, 2H).
-
- Example 157 was made analogously to Example 154 using 1,1,1-trifluoro-2-isothiocyanatoethane. C15H11ClF4N6O. 403.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.95 (s, 1H), 8.00 (d, J = 6.2 Hz, 1H), 7.05 (ddd, J = 19.0, 8.5, 4.0 Hz, 3H), 6.95 (d, J = 6.5 Hz, 1H), 6.57 (dt, J = 9.0, 3.3 Hz, 1H), 4.30 (s, 3H).
-
- Example 158 was made analogously to Example 154 using methyl isothiocyanate. C14H12ClFN6O. 335.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.08 (s, 1H), 11.37 (s, 1H), 8.96 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.08 (t, J = 9.1 Hz, 1H), 7.03 - 6.97 (m, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.56 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.00 (d, J = 4.8 Hz, 3H).
-
- Isopropyl (7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)carbamate. To a mixture of 2-amino-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (30 mg, 0.098mmol) and triethylamine (0.041 mL, 0.29 mmol) in dichloromethane at 0 °C was added solution of isopropyl chloroformate (1 M in toluene, 0.118 mL, 0.118 mmol). The reaction was allowed to warm to room temperature and stirred for 1 hr. Saturated sodium bicarbonate was added and the aqueous layer was washed three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was loaded onto a silica gel column and purified by silica gel chromatography to give the desired product mixed with isopropyl 7-((3-chloro-4-fluorophenyl)carbamoyl)-2-((isopropoxycarbonyl)amino)-1H-imidazo[4,5-b]pyridine-1-carboxylate. C17H15ClFN5O3. 392.2 (M+1).
- Isopropyl (7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)carbamate. Example 159 was made analogously to Example 107 using isopropyl (7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)carbamate in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17H16ClFN6O3. 407.0 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 8.83 (s, 1H), 8.18 (d, J = 5.4 Hz, 1H), 7.13 (t, J= 9.1 Hz, 1H), 7.02 - 6.91 (m, 2H), 6.67 - 6.57 (m, 1H), 5.00 (dq, J = 6.3, 6.3 Hz, 1H), 1.31 (d, J= 6.2 Hz, 6H).
-
- Example 160 was made analogously to Example 154 using O-ethyl carbonisothiocyanatidate. C16H14ClFN6O3. 393.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.54 (s, 1H), 8.83 (s, 1H), 8.20 (d, J = 5.6 Hz, 1H), 7.11 (t, J = 9.1 Hz, 1H), 7.03 (d, J = 5.6 Hz, 1H), 6.95 (dd, J = 6.5, 2.7 Hz, 1H), 6.62 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H).
-
- Example 161 was made analogously to Example 154 using cyclopropyl methyl isothiocyanate. C17H16ClFN6O. 375.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.37 (s, 1H), 8.93 (s, 1H), 7.94 (t, J = 5.3 Hz, 1H), 7.50-7.25 (m, 1H), 7.14-6.97 (m, 2H), 6.91 (d, J = 6.3 Hz, 1H), 6.58 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.31 (t, J = 6.5 Hz, 2H), 1.11 (d, J = 13.1 Hz, 1H), 0.57 - 0.40 (m, 2H), 0.33 - 0.19 (m, 2H).
-
- Example 162 was made analogously to Example 154 using 1,1-difluoro-3-isothiocyanatocyclobutane. C17H14ClF3N6O. 411.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.41 (d, J = 18.8 Hz, 1H), 8.97 (s, 1H), 8.69 (s, 1H), 7.99 (dd, J = 7.9, 6.6 Hz, 1H), 7.09 - 6.97 (m, 2H), 6.94 (d, J = 6.2 Hz, 1H), 6.54 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 4.28 (s, 1H), 3.03 (tt, J = 14.3, 7.9 Hz, 2H), 2.77 (d, J = 10.6 Hz, 2H).
-
-
- N-(3-chloro-4-fluorophenyl)-2-(ethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 163 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-(ethylamino)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C15H14ClFN6O. 349.1 (M+1).
-
-
- N-(3-chloro-4-fluorophenyl)-2-(cyclobutylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 164 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-(cyclobutylamino)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17H16ClFN6O. 375.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.40 (s, 1H), 8.98 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.1 Hz, 1H), 7.05 (dd, J = 6.1, 2.5 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.62 - 6.50 (m, 1H), 4.34 (q, J = 7.2 Hz, 1H), 2.39 - 2.24 (m, 2H), 2.15 - 1.98 (m, 2H), 1.82 - 1.58 (m, 2H).
-
-
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(isopropylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 165 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-2-(isopropylamino)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C16H16ClFN6O. 363.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.42 (s, 1H), 8.97 (s, 1H), 7.96 (d, J = 6.3 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.05 (dd, J = 6.6, 2.7 Hz, 1H), 6.92 (d, J = 6.3 Hz, 1H), 6.62 - 6.56 (m, 1H), 4.06 (sex, J= 6.5 Hz, 1H), 1.25 (d, J = 6.3 Hz, 6H).
-
- Example 166 was made analogously to Example 158 using N-(3-chloro-4-fluorophenyl)-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H13ClN6O, 316.3/318.6 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.42 (br. s, 1H), 8.97 (s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.06 (t, J = 8.1 Hz, 1H), 6.99 - 6.79 (m, 2H), 6.62 - 6.43 (m, 1H), 3.01 (d, J = 4.8 Hz, 3H).
-
- 1H-Imidazo[4,5-b]pyridine-7-carboxylic acid (10 g, 61 mmol, 1 equiv) was dissolved in methanol (160 mL), H2SO4 (10 mL, 189 mmol, 3.08 equiv) was added, and the reaction was stirred at 80 °C for overnight. The reaction was carefully quenched by the addition of a solution of NaOMe in methanol (80 mL, 13 wt% solution, 189 mmol, 3.08 equiv) at 0 °C. Methanol was subsequently removed in vacuo, the resulting solid was slurried in water and filtered. The solid was dried in a vacuum oven (65 °C) overnight. Methyl 1H-imidazo[4,5-b]pyridine-7-carboxylate was obtained as a brown solid. C8H7N3O2, 178.06 (M+1).
- To a suspension of methyl 1H-imidazo[4,5-b]pyridine-7-carboxylate (7.8 g, 44 mmol, 1 equiv) in a mixture of THF/DMF (70 mL, 6:1 ratio) was added a 60 wt% dispersion of NaH (2.1 g, 53 mmol, 1.2 equiv) in three portions. Once gas evolution ceased, the reaction mixture was cooled to 0 °C and SEM-Cl (9.3 mL, 53 mmol, 1.2 equiv) was added. The ice bath was subsequently removed and the reaction was stirred at room temperature for 3 hours before being quenched with saturated aqueous NH4Cl. The reaction mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by silica gel chromatography (0-5% MeOH/CH2Cl2 over 20 minutes). Methyl 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate was isolated as a yellow solid. C14H21N3O3Si. 308.01 (M+1).
- To a solution of methyl 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate (1.1 g, 4 mmol, 1 equiv) in acetonitrile (23.1 mL) was added NCS (0.72 g, 5 mmol, 1.5 equiv). The reaction mixture was stirred at 100 °C in a sealed vessel for 12 hours. Acetonitrile was subsequently removed in vacuo and the crude product purified by silica gel chromatography (0-5% MeOH/CH2Cl2 over 20 minutes). methyl 2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate was obtained as a yellow solid. C14H20ClN3O3Si. 341.94/343.93 (M+1).
- The above compound was made analogously to Example 39 using N,N-diethylethane-1,2-diamine in place of N,N-dimethylpropane-1,3-diamine and methyl 2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate in place of methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of methyl 2-((2-(diethylamino)ethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate was obtained as a yellow oil. C20H35N5O3Si. 422.23 (M+1).
- The above compound was made analogously to Example 39 using methyl 2-((2-(diethylamino)ethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboxamide was isolated as a white solid. C19H22ClFN6O. 405.21/407.14 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as a white solid. C19H23ClFN7O. 420.16/422.13 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.30 (s, 1H), 8.93 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.99 (dd, J = 6.5, 2.7 Hz, 1H), 6.94 (d, J = 6.0 Hz, 1H), 6.56 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.75 (m, 2H), 3.32 (t, J = 6.1 Hz, 2H), 3.23 (q, J = 7.2 Hz, 4H), 1.21 (t, J = 7.2 Hz, 6H). 19F NMR (376 MHz, DMSO-d6 ) δ -74.40 (9F), -126.69 (1F).
-
- The above compound was made analogously to Example 39 using 2-morpholinoethanamine in place of N,N-dimethylpropane-1,3-diamine and methyl 2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate in place of methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of methyl 2-((2-morpholinoethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate was isolated as a yellow oil. C20H33N5O4Si. 436.21 (M+1).
- The above compound was made analogously to Example 39 using methyl 2-((2-morpholinoethyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboxamide was isolated as a white solid. C19H20ClFN6O2. 419.22/421.14 (M+1).
- N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as a white solid. C19H21ClFN7O2. 434.16/436.14 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.31 (br s, 1H), 10.11 (br s, 1H), 8.94 (s, 1H), 7.98 (d, J = 6.2 Hz, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.00 (dd, J = 6.6, 2.7 Hz, 1H), 6.94 (d, J = 6.1 Hz, 1H), 6.57 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.87 - 3.71 (m, 8H), 3.44 - 3.20 (m, 4H). 19F NMR (376 MHz, DMSO-d6 ) δ -74.51 (9F), -126.65 (1F).
-
- Methyl 2-(dimethylamino)-1H-imidazo[4,5-b]pyridine-7-carboxylate. Dissolved methyl 2,3-diaminoisonicotinate (0.2g, 1 mmol) in DCM (5 mL), to the solution was added phosgeniminium chloride (0.39g, 2 mmol) and triethylamine (0.6g, 6 mmol). The reaction mixture was stirred at 40 degree for 3h. Then the reaction was quenched with NaHCO3 solution, diluted with EtOAc, evaporated organic solvent, the residue was purified with Combi-Flash column to afford the desired product. C10H12N4O2. 221.1 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-2-(dimethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 169 was made analogously to Example 107 using the general procedure for hydroxyamidine formation. C15H14ClFN6O. 349.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (d, J = 9.1 Hz, 1H), 10.09 (s, 1H), 9.00 (s, 1H), 7.94 (d, J = 6.3 Hz, 1H), 7.12 - 6.98 (m, 2H), 6.90 (d, J = 6.3 Hz, 1H), 6.54 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.87 (s, 6H).
-
- 2,3-diamino-N-(4-fluoro-3-(trifluoromethyl)phenyl)isonicotinamide. To a solution of 3-fluoro-4-trifluromethyl-aniline (0.1 g, 0.65 mmol), 2,3-diaminoisonicotinic acid (0.234 g, 1 mmol) and triethylamine (0.18 mL, 1 mmol) in DMF (2 mL) was added HATU (0.186 g, 0.78 mmol). The reaction stirred for 16 hr at RT. Saturated sodium bicarbonate was added and the aqueous layer was washed three times with AcOEt. The combined organic layers were dried over sodium sulfate, filtered and concentrated onto silica gel and purified by silica gel chromatography (0->100% ethyl acetate in hexanes) to give the desired product as yellow crystals. C13H10F4N4O. 315.1 (M+1).
- N-(4-fluoro-3-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-3H-imidazo[4,5-b]pyridine-7-carboxamide. 2,3-diamino-N-(4-fluoro-3-(trifluoromethyl)phenyl)isonicotinamide (0.078 g, 0.25 mmol) and 2-hydroxyacetic acid (0.378 g, 5 mmol) was heated neat in a microwave reactor to 170 C for 20 min. LiOH (0.15 g, 6 mmol) in dioxane/ water (0.6/ 2 mL) was added and stirred for 30 min. Saturated sodium bicarbonate was added and the aqueous layer was washed three times with AcOEt. The combined organic layers were dried over sodium sulfate, filtered to give the desired product. C15H10F4N4O2. 355.1 (M+1).
- 2-(Chloromethyl)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide. N-(4-fluoro-3-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-3H-imidazo[4,5-b]pyridine-7-carboxamide (0.22 g, 0.62 mmol), POCl3 (0.6 ml, 6 mM) and PCL5 (0.26g, 0.1 mM) was stirred in dioxane (0.6 ml) at RT for 30 min. Volatiles were removed and excess NH2OH in acetonitrile (2 ml, 1/10 50% NH2OH in water/ acetonitrile) was added, stirred at RT for 10 min. Volatiles were removed. Purification by preparatory HPLC (5-100% MeCN in water, 0.1% TFA) afforded the desired product. C15H10ClF4N5O. 386.1.08 (M-1).
-
- 2-(Chloromethyl)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide. (0.006 g, 0.17 mM), NaI (0.010g, 0.67 mM) and NaOAc (0.010g, 1.7 mM) were stirred in acetone (3 ml) at RT for 30 min. After filtration, volatiles were removed. Purification by preparatory HPLC (5-100% MeCN in water, 0.1% TFA) afforded the desired product. C15H11F4N5O2. Exact Mass: 370.1 (M+1).
-
- A suspension of 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (200 mg, 0.713 mmol) and 2-hydroxypropanoic acid (1.0 mL, 13 mmol) was sparged with argon for 1 min, then sealed and stirred at 180 °C for 1 h in a microwave reactor. The resulting mixture was cooled to room temperature and treated with 1 M lithium hydroxide (20 mL, 20 mmol), then stirred for 30 min. The resulting precipitate was filtered off and rinsed with water to afford N-(3-chloro-4-fluorophenyl)-2-(1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C15H12ClFN4O2. 335.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(1-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-2-(1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C24H32ClFN4O2Si. 491.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(1-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-2-(1-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C24H32ClFN4OSSi. 507.2 (M+1).
- A suspension of N-(3-chloro-4-fluorophenyl)-2-(1-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide (30 mg, 0.059 mmol) in methanol (3 mL) was treated with hydrogen chloride (4.0 M solution in dioxane, 0.12 mL, 0.46 mmol). The resulting solution was stirred at 70 °C overnight, then cooled to room temperature, treated with an additional quantity of hydrogen chloride (4.0 M solution in dioxane, 0.12 mL, 0.46 mmol), and stirred at 70 °C for an additional 7 h. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure. The resulting residue was taken up in methanol (2.4 mL), treated with hydroxylamine (50% solution in water, 0.370 mL, 6.0 mmol), and stirred at 70 °C for 2 h in a sealed vial. The mixture was then cooled to room temperature, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. C15H13ClFN5O2. 350.1 (M+1).
-
- A suspension of 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (400 mg, 1.43 mmol) and 2-hydroxy-2-phenylacetic acid acid (1.74 g, 11.4 mmol) in dioxane (3.5 mL) was sparged with argon for 1 min, then sealed and stirred at 180 °C for 1 h in a microwave reactor. The resulting mixture was cooled to room temperature and treated with 1 M lithium hydroxide (14.3 mL, 14.3 mmol), then stirred for 30 min. The resulting precipitate was filtered off and rinsed with water to afford N-(3-chloro-4-fluorophenyl)-2-(hydroxy(phenyl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C20H14ClFN4O2. 397.1 (M+1).
- 2-(((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-2-(hydroxy(phenyl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and tert-butyldimethylsilyl trifluoromethanesulfonate in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and triisopropylsilyl trifluoromethanesulfonate. C26H28ClFN4O2Si. 511.2 (M+1).
- 2-(((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide was made analogously to Example 183 using 2-(((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C26H28ClFN4OSSi. 527.1 (M+1).
- Example 173 was made analogously to Example 172 using 2-(((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide in place of N-(3-chloro-4-fluorophenyl)-2-(1-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide. C20H15ClFN5O2. 413.0 (M+1).
-
-
- 2-(((tert-butyldimethylsilyl)oxy)(cyclopropyl)methyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-2-(cyclopropyl(hydroxy)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and tert-butyldimethylsilyl trifluoromethanesulfonate in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and triisopropylsilyl trifluoromethanesulfonate. C23H28ClFN4O2Si. 475.2 (M+1).
- 2-(((tert-butyldimethylsilyl)oxy)(cyclopropyl)methyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide was made analogously to Example 183 using 2-(((tert-butyldimethylsilyl)oxy)(cyclopropyl)methyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C23H28ClFN4OSSi. 491.2 (M+1).
- Example 175 was made analogously to Example 172 using 2-(((tert-butyldimethylsilyl)oxy)(cyclopropyl)methyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide in place of N-(3-chloro-4-fluorophenyl)-2-(1-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide. C17H15ClFN5O2. 376.1 (M+1).
-
- A suspension of 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (400 mg, 1.43 mmol) and 2-hydroxy-2-methylpropanoic acid (1.19 g, 11.4 mmol) in dioxane (2 mL) was sparged with argon for 1 min, then sealed and stirred at 180 °C for 1 h in a microwave reactor. The resulting mixture was cooled to room temperature and treated with 1 M lithium hydroxide (14.3 mL, 14.3 mmol), then stirred for 30 min. The mixture was then filtered, and the resulting filtrate was acidified with 2 M hydrochloric acid to give a precipitate. The solids were filtered off and washed with water to provide N-(3-chloro-4-fluorophenyl)-2-(2-hydroxypropan-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C16H14ClFN4O2. 349.1 (M+1).
- 2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-2-(2-hydroxypropan-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and tert-butyldimethylsilyl trifluoromethanesulfonate in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and triisopropylsilyl trifluoromethanesulfonate. C22H28ClFN4O2Si. 463.2 (M+1).
- 2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide was made analogously to Example 183 using 2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C22H28ClFN4OSSi. 479.1 (M+1).
- Example 175 was made analogously to Example 172 using 2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide in place of N-(3-chloro-4-fluorophenyl)-2-(1-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide. C16H15ClFN5O2. 364.1 (M+1).
-
-
- 2-(1-((tert-Butyldimethylsilyl)oxy)-2,2,2-trifluoroethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 183 using N-(3-chloro-4-fluorophenyl)-2-(2,2,2-trifluoro-1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and tert-butyldimethylsilyl trifluoromethanesulfonate in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and triisopropylsilyl trifluoromethanesulfonate. C21H23ClF4N4O2Si. 503.1 (M+1).
- 2-(1-((tert-butyldimethylsilyl)oxy)-2,2,2-trifluoroethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide was made analogously to Example 183 using 2-(1-((tert-butyldimethylsilyl)oxy)-2,2,2-trifluoroethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C21H23ClF4N4OSSi. 519.1 (M+1).
- Example 176 was made analogously to Example 172 using 2-(1-((tert-butyldimethylsilyl)oxy)-2,2,2-trifluoroethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide in place of N-(3-chloro-4-fluorophenyl)-2-(1-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide. C15H10ClF4N5O2. 404.1 (M+1).
-
- A solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (20 mg, 0.055 mmol) in tetrahydrofuran (0.75 mL) was treated with water (0.75 mL) followed by 2 M sodium hydroxide (0.75 mL, 1.5 mmol). The mixture was stirred for 20 min, then acidified with acetic acid and purified by reverse phase preparative HPLC to provide the desired product. C14H11ClFN5O2. 336.1 (M+1).
-
- Example 178 was made analogously to Example 112 using methylamine (2.0 M solution in THF) in place of morpholine. C15H14ClFN6O. 349.1 (M+1).
-
- A solution of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate (10 mg, 0.019 mmol) in acetonitrile (0.5 mL) was treated with ammonia (0.5 M solution in dioxane, 0.50 mL, 0.25 mmol) and stirred at room temperature overnight. The mixture was then concentrated under reduced pressure. The resulting residue was taken up in tetrahydrofuran (0.50 mL) and treated with water (0.50 mL) followed by 2 M sodium hydroxide (0.20 mL, 0.40 mmol). The resulting mixture was stirred at room temperature for 5 min, then acidified with acetic acid and purified by reverse phase preparative HPLC to provide the desired product. C14H12ClFN6O. 335.1 (M+1).
-
- A solution of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate (36 mg, 0.069 mmol) in acetonitrile (2 mL) was treated with ammonia (0.5 M solution in dioxane, 1.9 mL, 0.97 mmol) and stirred at room temperature overnight. The mixture was then concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane (2 mL) and treated with pyridine (0.054 mL, 0.67 mmol) and divided into two batches of equal volume. One of these batches was then cooled to 0 °C and benzenesulfonyl chloride (0.78 M solution in dichloromethane, 0.130 mL, 0.100 mmol) was added dropwise with stirring. The reaction mixture was then warmed to room temperature and stirred for 10 min, then cooled to 0 °C and treated with water. The mixture was then partially concentrated under reduced pressure, then treated with tetrahydrofuran (1 mL) followed by 2 M sodium hydroxide (1 mL) and stirred for 15 min. The mixture was then acidified with acetic acid, partially concentrated under reduced pressure, diluted with dimethyl sulfoxide (1 mL), and purified by reverse phase preparative HPLC to provide the desired product. C20H16ClFN6O3S. 475.1 (M+1).
-
- Example 181 was prepared analogously to Example 180 using methanesulfonyl chloride in place of benzenesulfonyl chloride. C15H14ClFN6O3S. 413.0 (M+1).
-
- A solution of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate (59 mg, 0.114 mmol) in acetonitrile (3 mL) was treated with ammonia (0.5 M solution in dioxane, 1.9 mL, 0.97 mmol) and stirred at room temperature overnight. The solution was then divided into two batches of equal volume. One of the batches was concentrated under reduced pressure and the resulting residue taken up in DMSO (1 mL). The solution was treated with N,N-diisopropylethylamine (0.061 mL, 0.35 mmol) followed by 2-fluoropyrmidine (23 mg, 0.23 mmol) and stirred for at room temperature for 48 h. The mixture was then treated with water (1 mL) and 2 M sodium hydroxide (0.5 mL) and stirred for 15 min, then acidified acetic acid, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide the desired product. C18H14ClFN8O. 413.1 (M+1).
-
- Ethyl 2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)acetate. A suspension of 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (10.9 g, 38.8 mmol) and ethyl 3-ethoxy-3-iminopropanoate hydrochloride (30.4 g, 155 mmol) in ethanol (100 mL) was stirred at 80 °C for 24 h. The mixture was then cooled to room temperature and an additional portion of ethyl 3-ethoxy-3-iminopropanoate hydrochloride (30.4 g, 155 mmol) was added. The suspension was stirred at 80 °C for an additional 24 h. The mixture was then cooled to room temperature and the resulting solid filtered off, rinsed with water, and dried under a stream of air to afford the desired product. C17H14ClFN4O3. 377.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. To a stirring suspension of ethyl 2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)acetate (5.55 g, 14.7 mmol) in THF (210 mL) under a positive pressure of nitrogen was added lithium borohydride (3.21 g, 147 mmol) in five equal portions. The resulting mixture was then stirred at 40 °C for 1 h. The mixture was then cooled to 0 °C and water (83 mL) was slowly added, such that the internal temperature was kept below 15 °C. After 30 min of stirring, 1M hydrochloric acid (660 mL) was slowly added, such that the internal temperature was kept below 20 °C. The mixture was then heated to 40 °C and stirred for 2 h. The resulting solution was cooled to room temperature and extracted with ethyl acetate (3 x 500 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the desired product (2.46 g). The aqueous layer contained a yellow precipitate which was filtered off, rinsed with water, and dried under a stream of air to afford an additional quantity of desired product. C15H12ClFN4O2. 335.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. To a stirring suspension of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (2.46 g, 7.35 mmol) in dichloromethane (75 mL) under a nitrogen atmosphere was added 2,6-lutidine (10.2 mL, 88.2 mmol). The mixture was then cooled to 0 °C and triisopropylsilyl trifluoromethanesulfonate (11.9 mL, 44.1 mmol) was added dropwise with stirring. The mixture was then allowed to warm to room temperature and stirred for an additional 90 min. Water was added with vigorous stirring, then the organic and aqueous layers were separated and the organic layer washed four additional times with water. The organic layer was then adsorbed onto silica gel and purified by flash chromatography (0-100% EtOAc/hexanes). Product-containing fractions were combined and concentrated under reduced pressure, then triturated with acetonitrile to afford the desired product. C24H32ClFN4O2Si. 491.4 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide. A suspension of N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (2.27 g, 4.62 mmol) and 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide (3.74 g, 9.24 mmol) in toluene (92 mL) was stirred at 95 °C for 4 h. The mixture was then cooled to room temperature and filtered, rinsing with dichloromethane. The combined filtrates were adsorbed onto silica gel and purified by flash chromatography (0-75% EtOAc/hexanes) to provide the desired product. C24H32ClFN4OSSi. 507.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. A solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (40mg, 0.079mmol) and hydrogen chloride (4.0 M solution in dioxane, 0.158 mL, 0.631 mmol) in methanol (4 mL) was stirred at 70 °C overnight in a sealed screw-top flask. The mixture was then cooled to room temperature and concentrated under reduced pressure. The resulting residue was taken up in hydroxylamine (50% solution in water, 0.259 mL, 3.991mmol) in methanol (1.6 mL) was stirred at 70 °C in a sealed screw-top flask for 1 h. The mixture was then cooled to room temperature The mixture was acidified with acetic acid (0.300 mL, 5.24 mmol), diluted with dimethyl sulfoxide (4 mL), and purified by reverse phase preparative HPLC to provide the desired product. C15H13ClFN5O2. 350.10 (M+1).
-
- 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one. A suspension of N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide (1.70 g, 3.33 mmol) and hydroxylamine (50% solution in water, 20.4 mL, 333 mmol) in methanol (135 mL) was stirred at 70 °C in a sealed screw-top flask for 1 h. The mixture was then cooled to room temperature and partially concentrated under reduced pressure to afford a white aqueous suspension. The solids were filtered off and dried under reduced pressure, then taken up in ethyl acetate (135 mL) and treated with 1,1'-carbonyldiimidazole (702 mg, 4.33 mmol). The mixture was stirred at 30 °C for 1 h, then adsorbed onto silica gel and purified by flash chromatography (0-100% EtOAc/hexanes) to provide the desired product. C25H31ClFN5O3Si. 532.2 (M+1).
- 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate. A solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (1.95 g, 3.67 mmol) and hydrogen chloride (4.0 M solution in dioxane, 7.3 mL, 29 mmol) in methanol (180 mL) was stirred at 70 °C overnight in a sealed screw-top flask. The mixture was then cooled to room temperature and concentrated under reduced pressure. The resulting residue was taken up in dichloromethane (75 mL), treated with N,N-diisopropylethylamine (6.4 mL, 37 mmol), and cooled to 0 °C under a nitrogen atmosphere. Methanesulfonyl chloride (2.0 mL, 26 mmol) was added dropwise over 5 min with stirring. After 30 min, the mixture was treated with water, the layers were separated, and the organic layer was washed twice more with water. The organic phase was then concentrated under reduced pressure and purified by flash chromatography (0-65% EtOAc/hexanes) to provide the desired product (Note: the connectivity of the methanesulfonyl group on the imidazole ring was assumed to be at N(1) as indicated, though connectivity at N(3) was not rigorously ruled out). C18H15ClFN5O7S2. 532.1 (M+1).
- A solution of 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate (20 mg, 0.038 mmol) in acetonitrile (0.2 mL) was treated with dimethylamine (2.0 M solution in tetrahydrofuran, 0.38 mL, 0.75 mmol), and the resulting solution was stirred at room temperature for 1 h. The mixture was then concentrated under reduced pressure. The resulting residue was taken up in tetrahydrofuran (0.5 mL), treated with water (0.5 mL) followed by 2M sodium hydroxide (0.23 mL, 0.46 mmol), and stirred at room temperature for 15 min. The mixture was acidified with acetic acid (0.064 mL, 1.1 mmol), diluted with dimethyl sulfoxide (3 mL), and purified by reverse phase preparative HPLC to provide the desired product. C17H18ClFN6O. 377.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.11 (s, 1H), 8.91 (s, 1H), 8.31 (d, J = 5.1 Hz, 1H), 7.15 (d, J = 5.1 Hz, 1H), 7.05 (t, J = 9.1 Hz, 1H), 6.93 (dd, J= 6.5, 2.7 Hz, 1H), 6.51 (ddd, J= 9.0, 4.1, 2.7 Hz, 1H), 3.54 (t, J= 7.3 Hz, 2H), 3.30 (t, J= 7.3 Hz, 2H), 2.86 (s, 6H).
-
- Example 185 was made analogously to Example 184 using diethylamine in place of dimethylamine. C19H22ClFN6O. 405.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.08 (s, 1H), 8.91 (s, 1H), 8.30 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 5.2 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.50 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.52 (t, J = 7.5 Hz, 2H), 3.28 (t, J = 7.5 Hz, 2H), 3.21 (q, J = 7.2 Hz, 4H), 1.22 (t, J = 7.2 Hz, 6H).
-
- Example 186 was made analogously to Example 184 using 1-cyclopropyl-N-methylmethanamine in place of dimethylamine. C20H22ClFN6O. 417.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.08 (s, 1H), 8.90 (s, 1H), 8.31 (d, J = 5.1 Hz, 1H), 7.17 (d, J = 5.1 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.51 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.59 (br s, 2H), 3.33 (t, J = 7.4 Hz, 2H), 3.10 (d, J = 7.3 Hz, 2H), 2.88 (s, 3H), 1.18-1.06 (m, 1H), 0.70-0.62 (m, 2H), 0.44-0.38 (m, 2H).
-
- A solution of 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-l-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate (30 mg, 0.056 mmol) in acetonitrile (0.9 mL) was treated with N,N-diisopropylethylamine (0.20 mL, 1.1 mmol) followed by 2,2-difluoro-N-methylethanamine hydrochloride (148 mg, 1.13 mmol). The resulting solution was stirred for 2 h, then treated with dimethylamine (2.0 M solution in tetrahydrofuran, 0.5 mL, 1.0 mmol). After an additional 1 h of stirring, the mixture was treated with isopropylamine (0.2 mL, 2.3 mmol) and stirred for 20 min (in order to cleave the remaining imidazolyl methanesulfonyl group). The solution was then concentrated under reduced pressure and the resulting residue taken up in tetrahydrofuran (0.75 mL). The solution was treated with water (0.75 mL) followed by 2M sodium hydroxide (0.38 mL, 0.76 mmol), and stirred at room temperature for 20 min. An additional amount of 2M sodium hydroxide (0.75 mL, 1.5 mmol) was added, and stirring resumed for 15 min. Finally, the mixture was acidified with acetic acid, partially evaporated under reduced pressure, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide the desired product. C18H18ClF3N6O. 427.1 (M+1).
-
- A solution 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate. (20 mg, 0.038mmol) and methylamine (2.0 M solution in tetrahydrofuran, 0.376mL, 0.752mmol) in acetonitrile (1 mL) was stirred for 2hr. The reaction was concentrated. The residue was brought up in tetrahydrofuran (0.5 mL) and water (0.5 mL). To this solution was added 2 N sodium hydroxide (0.22 mL, 0.43 mmol) and the reaction mixture stirred for 10 min. To the mixture was added acetic acid (0.035 mL) and the solution was loaded directly onto a prep HPLC for purification to give the desired product. C16H16ClFN6O. 363.11(M+1).
-
- Example 189 was made analogously to Example 188 using ammonia (0.5 M solution in dioxane) in place of dimethylamine (2.0 M solution in tetrahydrofuran). C15H14ClFN6O. 349.1 (M+1).
-
- Example 190 was made analogously to Example 188 using 2-methoxyethanamine in place of dimethylamine (2.0 M solution in tetrahydrofuran). C18H20ClFN6O2. 407.1 (M+1).
-
- Example 191 was made analogously to Example 188 using morpholine in place of dimethylamine (2.0 M solution in tetrahydrofuran). C19H20ClFN6O2. 419.13 (M+1)
-
- Example 192 was made analogously to Example 184 using piperidine in place of dimethylamine. C20H22ClFN6O. 417.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.10 (s, 1H), 8.90 (s, 1H), 8.30 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 5.1 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.52 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.69-2.76 (m, 8H), 1.99-1.28 (m, 6H).
-
- Example 193 was made analogously to Example 184 using pyrrolidine in place of dimethylamine. C19H20ClFN6O. 403.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.10 (s, 1H), 8.89 (s, 1H), 8.31 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 5.1 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.94 (dd, J = 6.6, 2.7 Hz, 1H), 6.51 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.61 (t, J = 7.4 Hz, 2H), 3.57-2.99 (m, 6H), 1.96 (br s, 4H).
-
- Example 194 was made analogously to Example 187 using 2-methoxy-N-methylethanamine in place of 2,2-difluoro-N-methylethanamine hydrochloride and N,N-diisopropylethylamine. C19H22ClFN6O2. 421.1 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.09 (s, 1H), 8.89 (s, 1H), 8.30 (d, J = 5.1 Hz, 1H), 7.15 (d, J= 5.1 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.52 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.70 (t, J = 5.0 Hz, 2H), 3.60 (t, J = 7.4 Hz, 2H), 3.40 (t, J = 5.1 Hz, 2H), 3.36-3.29 (m, 5H), 2.86 (s, 3H).
-
- N-(3-chloro-4-fluorophenyl)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A solution of 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (3.00 g, 10.7 mmol) and 2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (50% by weight in dichloromethane, 13.9 g, 53.4 mmol) in dimethyl sulfoxide (110 mL) was stirred vigorously under an air atmosphere at 100 °C overnight. The mixture was cooled to room temperature, diluted with water and brine solution, and extracted with dichloromethane (700 mL). The organic layer was then washed three times with water (500 mL), concentrated under reduced pressure, and adsorbed onto silica gel for purification by flash chromatography (0-70% EtOAc/hexanes) to provide the desired product. C18H16ClFN4O3. 391.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(1,2-dihydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A suspension of N-(3-chloro-4-fluorophenyl)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (300 mg, 0.768 mmol) in methanol (38 mL) was treated with hydrogen chloride (4.0 M in dioxane, 1.5 mL, 6.0 mmol) and stirred at 70 °C overnight. The mixture was concentrated under reduced pressure to provide the desired product. C15H12ClFN4O3. 351.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A suspension of N-(3-chloro-4-fluorophenyl)-2-(1,2-dihydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (727 mg, 2.07 mmol) and 2,6-lutidine (3.9 mL, 33 mmol) in dichloromethane (41 mL) was cooled to 0 °C with stirring under a nitrogen atmosphere. The mixture was then treated with tert-butyldimethylsilyl trifluoromethanesulfonate (3.8 mL, 17 mmol) dropwise and with stirring. The mixture was then warmed to room temperature and stirred for 20 min, then adsorbed onto silica gel for purification by flash chromatography (0-40% EtOAc/hexanes) to provide the desired product. C27H40ClFN4O3Si2. 579.3 (M+1).
- 2-(1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A suspension of N-(3-chloro-4-fluorophenyl)-2-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (200 mg, 0.345 mmol) in ethanol (7 mL) was treated with pyridinium p-tolueneslfonate (781 mg, 3.11 mmol) and stirred at 80 °C for 90 min. The mixture was then cooled to room temperature, diluted with saturated aqueous sodium bicarbonate, and extracted three times with ethyl acetate. The combined organic layers were adsorbed onto silica gel for purification by flash chromatography (20-55% EtOAc/hexanes) to provide the desired product. C21H26ClFN4O3Si. 365.3 (M+1).
- 2-((tert-butyldimethylsilyl)oxy)-2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate. A solution of 2-(1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (90 mg, 0.19 mmol) and N,N-diisopropylethylamine (0.74 mL, 1.9 mmol) in dichloromethane (3.9 mL) was cooled to 0 °C with stirring under a nitrogen atmosphere. The mixture was treated with methanesulfonyl chloride (0.075 mL, 0.97 mmol) dropwise and with stirring. After 5 min, the mixture was diluted with water, then extracted three times with dichloromethane. The combined organic layers were loaded onto a silica gel cartridge for purification by flash chromatography (0-100% EtOAc/hexanes) to provide the desired product. C23H30ClFN4O7S2Si. 621.2 (M+1).
- 2-(1-((tert-butyldimethylsilyl)oxy)-2-(dimethylamino)ethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A solution of 2-((tert-butyldimethylsilyl)oxy)-2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate (90 mg, 0.145 mmol) in acetonitrile (2.9 mL) was treated with dimethylamine (2.0 M in tetrahydrofuran, 2.90 mL, 5.80 mmol) and stirred at 60 °C for for 3 h. Additional dimethylamine (2.0 M in tetrahydrofuran, 1.0 mL, 2.0 mmol) was then added, and stirring at 60 °C resumed for 2 h. The mixture was then cooled to room temperature and concentrated under reduced pressure. Purification of the resulting residue by flash chromatography (0-30% MeOH/DCM) provided the desired product. C23H31ClFN5O2Si. 492.3 (M+1).
- 2-(1-((tert-butyldimethylsilyl)oxy)-2-(dimethylamino)ethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide was made analogously to Example 183 using 2-(1-((tert-butyldimethylsilyl)oxy)-2-(dimethylamino)ethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-((triisopropylsilyl)oxy)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C23H31ClFN5OSSi. 508.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)-1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide. A solution of 2-(1-((tert-butyldimethylsilyl)oxy)-2-(dimethylamino)ethyl)-N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide (59 mg, 0.12 mmol) and hydrogen chloride (4.0 M solution in dioxane, 0.226 mL, 0.906 mmol) in methanol (5.8 mL) was stirred at 80 °C for 24 h. The mixture was then cooled to room temperature, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide the desired product. C17H17ClFN5OS. 594.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)-1-hydroxyethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. A solution of N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)-1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carbothioamide (5 mg, 0.013 mmol) and hydroxylamine (50% solution in water, 0.156 mL, 2.54 mmol) in methanol (1 mL) was stirred at 70 °C for 10 min. The mixture was then diluted with dimethyl sulfoxide and purified by reverse phase preparative HPLC to provide the desired product. C17H18ClFN6O2. 393.1 (M+1).
-
- Example 196 was synthesized analogously to Example 112 using 3-(2-(bromomethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-methylpropan-1-amine in place of (7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl methanesulfonate and morpholine, respectively. C18H20ClFN6O. 391.1 [M+1]+.
-
-
- 2-Methylamino-3-amino-4-methylpyridine. A mixture of N,4-dimethyl-3-nitropyridin-2-amine (2.01 g, 12.0 mmol) and 10% Paladium on Carbon (128 mg, 0.12 mmol) was mixed in a Parr Shaker at 40 psi hydrogen for 2 hr. The reaction mixture was filtered and concentrated to give the desired product. C7H11N3. 138.1 (M+1).
-
- 3-Methyl-3H-imidazo[4,5-b]pyridine-7-carboxylic acid. To a solution of 3,7-dimethyl-3H-imidazo[4,5-b]pyridine (726 mg, 4.93 mmol) sodium carbonate (523 mg, 4.93 mmol) in water (30 mL) at 100 C was added potassium permanganate (7.8 g, 49.2 mmol) in portions over two days. Na2CO3 and water are added to the starting material . The reaction mixture is heated until boiled, which caused a homogeneous solution. KMnO4 was added in small portions to the boiling solution. The reaction is stirred for another hour. LCMS shows low conversion. More KMnO4 was added in small batches at 100 °C for the next two days. The reaction mixture was filtered hot and the filtrate was acidified with 1 N HCl, concentrated and purified by prep HPLC to give the desired product. C8H7N3O2. 178.0 (M+1).
- N-(3-chloro-4-fluorophenyl)-3-methyl-3H-imidazo[4,5-b]pyridine-7-carboxamide. A solution of 3-methyl-3H-imidazo[4,5-b]pyridine-7-carboxylic acid (100 mg, 0.564 mmol), hydroxybenzotriazole (173 mg, 1.13 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (216 mg, 1.13 mmol), and diisopropylethylamine (0.690 mL, 3.95 mmol) in dimethylformamide (2 mL) was stirred for 18 hr. To the reaction mixture was added saturated sodium bicarbonate Stirred all together overnight. Added saturated aqueous sodium bicarbonate and the resulting solid was filtered, triturated with 10% citric acid, filtered, and dried on high vac. C14H10ClFN4O. 305.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3-methyl-3H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 197 was made analogously to Example 107 using N-(3-chloro-4-fluorophenyl)-3-methyl-3H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-Chloro-4-fluorophenyl)-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide. C14H11ClFN5O. 320.0 (M+1).
- The following compounds were prepared according to the procedures described herein using the appropriate starting materials.
-
-
-
-
-
-
-
- Example 204 was made analogously to Example 188 using ethylamine (2.0 M solution in tetrahydrofuran) in place of dimethylamine. C17H18ClFN6O. 377.1 (M+1).
-
- Example 205 was made analogously to Example 188 using isopropylamine in place of dimethylamine. C18H20ClFN6O. 391.1 (M+1).
-
- Example 206 was made analogously to Example 188 using isobutylamine in place of dimethylamine. C19H22ClFN6O. 405.1 (M+1).
-
- Example 207 was made analogously to Example 188 using cyclopropylamine in place of dimethylamine. C18H18ClFN6O. 389.1 (M+1).
-
- Example 208 was made analogously to Example 188 using cyclopropylmethanamine in place of dimethylamine. C19H20ClFN6O. 403.1 (M+1).
-
- Example 209 was made analogously to Example 188 using 4,5-dihydro-1H-imidazol-2-amine in place of dimethylamine. C18H18ClFN8O. 417.1 (M+1).
-
- Example 210 was made analogously to Example 112 using 2-(2-aminoethyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide in place of 4-(3-chloro-4-fluorophenyl)-3-(2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one. C17H15ClF3N5O3S. 462.3 (M+1).
-
-
- To a mixture of 2-(2-aminoethyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylic acid (2g, 8.29 mmol) in THF (30mL) and sat. sodium bicarbonate solution 30mL was added di-tertbutyldicarbonate (7.24g, 33mmol). Stirred for 72 h. Acidified with 4N HCl and brought the pH to ∼1. The reaction mixture was extracted with ethyl acetate (50mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography to give 2-(2-((tert-butoxycarbonyl)amino)ethyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylic acid. C15H17F2N3O4. 342.1 (M+1).
- tert-butyl (2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)ethyl)carbamate was made analogously to Example 53 using 2-(2-((tertbutoxycarbonyl)amino)ethyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylic acid in place of 2-(2-(dimethylamino)ethyl)-6,7-difluoro-1Hbenzo[d]imidazole-4-carboxylic. 469.12 (M+1). C21H20ClF3N4O3. 469.12 (M+1).
- 2-(2-aminoethyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was made analogously to Example 53 using tert-butyl (2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)ethyl)carbamate in place of N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. C16H13ClF3N5O. 384.2 (M+1).
-
- A 500mL round bottom flask equipped with a stir bar was charged with 2,3-diamino-N-(3-chloro-4-fluorophenyl)isonicotinamide (34g, 121.1 mmol) and 1,1'-carbonyldiimidazole (CDI) (29.5g, 181.7mmol) followed by THF (300mL). The reaction mixture was stirred at room temperature for 16hr. THF 150mL was removed under reduced pressure. Water 250mL was then slowly added to the reaction mixture. Reaction mixture was then stirred for 1 hour, and precipitate was isolated via vacuum filtration and washed with water (100mL x 3). The solid was dried in a vacuum oven at 40 °C overnight to afford a light red solid (34g, 110.8 mmol) and used in the next step without further purification. C13H8ClFN4O2. 307.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-7-carboxamide (5.0g, 16.3 mmol) was dissolved in POCl3 (33 eq., 538 mmol, 82.5 mL) and PCl5 (3 eq., 48.9 mmol, 10.19 g) was added. The reaction was sealed in a glass vessel and heated to 100 °C for 16 hours. The reaction was allowed to cool to room temperature and then transferred to a round bottom flask. The POCl3 was removed under reduced pressure and the residue was taken up in 100 mL of p-dioxane. In a separate round bottom flask, NH2OH (50% in water, 92.8 eq, 1.52 mol, 100 mL) was added to 200 mL p-dioxane and cooled to ∼3 °C in an ice bath with continuous stirring. The crude imidoyl chloride in p-dioxane mixture was added very slowly to the hydroxylamine mixture (over ∼45 mins, dropwise) while maintaining the hydroxylamine/dioxane solution ∼3 °C. Once the addition was complete, the reaction was allowed to slowly come to room temperature and stirred for 20 mins. The reaction was then diluted with EtOAc (500 mL), sat. sodium bicarbonate solution (300 mL), and brine (150 mL) and allowed to stir for an additional 20 mins. The reaction was extracted and the organic layer was washed once with brine (200 mL), dried over Na2SO4, filtered, and concentrated to dryness to give crude 2-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide which was used in the next step without further purification. C13H8Cl2FN5O. 340.1 (M+1).
- Crude 2-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide from previous step (5.5 g, 16.31 mmol assumed 100% yield from starting N-(3-chloro-4-fluorophenyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-7-carboxamide) was dissolved in ethyl acetate (80 mL, C=0.2 M) and 1,1'-carbonyldiimidazole (CDI) (2 eq, 5.3 g, 32.6 mmol) was added. The reaction was allowed to stir at room temperature (capped but under air) for 1 hour until no SM was seen by LCMS. The reaction was then carefully diluted with water (80 mL, some gas evolution seen) and the reaction was allowed to stir for 10 mins before being poured into a separatory funnel (∼15 mL of brine added to help break up emulsions) and the organic layer was extracted. The organic layer was washed once more with water (∼50mL with ∼10mL brine) and the organic layer was then concentrated. The crude was wet loaded on to silica gel and purified by column chromatography (Rf 0.75 in 100% EtOAc, column run 40-100% EtOAc/hex) to give 3-(2-chloro-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one as a pale yellow solid. C14H6Cl2FN5O2. 365.9 (M+1).
- 3-(2-chloro-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (804 mg, 2.2 mmol) was weighed into a round bottom flask which was then evacuated and purged twice with argon. CH2Cl2 (30.0 mL, C=0.075 M) was added via syringe and the reaction was cooled to 0 °C in an ice bath. Hunig's base (2.5 eq, 5.49 mmol, 0.956 mL) was added followed by SEM-Cl (2.3 eq, 5.051 mmol, 0.894 mL) (added dropwise). The reaction was allowed to stir at 0 °C for 20 mins until no starting material was seen by LCMS. The reaction was then poured into DI water (40 mL) in a separatory funnel and then shaken. The organic layer was removed and concentrated under reduced pressure. The crude was wet loaded on to a silica gel column and purified by normal phase column chromatography (20-80% EtOAc/hex, Rf= 0.42 in 40% EtOAc/hex) to give 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one as a pale yellow oil which solidified upon standing.
- 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (0.015g, 0.03mmol) was dissolved in DMSO (0.5 ml), and 2-methoxyethanamine (4.54mg, 0.060 mmol) was added to the solution. The reaction mixture was heated at 60°C for 2h. The mixture was cooled to rt and partitioned between sat. bicarb solution (1 mL) and EtOAc (2 mL) and the aqueous layer was extracted 1× with EtOAc (1 mL). The combined organic layers were washed with sat. bicarb solution (1 mL). Organic layers were then concentrated and taken up in DCM (1.6mL) and trifluoroacetic acid (0.4 mL). The reaction mixture was stirred for 1h and concentrated. The residue was brought up in tetrahydrofuran (0.5 mL). To this solution was added 2 N sodium hydroxide solution (0.22 mL, 0.44 mmol) and the reaction mixture stirred for 30 min. To the mixture was added acetic acid (0.10 mL), DMSO (2 mL) and water (2mL), the solution was loaded directly onto a prep HPLC for purification to give the desired product. C16H16ClFN6O2.379.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.72 (s, 1H), 11.43 (s, 1H), 8.95 (s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.3 Hz, 1H), 6.60 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.61 (t, J = 5.3 Hz, 2H), 3.53 (t, J = 5.1 Hz, 2H), 3.30 (s, 3H).
-
- Example 213 was made analogously to Example 211 using 2-(2-aminoethyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide in place of 2-(2-aminoethyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylic acid. C21H21ClF3N5O3. 484.4 (M+1).
-
- Example 214 was made analogously to Example 212 using 2-(4,4-difluoropiperidin-1-yl)ethanamine in place of 2-methoxyethanamine. C20H21ClF3N7O. 468.88 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H), 7.96 (d, J = 5.8 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.98 (s, 1H), 6.91 (d, J = 6.0 Hz, 1H), 6.55 (dt, J = 8.9, 3.5 Hz, 1H), 3.33 (m, 8H), 2.33 - 2.18 (m, 4H).
-
- Example 215 was made analogously to Example 212 using N1,N1-dimethylethane-1,2-diamine in place of 2-methoxyethanamine. C17H19ClFN7O. 392.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.93 (s, 1H), 7.94 (s, 1H), 7.08 (t, J = 9.1 Hz, 1H), 6.96 (s, 1H), 6.89 (d, J = 5.9 Hz, 1H), 6.54 (d, J = 8.6 Hz, 1H), 3.73 (s, 2H), 3.31 (s, 2H), 2.85 (s, 6H).
-
- Example 216 was made analogously to Example 212 using tert-butyl (2-aminoethyl)(methyl)carbamate in place of 2-methoxyethanamine. C16H17ClFN7O. 378.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H), 8.57 (s, 2H), 7.95 (d, J = 6.0 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.97 (s, 1H), 6.90 (d, J = 6.2 Hz, 1H), 6.59 - 6.47 (m, 1H), 3.67 (s, 2H), 3.16 (s, 2H), 2.61 (s, 3H).
-
- Example 217 was made analogously to Example 212 using 1-methylazepan-3-amine in place of 2-methoxyethanamine. C20H23ClFN7O. 432.2 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 8.92 (s, 1H), 7.96 (s, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.97 (s, 1H), 6.90 (d, J = 6.1 Hz, 1H), 6.55 (s, 1H), 4.25 (s, 1H), 3.6 - 3.3 (m, 3H), 3.18 (s, 2H), 2.87 (s, 3H), 2.13 - 1.41 (m, 6H).
-
- Example 218 was made analogously to Example 212 using 4-(2-aminoethyl)thiomorpholine 1,1-dioxide in place of 2-methoxyethanamine. C19H21ClFN7O3S. 482.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.40 (s, 1H), 8.97 (s, 1H), 7.96 (d, J = 6.4 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.61 - 6.52 (m, 1H), 3.55 (d, J = 5.9 Hz, 2H), 3.12 (s, 5H), 3.06 (s, 5H), 2.81 (s, 2H).
-
- Example 219 was made analogously to Example 212 using N1-(2-methoxyethyl)-N1-methylethane-1,2-diamine in place of 2-methoxyethanamine. C19H23ClFN7O2. 427.03 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.96 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.98 (d, J = 6.4 Hz, 1H), 6.93 (d, J = 6.2 Hz, 1H), 6.55 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.78 (s, 2H), 3.64 (t, J = 5.0 Hz, 2H), 3.37 (s, 4H), 3.24 (s, 3H), 2.86 (s, 3H).
-
- Example 220 was made analogously to Example 212 using N 1-(2,2-difluoroethyl)-N 1-methylethane-1,2-diamine in place of 2-methoxyethanamine. C18H19ClF3N7O. 442.1 (M+1). 1HNMR (400 MHz, DMSO-d6) δ 11.40 (s, 1H), 8.96 (s, 1H), 7.96 (d, J = 6.3 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.01 (dd, J = 6.5, 2.8 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.56 (ddd, J = 8.9, 3.9, 2.7 Hz, 1H), 6.25 (t, J = 55.0 Hz, 1H), 3.62 (d, J = 6.5 Hz, 2H), 3.18 (s, 2H), 2.97 (s, 2H), 2.57 (s, 2H).
-
- Example 221 was made analogously to Example 212 using 3-morpholinylpropan-1-amine in place of 2-methoxyethanamine. C20H23ClFN7O2. 448.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 1H), 8.96 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.01 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.60 - 6.52 (m, 1H), 4.2-3.55 (m, 8H), 3.49 (d, J = 6.5 Hz, 2H), 3.15 (t, J = 8.0 Hz, 2H), 1.98 (d, J = 8.0 Hz, 2H).
-
- Example 222 was made analogously to Example 212 using 2-(piperidin-1-yl)ethanamine in place of 2-methoxyethanamine. C20H23ClFN7O.432.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.98 (d, J = 6.3 Hz, 1H), 6.91 (d, J = 6.0 Hz, 1H), 6.60 - 6.51 (m, 1H), 3.74 (M, 4H), 3.28 (d, J = 7.0 Hz, 2H), 1.73 (s, 5H), 1.54 (s, 3H).
-
- Example 223 was made analogously to Example 212 using 2-(3-fluoropiperidin-1-yl)ethanamine in place of 2-methoxyethanamine. C21H24ClFN6O. 431.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.37 (s, 1H), 8.94 (s, 1H), 7.93 (s, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.02 (m, 1H), 6.90 (s, 1H), 6.56 (d, J = 9.0 Hz, 1H), 1.68 (m, 6H), 1.46 (d, J = 7.7 Hz, 2H), 1.30 (s, 1H), 1.16 (m, 3H), 0.90 m, 3H).
-
- Example 224 was made analogously to Example 212 using 2-(tetrahydro-2H-pyran-4-yl)ethanamine in place of 2-methoxyethanamine. C20H22ClFN6O2. 433.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.95 (s, 1H), 7.94 (d, J = 6.2 Hz, 1H), 7.08 (t, J = 9.1 Hz, 1H), 7.04 - 6.99 (m, 1H), 6.90 (d, J = 6.1 Hz, 1H), 6.60 - 6.51 (m, 1H), 3.82 (dd, J = 11.0, 4.2 Hz, 2H), 3.26 (d, J = 12.0 Hz, 2H), 1.62 - 1.43 (m, 7H), 1.17 (d, J = 12.6 Hz, 2H).
-
- Example 225 was made analogously to Example 212 using 2,2-difluoroethanamine in place of 2-methoxyethanamine. C15H12ClF3N6O. 385.1 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ 11.46 (s, 1H), 8.98 (s, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.3 Hz, 1H), 6.62 - 6.52 (m, 1H), 6.22 (t, J = 55.3 Hz, 1H), 3.87 (d, J = 16.8 Hz, 2H).
-
- Example 226 was made analogously to Example 212 using oxetan-3-amine in place of 2-methoxyethanamine. C16H14ClFN6O2. 377.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.88 (s, 1H), 7.96 (s, 1H), 7.06 (t, J = 9.1 Hz, 1H), 7.01 (d, J = 5.4 Hz, 1H), 6.96 (d, J = 6.5 Hz, 1H), 6.54 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.57 (s, 1H), 4.32 (t, J = 9.8 Hz, 1H), 4.05 (s, 1H), 3.58 (s, 2H).
-
- Example 227 was made analogously to Example 212 using tetrahydrofuran-3-amine in place of 2-methoxyethanamine. C17H16ClFN6O2. 391.1 (M+1). 1H NMR(400 MHz, DMSO-d6) δ 11.40 (s, 1H), 8.94 (s, 1H), 8.50 (s, 1H), 7.96 (d, J = 6.3 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.3 Hz, 1H), 6.57 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 4.44 (q, J = 5.8, 3.7 Hz, 1H), 3.93 - 3.78 (m, 2H), 3.74 (td, J = 8.4, 5.3 Hz, 1H), 3.69 (d, 1H), 2.30-2.18 (m, 1H), 1.90 (dd, J = 14.8, 7.7 Hz, 1H).
-
- Example 228 was made analogously to Example 212 using tetrahydro-2H-pyran-4-amine in place of 2-methoxyethanamine. C18H18ClFN6O2. 405.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H), 8.97 (s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.06 (dd, J = 6.7, 2.9 Hz, 1H), 6.94 (d, J = 6.3 Hz, 1H), 6.58 (dt, J = 8.9, 3.4 Hz, 1H), 4.04-3.86 (m, 3H), 3.41 (td, J = 11.7, 2.1 Hz, 2H), 1.87 (d, J = 12.5 Hz, 2H), 1.70 - 1.48 (m, 2H).
-
- A mixture of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (0.025 g, 0.047 mmol), 3-aminopropanamide hydrochloride (0.023 g, 0.188 mmol) and DIPEA (0.05 mL, 0.282 mmol) in DMSO (0.5 mL) stirred at 60 °C for 16 h. The mixture was cooled to rt, diluted with water, and extracted 3× with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated. The resulting residue was brought up in DCM (0.5 mL) and TFA (0.5 mL) and stirred for 16 h. The reaction solution was concentrated. The resulting residue was brought up in THF (0.5 mL) and water (0.5 mL) and sodium hydroxide (0.76 mL of a 2 N solution, 1.5 mmol). The resulting solution was stirred for 10 min, acidified with AcOH (0.10 mL, 1.8 mmol), and purified by preparative HPLC to give the desired product (0.009 g). C17H14ClF3N6O2. 427.0 (M+1).
-
- Example 230 was made analogously to Example 229 using N1-(2,2-difluoroethyl)ethane-1,2-diamine hydrochloride in place of 3-aminopropanamide hydrochloride. C17H17ClF3N7O. 428.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.28 (s, 1H), 8.91 (s, 1H), 7.95 (d, J = 6.1 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.97 (dd, J = 6.6, 2.7 Hz, 1H), 6.90 (d, J = 6.1 Hz, 1H), 6.56 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 6.53 - 6.21 (m, 1H), 3.8 - 3.3 (m, 5H) 3.26 (t, J = 5.9 Hz, 2H).
-
- Example 231 was made analogously to Example 212 using N 1-cyclopropyl-N 1-methylethane-1,2-diamine in place of 2-methoxyethanamine. C19H21ClFN7O. 418.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.27 (s, 1H), 8.92 (s, 1H), 7.95 (d, J = 6.0 Hz, 1H), 7.83 (s, 1H), 7.08 (t, J = 9.1 Hz, 1H), 6.97 (d, J = 6.4 Hz, 1H), 6.91 (d, J = 6.0 Hz, 1H), 6.55 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.76 (s, 3H), 2.90 (s, 3H), 1.02 - 0.66 (m, 5H).
-
- Example 232 was made analogously to Example 212 using N 1-cyclopropyl-N 1-(2-methoxyethyl)ethane-1,2-diamine in place of 2-methoxyethanamine. C21H25ClFN7O2. 462.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.32 (s, 1H), 8.93 (s, 1H), 7.96 (d, J = 6.1 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.02 - 6.89 (m, 2H), 6.56 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 3.76 (s, 4H), 3.65 (d, J = 5.1 Hz, 1H), 3.37 (s, 4H), 3.26 (s, 3H), 0.79 (s, 4H).
-
- Example 233 was made analogously to Example 212 using 22-(azetidin-1-yl)ethanamine in place of 2-methoxyethanamine. C18H19ClFN7O. 404.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.31 (s, 1H), 9.92 (s, 1H), 8.92 (s, 1H), 7.96 (d, J = 6.1 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 6.98 (dd, J = 6.6, 2.7 Hz, 1H), 6.93 (d, J = 6.1 Hz, 1H), 6.55 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 4.10 (d, J = 8.9 Hz, 4H), 3.38 (s, 4H), 2.32 (d, J = 6.7 Hz, 2H).
-
- Example 234 was made analogously to Example 212 using 3-methoxypropan-1-amine in place of 2-methoxyethanamine. C17H18ClFN6O2. 427.03 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.89 (s, 1H), 11.39 (s, 1H), 8.95 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.59 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.49 (q, J = 6.6 Hz, 2H), 3.41 (t, J = 6.0 Hz, 2H), 3.25 (s, 3H), 1.83 (p, J = 6.5 Hz, 2H).
-
- Example 235 was made analogously to Example 212 using 1-(2-aminoethyl)pyrrolidin-2-one in place of 2-methoxyethanamine. C19H19ClFN7O2. 432.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.99 (s, 1H), 11.43 (s, 1H), 8.97 (s, 1H), 7.98 (d, J = 6.3 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.8 Hz, 1H), 6.96 (d, J = 6.3 Hz, 1H), 6.58 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 3.59 (q, J = 6.0 Hz, 2H), 3.41 (dt, J = 14.1, 6.5 Hz, 4H), 2.17 (dd, J = 8.7, 7.5 Hz, 2H), 2.01 - 1.73 (m, 2H).
-
- Example 236 was made analogously to Example 212 using 2-(morpholinosulfonyl)ethanamine in place of 2-methoxyethanamine. C19H21ClFN7O4S. 498.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.45 (s, 1H), 8.96 (s, 1H), 7.97 (d, J = 6.4 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.4 Hz, 1H), 6.57 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.86 (q, J = 6.5 Hz, 2H), 3.68 - 3.58 (m, 4H), 3.43 (t, J = 6.7 Hz, 2H), 3.21 - 3.09 (m, 4H).
-
- Example 237 was made analogously to Example 212 using 2-(3-fluoropiperidin-1-yl)ethanamine TFA salt in place of 2-methoxyethanamine. C20H22ClF2N7O. 450.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.33 (s, 1H), 8.95 (s, 1H), 7.99 (d, J = 6.1 Hz, 1H), 7.11 (t, J = 9.1 Hz, 1H), 7.01 (dd, J = 6.5, 2.8 Hz, 1H), 6.94 (d, J = 6.1 Hz, 1H), 6.58 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 5.09 (d, J = 44.9 Hz, 1H), 3.88 - 3.73 (m, 2H), 3.43 (s, 2H), 3.35 (s, 2H), 3.11 (s, 2H), 2.03 - 1.66 (m, 4H).
-
- Example 238 was made analogously to Example 212 using 4-(3-bromo-4-fluorophenyl)-3-(2-chloro-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and 2-morpholinoethanamine in place of 3-(2-chloro-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-methoxyethanamine, respectively. C19H21BrFN7O2. 478.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.30 (s, 1H), 8.92 (s, 1H), 7.97 (d, J = 6.1 Hz, 1H), 7.12 (dd, J = 6.1, 2.7 Hz, 1H), 7.05 (t, J = 8.7 Hz, 1H), 6.92 (d, J = 6.1 Hz, 1H), 6.58 (ddd, J = 8.9, 4.1, 2.7 Hz, 1H), 3.80 (m, 6H), 3.33 (s, 6H).
-
- Example 239 was made analogously to Example 212 using N1-methyl-N1-(tetrahydro-2H-pyran-4-yl)ethane-1,2-diamine in place of 2-methoxyethanamine. C21H25ClFN7O2. 462.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.91 (s, 1H), 7.08 (t, J = 9.1 Hz, 1H), 6.95 (s, 1H), 6.90 (d, J = 6.0 Hz, 1H), 6.54 (dt, J = 9.0, 3.4 Hz, 1H), 3.94 (d, J = 11.8 Hz, 2H), 3.31 (d, J = 12.1 Hz, 3H), 2.82 (s, 3H), 1.87 (d, J = 13.4 Hz, 2H), 1.65 (dd, J = 12.0, 4.6 Hz, 2H).
-
- Example 240 was made analogously to Example 212 using N1-isopropyl-N1-methylethane-1,2-diamine in place of 2-methoxyethanamine. C19H23ClFN7O. 420.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.28 (s, 1H), 8.91 (s, 1H), 7.95 (d, J = 5.9 Hz, 1H), 7.84 (s, 1H), 7.08 (t, J = 9.0 Hz, 1H), 6.96 (s, 1H), 6.90 (d, J = 6.0 Hz, 1H), 6.54 (dt, J = 8.8, 3.5 Hz, 1H), 3.74 (s, 2H), 3.69 - 3.59 (m, 1H), 3.27 (s, 2H), 2.76 (s, 3H), 1.20 (d, J = 6.6 Hz, 6H).
-
- Example 241 was made analogously to Example 212 using tert-butyl (1-(aminomethyl)cyclopropyl)carbamate in place of 2-methoxyethanamine. C17H17ClFN7O. 390.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.92 (s, 1H), 8.34 (s, 3H), 7.95 (d, J = 6.1 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.98 (dd, J = 6.5, 2.7 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.56 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.68 (s, 2H), 0.92 (d, J = 5.5 Hz, 4H).
-
- Example 242 was made analogously to Example 212 using tert-butyl (1-(2-aminoethyl)cyclopropyl)carbamate in place of 2-methoxyethanamine. C18H19ClFN7O. 404.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.33 (s, 1H), 8.93 (s, 1H), 8.20 (s, 3H), 7.95 (d, J = 6.2 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 6.99 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.1 Hz, 1H), 6.61 - 6.50 (m, 1H), 3.57 (t, 2H), 1.89 (t, J = 7.0 Hz, 2H), 0.81 (d, J = 6.9 Hz, 2H), 0.69 (d, J = 5.9 Hz, 2H).
-
- tert-butyl (2-(2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)ethyl)carbamate. A mixture of tert-butyl (2-bromoethyl)carbamate (0.500 g, 3.688 mmol), 2-oxa-5-azabicyclo[4.1.0]heptane hydrochloride (0.826 g, 3.688 mmol) and DIPEA (1.285 mL, 7.375 mmol) in DMSO (4 mL) was stirred at 40 °C for 16 h. The mixture was diluted with sat NaHCO3 soln. The aqueous layer was extracted 3× with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified via silica gel chromatography to give the desired product (0.440 g). C12H22N2O3. 243.1 (M+1).
- 2-(2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)ethanamine hydrochloride. To a solution of tert-butyl (2-(2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)ethyl)carbamate (0.08 g, 0.33 mmol) in THF was added HCl (2.0 mL of a 4 M soln in dioxane, 8 mmol). The mixture stirred at rt for 16 h. The mixture was concentrated to give the desired product as the HCl salt (0.071 g). C7H16N2O. 143.1 (M+1).
- Example 243 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)ethanamine hydrochloride in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. C20H21ClFN7O2. 446.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.35 (s, 1H), 8.96 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.00 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.56 (dt, J = 9.0, 3.4 Hz, 1H), 3.80-3.63 (m, 4H), 3.53 (t, J = 11.5 Hz, 2H), 3.18 (s, 2H), 2.96 - 2.60 (m, 2H), 0.90 (d, J = 149.8 Hz, 2H).
-
-
-
- Example 244 was made analogously to Example 229 using 2-(7-oxa-4-azaspiro[2.5]octan-4-yl)ethanamine in place of 3-aminopropanamide hydrochloride. C21H23ClFN7O2. 460.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.96 (s, 1H), 7.97 (d, J = 6.1 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.98 (d, J = 6.0 Hz, 1H), 6.93 (d, J = 6.1 Hz, 1H), 6.56 (dt, J = 8.8, 3.7 Hz, 1H), 4.2-3.00 (m, 10H), 1.20 - 0.34 (m, 4H).
-
-
-
- Example 245 was made analogously to Example 229 using (R)-2-(3-fluoropyrrolidin-1-yl)ethanamine hydrochloride in place of 3-aminopropanamide hydrochloride. C19H20ClF2N7O. 436.2(M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.95 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.98 (dd, J = 6.3, 2.7 Hz, 1H), 6.92 (d, J = 6.1 Hz, 1H), 6.55 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 5.48 (d, J = 53.2 Hz, 1H), 3.90 - 3.35 (m, 8H), 2.43 - 2.09 (m, 2H).
-
-
-
- Example 246 was made analogously to Example 229 using (S)-2-(3-fluoropyrrolidin-1-yl)ethanamine hydrochloride in place of 3-aminopropanamide hydrochloride. C19H20ClF2N7O. 436.2 (M+1) 1H NMR (400 MHz, DMSO-d6) δ 11.35 (s, 1H), 8.95 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.99 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.55 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 5.48 (d, J = 53.1 Hz, 1H), 3.90 - 3.35 (m, 8H), 2.44 - 2.11 (m, 2H).
-
-
-
- Example 247 was made analogously to Example 229 using 2-(2-azabicyclo[4.1.0]heptan-2-yl)ethanamine hydrochloride in place of 3-aminopropanamide hydrochloride. C21H23ClFN7O. 444.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.96 (s, 1H), 8.08 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.99 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.2 Hz, 1H), 6.55 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.90 - 3.30 (m, 5H), 3.12 (s, 1H), 3.01 (s, 1H), 2.90 (d, J = 19.4 Hz, 1H), 1.98 (d, J = 10.9 Hz, 1H), 1.54 (s, 2H), 1.43 - 1.28 (m, 1H), 1.00 - 0.91 (m, 1H), 0.91 - 0.81 (m, 1H).
-
-
-
- Example 248 was made analogously to Example 229 using 2-(4-azaspiro[2.5]octan-4-yl)ethanamine hydrochloride in place of 3-aminopropanamide hydrochloride. C22H25ClFN7O. 458.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.31 (s, 1H), 8.95 (s, 1H), 7.97 (d, J = 6.0 Hz, 1H), 7.78 (s, 1H), 7.08 (t, J = 9.0 Hz, 1H), 6.96 (s, 1H), 6.92 (d, J = 6.0 Hz, 1H), 6.54 (dt, J = 9.0, 3.5 Hz, 1H), 3.8-3.3 (m, 8H), 1.80 (s, 2H), 1.65 (s, 2H), 1.04 (s, 2H), 0.76 (s, 2H).
-
-
-
- Example 249 was made analogously to Example 229 using 2-(3-fluoroazetidin-1-yl)ethanamine hydrochloride in place of 3-aminopropanamide hydrochloride. C18H18ClF2N7O. 422.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.95 (s, 1H), 11.34 (s, 1H), 8.94 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 6.98 (dd, J = 6.4, 2.7 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.55 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 5.45 - 5.30 (m, 1H), 4.52 (dd, J = 20.6, 12.4, 5.9 Hz, 2H), 4.33 (dd, J = 22.1, 12.2 Hz, 2H), 3.63 (s, 2H), 3.48 (s, 2H).
-
-
-
- Example 250 was made analogously to Example 229 using 2-(3,3-difluoroazetidin-1-yl)ethanamine hydrochloride in place of 3-aminopropanamide hydrochloride. C18H17ClF3N7O. 440.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.41 (s, 1H), 8.96 (s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.01 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.3 Hz, 1H), 6.56 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 4.09 (s, 4H), 3.54 (s, 2H), 3.07 (s, 2H).
-
-
-
- Example 251 was made analogously to Example 229 using 2-(4-azaspiro[2.4]heptan-4-yl)ethanamine hydrochloride in place of 3-aminopropanamide hydrochloride. C21H23ClFN7O. 444.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.33 (s, 1H), 8.95 (s, 1H), 7.97 (d, J = 6.1 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 6.98 (d, J = 6.4 Hz, 1H), 6.93 (d, J = 6.1 Hz, 1H), 6.55 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 3.65 -3.75 (m, 4H), 3.17 (t, J = 6.0 Hz, 2H), 2.17 - 1.92 (m, 4H), 1.22 (t, 2H), 0.84 (t, 2H).
-
-
-
- Example 252 was made analogously to Example 229 using 3-(3-fluoropiperidin-1-yl)propan-1-amine hydrochloride in place of 3-aminopropanamide hydrochloride. C21H24ClF2N7O.464.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.07 (s, 1H), 11.38 (s, 1H), 8.96 (s, 1H), 8.22 (d, J = 58.7 Hz, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.01 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.2 Hz, 1H), 6.56 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 5.08 (d, J = 45.5 Hz, 1H), 3.47 (d, J = 6.4 Hz, 1H), 3.35 (s, 3H), 3.12 (q, J = 7.4 Hz, 2H), 3.02 (s, 2H), 2.08 - 1.84 (m, 4H), 1.75 (d, J = 14.5 Hz, 2H).
-
- Example 253 was made analogously to Example 212 using N 1-phenylethane-1,2-diamine in place of 2-methoxyethanamine. C21H19ClFN7O. 440.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.96 (s, 1H), 7.95 (d, J = 6.3 Hz, 1H), 7.14 - 7.04 (m, 4H), 7.02 (dd, J = 6.5, 2.8 Hz, 1H), 6.90 (d, J = 6.3 Hz, 1H), 6.65 - 6.50 (m, 4H), 3.62 (d, J = 6.0 Hz, 2H), 3.28 (t, J = 6.3 Hz, 2H).
-
- Example 254 was made analogously to Example 212 using N 1-methyl-N 1-phenylethane-1,2-diamine in place of 2-methoxyethanamine. C22H21ClFN7O. 454.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.95 (s, 1H), 11.42 (s, 1H), 8.97 (s, 1H), 7.95 (d, J = 6.4 Hz, 1H), 7.19 - 7.12 (m, 2H), 7.09 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.3 Hz, 1H), 6.75 (d, J = 8.1 Hz, 2H), 6.61 (tt, J = 7.3, 1.0 Hz, 1H), 6.56 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.64 (M, 4H), 2.89 (s, 3H).
-
- Example 255 was made analogously to Example 212 using 3-(aminomethyl)tetrahydro-2H-thiopyran 1,1-dioxide in place of 2-methoxyethanamine. C19H20ClFN6O3S. 467.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.41 (s, 1H), 8.96 (s, 1H), 7.95 (d, J = 6.3 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.3 Hz, 1H), 6.57 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.06 (m, 2H), 3.00 - 2.87 (m, 1H), 2.31 (m, 2H), 2.06 (dd, J = 10.3, 3.9 Hz, 2H), 1.76 (d, J = 13.6 Hz, 2H), 1.24 (q, J = 12.4 Hz, 2H).
-
- Example 256 was made analogously to Example 212 using 2-methoxycyclopropanamine in place of 2-methoxyethanamine. C18H18ClFN6O2. 405.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.95 (s, 1H), 7.98 (d, J = 6.3 Hz, 1H), 7.07 (t, J = 9.1 Hz, 1H), 7.02 (d, J = 5.5 Hz, 1H), 6.94 (d, J = 6.2 Hz, 1H), 6.55 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 3.67 - 3.51 (m, 2H), 2.88 (s, 1H), 1.13 (t, J = 7.0 Hz, 3H), 1.11 - 1. 04 (m, 2H), 0.83 (s, 1H).
-
- Example 257 was made analogously to Example 212 using 4-(3-bromo-4-fluorophenyl)-3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and methylamine (2.0 M solution in tetrahydrofuran) in place of 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-methoxyethanamine, respectively. C14H12BrFN6O. 379.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.12 (s, 1H), 11.38 (s, 1H), 8.95 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.16 (dd, J = 6.1, 2.7 Hz, 1H), 7.04 (t, J = 8.8 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.58 (ddd, J = 8.9, 4.1, 2.7 Hz, 1H), 3.00 (d, J = 4.7 Hz, 3H).
-
- Example 258 was made analogously to Example 184 using hexamethyleneimine in place of dimethylamine. C21H24ClFN6O. 431.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.90 (s, 1H), 8.30 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 5.1 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.51 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.58 (t, J = 7.5 Hz, 2H), 3.45 - 3.22 (m, 6H), 1.90 - 1.74 (m, 4H), 1.69 - 1.57 (m, 4H).
-
- Example 259 was made analogously to Example 184 using azetidine hydrochloride and N,N-diisopropylethylamine in place of dimethylamine. C18H18ClFN6O. 389.1 (M+1).
-
- Example 260 was made analogously to Example 184 using (R)-pyrrolidin-3-ol in place of dimethylamine. C19H20ClFN6O2. 419.1 (M+1).
-
- Example 261 was made analogously to Example 184 using (S)-pyrrolidin-3-ol hydrochloride and N,N-diisopropylethylamine in place of dimethylamine. C19H20ClFN6O2. 419.1 (M+1).
-
- Example 262 was made analogously to Example 184 using 4-hydroxypiperidine in place of dimethylamine. C20H22ClFN6O2. 433.1 (M+1).
-
-
- N-(3-bromo-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using ethyl 2-(7-((3-bromo-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)acetate in place of ethyl 2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)acetate. C15H12BrFN4O2. 379.0, 381.0 (M+1).
- N-(3-bromo-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using N-(3-bromo-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17Hl17BrFN5O. 406.1, 408.1 (M+1).
- N-(3-bromo-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example XX was made analogously to Example 184 using N-(3-bromo-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17H18BrFN6O. 421.0, 423.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.86 (s, 1H), 8.27 (dd, J = 5.0, 0.5 Hz, 1H), 7.13 (d, J = 5.1 Hz, 1H), 7.07 (dd, J = 6.1, 2.7 Hz, 1H), 6.99 (t, J = 8.8 Hz, 1H), 6.53 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.38 - 3.18 (m, 4H), 2.69 (s, 6H).
-
-
- N-(3-chlorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using ethyl 2-(7-((3-chlorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)acetate in place of ethyl 2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)acetate. C15H13ClN4O2. 317.1 (M+1).
- N-(3-chlorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using N-(3-chlorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H -imidazo[4,5-b]pyridine-7-carboxamide. C17H18ClN5O. 344.3 (M+1).
- N-(3-chlorophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was made analogously to Example 184 using N-(3-chlorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17H19ClN6O. 359.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.49 (s, 1H), 11.10 (s, 1H), 8.86 (s, 1H), 8.22 (d, J = 5.2 Hz, 1H), 7.08 (d, J = 5.0 Hz, 1H), 6.97 (t, J = 8.0 Hz, 1H), 6.83 (t, J = 2.1 Hz, 1H), 6.77 (dd, J = 7.8, 1.9 Hz, 1H), 6.44 (dd, J = 8.1, 2.1 Hz, 1H), 2.93 (t, J = 7.3 Hz, 2H), 2.61 (t, J = 7.3 Hz, 2H), 2.16 (s, 6H).
-
-
- N-(3-bromophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using ethyl 2-(7-((3-bromophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)acetate in place of ethyl 2-(7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)acetate. C15H13BrN4O2. 361.0, 363.0 (M+1).
- N-(3-bromophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using N-(3-bromophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17H18BrN5O. 388.2, 390.2 (M+1).
- N-(3-bromophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. Example 266 was made analogously to Example 184 using N-(3-bromophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C17H19BrN6O. 403.0, 405.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.85 (s, 1H), 8.23 (dd, J = 5.1, 0.5 Hz, 1H), 7.09 (d, J = 5.1 Hz, 1H), 7.00 - 6.97 (m, 1H), 6.93 - 6.87 (m, 2H), 6.50 - 6.45 (m, 1H), 2.95 (t, J = 7.3 Hz, 2H), 2.69 - 2.62 (m, 2H), 2.19 (s, 6H).
-
- N-(2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl)-N-(2,4-dimethoxybenzyl)methanesulfonamide. A solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (15 mg, 0.029 mmol) and pyridine (0.046 mL, 0.57 mmol) in dichloromethane (1.0 mL) was cooled in an ice bath with stirring and treated with methanesulfonyl chloride (0.022 mL, 0.29 mmol). The reaction mixture was then allowed to warm to room temperature. After 35 min, another portion of methanesulfonyl chloride (0.022 mL, 0.29 mmol) was added, followed 15 min later by further treatment with pyridine (0.023 mL, 0.29 mmol). After another 15 min, the reaction appeared to have stalled (based on LCMS analysis), with added reagents having no effect, so N,N-diisopropylethylamine (0.10 mL, 0.57 mmol) was added, resulting in complete conversion within 15 min. The reaction mixture was concentrated under reduced pressure, and loaded directly onto a silica gel cartridge for purification by flash chromatography (0-20% methanol/dichloromethane) to afford the desired product (20 mg) C27H26ClFN6O8S2. 681.0 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methylsulfonamido)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. A solution of N-(2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl)-N-(2,4-dimethoxybenzyl)methanesulfonamide (20 mg, 0.029 mmol) and triethylsilane (0.023 mL, 0.15 mmol) in dichloromethane (1 mL) was treated with trifluoroacetic acid (1 mL), and the reaction mixture was stirred overnight at room temperature. The mixture was then concentrated under reduced pressure and taken up in tetrahydrofuran (0.75 mL) and water (0.75 mL), and treated with a 2M aqueous solution of sodium hydroxide (0.75 mL, 1.5 mmol). After 15 min of stirring at room temperature, the reaction mixture was acidified with acetic acid, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide the desired product (7 mg). C16H16ClFN6O3S. 427.0 (M+1).
-
- A suspension of 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (15 mg, 0.029 mmol) and sulfamide (27 mg, 0.29 mmol) in pyridine (1 mL) was stirred at 120 °C for 20 min. The mixture was then cooled to room temperature and concentrated under reduced pressure. The resulting residue was suspended in dichloromethane (0.5 mL) and treated with triethylsilane (0.022 mL, 0.14 mmol) followed by trifluoroacetic acid (0.5 mL). After stirring at room temperature for 1 h, the reaction mixture was concentrated under reduced pressure and taken up in tetrahydrofuran (0.75 mL) and water (0.75 mL), and treated with a 2M aqueous solution of sodium hydroxide (0.75 mL, 1.5 mmol). After 15 min, another portion of 2M sodium hydroxide (1 mL, 2 mmol) was added, and the reaction was stirred for an additional 15 min. The mixture was then acidified with acetic acid, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide the desired product (7 mg). C15H15ClFN7O3S. 428.0 (M+1).
-
- N-(3-chlorophenyl)-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using N-(3-chlorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and pyrrolidine in place of dimethylamine. C19H20ClN5O. 370.1 (M+1).
- N-(3-chlorophenyl)-N'-hydroxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was made analogously to Example using N-(3-chlorophenyl)-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C19H21ClN6O. 385.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.90 (s, 1H), 8.26 (dd, J = 5.1, 0.6 Hz, 1H), 7.11 (d, J = 5.0 Hz, 1H), 6.98 (t, J = 8.0 Hz, 1H), 6.84 - 6.76 (m, 2H), 6.46 (dd, J = 8.1, 2.1 Hz, 1H), 3.50 - 2.84 (m, 8H), 1.87 (s, 4H).
-
- N-(3-bromophenyl)-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using N-(3-bromophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and pyrrolidine in place of dimethylamine. C19H20BrN5O. 414.1, 416.1 (M+1).
- N-(3-bromophenyl)-N'-hydroxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. To a suspension of N-(3-bromophenyl)-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (54 mg, 0.13 mmol) in 1,2-dichloroethane (1.0 mL) and phosphorus oxychloride (1.0 mL) was added phosphorus pentachloride (33 mg, 0.16 mmol). The mixture was stirred at 90 °C for 1 h. Another portion of phosphorus pentachloride (33 mg, 0.16 mmol) was then added, and stirring resumed for an additional 45 min at 90 °C. A third portion of phosphorus pentachloride (33 mg, 0.16 mmol) was then added, and stirring resumed for an additional 1h at 90 °C. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure. The resulting residue was treated with hydroxylamine (50 wt. % in water, 1.0 mL, 16 mmol) in ethanol (1.0 mL) with vigorous stirring. The mixture was stirred for 15 min, then diluted with saturated aqueous sodium chloride and dichloromethane/isopropanol (2:1). The layers were then separated, and the organic phase was concentrated under reduced pressure. The resulting crude residue was suspended in 30% methanol in dichloromethane, filtered to remove salts, and loaded directly onto a silica gel cartridge for purification by flash chromatography (0-50% methanol/dichloromethane). Product-containing fractions were pooled and concentrated under reduced pressure, then taken up in 5% methanol in dichloromethane and filtered through celite to remove silica gel that may have eluted from the column with the material. The filtrate was concentrated under reduced pressure, coevaporated with methanol (3x) to remove residual dichloromethane, dissolved in methanol/water, frozen, and lyophilized to afford the product as an off-white solid (30 mg). C19H21BrN6O. 429.1, 431.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.90 (s, 1H), 8.27 (d, J = 5.1 Hz, 1H), 7.15 - 7.09 (m, 1H), 7.01 - 6.96 (m, 1H), 6.95 - 6.88 (m, 2H), 6.51 - 6.47 (m, 1H), 3.71 - 2.85 (m, 8H), 1.89 (s, 4H).
-
- A solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (15 mg, 0.029 mmol) and 4-(dimethylamino)pyridine (1 flake) in dichloromethane (1 mL) was treated with acetic anhydride (0.027 mL, 0.29 mmol) and stirred at room temperature for 10 min. The reaction mixture was then concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane (0.5 mL) and treated with triethylsilane (0.022 mL, 0.14 mmol) followed by trifluoroacetic acid (0.5 mL). The reaction solution was stirred at room temperature overnight, then concentrated under reduced pressure, taken up in tetrahydrofuran (1 mL) and water (1 mL), and treated with a 2M aqueous solution of sodium hydroxide (1 mL, 2 mmol). After stirring for 15 min, the mixture was acidified with acetic acid, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide the desired product (9 mg). C17H16ClFN6O2. 391.1 (M+1).
-
- N-(3-chlorophenyl)-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using N-(3-chlorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and piperidine in place of dimethylamine. C20H22ClN5O. 384.3 (M+1).
- N-(3-chlorophenyl)-N'-hydroxy-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was made analogously to Example 184 using N-(3-chlorophenyl)-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C20H23ClN6O. 399.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.91 (s, 1H), 8.27 (dd, J = 5.0, 0.7 Hz, 1H), 7.11 (d, J = 5.0 Hz, 1H), 6.98 (t, J = 8.0 Hz, 1H), 6.84 - 6.76 (m, 2H), 6.46 (dd, J = 8.2, 2.1 Hz, 1H), 3.67 - 2.70 (m, 8H), 1.73 (s, 4H), 1.53 (s, 2H).
-
- N-(3-bromophenyl)-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide was made analogously to Example 184 using N-(3-bromophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and piperidine in place of dimethylamine. C20H22BrN5O. 428.3, 430.3 (M+1).
- N-(3-bromophenyl)-N'-hydroxy-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was made analogously to Example 184 using N-(3-bromophenyl)-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C20H23BrN6O. 443.1, 445.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.90 (s, 1H), 8.27 (dd, J = 5.1, 0.8 Hz, 1H), 7.12 (d, J = 4.5 Hz, 1H), 6.98 - 6.96 (m, 1H), 6.95 - 6.89 (m, 2H), 6.52 - 6.47 (m, 1H), 3.63 - 2.72 (m, 8H), 1.88 - 1.35 (m, 6H).
-
- A solution of 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one (30 mg, 0.057 mmol) and N,N-diisopropylethylamine (0.20 mL, 1.2 mmol) in dichloromethane (1 mL) was treated with methyl chloroformate (0.044 mL, 0.57 mmol) dropwise and with stirring. After 1 h, another portion of methyl chloroformate (0.044 mL, 0.57 mmol) was added, and the reaction mixture was stirred for an additional 5 min. The mixture was the concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane (0.5 mL) and treated with triethylsilane (0.046 mL, 0.29 mmol) followed by trifluoroacetic acid (0.5 mL). The reaction solution was stirred at room temperature overnight, then concentrated under reduced pressure, taken up in tetrahydrofuran (0.75 mL) and water (0.75 mL), and treated with a 2M aqueous solution of sodium hydroxide (1.5 mL, 3 mmol). After stirring for 5 min, the mixture was acidified with acetic acid, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide the desired product. C17H16ClFN6O3. 407.1 (M+1).
-
- 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one. A solution of 2-(7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-2-yl)ethyl methanesulfonate (60 mg, 0.11 mmol) in acetonitrile (2.2 mL) was treated with 2,4-dimethoxybenzylamine (0.34 mL, 2.2 mmol). The resulting solution was stirred for 2.5 h at room temperature. The reaction mixture was then concentrated under reduced pressure, and the resulting residue was taken up in dichloromethane (1 mL) and treated with trifluoroacetic acid (1 mL). The solution was stirred overnight at room temperature, then concentrated under reduced pressure. The crude material was dissolved in dichloromethane and washed with saturated aqueous potassium carbonate. The aqueous layer was extracted twice with dichloromethane, and the combined organic layers were loaded onto a silica gel cartridge for purification by flash chromatography (0-20% methanol/dichloromethane) to provide the desired product. C25H22ClFN6O4. 525.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was made analogously to Example 177 using 4-(3-chloro-4-fluorophenyl)-3-(2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-1H-imidazo[4,5-b]295yridine-7-yl)-1,2,4-oxadiazol-5(4H)-one in place of 4-(3-chloro-4-fluorophenyl)-3-(2-(hydroxymethyl)-1H-imidazo[4,5-b]295yridine-7-yl)-1,2,4-oxadiazol-5(4H)-one. C24H24ClFN6O3. 499.2 (M+1).
-
- Example 275 was made analogously to Example 184 using 4-benzylpiperidine in place of dimethylamine. C27H28ClFN6O. 507.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.91 (s, 1H), 8.29 (d, J = 5.1 Hz, 1H), 7.34 - 7.25 (m, 2H), 7.24 - 7.12 (m, 4H), 7.03 (t, J = 9.1 Hz, 1H), 6.92 (dd, J = 6.4, 2.7 Hz, 1H), 6.55 - 6.46 (m, 1H), 3.51 (s, 4H), 3.29 (t, J = 7.4 Hz, 2H), 2.96 (s, 2H), 2.62 - 2.48 (m, 2H), 1.78 (d, J = 14.5 Hz, 3H), 1.41 (s, 2H).
-
- Example 276 was made analogously to Example 184 using 3-azabicyclo[3.3.1]nonane hydrochloride and N,N-diisopropylethylamine in place of dimethylamine. C23H26ClFN6O. 457.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.93 (s, 1H), 8.32 (dd, J = 5.0, 3.2 Hz, 1H), 7.14 (dd, J = 5.0, 3.0 Hz, 1H), 7.05 (td, J = 9.1, 3.0 Hz, 1H), 6.93 - 6.88 (m, 1H), 6.50 (ddd, J = 8.7, 6.2, 2.6 Hz, 1H), 3.69 (d, J = 12.4 Hz, 2H), 3.54 - 3.47 (m, 2H), 3.41 - 3.34 (m, 2H), 3.25 (d, J = 12.3 Hz, 2H), 2.14 (s, 3H), 1.89 - 1.57 (m, 7H).
-
- Example 277 was made analogously to Example 184 using 3-azabicyclo[3.2.1]octane hydrochloride and N,N-diisopropylethylamine in place of dimethylamine. C22H24ClFN6O. 443.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.92 (s, 1H), 8.31 (d, J = 5.1 Hz, 1H), 7.15 (d, J = 5.1 Hz, 1H), 7.05 (t, J = 9.0 Hz, 1H), 6.92 (dd, J = 6.5, 2.6 Hz, 1H), 6.53 - 6.46 (m, 1H), 3.50 (t, J = 6.9 Hz, 2H), 3.42 (d, J = 11.7 Hz, 2H), 3.30 (t, J = 7.2 Hz, 2H), 3.08 (d, J = 11.6 Hz, 2H), 2.40 (s, 2H), 1.80 (s, 4H), 1.70 (d, J = 11.2 Hz, 1H), 1.49 (d, J = 10.0 Hz, 1H).
-
- Example 278 was made analogously to Example 212 using 1-methylpiperidin-3-amine in place of 2-methoxyethanamine. C19H21ClFN7O. 418.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 9.79 (s, 1H), 8.95 (s, 1H), 7.98 (d, J = 5.1 Hz, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.05 - 6.90 (m, 2H), 6.61 - 6.55 (m, 1H), 4.18 - 4.01 (m, 1H), 2.97 - 2.72 (m, 6H), 2.11 - 1.62 (m, 4H), 1.57 - 1.41 (m, 1H).
-
- A solution of 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (25 mg, 0.050 mmol) in DMSO (0.5 mL) was treated with (S)-1-(2-aminoethyl)pyrrolidin-3-ol (13 mg, 0.10 mmol). The solution was stirred at 60 °C overnight, then cooled to room temperature, diluted with ethyl acetate, and washed with saturated aqueous sodium chloride (3 x). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane (0.5 mL) and treated with trifluoroacetic acid (0.5 mL). The solution was stirred at room temperature for 1 h, then concentrated under reduced pressure, taken up in tetrahydrofuran (0.5 mL) and water (0.5 mL) and treated with 2M aqueous sodium hydroxide (0.99 mL, 2.0 mmol). After stirring for 10 min, the mixture was acidified with acetic acid, diluted with dimethyl sulfoxide, and purified by reverse phase preparative HPLC to provide (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide (10 mg) and (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(3-hydroxypyrrolidin-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide (4 mg).
- (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. C19H21ClFN7O2. 434.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.40 (s, 1H), 8.99 (s, 1H), 7.99 (d, J = 6.2 Hz, 1H), 7.15 - 7.07 (m, 1H), 7.04 - 6.98 (m, 1H), 6.98 - 6.93 (m, 1H), 6.61 - 6.54 (m, 1H), 4.45 (s, 1H), 4.16 - 2.91 (m, 8H), 2.14 (s, 1H), 1.94 - 1.82 (m, 1H).
- (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(3-hydroxypyrrolidin-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. C17H16ClFN6O2. 391.1 (M+1). 1H NMR (400 MHz, DMSO-d 6) δ 11.38 (s, 1H), 9.03 (s, 1H), 8.02 - 7.94 (m, 1H), 7.11 - 7.03 (m, 2H), 6.91 (d, J = 6.0 Hz, 1H), 6.60 - 6.53 (m, 1H), 4.46 (s, 1H), 3.79 - 3.50 (m, 4H), 2.14 - 2.02 (m, 1H), 1.98 (s, 1H).
-
- Example 281 was made analogously to Example 212 using 1-(2-methoxyethyl)pyrrolidin-3-amine in place of 2-methoxyethanamine. C20H23ClFN7O2. 448.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.32 (s, 1H), 9.98 (s, 1H), 8.95 (s, 1H), 7.99 (d, J = 4.3 Hz, 1H), 7.09 (t, J = 9.1 Hz, 1H), 7.04 - 6.92 (d, J = 17.3 Hz, 3H), 6.57 (ddd, J = 8.3, 5.8, 2.4 Hz, 1H), 4.70 - 4.49 (m, 2H), 4.00 - 3.09 (m, 10H), 2.08 (s, 1H), 1.97 (s, 1H).
-
- Example 282 was made analogously to Example 212 using (4-methylmorpholin-3-yl)methanamine in place of 2-methoxyethanamine. C19H21ClFN7O2. 434.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.40 (s, 1H), 8.97 (s, 1H), 7.99 (d, J = 6.3 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.01 (dd, J = 6.6, 2.6 Hz, 1H), 6.96 (d, J = 6.2 Hz, 1H), 6.57 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 4.12 - 3.75 (m, 6H), 3.28 - 3.14 (m, 3H), 3.01 (s, 3H).
-
- Example 283 was made analogously to Example 212 using 2-(pyrrolidin-1-yl)ethan-1-amine in place of 2-methoxyethanamine. C19H21ClFN7O. 418.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.35 (s, 1H), 8.97 (s, 1H), 7.98 (d, J = 6.2 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.03 - 6.98 (m, 1H), 6.94 (d, J = 6.1 Hz, 1H), 6.57 (ddd, J = 9.1, 4.1, 2.8 Hz, 1H), 3.82 - 3.35 (m, 8H), 1.94 (s, 4H).
-
- Example 284 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one, 2H-pyran-4-methanamine, tetrahydro-4-[(methylsulfonyl)methyl]- hydrochloride, and N,N-diisopropylethylamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate (bis-TFA salt, white solid). C21H24ClFN6O4S. 511.4 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.45 (s, 1H), 8.96 (s, 1H), 7.95 (d, J = 6.4 Hz, 1H), 7.12 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.4 Hz, 1H), 6.60 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 3.85 (d, J = 6.6 Hz, 4H), 3.81 - 3.45 (m, 4H), 3.10 (s, 3H), 1.77 - 1.65 (m, 2H), 1.61 (dd, J = 8.5, 4.6 Hz, 2H). 19F NMR (377 MHz, DMSO-d6 ) δ -74.67 (6F), -126.62 (1F).
-
- Example 285 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one, (2-methylsulfonylphenyl)methanamine hydrochloride, and N,N-diisopropylethylamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate (bis-TFA salt, white solid). C21H18ClFN6O3S. 489.4 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.88 (br s, 1H), 11.43 (s, 1H), 8.95 (s, 1H), 8.31 (br s, 1H), 8.03 - 7.91 (m, 2H), 7.75 - 7.67 (m, 1H), 7.66 - 7.56 (m, 2H), 7.09 (t, J = 9.0 Hz, 1H), 7.03 (d, J = 6.3 Hz, 1H), 6.93 (d, J = 6.3 Hz, 1H), 6.59 (dt, J = 8.9, 3.5 Hz, 1H), 5.06 (d, J = 6.2 Hz, 2H), 3.39 (s, 3H). 19F NMR (376 MHz, DMSO-d6 ) δ -74.4 (6F), -126.6 (1F).
-
- Example 286 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 1-(3-aminopiperidin-1-yl)ethanone in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively (bis-TFA salt, off-white solid). C20H21ClFN7O2. 446.4 (M+1). 1H NMR (400 MHz, DMSO-d6 ) δ 11.46 (s, 1H), 8.98 (s, 1H), 8.17 (br s, 1H), 7.98 (t, J = 6.6 Hz, 1H), 7.11 (td, J = 9.0, 4.1 Hz, 1H), 7.04 (td, J = 6.7, 2.6 Hz, 1H), 6.92 (dd, J = 8.6, 6.3 Hz, 1H), 6.66 - 6.51 (m, 1H), 4.06 - 3.70 (m, 3H), 3.30 - 3.20 (m, 3H), 2.01 (d, J = 27.2 Hz, 3H), 1.98 - 1.95 (m, 1H) 1.80 - 1.60 (m, 2H), 1.59 - 1.41 (m, 1H). 19F NMR (376 MHz, DMSO-d6 ) δ -74.53 (6F), -126.59 (1F).
-
-
- N-(3-chloro-4-fluorophenyl)-4-fluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxamide was prepared analogously to Example 45, using methyl 4-fluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxylate. C16H12ClF2N3O2. 352.0 (M+1).
- 4-(3-chloro-4-fluorophenyl)-3-(4-fluoro-2-(methoxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one was prepared analogously to Example 45, using N-(3-chloro-4-fluorophenyl)-4-fluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazole-7-carboxamide. C17H11ClF2N4O3. 393.0 (M+1).
- 3-(2-(bromomethyl)-4-fluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one was prepared analogously to Example 45, using 4-(3-chloro-4-fluorophenyl)-3-(4-fluoro-2-(methoxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one in place of 4-(3-chloro-4-fluorophenyl)-3-(4,5-difluoro-2-(methoxymethyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one. C16H8BrClF2N4O2. 440.9/442.9 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-((ethylamino)methyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide. Example 287 was prepared analogously to Example 45 using 3-(2-(bromomethyl)-4-fluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and ethylamine (2 M in THF) in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C17H16ClF2N5O. 360.1 (M+1).
-
- Example 288 was prepared analogously to Example 45 using 3-(2-(bromomethyl)-4-fluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and dimethylamine (2 M in THF) in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C17H16ClF2N5O. 380.0 (M+1).
-
- Example 289 was prepared analogously to Example 45 using 3-(2-(bromomethyl)-4-fluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and isopropylamine in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C18H18ClF2N5O. 394.1 (M+1).
-
- Example 290 was prepared analogously to Example 45 using 3-(2-(bromomethyl)-4-fluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and methylamine (2 M in THF) in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C16H14ClF2N5O. 366.0 (M+1).
-
- Example 291 was prepared analogously to Example 45 using 3-(2-(bromomethyl)-4-fluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and ammonia (0.5 M in dioxane) in place of 3-(2-(bromomethyl)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-methoxypropylamine, respectively. C15H12ClF2N5O. 352.0 (M+1).
-
- Example 292 was prepared analogously to Example 333 using 1-amino-2-methylpropan-2-ol in place of tert-butyl (2-aminoethyl)carbamate. C18H17ClF3N5O2. 428.1 (M+1).
-
- Example 293 was prepared analogously to Example 333 using 1-aminopropan-2-ol in place of tert-butyl (2-aminoethyl)carbamate. C17H15ClF3N5O2. 414.1 (M+1).
-
- Example 294 was prepared analogously to Example 333 using 2-aminoacetamide in place of tert-butyl (2-aminoethyl)carbamate. C16H12ClF3N6O2. 413.3 (M+1).
-
- Example 295 was prepared analogously to Example 333 using 2-aminoethan-1-ol in place of tert-butyl (2-aminoethyl)carbamate. C16H13ClF3N5O2. 400.1 (M+1).
-
- Example 296 was prepared analogously to Example 333 using 3-aminocyclobutanol in place of tert-butyl (2-aminoethyl)carbamate. C18H15ClF3N5O2. 426.3 (M+1).
-
- Example 297 was prepared analogously to Example 333 using N-(3-aminopropyl)pyridine-2-amine in place of tert-butyl (2-aminoethyl)carbamate. C22H19ClF3N7O. 490.3 (M+1).
-
- Example 298 was prepared analogously to Example 333 using 2-aminoethanesulfonamide in place of tert-butyl (2-aminoethyl)carbamate. C16H14ClF3N6O3S. 463.1 (M+1).
-
- Example 299 was prepared analogously to Example 333 using (1-methyl-1H-pyrazol-5-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. C19H15ClF3N7O. 450.1 (M+1).
-
- Example 300 was prepared analogously to Example 333 using 2-(1H-pyrazol-1-yl)ethan-1-amine in place of tert-butyl (2-aminoethyl)carbamate. C19H15ClF3N7O. 450.1 (M+1).
-
- Example 301 was prepared analogously to Example 333 using glycine dimethylamide in place of tert-butyl (2-aminoethyl)carbamate. C18H16ClF3N6O2. 441.1 (M+1).
-
- 4,5-difluoro-2-(2-hydroxy-2-methylpropyl)-1H-benzo[d]imidazole-7-carboxylic acid. A mixture of 3-hydroxy-3-methylbutyric acid (1.6 mL, 15.1 mmol) and methyl 2,3-diamino-4,5-difluorobenzoate (1.529 g, 7.56 mmol) in HCl (7.5 mL of a 6 M aqueous soln) stirred at 120 °C in a sealed tube for 16 h. The mixture was cooled to rt and concentrated to remove HCl. The remaining solution was frozen and lyophilized to give the crude desired product. C12H12F2N2O3. 271.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-hydroxy-2-methylpropyl)-1H-benzo[d]imidazole-7-carboxamide was prepared analogously to Example 80 using 4,5-difluoro-2-(2-hydroxy-2-methylpropyl)-1H-benzo[d]imidazole-7-carboxylic acid and 3-chloro-4-fluoroaniline in place of 1Himidazo[4,5-b]pyridine-7-carboxylic acid and 3-bromoaniline, respectively. C18H15ClF3N3O2. 420.1 (M+23).
- 2-(2-((tert-butyldimethylsilyl)oxy)-2-methylpropyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. To a solution of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(2-hydroxy-2-methylpropyl)-1H-benzo[d]imidazole-7-carboxamide (0.145 g, 0.365 mmol) and 2,6-lutidine (0.34 mL, 2.9 mmol) in DCM (7 mL) at 0 °C was added tert-butyldimethylsilyl trifluoromethanesulfonate (0.17 mL, 0.740 mmol). The mixture warmed to rt and stirred 48 h. 2,6-Lutidine (0.34 mL, 2.9 mmol) and tert-butyldimethylsilyl trifluoromethanesulfonate (0.34 mL, 1.48 mmol) were added. After 4 h, 2,6-lutidine (0.34 mL, 2.9 mmol) and tert-butyldimethylsilyl trifluoromethanesulfonate (0.34 mL, 1.48 mmol) were added and the mixture stirred 4 h. The mixture was concentrated onto silica gel and purified via silica gel chromatography to give the desired product. C24H29ClF3N3O2Si. 512.2 (M+1).
- 2-(2-((tert-butyldimethylsilyl)oxy)-2-methylpropyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carbothioamide was prepared analogously to Example 13, using 2-(2-((tert-butyldimethylsilyl)oxy)-2-methylpropyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of 2-amino-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. C24H29ClF3N3OSSi. 528.3 (M+1).
- 2-(2-((tert-butyldimethylsilyl)oxy)-2-methylpropyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was prepared analogously to Example 13, using 2-(2-((tert-butyldimethylsilyl)oxy)-2-methylpropyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carbothioamide in place of 2-amino-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carbothioamide. C24H30ClF3N4O2Si. 527.3 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(2-hydroxy-2-methylpropyl)-1H-benzo[d]imidazole-7-carboximidamide. To a soln of 2-(2-((tert-butyldimethylsilyl)oxy)-2-methylpropyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide (0.007 g, 0.013 mmol) in THF (1 mL) at 0 °C was added HF·pyridine (0.02 mL, 0.664 mmol). Mixture warmed to rt and stirred 16 h. HF·pyridine (0.04 mL, 1.32 mmol) was added and mixture stirred an additional 24 h. The mixture was diluted with EtOAc and washed with sat NaHCO3 soln. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine and concentrated. The residue was purified by silica gel chromatography to give the desired product (0.001 g). C18H16ClF3N4O2. 413.1 (M+H).
-
- Example 303 was prepared analogously to Example 333 using 4-dimethylaminobutan-1-amine in place of tert-butyl (2-aminoethyl)carbamate. C20H22ClF3N6O. 455.2 (M+H).
-
- Example 304 was prepared analogously to Example 333 using 1-Boc-3-(aminomethyl)piperidine in place of tert-butyl (2-aminoethyl)carbamate. C20H20ClF3N6O. 453.2 (M+H).
-
- 2-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylic acid. A suspension of 2,3-diaminoisonicotinic acid hydrochloride (200 mg, 0.106 mmol) and 2-(1-methylpiperidin-2-yl)acetic acid (498 mg, 0.317 mmol) in sulfuric acid (1.5 mL) was stirred at room temperature for 5 min and, then, was sealed in a vial and stirred at 160 °C for 3 hours. Once the mixture had cooled, water (2 mL) was added and the solution was purified by preparative HPLC to give the desired product. C14H18N4O2. 275.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. A solution of 2-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylic acid (75 mg, 0.273 mmol), 4-fluoro-3-chloroaniline (60 mg, 0.410 mmol), bis(2-oxo-3-oxazolidinyl)phosphinic chloride (139 mg, 0.547 mmol) and N,N-diisopropylethylamine (0.240 ml, 1.37 mmol) in dichloromethane (1.5 mL) was stirred for 3 hours. The reaction mixture was concentrated and purified by preparative HPLC. The resulting lyophilized material was mixed with saturated aqueous sodium bicarbonate (5 mL), filtered, washed with water and dried on high vacuum to give the desired product. C20H21ClFN5O. 402.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. To a mixture ofN-(3-chloro-4-fluorophenyl)-2-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (11 mg, 0.027 mmol) and potassium carbonate (26 mg, 0.192 mmol) in dichloromethane (0.5 ml) was added phosphorous pentachloride (11 mg, 0.055 mmol). The reaction mixture stirred for 2 hours and was concentrated. The residue was brought up in ethanol (0.5 ml) and hydroxylamine (0.07 mL, 50% in water, 1.08 mmol) and stirred for 1 hour. The reaction mixture was concentrated and purified by preparative HPLC to give the desired product. C20H22ClFN6O. 417.1 (M+1).
-
- Example 306 was prepared analogously to Example 333 using 4-(3-bromophenyl)-3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and 2-morpholinoethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C19H22BrN7O2. 460.2/462.1 (M+H). 1H NMR (400 MHz, DMSO-d6) δ 11.35 (s, 1H), 8.94 (s, 1H), 7.98 (d, J = 6.1 Hz, 1H), 7.09 - 6.95 (m, 3H), 6.93 (d, J = 5.9 Hz, 1H), 6.61 - 6.50 (m, 1H), 3.95 - 3.20 (m, 12H).
-
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxamide. To a solution of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide (1.92 g, 5.89 mmol) and TEA (3.3 mL, 23.6 mmol) in DCM (60 mL) was added SEMCl (2.6 mL, 14.7 mmol). After 45 min, TEA (1.1 mL, 7.9 mmol) and SEMCl (0.9 mL, 4.9 mmol) were added. After 20 min, the mixture was diluted with EtOAc, concentrated onto silica gel, and purified via silica gel chromatography to give the desired product. C20H21ClF3N3O2Si. 456.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-5-fluoro-4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxamide. A mixture of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxamide (0.250 g, 0.548 mmol) and sodium methoxide (0.50 mL of a 25% soln in MeOH, 2.19 mmol) in MeOH (1 mL) was stirred at 65 °C for 8 h. Mixture was cooled to rt and diluted with sat. NH4Cl soln. The aqueous layer was extracted 3 × with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated to give the desired product. C21H24ClF2N3O3Si. 468.3 (M+1).
- N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-4-methoxy-1H-benzo[d]imidazole-7-carboximidamide was prepared analogously to Example 305 using N-(3-chloro-4-fluorophenyl)-5-fluoro-4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. C15H11ClF2N4O2. 353.1 (M+H).
-
- Example 308 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-picolylamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C19H15ClFN7O. 412.2 (M+H). 1H NMR (400 MHz, DMSO-d6) δ 11.48 (s, 1H), 8.99 (s, 1H), 8.59 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.98 (d, J = 6.4 Hz, 1H), 7.84 (td, J = 7.7, 1.8 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.36 (ddd, J = 7.4, 5.0, 1.1 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.05 (dd, J = 6.5, 2.7 Hz, 1H), 6.95 (d, J = 6.3 Hz, 1H), 6.60 (ddd, J = 9.0, 3.9, 3.0 Hz, 1H), 4.80 (d, J = 5.7 Hz, 2H).
-
- Example 309 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(1H-pyrazol-1-yl)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C18H16ClFN8O. 415.2 (M+H).
-
- Example 310 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (1-methyl-1H-pyrazol-3-yl)methanamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C18H16ClFN8O. 415.2 (M+H).
-
- Example 311 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 4,4,4-trifluorobutylamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C17H15ClF4N6O. 431.1 (M+H).
-
- Example 312 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3,3,3-trifluoropropylamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C16H13ClF4N6O. 417.1 (M+H). 1H NMR (400 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.98 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.3, 2.4 Hz, 1H), 6.94 (d, J = 6.3 Hz, 1H), 6.58 (ddd, J = 9.0, 4.0, 3.0 Hz, 1H), 3.78 - 3.63 (m, 2H), 2.76 - 2.56 (m, 2H).
-
- Example 313 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(2-methoxyethoxy)ethanamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C18H20ClN6O3. 423.2 (M+H).
-
- 2-(3-(cyclopropyl(methyl)amino)propyl)isoindoline-1,3-dione. A solution of 2-(3-bromopropyl)isoindoline-1,3-dione (1.89 g, 7.03 mmol), cyclopropylmethylamine (0.59 mL, 7.03 mmol), and potassium carbonate (1.94 g, 14 mmol) in dimethylformamide (7 mL) was stirred at 40 °C for 6 hr. Water was added and the aqueous layer was washed three times with diethyl ether. The combined organic layers were washed with brine and dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography to give the desired product (1.8 g). C15H18N2O2. 259.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-((3-(cyclopropyl(methyl)amino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide. A solution of 2-(3-(cyclopropyl(methyl)amino)propyl)isoindoline-1,3-dione (63 mg, 0.24 mmol) and hydrazine (0.006 mL, 0.2 mmol) in ethanol (1 mL) was stirred at 80 °C for one hour. The reaction was cooled to room temperature, filtered and concentrated. To the resulting residue was added 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (24 mg, 0.024 mmol), and dimethylsulfoxide (0.25 mL). The resulting solution was stirred at 65 °C for one hour. The reaction mixture was cooled and diluted with ethyl acetate and washed three times with saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, filtered and concentrated. The resulting residue was brought up in dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) and stirred for 3 hours. The reaction solution was concentrated. The resulting residue was brought up in tetrahydrofuran (0.2 mL) and methanol (0.2 mL) and to this solution was added 2 N sodium hydroxide (0.24 mL, 0.48 mmol). The resulting solution was stirred for 30 min and concentrated and purified by preparative HPLC to give the desired product (9 mg). C20H23ClFN7O. 432.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.95 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.00 (d, J = 5.6 Hz, 1H), 6.92 (d, J = 6.1 Hz, 1H), 6.61 - 6.53 (m, 1H), 3.54 - 3.42 (m, 2H), 3.30 - 3.19 (m, 3H), 2.92 - 2.77 (m, 5H), 2.05 - 1.92 (m, 3H), 0.96 - 0.78 (m, 6H).
-
-
- N-(3-chloro-4-fluorophenyl)-2-((3-(cyclopropylamino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was prepared analogously to Example 314 using 2-(3-(cyclopropylamino)propyl)isoindoline-1,3-dione in place of 2-(3-(cyclopropyl(methyl)amino)propyl)isoindoline-1,3-dione. C19H21ClFN7O. 418.2 (M+H).
-
-
- N-(3-chloro-4-fluorophenyl)-2-((3-(cyclopropyl(ethyl)amino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was prepared analogously to Example 314 using 2-(3-(cyclopropyl(ethyl)amino)propyl)isoindoline-1,3-dione in place of 2-(3-(cyclopropyl(methyl)amino)propyl)isoindoline-1,3-dione. C21H25ClFN7O. 446.2 (M+H). 1H NMR (400 MHz, DMSO-d6) δ 11.33 (s, 1H), 8.96 (s, 1H), 7.97 (d, J = 6.1 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.05 - 6.98 (m, 1H), 6.97 - 6.89 (m, 1H), 6.58 (dt, J = 8.9, 3.5 Hz, 1H), 3.51 (s, 2H), 3.35 - 3.18 (m, 4H), 2.94 - 2.73 (m, 1H), 2.15 - 1.92 (m, 2H), 1.26 (t, J = 7.3 Hz, 3H), 1.02 - 0.78 (m, 4H).
-
- Example 317 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(4-fluoropiperidin-1-yl)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C20H22ClF2N7O. 450.2 (M+H). 1H NMR (400 MHz, DMSO-d6) δ 11.30 (s, 1H), 8.94 (s, 1H), 7.98 (d, J = 5.6 Hz, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.99 (d, J = 5.7 Hz, 1H), 6.96 - 6.85 (m, 1H), 6.64 - 6.45 (m, 1H), 5.10-4.80 (m, 1H), 3.86 - 3.70 (m, 2H), 3.50 - 3.20 (m, 6H), 2.23 - 1.93 (m, 4H).
-
- Example 318 was prepared analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(2,2,2-trifluoroethoxy)ethan-1-amine hydrochloride in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. C17H15ClF4N6O2. 447.1 (M+H).
-
- Example 319 was prepared analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-(2,2,2-trifluoroethoxy)propan-1-amine hydrochloride in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. C18H17ClF4N6O2. 461.2 (M+H). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.94 (s, 1H), 7.94 (d, J = 6.2 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.01 (dd, J = 6.5, 2.3 Hz, 1H), 6.89 (d, J = 6.3 Hz, 1H), 6.56 (ddd, J = 8.9, 3.9, 2.8 Hz, 2H), 4.04 (q, J = 9.5 Hz, 2H), 3.65 (t, J = 6.1 Hz, 2H), 3.52 - 3.42 (m, 2H), 1.85 (p, J = 6.9 Hz, 2H).
-
- tert-Butyl (2-(3-methoxypiperidin-1-yl)ethyl)carbamate. A mixture of tert-butyl (2-bromoethyl)carbamate (0.147 g, 0.656 mmol), 3-methoxypiperidine hydrochloride (0.099 g, 0.656 mmol) and DIPEA (0.25 mL, 1.44 mmol) in DMSO (1.5 mL) was stirred at 40 °C for 16 h. The mixture was diluted with sat NaHCO3 soln. The aqueous layer was extracted 3 × with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified via silica gel chromatography to give the desired product (0.047 g). C13H26N2O3. 259.2 (M+1).
- 2-(3-Methoxypiperidin-1-yl)ethan-1-amine. To a solution of tert-butyl (2-(3-methoxypiperidin-1-yl)ethyl)carbamate (0.047 g, 0.182 mmol) in THF was added HCl (2.3 mL of a 4 M soln in dioxane, 9.1 mmol). The mixture stirred at rt for 16 h. The mixture was concentrated to give the desired product as the HCl salt (0.042 g). C8H18N2O. 159.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(3-methoxypiperidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was prepared analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(3-methoxypiperidin-1-yl)ethan-1-amine hydrochloride in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. C21H25ClFN7O2. 462.2 (M+H). 1H NMR (400 MHz, DMSO-d 6) δ 11.30 (s, 1H), 8.93 (s, 1H), 7.97 (d, J = 5.6 Hz, 0H), 7.09 (t, J = 9.1 Hz, 1H), 7.03 - 6.75 (m, 2H), 6.55 (ddd, J = 9.0, 3.9, 2.7 Hz, 1H), 3.88 - 3.02 (m, 14H), 2.00 - 1.54 (m, 2H).
-
- Example 321 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-(difluoromethoxy)propan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C17H16ClF3N6O2. 429.1 (M+H). 1H NMR (400 MHz, DMSO-d 6) δ 11.38 (s, 1H), 8.94 (s, 1H), 7.94 (d, J = 6.2 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.05 - 6.96 (m, 1H), 6.93 - 6.80 (m, 1H), 6.66 (t, J = 76.1 Hz, 1H), 6.56 (ddd, J = 8.8, 4.2, 2.8 Hz, 1H), 3.90 (t, J = 6.2 Hz, 2H), 3.55 - 3.45 (m, 2H), 1.96 - 1.83 (m, 2H).
-
- Example 322 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (R)-(-)-tetrahydrofurfurylamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C18H18ClFN6O2. 405.2 (M+1).
-
- Example 323 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (S)-(+)-tetrahydrofurfurylamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C18H18ClFN6O2. 405.2 (M+H). 1H NMR (400 MHz, DMSO-d 6) δ 11.45 (s, 1H), 8.97 (s, 1H), 7.98 (d, J = 6.3 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.8 Hz, 1H), 6.93 (d, J = 6.3 Hz, 1H), 6.60 (ddd, J = 8.9, 4.0, 3.0 Hz, 1H), 4.09 - 3.98 (m, 1H), 3.80 (dt, J = 8.2, 6.7 Hz, 1H), 3.68 (dt, J = 8.1, 6.8 Hz, 1H), 3.63 - 3.52 (m, 1H), 3.51 - 3.38 (m, 1H), 2.03 - 1.76 (m, 3H), 1.66 - 1.49 (m, 1H).
-
- Example 324 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(oxolan-2-yl)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)carbamate, respectively. C19H20ClFN6O2. 419.2 (M+H). 1H NMR (400 MHz, DMSO-d 6) δ 11.38 (s, 1H), 8.96 (s, 1H), 7.95 (d, J = 6.1 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.5, 2.7 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.58 (ddd, J = 9.0, 4.1, 3.0 Hz, 1H), 3.89 - 3.75 (m, 2H), 3.62 (td, J = 7.9, 6.4 Hz, 1H), 3.54 - 3.47 (m, 2H), 2.03 - 1.67 (m, 5H), 1.52 - 1.37 (m, 1H).
-
- 2-(piperidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboxylic acid. A suspension of 2,3-diaminoisonicotinic acid hydrochloride (200 mg, 0.106 mmol) and 2-(piperidin-2-yl)acetic acid (453 mg, 0.317 mmol) in sulfuric acid (1.5 mL) was stirred at room temperature for 5 min and, then, was sealed in a vial and stirred at 160 °C for 3 hours. Once the mixture had cooled, water (2 mL) was added and the solution was purified by preparative HPLC to give the desired product. C13H16N4O2. 261.1 (M+1).
- 2-((1-(tert-butoxycarbonyl)piperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylic acid. A solution of 2-(piperidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboxylic acid (205 mg, 0.788 mmol), di-tert-butyl dicarbonate (189 mg, 0.866 mmol), and triethylamine (0.440 ml, 3.15 mmol) in dichloromethane (8 mL) was stirred for 3 hr and concentrated to give the desired product. C18H24N4O4. 361.1 (M+1).
- tert-butyl 2-((7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl)piperidine-1-carboxylate. A solution of 2-((1-(tert-butoxycarbonyl)piperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxylic acid (283 mg, 0.785 mmol), 4-fluoro-3-chloroaniline (171 mg, 1.18 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (388 mg, 1.02 mmol) and N,N-diisopropylethylamine (0.684 ml, 3.93 mmol) in dimethylformamide (1.5 mL) was stirred for 3 hours. The reaction mixture was concentrated and purified by preparative HPLC. The resulting lyophilized material was mixed with saturated aqueous sodium bicarbonate (5 mL), filtered, washed with water and dried on high vacuum to give the desired product. C24H27ClFN5O3. 488.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(piperidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide. To a mixture of tert-butyl 2-((7-((3-chloro-4-fluorophenyl)carbamoyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl)piperidine-1-carboxylate (100 mg, 0.205 mmol) and potassium carbonate (198 mg, 1.43 mmol) in dichloromethane (2 ml) was added phosphorous pentachloride (85 mg, 0.409 mmol). The reaction mixture stirred for 2 hours and was concentrated. The residue was brought up in ethanol (2 ml) and hydroxylamine (0.50 mL, 50% in water, 8 mmol) and stirred for 1 hour. The reaction mixture was concentrated and purified by preparative HPLC to give the desired product. C19H20ClFN6O. 403.1 (M+1).
-
- Example 326 was prepared analogously to Example 305 using 3-(dimethylamino)-2-methylpropanoic acid in place of 2-(1-methylpiperidin-2-yl)acetic acid. C18H20ClFN6O. 391.1 (M+1).
-
- Example 327 was prepared analogously to Example 325 using 3-(methylamino)butanoic acid in place of 2-(piperidin-2-yl)acetic acid. C17H18ClFN6O. 377.1 (M+1).
-
- Example 328 was prepared analogously to Example 305 using 3-(dimethylamino)butanoic acid in place of 2-(1-methylpiperidin-2-yl)acetic acid. C18H20ClFN6O. 391.1 (M+1).
-
- Example 329 was prepared analogously to Example 325 using 2-(pyrrolidin-2-yl)acetic acid in place of 2-(piperidin-2-yl)acetic acid. C18H18ClFN6O. 389.1 (M+1).
-
- Example 330 was prepared analogously to Example 39 using 2-(pyrrolidin-1-yl)ethanamine in place of N,N-dimethylpropane-1,3-diamine and 3-chloroaniline in place of 3-chloro-4-fluoroaniline. C20H21ClF2N6O. 435.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.02 - 10.85 (m, 1H), 10.79 (s, 1H), 9.83 - 9.63 (m, 1H), 8.68 (s, 1H), 7.03 (t, J = 8.0 Hz, 1H), 6.89 - 6.73 (m, 2H), 6.55 - 6.44 (m, 1H), 3.74 - 3.60 (m, 2H), 3.44 - 3.32 (m, 2H), 2.05 - 1.83 (m, 4H).
-
- Example 331 was prepared analogously to Example 39 using 2-(pyrrolidin-1-yl)ethanamine in place of N,N-dimethylpropane-1,3-diamine and 3-bromoaniline in place of 3-chloro-4-fluoroaniline. C20H21BrF2N6O. 479.1 (M+1). NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 9.83 - 9.67 (m, 1H), 8.67 (s, 1H), 7.01 - 6.73 (m, 6H), 6.52 (dt, J = 7.7, 1.8 Hz, 1H), 3.71 - 3.59 (m, 2H), 3.42 - 3.32 (m, 2H), 1.93 (s, 4H).
-
- Example 332 was prepared analogously to Example 39 using 2-(pyrrolidin-1-yl)ethanamine in place of N,N-dimethylpropane-1,3-diamine and 3-bromo-4-fluoroaniline in place of N,N-dimethylpropane-1,3-diamine. C20H20BrF3N6O. 497.1 (M+1).
-
- Methyl 6,7-difluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate. A solution of methyl 2,3-diamino-4,5-difluorobenzoate (10 g, 50 mmol) and carbonyldiimidazole (12 g, 75 mmol) in THF (100 mL) was stirred overnight. Diethyl ether was added to the reaction mixture and the precipitate was filtered and dried on high vacuum to give the desired product. C9H6F2N2O3. 229.5 (M+1).
- Methyl 2-chloro-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate. A mixture of methyl 6,7-difluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate (9.98 g, 43.7 mmol) in phosphoryl chloride (80 mL) was stirred overnight at 120 °C. The solution was cooled and concentrated. To the solid residue cooled in an ice bath was cautiously added a saturated aqueous sodium bicarbonate solution. The slurry was filtered and the filtrate was washed with water and dried on high vacuum to give the desired product. C9H5ClF2N2O2. 247.2 (M+1).
- 2-chloro-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. To a solution of the 3-chloro-4-fluoroaniline (4.43 g, 30 mmol) in dichloroethane (50 mL) at 0 °C was added a solution of trimethylaluminum (30.4 mL, 2 M in heptane, 61 mmol) dropwise over 5 min. The ice bath was removed and the mixture stirred for 30 minutes. The solution was cooled back down with and ice bath and methyl 2-chloro-4,5-difluoro-1H-benzo[d]imidazole-7-carboxylate (5 g, 20 mmol) was added to this solution as a solid. The reaction stirred at 60 °C for 6 hours. The reaction was cooled in an ice bath and to this cooled mixture was added 10% citric acid (30 mL). To this solution was added 2N sodium hydroxide and the aqueous layer was washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the desired product. C14H6Cl2F3N3O. 360.5 (M+1).
- 3-(2-chloro-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. A mixture of 2-chloro-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide (6.56 g, 18.2 mmol) and potassium carbonate (17.6 g, 127 mmol) in dichloromethane (100 mL) was stirred together for 5 min. To this mixture was added phosphorus pentachloride (7.58 g, 36 mmol) and the mixture stirred for two hours. More phosphorus penetachloride was added (7.58 g, 36 mmol) and the mixture stirred for another three hours. The reaction mixture was concentrated and placed in an ice bath. To the cooled residue was added a solution of hydroxyamine (44.5 mL, 50% in water, 728 mmol) and ethanol (100 mL) over 20 min. The ice bath was removed and the reaction stirred for 30 min. The reaction mixture was concentrated and brought up in water and washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated to about 50 ml. To this solution was added carbonyldiimidazole (5.9 g, 36 mmol). The reaction solution stirred for 30 min and was diluted with ethyl acetate and washed twice with 1 N hydrochloric acid and once with saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, filtered, and concentrated to give the desired product. C15H5Cl2F3N4O2. 401.0 (M+1).
- 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. To a solution of 3-(2-chloro-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (7.3 g, 18 mmol) and triethylamine (15 mL, 109 mmol) in dichloromethane (200 mL) was added (2-(chloromethoxy)ethyl)trimethylsilanel (8 mL, 46 mmol). Reaction was stirred for 2 hr, and was adsorbed onto silica gel and purified by silica gel chromatography to give the desired product. C21H19C12F3N4O3Si. 554.9 (M+23).
- 3-(2-((2-aminoethyl)amino)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. A solution of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (390 mg, 0.734 mmol), and tert-butyl (2-aminoethyl)carbamate (141 mg, 0.881 mmol) in dimethylsulfoxide (3.5 mL) was stirred at 65 °C overnight. The reaction mixture was cooled and diluted with ethyl acetate and washed three times with saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, filtered and concentrated. The resulting residue was brought up in dichloromethane (3 mL) and trifluoroacetic acid (3 mL) and stirred for 3 hours. The reaction solution was concentrated and brought up in saturated aqueous sodium bicarbonate and washed three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the desired product (312 mg). C17H12ClF3N6O2. 425.2 (M+1).
- 2-((2-aminoethyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide. A solution of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (29 mg, 0.056 mmol), and tert-butyl (2-aminoethyl)carbamate (44 mg, 0.27 mmol) in dimethylsulfoxide (0.2 mL) was stirred at 65 °C overnight. The reaction mixture was cooled and diluted with ethyl acetate and washed three times with saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, filtered and concentrated. The resulting residue was brought up in dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) and stirred for 3 hours. The reaction solution was concentrated. The resulting residue was brought up in tetrahydrofuran (0.2 mL) and methanol (0.2 mL) and to this solution was added 2 N sodium hydroxide (0.27 mL, 0.54 mmol). The resulting solution was stirred for 30 min and concentrated and purified by preparative HPLC to give the desired product. C16H14ClF3N6O. 399.1 (M+1).
-
- To a solution of 3-(2-((2-aminoethyl)amino)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (29 mg, 0.068 mmol) and triethylamine (0.048 mL, 0.34 mmol) in tetrahydrofuran (0.5 mL) was added acetyl chloride (0.007 mL, 0.10 mmol). The resulting solution stirred for one hour and was concentrated. The resulting residue was brought up in tetrahydrofuran (0.4 mL) and methanol (0.4 mL) and to this solution was added 2 N sodium hydroxide (0.34 mL, 0.68 mmol). The resulting solution was stirred for one hour, concentrated and purified by preparative HPLC to give the desired product (11 mg). C18H16ClF3N6O2. 441.1 (M+1).
-
- Example 335 was prepared analogously to Example 334 using methanesulfonyl chloride in place of acetyl chloride. C17H16ClF3N6O3S. 477.1 (M+1).
-
- Example 336 was prepared analogously to Example 334 using cyclopropylsulfonyl chloride in place of acetyl chloride. C19H18ClF3N6O3S. 503.1 (M+1).
-
- Example 337 was prepared analogously to Example 334 using methyl chloroformate in place of acetyl chloride. C18H16ClF3N6O3. 457.1 (M+1).
-
- A solution of 3-(2-((2-aminoethyl)amino)-4,5-difluoro-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (33 mg, 0.078 mmol) and sulfamide (75 mg, 0.78 mmol) was stirred at 110 °C for 20 min and was concentrated. The resulting residue was brought up in tetrahydrofuran (0.4 mL) and methanol (0.4 mL) and to this solution was added 2 N sodium hydroxide (0.38 mL, 0.76 mmol). The resulting solution was stirred for one hour, concentrated and purified by preparative HPLC to give the desired product. C16H15ClF3N7O3S. 478.1 (M+1).
-
- Example 339 was prepared analogously to Example 334 using benzenesulfonyl chloride in place of acetyl chloride. C22H18ClF3N6O3S. 539.1 (M+1).
-
- Example 340 was prepared analogously to Example 333 using 3-aminopropanenitrile in place of tert-butyl (2-aminoethyl)carbamate. C17H12ClF3N6O. 409.4 (M+1).
-
- Example 341 was prepared analogously to Example 334 using ethyl isocyanate in place of acetyl chloride. C19H19ClF3N7O2. 470.0 (M+1).
-
- Example 342 was prepared analogously to Example 333 using 2-picolylamine in place of tert-butyl (2-aminoethyl)carbamate. C20H14ClF3N6O. 447.2 (M+1).
-
- Example 343 was prepared analogously to Example 333 using 2-picolylamine in place of tert-butyl (2-aminoethyl)carbamate. C20H14ClF3N6O. 447.3 (M+1).
-
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((pyridin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide. Example 344 was prepared analogously to Example 333 using 2-(1-methyl-1H-imidazol-2-yl)ethanamine in place of tert-butyl (2-aminoethyl)carbamate. C20H17ClF3N7O. 464.3 (M+1).
-
- Example 345 was prepared analogously to Example 333 using (1H-imidazol-2-yl)methanamine dihydrochloride and diisopropylethylamine in place of tert-butyl (2-aminoethyl)carbamate. C18H13ClF3N7O. 436.3 (M+1). Unreacted 2-((2-aminoethyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide through this sequence gave Example 346 (2-chloro-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide). C14H7Cl2F3N4O. 375.1 (M+1).
-
- Example 347 was prepared analogously to Example 333 using 2-(aminomethyl)aniline in place of tert-butyl (2-aminoethyl)carbamate. C21H16ClF3N6O. 461.1 (M+1).
-
- Example 348 was prepared analogously to Example 333 using 2-(aminomethyl)-N,N-dimethylaniline in place of tert-butyl (2-aminoethyl)carbamate. C23H20ClF3N6O. 489.2 (M+1).
-
- Example 349 was prepared analogously to Example 333 using (1-methyl-1H-imidazol-2-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. C19H15ClF3N7O. 450.1 (M+1).
-
- Example 350 was prepared analogously to Example 333 using pyrimidin-2-ylmethanamine hydrochloride and diisopropylethylamine in place of tert-butyl (2-aminoethyl)carbamate. C19H13ClF3N7O. 448.1 (M+1).
-
- Example 351 was prepared analogously to Example 333 using N1,N1,2,2-tetramethylpropane-1,3-diamine in place of tert-butyl (2-aminoethyl)carbamate. C21H24ClF3N6O. 469.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 8.71 (s, 1H), 7.08 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.89 - 6.80 (m, 1H), 6.52 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.33 (s, 2H), 2.98 (s, 2H), 2.85 (s, 6H), 1.03 (s, 6H).
-
- Example 352 was prepared analogously to Example 333 using N1,N1,2-trimethylpropane-1,3-diamine in place of tert-butyl (2-aminoethyl)carbamate. C20H22ClF3N6O. 455.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 8.74 (s, 1H), 7.07 (t, J = 9.1 Hz, 1H), 6.97 - 6.80 (m, 2H), 6.52 (dt, J = 8.2, 3.5 Hz, 1H), 3.38 - 3.25 (m, 2H), 3.02 - 2.61 (m, 8H), 2.31 - 2.16 (m, 1H), 1.01 - 0.89 (m, 3H).
-
- Example 353 was prepared analogously to Example 333 using N3,N3-dimethylbutane-1,3-diamine in place of tert-butyl (2-aminoethyl)carbamate. C20H22ClF3N6O. 455.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H), 8.71 (s, 1H), 7.07 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.6, 2.7 Hz, 1H), 6.89 - 6.79 (m, 1H), 6.52 (dt, J = 9.0, 3.4 Hz, 1H), 3.49 - 3.28 (m, 3H), 2.69 (d, J = 4.4 Hz, 6H), 2.01 (d, J = 11.7 Hz, 1H), 1.71 (dt, J = 14.1, 7.5 Hz, 1H), 1.22 (d, J = 6.5 Hz, 3H).
-
- Example 354 was prepared analogously to Example 333 using 2-(1-methylpyrrolidin-2-yl)ethanamine in place of tert-butyl (2-aminoethyl)carbamate. C21H22ClF3N6O. 467.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 9.55 (s, 1H), 8.70 (s, 1H), 7.07 (t, J = 9.1 Hz, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.89 - 6.81 (m, 1H), 6.51 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.62 - 3.47 (m, 1H), 3.47 - 3.32 (m, 2H), 3.32 - 3.18 (m, 1H), 3.11 - 2.98 (m, 1H), 2.81 (d, J = 4.6 Hz, 3H), 2.34 - 2.09 (m, 2H), 2.05 - 1.69 (m, 3H), 1.68 - 1.57 (m, 1H).
-
- Example 355 was prepared analogously to Example 333 using 2-(1-methylpiperidin-2-yl)ethanamine in place of tert-butyl (2-aminoethyl)carbamate. C22H24ClF3N6O. 481.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.75 (s, 1H), 9.13 (s, 1h), 8.67 (s, 1H), 7.07 (t, J = 8.9 Hz, 1H), 6.93 - 6.88 (m, 1H), 6.80-6.74 (m, 1H), 6.55 - 6.49 (m, 1H), 2.85 - 2.81 (m, 2H), 2.80-2.75, (m, 2H), 2.56-2.6 (m, 1H), 2.52 (s, 3H), 1.83 - 1.35 (m, 8H).
-
- Example 356 was prepared analogously to Example 333 using (4-methylmorpholin-2-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. C20H20ClF3N6O2. 469.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 9.89 (s, 1H), 8.67 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.8 Hz, 1H), 6.81 (dd, J = 12.3, 6.9 Hz, 1H), 6.53 (ddd, J = 8.9, 4.1, 2.7 Hz, 1H), 4.07 (d, J = 12.7 Hz, 1H), 3.96 - 3.83 (m, 1H), 3.66 (t, J = 12.4 Hz, 1H), 3.59 - 3.32 (m, 4H), 3.10 - 2.95 (m, 1H), 2.90 - 2.80 (m, 4H).
-
- Example 357 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (4-methylmorpholin-2-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. C19H21ClFN7O2. 434.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 1H), 10.18 (s, 1H), 8.93 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 6.99 (dd, J = 6.5, 2.8 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.58 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.07 (d, J = 12.8 Hz, 1H), 3.90 (s, 1H), 3.73 - 3.34 (m, 5H), 3.08 - 2.94 (m, 1H), 2.92 - 2.77 (m, 4H).
-
- Example 358 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (1-methyl-1H-pyrazol-5-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. C18H16ClFN8O. 415.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.45 (s, 1H), 8.98 (s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.32 (d, J = 1.9 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.4 Hz, 1H), 6.61 - 6.53 (m, 1H), 6.18 (d, J = 1.9 Hz, 1H), 4.71 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H).
-
- Example 359 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (4-methylmorpholin-2-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. C17H17ClFN7O2. 406.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H), 8.95 (s, 1H), 7.98 (d, J = 6.2 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.58 (ddd, J = 8.9, 3.9, 2.7 Hz, 1H), 4.30 (d, J = 4.9 Hz, 2H), 2.98 (s, 3H), 2.89 (s, 3H).
-
- Examples 360 and 361 were prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and oxetan-3-ylmethanamine in place of tert-butyl (2-aminoethyl)carbamate. C17H16ClFN6O2. 391.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.73 (s, 1H), 11.22 (s, 1H), 8.92 (s, 1H), 8.09 (s, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.03 (d, J = 5.4 Hz, 1H), 6.99 (dd, J = 6.4, 2.7 Hz, 1H), 6.53 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.98 (s, 1H), 4.23 (dd, J = 12.4, 4.9 Hz, 1H), 3.78 (dd, J = 12.3, 8.6 Hz, 1H), 3.35 - 3.23 (m, 1H). C17H16ClFN6O2. 391.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.16 (s, 1H), 9.44-9.28 (m, 1H), 9.09 (s, 1H), 7.97-7.85 (m, 1H), 7.09 (dd, J = 6.5, 2.7 Hz, 1H), 7.04 (t, J = 9.0 Hz, 1H), 6.83 (s, 1H), 6.59 (dt, J = 8.9, 3.6 Hz, 1H), 4.26 (dd, J = 12.3, 4.8 Hz, 1H), 3.91 - 3.81 (m, 1H), 3.25 (t, J = 10.9 Hz, 1H).
-
- Example 362 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(1-methyl-1H-imidazol-2-yl)ethanamine in place of tert-butyl (2-aminoethyl)carbamate. C19H18ClFN8O.429.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.96 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 6.99 (dd, J = 6.5, 2.7 Hz, 1H), 6.94 (d, J = 6.2 Hz, 1H), 6.60 - 6.50 (m, 1H), 3.83 - 3.68 (m, 5H), 3.31 - 3.21 (m, 2H).
-
- Example 363 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and N1-(pyridin-2-yl)propane-1,3-diamine in place of tert-butyl (2-aminoethyl)carbamate. C21H20ClFN8O.455.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.95 (s, 1H), 7.95 (d, J = 6.2 Hz, 1H), 7.92 (d, J = 6.2 Hz, 1H), 7.85 - 7.74 (m, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.01 (dd, J = 6.5, 2.7 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.84 - 6.72 (m, 1H), 6.56 (dt, J = 9.0, 4.0, 3.0 Hz, 1H), 3.56 - 3.44 (m, 2H), 3.42 - 3.31 (m, 2H), 1.96 - 1.83 (m, 2H).
-
- Example 364 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and isopentylamine in place of tert-butyl (2-aminoethyl)carbamate. C18H20ClFN6O. 391.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.41 (s, 1H), 8.95 (s, 1H), 7.95 (d, J = 6.3 Hz, 1H), 7.09 (t, J = 8.9 Hz, 1H), 7.03 (dd, J = 6.6, 2.7 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.62 - 6.53 (m, 1H), 3.27 (d, J = 6.3 Hz, 2H), 0.92 (s, 9H).
-
- Example 365 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and isobutylamine in place of tert-butyl (2-aminoethyl)carbamate. C17H18ClFN6O. 377.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 1H), 8.95 (s, 1H), 7.95 (d, J = 6.2 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.6, 2.7 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.61 - 6.51 (m, 1H), 3.29 - 3.18 (m, 2H), 1.95 - 1.78 (m, 1H), 0.90 (d, J = 6.7 Hz, 6H).
-
- Example 366 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (tetrahydro-2H-pyran-2-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. C19H20ClFN6O2. 419.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H), 8.95 (s, 1H), 7.95 (d, J = 6.4 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.90 (d, J = 6.3 Hz, 1H), 6.62 - 6.54 (m, 1H), 3.91 (d, J = 11.2 Hz, 1H), 3.57 - 3.43 (m, 2H), 3.44 - 3.30 (m, 2H), 1.84 - 1.71 (m, 1H), 1.58 (d, J = 12.7 Hz, 1H), 1.54 - 1.38 (m, 3H), 1.30 - 1.14 (m, 1H).
-
- Example 367 was prepared analogously to Example 333 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (tetrahydrofuran-3-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. C18H18ClFN6O2. 405.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 1H), 8.96 (s, 1H), 7.95 (d, J = 6.3 Hz, 1H), 7.08 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.5, 2.7 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.59 - 6.53 (m, 1H), 3.75 (td, J = 8.1, 5.6 Hz, 1H), 3.68 (dd, J = 8.6, 7.0 Hz, 1H), 3.62 (td, J = 8.0, 6.7 Hz, 1H), 3.47 (dd, J = 8.7, 5.1 Hz, 1H), 3.43 - 3.36 (m, 2H), 2.00 - 1.90 (m, 1H), 1.58 (dq, J = 12.8, 6.4, 6.3 Hz, 1H).
-
- Methyl 2,3-diamino-4-fluorobenzoate (0.150 g, 0.814 mmol) was dissolved in THF (4.0 mL) and 4-(2-isothiocyanatoethyl)morpholine (5.0 mmol) and triethylamine (7.0 mmol) was added. The reaction was sealed in a vial and heated to 66 °C for 12 hours. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (5.0 mmol) was added in one portion and the reaction was allowed to heat an additional 1 hour at 66 °C. The reaction was cooled to rt and quenched with saturated sodium bicarbonate solution (4 mL). The reaction mixture was extracted with EtOAc (3 x 3 mL) and the combined organic layers were washed once with water, concentrated, and purified by silica gel column chromatography (0-15% MeOH/CH2Cl2, Rf= 0.33 in 10% MeOH/ CH2Cl2) to give methyl 4-fluoro-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboxylate.
- Methyl 4-fluoro-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboxylate (0.208g, 0.645 mmol) and 3-chloro-4-fluoroaniline (3.0 mmol) were dissolved in DCE (6.0 mL) under inert conditions. Trimethylaluminium (5.0 mmol, 2.26 mL) was added at 0 C and the reaction was then heated to 60 C overnight. The reaction was allowed to cool to rt, quenched with water (3 mL) and extracted with EtOAc (4 x 3 mL). The combined organic layers were washed once with water, concentrated, and purified by silica gel chromatography (Rf= 0.37 10% MeOH/DCM) to give the desired product.
- N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was made analogously to Example 10 using the procedure for hydroxyamidine formation. C20H21ClF2N6O2. 451.8 (M+1).
-
- 1H-imidazo[4,5-b]pyridine-7-carboxylic acid (0.20 g, 1.22 mmol) and 3-chloro-4-fluoro-N-methylaniline hydrochloride (1.02 mmol) were dissolved in DMF (3.0 mL) and HATU (1.2 mmol) and DIPEA (2.78 mmol) were added and the reaction was allowed to stir overnight at rt. The reaction was quenched with sat/ sodium bicarbonate solution (3.0 mL) and the reaction was extracted with EtOAc (3 2 mL). Combined organic layers were washed with water (1x 4 mL) and the crude was purified by silica gel chromatography (Rf=0.25 50% EtOAc/hex) to give N-(3-chloro-4-fluorophenyl)-N-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide.
- N-(3-chloro-4-fluorophenyl)-N-methyl-1H-imidazo[4,5-b]pyridine-7-carboxamide (0.05g, 0.164 mmol) was dissolved in toluene (3.0 mL) and Lawesson's reagent (0.656 mmol) was added. The reaction was sealed in a vial and heated overnight at 100 C. The reaction was then cooled to rt and solids were removed by vacuum filtration. The filtrate was concentrated and purified by silica gel chromatography to give N-(3-chloro-4-fluorophenyl)-N-methyl-1H-imidazo[4,5-b]pyridine-7-carbothioamide.
- N-(3-chloro-4-fluorophenyl)-N-methyl-1H-imidazo[4,5-b]pyridine-7-carbothioamide (0.014 g, 0.0455 mmol) was dissolved in ethanol (3.0 mL) and hydroxylamine (50% solution in water) (0.455 mmol) was added and the reaction was allowed to stir at rt overnight. The reaction was concentrated to dryness then purified by RP HPLC to give N-(3-chloro-4-fluorophenyl)-N'-hydroxy-N-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide (3.1 mg, 21%). C14H11ClFN5O. 320.7 (M+1).
-
- 2,3-diamino-5-fluorobenzoic acid (5.0 g, 29 mmol) was dissolved in sulfuric acid (5.0 mL) and MeOH (40.0 mL) and heated to 71 C overnight. The reaction was allowed to cool to rt then concentrated to approximately half the volume. The reaction was neutralized to pH=7 with saturated sodium carbonate solution then extracted with EtOAc (5 x 20 mL). Combined organic layers were washed once with water and concentrated to dryness to give methyl 2,3-diamino-5-fluorobenzoate.
- Methyl 2,3-diamino-5-fluorobenzoate (2.0 g, 11.0 mmol) and cyanogen bromide (11.0 mmol) were dissolved in methanol (45 mL) and water (20 mL) and heated to 70 C for 30 mins. The reaction was cooled to rt and diluted with water (5 mL) and EtOAc (20 mL). The water layer was separated and neutralized to pH=7 with saturated sodium carbonate solution then extracted with EtOAc (4 x 10 mL). The combined organic layers were washed once with water then concentrated to give methyl 2-amino-5-fluoro-1H-benzo[d]imidazole-7-carboxylate.
- Methyl 2-amino-5-fluoro-1H-benzo[d]imidazole-7-carboxylate (0.2g, 0.956 mmol) and 3-chloro-4-fluoroaniline (4.0 mmol) were dissolved in DCE (3.0 mL) and cooled to 0 C under an inert atmosphere. Trimethylaluminium (7.0 mmol, 3.34 mL) was added and the reaction was slowly heated to 65 C overnight. The reaction was cooled to rt, quenched with water (3 mL) and extracted with EtOAc (3 x 5 mL). Combined organic layers were washed once with water and purified by silica gel chromatography (Rf 100% EtOAc = 0.32) to give 2-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-1H-benzo[d]imidazole-7-carboxamide.
- 2-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-1H-benzo[d]imidazole-7-carboxamide and Lawesson's reagent (3.0 mmol) were dissolved in toluene and heated overnight at 100 C. The reaction was allowed to cool to rt and the solids were removed by filtration. The filtrate was concentrated and used directly in the next reaction with no further purification.
- 2-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-1H-benzo[d]imidazole-7-carbothioamide (0.267 g, 0.788 mmol) was dissolved in ethanol (3 mL) and hydroxylamine (50% solution in water) (0.5 mL) was added and the reaction was allowed to stir overnight at rt. The reaction was concentrated and purified by RP HPLC to give 2-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide. C14H10ClF2N5O. 338.1 (M+1).
-
- Example 371 was made analogously to Example 370 using 3-chloroaniline in place of 3-chloro-4-fluoroaniline. C14H11ClFN5O. 320.7 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.05 (s, 1H), 11.10 (s, 1H), 8.83 (s, 1H), 8.26 (s, 2H), 7.26 (dd, J = 8.3, 2.4 Hz, 1H), 7.06 (t, J = 8.3 Hz, 1H), 6.91 (dd, J = 10.5, 2.4 Hz, 1H), 6.88 - 6.83 (m, 2H), 6.57 - 6.48 (m, 1H).
-
- Example 372 was made analogously to Example 370 using 3-bromoaniline in place of 3-chloro-4-fluoroaniline. C14H11BrFN5O. 365.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.05 (s, 1H), 11.10 (s, 1H), 8.82 (s, 1H), 8.27 (s, 2H), 7.26 (dd, J = 8.3, 2.4 Hz, 1H), 7.04 - 6.95 (m, 3H), 6.91 (dd, J = 10.5, 2.4 Hz, 1H), 6.60 - 6.51 (m, 1H).
-
- Example 373 was made analogously to Example 370 using 3-bromo-4-fluoroaniline in place of 3-chloro-4-fluoroaniline. C14H10BrF2N5O. 383.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.11 (s, 1H), 11.03 (s, 1H), 8.79 (s, 1H), 8.36 - 8.23 (m, 2H), 7.26 (dd, J = 8.3, 2.4 Hz, 1H), 7.13 - 7.04 (m, 2H), 6.92 (dd, J = 10.5, 2.4 Hz, 1H), 6.60 (ddd, J = 8.9, 4.2, 2.8 Hz, 1H).
-
- Example 374 was made analogously to Example 32 using 4-(2-aminoethyl)thiomorpholine 1,1-dioxide. C20H20ClF3N6O3S. 517.9 (M+1).
-
- N1,N1-diethylethane-1,2-diamine (0.50 g, 4.0 mmol) and sodium bicarbonate (86 mmol) were dissolved in DCM (12.0 mL) under argon. Thiophosgene (17.0 mmol) was added dropwise and the reaction was allowed to stir at rt for 2 hours. DCM (10 mL) and water (10 mL) were added and the water layer was extracted with DCM (2 x 8 mL). Combined organic layers were washed with water (1 x 20 mL) and concentrated to a volume of 5 mL to give N,N-diethyl-2-isothiocyanatoethan-1-amine which was used without further purification.
- N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was made analogously to Example 23 using N,N-diethyl-2-isothiocyanatoethan-1-amine, methyl 2,3-diamino-4-fluorobenzoate, and 3-chloro-4-fluoroaniline. C20H22ClF3N6O. 437.9 (M+1).
-
- Example 376 was made analogously to Example 375 using 2-(pyrrolidin-1-yl)ethan-1-amine in place of N1,N1-diethylethane-1,2-diamine. C20H21ClF2N6O. 435.8 (M+1).
-
- Example 377 was made analogously to Example 32 using 2-morpholinopropan-1-amine. C21H22ClF3N6O2. 483.9 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.82 (s, 1H), 8.71 (s, 1H), 7.17 (s, 1H), 7.09 (td, J = 9.1, 2.4 Hz, 2H), 6.94 (dd, J = 6.5, 2.7 Hz, 1H), 6.88 (dd, J = 12.2, 6.9 Hz, 1H), 6.78 (d, J = 6.4 Hz, 1H), 6.60 (d, J = 9.1 Hz, 1H), 6.54 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.89 (s, 4H), 3.72 (s, 1H), 3.69 - 3.55 (m, 2H), 3.37 (s, 4H), 1.29 (d, J = 6.6 Hz, 3H).
-
- Exampl 378 was made analogously to Example 23 using N1,N1-dimethylpropane-1,2-diamine. C19H20ClF3N6O. 441.8 (M+1).
-
- Example 379 was made analogously to Example 23 using methyl 2,3-diamino-5-fluorobenzoate and 2-isothiocyanato-N,N-dimethylethan-1-amine. C18H19ClF2N6O. 409.8 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.19 (dd, J = 8.1, 2.4 Hz, 1H), 6.97 (t, J = 8.9 Hz, 1H), 6.94 - 6.89 (m, 2H), 6.69 (dt, J = 8.8, 3.4 Hz, 1H), 3.85 (d, J = 5.8 Hz, 3H), 3.46 (dd, J = 12.2, 6.4 Hz, 3H), 2.99 (s, 6H).
-
- Example 380 was made analogously to Example 375 using 1-(2-isothiocyanatoethyl)pyrrolidine. C20H21ClF2N6O. 435.8 (M+1).
-
- Example 381 was made analogously to Example 23 using methyl 2,3-diamino-4-fluorobenzoate and 3-isothiocyanato-N,N,2,2-tetramethylpropan-1-amine (made from N1,N1,2,2-tetramethylpropane-1,3-diamine). C21H25ClF2N6O. 451.9 (M+1).
-
- Example 382 was made analogously to Example 23 using methyl 2,3-diamino-4-fluorobenzoate, 2-isothiocyanato-N,N-dimethylethan-1-amine, and 3-bromo-4-fluoroaniline. C18H19BrF2N6O. 454.3 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.41 (dd, J = 6.0, 2.4 Hz, 1H), 7.36 (dd, J = 8.7, 4.4 Hz, 1H), 7.16 (dd, J = 9.9, 8.7 Hz, 1H), 7.09 - 7.01 (m, 2H), 3.94 (t, J = 5.9 Hz, 2H), 3.52 (t, J = 6.0 Hz, 2H), 3.01 (s, 6H).
-
- Example 383 was made analogously to Example 23 using methyl 2,3-diamino-4-fluorobenzoate, 2-isothiocyanato-N,N-dimethylethan-1-amine, and 3-bromoaniline. C18H20BrFN6O. 436.3 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.33 (dd, J = 8.8, 4.5 Hz, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.19 - 7.06 (m, 2H), 6.93 (d, J = 8.6 Hz, 1H), 3.92 (t, J = 6.0 Hz, 2H), 3.51 (t, J = 6.0 Hz, 2H), 3.01 (s, 6H).
-
- Example 384 was made analogously to Example 23 using methyl 2,3-diamino-4-fluorobenzoate, 2-isothiocyanato-N,N-dimethylethan-1-amine, and 3-chloroaniline. C18H20ClFN6O. 391.8 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.39 (dd, J = 8.7, 4.4 Hz, 1H), 7.22 - 7.01 (m, 5H), 6.94 (dq, J = 7.1, 2.3 Hz, 1H), 3.94 (t, J = 6.0 Hz, 2H), 3.52 (t, J = 6.1 Hz, 3H), 3.00 (s, 6H).
-
- Example 385 was made analogously to Example 32 using methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate, N1,N1-dimethylpropane-1,3-diamine, and 3-chloroaniline. C19H21ClF2N6O. 423.9 (M+1). 1HNMR (400 MHz, DMSO-d6) δ 10.88 (s, 1H), 9.69 (s, 1H), 8.74 (s, 1H), 7.05 (t, J = 8.3 Hz, 1H), 6.95 - 6.78 (m, 3H), 6.52 (dt, J = 8.3, 1.6 Hz, 1H), 3.42 (d, J = 6.4 Hz, 2H), 3.09 (d, J = 10.5 Hz, 2H), 2.80 (d, J = 4.4 Hz, 6H), 1.94 (p, J = 6.8 Hz, 2H).
-
- Example 386 was made analogously to Example 32 using methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate, N1,N1-dimethylpropane-1,3-diamine, and 3-bromoaniline. C19H21BrF2N6O. 468.3 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.37 - 7.27 (m, 1H), 7.10 - 6.99 (m, 3H), 6.69 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 3.57 (t, J = 6.6 Hz, 2H), 3.28 - 3.21 (m, 2H), 2.93 (s, 6H), 2.18-2.08 (m, 2H).
-
- Example 387 was made analogously to Example 32 using methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate, N1,N1-dimethylpropane-1,3-diamine, and 3-bromo-4-fluoroaniline. C19H20BrF3N6O. 486.3 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.14 - 7.04 (m, 2H), 6.96 (t, J = 8.6 Hz, 1H), 6.74 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 3.56 (t, J = 6.6 Hz, 2H), 3.28 - 3.21 (m, 2H), 2.93 (s, 6H), 2.17 - 2.09 (m, 2H).
-
- Example 388 was made analogously to Example 23 using methyl 2,3-diamino-4-fluorobenzoate and 3-isothiocyanato-N,N-dimethylpropan-1-amine. C19H21ClF2N6O. 423.8 (M+1) 1H NMR (400 MHz, Methanol-d4) δ 7.44 (dd, J = 8.8, 4.3 Hz, 1H), 7.39 (dd, J = 6.4, 2.3 Hz, 1H), 7.23 (dd, J = 9.8, 8.8 Hz, 1H), 7.15 - 7.05 (m, 2H), 3.62 (t, J = 6.8 Hz, 2H), 3.34 - 3.30 (m, 2H), 2.17 (t, J = 8.0 Hz, 2H).
-
- Example 389 was made analogously to Example 23 using methyl 2,3-diamino-5-fluorobenzoate, 3-isothiocyanato-N,N-dimethylpropan-1-amine, and 3-chloro-4-fluoroaniline. C19H21ClF2N6O. 423.8 (M+1).
-
- Example 390 was made analogously to Example 32 using N1-benzyl-N1-methylethane-1,2-diamine. C24H22ClF3N6O. 503.9 (M+1).
-
- Example 391 was made analogously to Example 184 using N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and 1-cyclohexyl-N-methylmethanamine. C23H28ClFN6O. 459.9 (M+1).
-
- Example 392 was made analogously to Example 184 using N,2,2-trimethylpropan-1-amine hydrochloride. C21H26ClFN6O. 434.1 (M+1).
-
- Example 393 was made analogously to Example 184 using N-methylcyclohexanamine. C22H26ClFN6O. 445.9 (M+1).
-
- Methyl 2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate (1.39 g, 4.0 mmol) and tert-butyl (2-aminoethyl)(methyl)carbamate (6.0 mmol) were dissolved in DMSO (5.0 mL) and heated overnight at 60 C. The reaction was allowed to cool to rt and quenched with water (3 mL). The reaction was extracted with EtOAc (5 x 3mL) and combined organic layers were washed once with water and purified by silica gel column chromatography to give methyl 2-((2-((tert-butoxycarbonyl)(methyl)amino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate.
- Methyl 2-((2-((tert-butoxycarbonyl)(methyl)amino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate (1.14 g, 2.0 mmol) and 3-chloro-4-fluoroaniline (9.0 mmol) were dissolved in DCE (15.0 mL) under an inert atmosphere. Triemthylaluminium (9.0 mmol, 4.430 mL) was added at 0 C and the reaction was allowed to come to rt and stir overnight. The reaction was quenched with water (5 mL) and extracted with DCM (3 x 6 mL). Combined organic layers were washed with water (1 x 8 mL) and concentrated to dryness. The crude was dissolved in DCM (8 mL) and TFA (4 mL) was added and the reaction was allowed to stir at rt for 1 hour. The reaction was concentrated and purified by silica gel chromatography to give N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-(methylamino)ethyl)amino)-1H-benzo[d]imidazole-7-carboxamide.
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-(methylamino)ethyl)amino)-1H-benzo[d]imidazole-7-carboxamide (0.053 g, 0.132 mmol) and tetrahydro-2H-pyran-4-carbaldehyde (0.126 mmol) were dissolved in DCE (2.0 mL) under inert conditions. Sodium triacetoxyborohydride (STAB) (0.176 mmol) was added and the reaction was allowed to stir for 2 hours at rt. The reaction was quenched with water (3 mL) and then extracted with DCM (3 x 4 mL). Combined organic layers were washed once with water, dried over Mg2SO4, filtered, and concentrated to give N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((2-(methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)amino)-1H-benzo[d]imidazole-7-carboxamide, which was then converted to N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide using hydroxyamidine formation conditions described herein. C23H26ClF3N6O2. 512.0 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.45 (s, 1H), 6.95 (t, J = 8.9 Hz, 1H), 6.86 (td, J = 7.4, 4.9 Hz, 2H), 6.66 - 6.60 (m, 1H), 3.90 - 3.81 (m, 2H), 3.75 (t, J = 5.1 Hz, 2H), 3.43 (d, J = 5.9 Hz, 2H), 3.41 - 3.35 (m, 2H), 3.14 (d, J = 7.1 Hz, 2H), 3.00 (s, 3H), 1.71 (d, J = 13.0 Hz, 2H), 1.43 - 1.26 (m, 3H).
-
- 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (0.03 g, 0.0565 mmol) and tert-butyl (2-aminoethyl)(methyl)carbamate (0.0847 mmol) were dissolved in DMS (0.6 mL) and heated overnight at 60 C. The reaction was cooled to rt, diluted with water, and extracted with DCM (3 x 1 mL). Combined organic layers were washed once with water and concentrated to give tert-butyl (2-((7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)amino)ethyl)(methyl)carbamate which was used without further purification.
- Tert-butyl (2-((7-(4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)amino)ethyl)(methyl)carbamate (0.057 mmol) was dissolved in DCM (2 mL) and TFA (1.0 mL) was added and the reaction was allowed to stir at rt for 2 hours before being concentrated to dryness. The residue was then dissolved in MeOH (2.0 mL) and 1M NaOH (0.5 mL) was added and the reaction was allowed to stir at rt for 30 mins. The reaction was then concentrated and purified by RP HPLC to N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methylamino)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide. C17H16ClF3N6O. 413.8 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.72 (s, 1H), 8.65 (s, 1H), 8.50 (s, 2H), 6.98 (t, J = 9.1 Hz, 1H), 6.85 - 6.80 (m, 1H), 6.76 (s, 1H), 6.42 (dt, J = 8.9, 3.4 Hz, 1H), 3.52 (d, J = 5.8 Hz, 2H), 3.04 (t, J = 5.9 Hz, 2H), 2.50 (t, J = 5.3 Hz, 3H).
-
- Example 396 was made analogously to Example 184 using N-(3-chloro-4-fluorophenyl)-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide and N-methyl-1-phenylmethanamine. C23H22ClFN6O. 454.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.90 (s, 1H), 8.30 (d, J = 5.0 Hz, 1H), 7.56 (dd, J = 6.4, 3.3 Hz, 2H), 7.50 (dt, J = 4.5, 2.9 Hz, 3H), 7.15 (d, J = 5.1 Hz, 1H), 7.03 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.51 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 4.44 (s, 2H), 3.57 (t, J = 7.5 Hz, 2H), 3.36 (t, J = 7.4 Hz, 2H), 2.76 (s, 3H).
-
- Example 397 was made analogously to Example 395 using 2-ethylbutanal for the reductive amination. C23H28ClF3N6O. 498.1 (M+1).
-
- Example 398 was made analogously to Example 394 using cyclopropanecarbaldehyde for the reductive amination. C21H22CIF3N6O. 468.1 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 6.95 (t, J = 8.9 Hz, 1H), 6.92 - 6.86 (m, 2H), 6.66 (ddd, J = 8.9, 3.9, 2.8 Hz, 1H), 3.77 (t, J = 5.3 Hz, 2H), 3.46 (d, J = 8.4 Hz, 2H), 3.14 (d, J = 7.2 Hz, 2H), 3.02 (s, 3H), 1.16 (ddd, J = 7.7, 4.7, 2.9 Hz, 1H), 0.71 (dd, J = 8.1, 1.5 Hz, 2H), 0.40 (dd, J = 4.7, 1.3 Hz, 2H).
-
- Example 399 was made analogously to Example 184 using N-methyl-1-(tetrahydro-2H-pyran-4-yl)methanamine. C22H26ClFN6O2. 461.9 (M+1).
-
- Example 400 was made analogously to Example 184 using 1-(1,4-dioxan-2-yl)-N-methylmethanamine hydrochloride. C21H24ClFN6O3. 463.9 (M+1). 1HNMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.89 (s, 1H), 8.31 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 5.1 Hz, 1H), 7.05 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.52 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 4.10 - 4.01 (m, 1H), 3.83 - 3.20 (m, 13H), 2.89 (s, 3H).
-
- Example 401 was made analogously to Example 184 using N-methyl-2-(tetrahydro-2H-pyran-4-yl)ethan-1-amine. C23H28ClFN6O2. 476.0 (M+1). 1HNMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.91 (s, 1H), 8.30 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 5.1 Hz, 1H), 7.04 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.55 - 6.48 (m, 1H), 3.83 (dd, J = 11.2, 4.3 Hz, 2H), 3.55 (s, 1H), 3.35 - 3.23 (m, 4H), 3.23 - 3.15 (m, 2H), 2.84 (s, 3H), 1.59 (dd, J = 15.6, 10.5 Hz, 6H), 1.20 (d, J = 11.8 Hz, 2H).
-
- Example 402 was made analogously to Example 395 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and tert-butyl (2-aminoethyl)(cyclopropyl)carbamate. C18H19ClFN7O. 404.8 (M+1). 1HNMR (400 MHz, DMSO-d6) δ 11.39 (s, 1H), 8.97 (s, 3H), 7.99 (d, J = 6.3 Hz, 1H), 7.11 (t, J = 9.1 Hz, 1H), 7.01 (dd, J = 6.5, 2.7 Hz, 1H), 6.95 (d, J = 6.3 Hz, 1H), 6.58 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.75 (s, 2H), 3.31 (s, 2H), 2.80 (s, 1H), 0.87 - 0.75 (m, 4H).
-
- Example 403 was made analogously to Example 402 using N1-cyclopropyl-N1-ethylethane-1,2-diamine. C20H23ClFN7O. 432.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 1H), 7.97 (d, J = 6.1 Hz, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.99 (s, 1H), 6.93 (d, J = 6.0 Hz, 1H), 6.61 - 6.53 (m, 1H), 3.80 (s, 2H), 3.45 (s, 2H), 3.33 (s, 2H), 2.86 (s, 1H), 1.27 (t, J = 7.2 Hz, 3H), 1.00 - 0.78 (m, 4H).
-
- Example 404 was made analogously to Example 402 using N-(2-aminoethyl)acetamide. C17H17ClFN7O2. 406.3 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.97 (s, 1H), 8.03 (s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.3 Hz, 1H), 6.63 - 6.55 (m, 1H), 3.50 (d, J = 6.0 Hz, 2H), 3.30 (d, J = 6.0 Hz, 2H), 1.82 (s, 3H).
-
- Example 405 was made analogously to Example 402 using N-(2-aminoethyl)methanesulfonamide. C16H17ClFN7O3S. 442.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.44 (s, 1H), 8.97 (s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.25 (d, J = 5.8 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.03 (s, 1H), 6.92 (d, J = 6.4 Hz, 1H), 6.59 (dt, J = 8.9, 3.4 Hz, 1H), 3.57 (d, J = 6.2 Hz, 2H), 3.21 (d, J = 6.1 Hz, 2H), 2.94 (s, 3H).
-
- Example 406 was made analogously to Example 402 using N1-cyclopropyl-N1-isopropylethane-1,2-diamine. C21H25ClFN7O. 446.4 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.30 (s, 1H), 8.94 (s, 1H), 7.97 (s, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.03 - 6.94 (m, 1H), 6.92 (d, J = 6.0 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H), 3.80 (s, 3H), 3.42 (s, 2H), 2.86 (s, 1H), 1.30 (d, J = 6.7 Hz, 6H), 1.01 (s, 2H), 0.89 (s, 2H).
-
- Example 407 was made analogously to Example 402 using 2-((2-aminoethyl)(cyclopropyl)amino)ethan-1-ol dihydrochloride and Hunig's base. C20H23ClFN7O2. 448.2 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.89 (d, J = 6.5 Hz, 1H), 7.05 (d, J = 6.5 Hz, 1H), 7.03 - 6.95 (m, 2H), 6.67 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 4.06 (t, J = 6.3 Hz, 2H), 4.01 - 3.95 (m, 2H), 3.71 (t, J = 6.3 Hz, 2H), 3.59 - 3.52 (m, 2H), 2.98 (dt, J = 7.3, 3.5 Hz, 1H), 1.19 - 1.12 (m, 2H), 1.07 - 1.01 (m, 2H).
-
- Example 408 was made analogously to Example 402 using tert-butyl (2-aminoethyl)carbamate. C15H15ClFN7O. 364.9 (M+1).
-
- Example 409 was made analogously to Example 402 using 4-(aminomethyl)pyrrolidin-2-one. C18H17ClFN7O2. 418.4 (M+1).
-
- Example 410 was made analogously to Example 402 using (1H-pyrazol-5-yl)methanamine. C17H14ClFN8O. 401.1 (M+1).
-
- 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (0.06 g, 0.121 mmol) and tert-butyl (3-aminopropyl)carbamate (0.181 mmol) were dissolved in DMSO (2.80 mL) and heated overnight at 60 C. The reaction was cooled to rt, diluted with water (3 mL) and extracted with EtOAc (3 x 2mL). Combined organic layers were washed with water (1 x 5 mL) and concentrated. The crude was dissolved in DCM (2 mL) and TFA (1.0 mL) was added and the reaction was allowed to stir at rt for 2 hours before being concentrated to dryness to give 3-(2-((3-aminopropyl)amino)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one.
- 3-(2-((3-aminopropyl)amino)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (0.015 g, 0.0317 mmol) was dissolved in THF (1.0 mL) and triethylamine (0.186 mmol) was added. Acetyl chloride (0.0557 mmol) was added slowly and the reaction was allowed to stir at rt for 1 hour before being concentrated to dryness. The residue was dissolved in THF (0.4 mL), MeOH (0.4 mL) and 1M NaOH (0.6 mL) and stirred at rt for 1 hour. The reaction was concentrated and purified by RP HPLC to give two products: N-(3-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)amino)propyl)acetamide (2.8 mg, 18%) and 2-((3-aminopropyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide.
- N-(3-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)amino)propyl)acetamide: C18H19ClFN7O2. 420.2 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.84 (d, J = 6.5 Hz, 1H), 7.04 - 6.96 (m, 3H), 6.67 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 3.58 (t, J = 6.7 Hz, 2H), 3.28 (d, J = 6.7 Hz, 2H), 1.96 (s, 3H), 1.87 (t, J = 6.7 Hz, 2H).
- 2-((3-aminopropyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide: C16H17ClFN7O. 378.3 (M+1). 1HNMR (400 MHz, Methanol-d4) δ 7.85 (d, J = 6.6 Hz, 1H), 7.04 - 6.95 (m, 3H), 6.68 (ddd, J = 8.9, 3.9, 2.8 Hz, 1H), 3.68 (t, J = 6.6 Hz, 2H), 3.11 - 3.03 (m, 2H), 2.12 - 2.02 (m, 2H).
-
- Example 413 was made analogously to Example 411 using 3-(2-((2-aminoethyl)amino)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one, sulfamide, and pyridine. C15H16ClFN8O3S. 443.1 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.84 (d, J = 6.5 Hz, 1H), 7.04 - 6.95 (m, 3H), 6.67 (ddd, J = 8.8, 4.0, 2.7 Hz, 1H), 3.73 (td, J = 6.1, 5.6, 0.9 Hz, 3H), 1.87 (ddt, J = 6.6, 4.6, 2.4 Hz, 1H).
-
- Example 414 was made analogously to Example 411 using 3-(2-((2-aminoethyl)amino)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one, benzenesulfonyl chloride, and triethylamine. C21H19ClFN7O3S. 504.1 (M+1).
-
- Example 415 was made analogously to Example 411 using 3-(2-((2-aminoethyl)amino)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one, methyl chloroformate, and triethylamine. C17H17ClFN7O3. 422.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H), 8.96 (s, 1H), 7.97 (d, J = 6.4 Hz, 1H), 7.28 (s, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.8 Hz, 1H), 6.93 (d, J = 6.3 Hz, 1H), 6.59 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.53 (d, J = 3.9 Hz, 5H), 3.25 (d, J = 6.0 Hz, 2H).
-
- Example 416 was made analogously to Example 411 using 3-(2-((2-aminoethyl)amino)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one, cyclopropanesulfonyl chloride, and triethylamine. C18H19ClFN7O3S. 468.9 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.84 (d, J = 6.5 Hz, 1H), 7.04 - 6.96 (m, 3H), 6.67 (ddd, J = 8.9, 3.9, 2.8 Hz, 1H), 3.70 (dd, J = 6.5, 5.3 Hz, 2H), 3.42 (dd, J = 6.6, 5.3 Hz, 2H), 2.56 (ddd, J = 7.9, 5.5, 2.9 Hz, 1H), 1.10 - 0.97 (m, 4H).
-
- Example 417 was made analogously to Example 411 using 3-(2-((2-aminoethyl)amino)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one, trifluoromethanesulfonyl chloride, and triethylamine. C16H14ClF4N7O3S. 496.3 (M+1).
-
- Example 418 was made analogously to Example 402 using (1H-imidazol-2-yl)methanamine dihydrochloride and Hunig's base. C17H14ClFN8O. 401.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.90 (s, 1H), 7.97 (d, J = 5.9 Hz, 1H), 7.60 (s, 2H), 7.10 (t, J = 9.0 Hz, 1H), 6.94 (d, J = 15.7 Hz, 2H), 6.60 - 6.53 (m, 1H), 4.92 (s, 2H).
-
- Example 419 was made analogously to Example 402 using (1H-imidazol-5-yl)methanamine dihydrochloride and Hunig's base. C17H14ClFN8O. 401.2 (M+1).
-
- Example 420 was made analogously to Example 402 using (3-methyl-1,2,4-oxadiazol-5-yl)methanamine. C17H14ClFN8O2. 417.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H), 8.50 (d, J = 12.2 Hz, 1H), 7.99 (d, J = 6.4 Hz, 1H), 7.11 (d, J = 9.1 Hz, 1H), 7.08 - 7.03 (m, 1H), 6.96 (d, J = 6.4 Hz, 1H), 6.60 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 4.97 (d, J = 6.0 Hz, 2H), 2.32 (s, 3H).
-
- Example 421 was made analogously to Example 402 using 4-(3-bromophenyl)-3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and methylamine (2.0 M in MeOH). C14H13BrN6O. 361.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.07 (d, J = 2.0 Hz, 1H), 7.02 - 6.92 (m, 3H), 6.57 (dt, J = 7.0, 2.1 Hz, 1H), 3.02 (d, J = 4.7 Hz, 3H).
-
- Example 422 was made analogously to Example 411 using 3-(2-((3-aminopropyl)amino)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one, methyl chloroformate, and triethylamine. C18H19ClFN7O3. 436.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.19 (d, J = 5.6 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.6, 2.7 Hz, 1H), 6.91 (d, J = 6.2 Hz, 1H), 6.59 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 3.53 (s, 3H), 3.44 (d, J = 6.5 Hz, 2H), 3.07 (d, J = 6.3 Hz, 2H), 1.79 - 1.64 (m, 2H).
-
- Example 423 was made analogously to Example 402 using 4-(3-bromophenyl)-3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and sodium hydride in MeOH to generate sodium methoxide in situ. C14H12BrN5O2. 362.0 (M+1).
-
- Example 424 was made analogously to Example 402 using 4-(3-bromophenyl)-3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one, 2-(methylsulfonyl)ethan-1-amine hydrochloride, and Hunig's base. C16H17BrN6O3S. 453.2 (M+1).
-
- Example 425 was made analogously to Example 424 using N-(2-aminoethyl)methanesulfonamide. C16H18BrN7O3S. 468.2 (M+1).
-
- Example 426 was made analogously to Example 424 using 4-(3-bromophenyl)-3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one and 2-aminoethane-1-sulfonamide. C15H16BrN7O3S. 454.2 (M+1).
-
- Example 427 was made analogously to Example 402 using (5-methyl-1,3,4-oxadiazol-2-yl)methanamine oxalate and Hunig's base. C17H14ClFN8O2. 417.2 (M+1).
-
- Methyl 4,5-difluoro-2-(((1-methylpiperidin-2-yl)methyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using (1-methylpiperidin-2-yl)methanamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-(((1-methylpiperidin-2-yl)methyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C22H34F2N4O3Si. 469.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((1-methylpiperidin-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-(((1-methylpiperidin-2-yl)methyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((1-methylpiperidin-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C21H21ClF3N5O. 452.2/454.1 (M+1).
- Example 428 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((1-methylpiperidin-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1-methylpiperidin-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O.467.2/469.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H), 9.25 (s, 1H), 8.69 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.00 (s, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.83 (dd, J = 12.2, 6.8 Hz, 1H), 6.53 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.79 (m, 1H), 3.68 (m, 1H), 3.41 (m, 1H), 3.24 (m, 1H), 3.04 (m, 1H), 2.97 (s, 3H), 2.83 (m, 1H), 1.94 (m, 1H), 1.85 - 1.70 (m, 2H), 1.65 - 1.40 (m, 2H).19F NMR (377 MHz, DMSO) δ -75.02 (9F), -127.46 (1F), -150.44 (1F), -157.01 (1F).
-
- Example 429 was made analogously to Example 39 using (4-methylmorpholin-3-yl)methanamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-(((4-methylmorpholin-3-yl)methyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C21H32F2N4O4Si. 471.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-(((4-methylmorphohn-3-yl)methyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C20H19ClF3N5O2. 454.2/456.1 (M+1).
- Example 429 was made analogously to Example 59 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O2.469.1/471.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.76 (s, 1H), 8.68 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.92 (dd, J = 6.5, 2.8 Hz, 2H), 6.83 (dd, J = 12.2, 6.8 Hz, 1H), 6.53 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 4.10 - 3.84 (m, 4H), 3.80 - 3.65 (m, 2H), 3.58 - 3.34 (m, 2H), 3.26 (m, 1H), 3.03 (s, 3H). 19F NMR (377 MHz, DMSO-d6) δ - 74.98 (9F), -127.43 (1F), -150.47 (dd, J = 21.1, 12.8 Hz, 1F), -157.02 (1F).
-
- N-(3-bromophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-bromophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C18H18BrF2N5O. 438.1/440.1 (M+1).
- Example 430 was made analogously to Example 59 using N-(3-bromophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-bromophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C18H19BrF2N6O.455.1/456.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 8.68 (s, 1H), 7.04 - 6.93 (m, 3H), 6.89 (s, 1H), 6.81 (dd, J = 12.2, 6.9 Hz, 1H), 6.54 (dt, J = 7.7, 1.7 Hz, 1H), 3.70 (m, 2H), 3.32 (m, 2H), 2.86 (s, 6H). 19F NMR (377 MHz, DMSO) δ -74.85 (9F), -150.52 (1F), -157.05 (1F).
-
- N-(3-chlorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chlorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C18H18ClF2N5O. 394.1/396.2 (M+1).
- Example 431 was made analogously to Example 59 using N-(3-chlorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-chlorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid . C18H19ClF2N6O.409.1/411.1 (M+1)). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.68 (s, 1H), 7.05 (t, J = 8.0 Hz, 1H), 6.86 - 6.72 (m, 3H), 6.54 - 6.46 (m, 1H), 3.69 (s, 3H), 3.32 (s, 4H), 2.86 (s, 6H). 19F NMR (376 MHz, DMSO-d6) δ -74.52, - 150.61, -157.17.
-
- N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate and 3-bromo-4-fluoroaniline in place of 3-chloro-4-fluoroaniline. The TFA salt of N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C18H17BrF3N5O. 456.1/458.1 (M+1).
- Example 432 was made analogously to Example 59 using N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide. The TFA salt of N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C18H18BrF3N6O.471.2/474.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.71 (s, 1H), 8.64 (s, 1H), 7.08 - 7.01 (m, 2H), 6.79 (s, 2H), 6.54 (ddd, J = 9.0, 4.2, 2.7 Hz, 1H), 3.66 (s, 2H), 3.30 (s, 2H), 2.84 (s, 6H).
-
- Methyl 4,5-difluoro-2-((3-morpholinopropyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 3-morpholinopropan-1-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-((3-morpholinopropyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C22H34F2N4O4Si. 485.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((3-morpholinopropyl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((3-morpholinopropyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((3-morpholinopropyl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C21H21ClF3N5O2. 468.2/470.1 (M+1).
- Example 433 was made analogously to Example 432 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((3-morpholinopropyl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((3-morpholinopropyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O2.483.1/485.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.75 (s, 1H), 8.66 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.82 (s, 2H), 6.54 (dq, J = 9.0, 3.1 Hz, 1H), 3.82 (m, 2H), 3.42 (m, 2H), 3.27 (m, 2H), 3.17 (t, J = 7.9 Hz, 2H), 1.97 (t, J = 7.8 Hz, 2H).
-
- Methyl 4,5-difluoro-2-((3-(pyrrolidin-1-yl)propyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 3-(pyrrolidin-1-yl)propan-1-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-((3-(pyrrolidin-1-yl)propyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C22H34F2N4O3Si. 469.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((3-(pyrrolidin-1-yl)propyl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((3-(pyrrolidin-1-yl)propyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((3-(pyrrolidin-1-yl)propyl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C21H21ClF3N5O. 452.0/454.1 (M+1).
- Example 434 was made analogously to Example 432 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((3-(pyrrolidin-1-yl)propyl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((3-(pyrrolidin-1-yl)propyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O.467.2/469.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.75 (s, 1H), 9.68 (s, 1H), 8.66 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.90-6.75 (m, 2H), 6.54 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.55 - 3.34 (m, 8H), 3.17 (m, 2H), 1.93 (m, 6H). 19F NMR (377 MHz, DMSO) δ -74.57, -127.43, -150.48, - 157.56.
-
- Methyl (S)-4,5-difluoro-2-((1-methylpyrrolidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using (S)-1-methylpyrrolidin-3-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl (S)-4,5-difluoro-2-((1-methylpyrrolidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C21H32F2N4O3Si. 441.0 (M+1).
- (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl (S)-4,5-difluoro-2-((1-methylpyrrolidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C19H17ClF3N5O. 424.1/426.1 (M+1).
- Example 435 was made analogously to Example 432 using (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of 2-(((3R)-4-amino-1-methylpyrrolidin-3-yl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid (15.8 mg, 67%). C19H19ClF3N7O.454.1/456.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 8.67 (s, 1H), 7.10 (t, J = 9.2 Hz, 1H), 7.08 (br s, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.83 (dd, J = 12.2, 7.0 Hz, 1H), 6.54 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 6.10 (s, 2H), 4.77 (s, 1H), 4.00 (dq, J = 8.3, 7.0 Hz, 1H), 3.90 (dd, J = 12.5, 8.1 Hz, 1H), 3.82 (t, J = 9.9 Hz, 1H), 3.67 (d, J = 12.7 Hz, 1H), 3.58 (td, J = 11.2, 8.1 Hz, 1H), 3.38 (s, 3H), 2.76 - 2.64 (m, 1H), 2.25 - 2.12 (m, 1H). 19F NMR (376 MHz, DMSO) δ -74.87, -127.5, -150.4, -156.9.
-
- Methyl 2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-l-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using N 1 ,N 1-dimethyl-1-phenylethane-1,2-diamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C25H34F2N4O3Si. 505.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d|imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C24H21ClF3N5O. 488.1/490.1 (M+1).
- Example 436 was made analogously to Example 432 using N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C24H22ClF3N6O.503.1/505.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.75 (s, 1H), 10.68 (s, 1H), 8.66 (s, 1H), 7.62 - 7.55 (m, 1H), 7.53 (d, J = 3.3 Hz, 3H), 7.09 (t, J = 8.9 Hz, 1H), 6.89 (dd, J = 6.5, 2.7 Hz, 1H), 6.85 - 6.74 (m, 1H), 6.67 - 6.58 (m, 1H), 6.54 - 6.46 (m, 1H), 4.69 (m, 1H), 4.26 (m, 1H), 3.97 (m, 1H), 2.75 (s, 6H). 19F NMR (377 MHz, DMSO-d6) δ -74.37 (9F), -127.54 (1F), -150.55 (1F), -156.90 (1F).
-
- Methyl 2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using (1R,2R)-N 1 ,N 1-dimethylcyclohexane-1,2-diamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C23H36F2N4O3Si. 483.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C22H23ClF3N5O. 466.2/468.1 (M+1).
- Example 437 was made analogously to Example 402 using N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H24ClF3N6O.481.2/483.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H), 8.91 (s, 1H), 8.67 (s, 1H), 7.11 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.84 (dd, J = 12.3, 7.0 Hz, 1H), 6.79 (d, J = 9.7 Hz, 1H), 6.53 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 4.02 (m, 1H), 3.33 (m, 1H), 2.77 (s, 3H), 2.78 (s, 3H), 2.07 (m, 1H), 1.93 (app. d, J = 9.9 Hz, 1H), 1.83 (app. d, J = 11.8 Hz, 1H), 1.70 (app. d, J = 9.5 Hz, 1H), 1.63 - 1.48 (m, 1H), 1.36 (dq, J = 27.4, 13.2, 12.3 Hz, 3H). 19F NMR (377 MHz, DMSO-d6) δ -75.02 (9F), -127.56 (1F), -150.41 (1F), -156.89 (1F).
-
- Methyl 2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 1-(aminomethyl)-N,N-dimethylcyclopentan-1-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C23H36F2N4O3Si 483.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C22H23ClF3N5O. 466.2/468.1 (M+1).
- Example 438 was made analogously to Example 402 using N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H24ClF3N6O.481.2/483.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 9.68 (s, 1H), 8.70 (s, 1H), 7.15 - 7.01 (m, 2H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.85 (dd, J = 12.2, 6.9 Hz, 1H), 6.52 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.74 (d, J = 6.6 Hz, 2H), 2.84 (s, 3H), 2.83 (s, 3H), 1.96 - 1.79 (m, 4H), 1.71 (t, J = 5.6 Hz, 4H). 19F NMR (377 MHz, DMSO) δ -74.89 (9F), -127.51 (1F), -150.42 (1F), -157.09 (1F).
-
- Methyl 2-((3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using N 1,N 1-dimethylcyclohexane-1,3-diamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-((3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C23H36F2N4O3Si 483.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-((3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C22H23ClF3N5O. 466.2 (M+1).
- Example 439 was made analogously to Example 402 using N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The two diastereomers were separated by reverse phase HPLC and the TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1S,3S)-3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. (C22H24ClF3N6O. 481.1/483.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.81 (s, 1H), 9.45 (s, 1H), 8.69 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.81 (t, J = 9.8 Hz, 1H), 6.54 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.33 (m, 1H), 2.76 (d, J = 5.0 Hz, 3H), 2.74 (d, J = 4.9 Hz, 3H), 2.39 (d, J = 11.9 Hz, 1H), 1.93 (dd, J = 27.6, 11.7 Hz, 4H), 1.48 - 1.30 (m, 4H), 1.21 (d, J = 13.5 Hz, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.82, -127.48, -149.43, -156.88.
-
- The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1S,3R)-3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated from the sequence described in Example 439 as an off-white solid. C22H24ClF3N6O. 481.1/483.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.77 (s, 1H), 9.27 (s, 1H), 8.65 (s, 1H), 7.11 (t, J = 9.1 Hz, 1H), 7.00 (s, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.79 (dd, J = 12.0, 7.5 Hz, 1H), 6.54 (dt, J = 9.1, 3.5 Hz, 1H), 5.06 (q, J = 9.0 Hz, 1H), 4.21 (m, 1H), 3.29 (m, 1H), 2.77 (d, J = 4.6 Hz, 3H), 2.72 (d, J = 4.7 Hz, 3H), 2.29 (d, J = 14.9 Hz, 1H), 1.98 (m, 1H), 1.77 (m, 3H), 1.56 (m, 3H).
-
- Methyl 2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 1-(aminomethyl)-N,N-dimethylcyclobutan-1-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C22H34F2N4O3Si. 469.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C21H21ClF3N5O. 452.2/545.1 (M+1).
- Example 441 was made analogously to Example 402 using N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O. 467.2/469.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.70 (s, 1H), 7.17 (t, J = 6.6 Hz, 1H), 7.08 (t, J = 9.1 Hz, 1H), 6.94 (dd, J = 6.5, 2.7 Hz, 1H), 6.87 (dd, J = 12.2, 6.9 Hz, 1H), 6.54 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 6.06 (s, 1H), 4.06 (d, J = 6.6 Hz, 2H), 3.20 (s, 6H), 2.74 (dt, J = 14.1, 10.0 Hz, 2H), 2.12 - 1.99 (m, 2H), 1.85 - 1.70 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ -75.09, -127.43, -150.31, - 156.83.
-
- Methyl 4,5-difluoro-2-((1-methylpiperidin-4-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 1-methylpiperidin-4-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-((1-methylpiperidin-4-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C21H32F2N4O3Si. 455.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpiperidin-4-yl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((1-methylpiperidin-4-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d|imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpiperidin-4-yl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C20H19ClF3N5O. 438.2/440.3 (M+1).
- Example 442 was made analogously to Example 402 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpiperidin-4-yl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-4-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O. 453.1/455.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H), 9.26 (s, 1H), 8.68 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.92 (m, 1H), 6.82 (m, 1H), 6.53 (ddd, J = 8.9, 4.1, 2.7 Hz, 1H), 4.31 - 4.17 (m, 1H), 3.09 (q, J = 11.6 Hz, 4H), 2.80 (d, J = 4.7 Hz, 3H), 2.17 (d, J = 13.6 Hz, 2H), 1.64 (q, J = 13.0, 11.7 Hz, 2H).
-
- Methyl 4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 1-methylpiperidin-3-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C21H32F2N4O3Si. 455.2 (M+1).
- N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C20H19ClF3N5O. 438.2/440.1 (M+1).
- Example 443 was made analogously to Example 402 using N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O. 453.2/455.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 9.63 (s, 1H), 8.68 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.92 (dd, J = 6.5, 2.8 Hz, 1H), 6.82 (dd, J = 12.3, 6.9 Hz, 1H), 6.54 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 4.03 (m, 1H), 3.65 (m, 1H), 3.42 (m, 1H), 2.88 (d, J = 4.7 Hz, 1H), 2.83 (d, J = 4.6 Hz, 3H), 2.78 (d, J = 8.7 Hz, 1H), 2.06 - 1.65 (m, 3H), 1.53 - 1.38 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.95 (9F), -127.50 (1F), -150.55 (1F), -156.90 (1F).
-
- Methyl 2-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using (1S,2S)-N1,N1-dimethylcyclohexane-1,2-diamine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C23H36F2N4O3Si. 483.2/484.1 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 2-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C22H23ClF3N5O. 466.2/468.1 (M+1).
- Example 444 was made analogously to Example 402 using N-(3-chloro-4-fluorophenyl)-2-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide in place of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H24ClF3N6O. 481.2/483.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.92 - 10.67 (m, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 7.11 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.88 - 6.75 (m, 2H), 6.53 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 4.04 (m, 1H), 3.33 (td, J = 11.6, 3.5 Hz, 1H), 2.77 (d, J = 4.3 Hz, 6H), 2.13 - 2.03 (m, 1H), 1.94 (app. d, J = 10.7 Hz, 1H), 1.83 (app. d, J = 11.9 Hz, 1H), 1.70 (app. d, J = 9.4 Hz, 1H), 1.53 (app. dd, J = 13.6, 10.1 Hz, 1H), 1.37 (m, 3H). 19F NMR (376 MHz, DMSO-d6) δ -75.01 (9F), -127.56 (1F), -150.41 (1F), -156.9 (d, J = 22.3 Hz, IF).
-
- Example 445 was made analogously to Example 333 using tert-butyl (S)-3-aminopiperidine-1-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(piperidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C19H18ClF3N6O. 439.2/441.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H), 8.69-8.50 (m, 3H), 7.10 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.86 (m, 1H), 6.79 (m, 1H), 6.55 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.00 (m, 1H), 3.47 (app. d, J = 11.9 Hz, 1H), 3.21 (app. d, J = 12.3 Hz, 1H), 2.93 - 2.79 (m, 2H), 2.00 (m, 1H), 1.89 (m, 1H), 1.80 - 1.63 (m, 1H), 1.57 (m, 1H). 19F NMR (376 MHz, DMSO) δ -74.92, -127.48, - 150.57, -156.96.
-
- Example 446 was made analogously to Example 333 using tert-butyl (R)-3-aminopiperidine-1-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(piperidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C19H18ClF3N6O. 439.2/441.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.78 - 8.51 (m, 3H), 7.10 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.86 (d, J = 6.6 Hz, 1H), 6.81 (dd, J = 12.1, 6.8 Hz, 1H), 6.54 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 4.02 (m, 1H), 3.47 (app. d, J = 12.2 Hz, 1H), 3.21 (app. d, J = 12.4 Hz, 1H), 2.93 - 2.80 (m, 2H), 2.00 (app. d, J = 12.2 Hz, 1H), 1.89 (m, 1H), 1.71 (m, 1H), 1.56 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.88 (9F), -127.50 (1F), -150.58 (1F), -156.99 (1F).
-
- Example 447 was made analogously to Example 333 using (S)-1-methylpyrrolidin-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C19H18ClF3N6O.439.2/441.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.76 (br. s, 1H), 9.75 (br. s, 1H), 8.67 (d, J = 3.5 Hz, 1H), 7.09 (td, J = 9.1, 3.4 Hz, 1H), 6.98 (m, 1H), 6.92 (dt, J = 6.5, 2.4 Hz, 1H), 6.85 (m, 1H), 6.53 (dt, J = 8.9, 3.5 Hz, 1H), 4.49 (m, 1H), 3.94 (m, 1H), 3.36 (m, 1H), 3.23 (m, 1H), 3.06 (m, 1H), 2.89 (app. dd, J = 9.0, 4.8 Hz, 3H), 2.06 (m, 1H), 1.90 (m, 1H). 19F NMR (376 MHz, DMSO-d6) δ -74.77, -127.47, - 150.47, -156.78.
-
- Example 448 was made analogously to Example 333 using 1-amino-3-(dimethylamino)propan-2-ol in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)-2-hydroxypropyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C19H20ClF3N6O2.457.2/459.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.86 (br. s, 1H), 9.38 (br. s, 1H), 8.73 (s, 1H), 7.30 (m, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.94 (dd, J = 6.5, 2.7 Hz, 1H), 6.88 (dd, J = 12.2, 6.9 Hz, 1H), 6.54 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 4.11 (dq, J = 9.7, 5.0 Hz, 1H), 3.47 (dt, J = 13.9, 5.5 Hz, 1H), 3.39 (m, 1H), 3.16 (app. d, J = 12.8 Hz, 1H), 3.06 (dd, J = 12.9, 10.1 Hz, 1H), 2.81 (s, 6H). 19F NMR (377 MHz, DMSO-d6) δ -75.02, -127.32, -149.66, -156.59.
-
- Example 449 was made analogously to Example 333 using 4-(2-aminoethyl)-1-methylpiperazin-2-one in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(4-methyl-3-oxopiperazin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H21ClF3N7O2.496.2/498.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.81 (br. s, 1H), 8.71 (s, 1H), 7.14 (br. s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.94 (dd, J = 6.5, 2.7 Hz, 1H), 6.87 (dd, J = 12.2, 6.9 Hz, 1H), 6.53 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 3.90 (s, 2H), 3.71 (m, 2H), 3.65 - 3.50 (m, 4H), 3.35 (m, 2H), 2.89 (s, 3H). 19F NMR (376 MHz, DMSO-d6) δ -75.14, -127.23, -149.86, -156.94.
-
- Methyl 4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 1-(aminomethyl)-N,N-dimethylcyclohexan-1-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as a yellow oil. C21H32F2N4O3Si. 497.3 (M+1).
- N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide was isolated as a white solid. C23H25ClF3N5O. 480.2/482.1 (M+1).
- The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-1H-benzo[d]imidazole-7-carboxamide (103 mg, 0.15 mmol, 1 equiv) was dissolved in EtOAc, saturated aqueous NaHCO3 was added and the mixture was extracted twice with EtOAc. The combined organics were dried over MgSO4, filtered and concentrated in vacuo. The resulting residue was dissolved in CH2Cl2 (1 mL) and potassium carbonate (148 mg, 01.05 mmol, 7 equiv) and PCl5 (95 mg, 0.46 mmol, 3 equiv) were added. The reaction was stirred at room temperature for 3 hours before being concentrated in vacuo. A solution of TMSONH2 (0.185 mL, 1.5 mmol, 10 equiv) in trifluoroethanol (1.5 mL) was added at 0 °C. The reaction was slowly warmed to room temperature and stirred for 1 hour before being concentrated in vacuo. A solution of 2N HCl was added and the resulting mixture was stirred for 30 minutes before diluting with DMF/H2O and purification by reverse phase HPLC. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C23H26ClF3N6O.495.2/497.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 9.49 (br. s, 1H), 8.68 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.03 (br. s, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.85 (dd, J = 12.2, 6.9 Hz, 1H), 6.53 (dt, J = 8.9, 3.5 Hz, 1H), 4.31 (m, 1H), 3.86 (d, J = 6.5 Hz, 1H), 2.81 (s, 3H), 2.80 (s, 3H), 1.83-1.93 (m, 2H), 1.74 - 1.43 (m, 7H), 1.20 (m, 1H). 19F NMR (376 MHz, DMSO) δ -75.00, -127.52, -150.3, -156.97.
-
- Example 451 was made analogously to Example 333 using 1-methylazepan-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylazepan-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O.467.2/469.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.77 (s, 1H), 9.68 (br. s, 1H), 8.66 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.83 (m, 1H), 6.54 (m, 1H), 4.19 (m, 1H), 3.37 (m, 2H), 3.20 (m, 2H), 2.87 (s, 3H), 2.03 (m, 1H), 1.97 - 1.54 (m, 5H). 19F NMR (376 MHz, DMSO-d6) δ -74.83, -127.52, -150.54, - 156.65.
-
- Example 452 was made analogously to Example 333 using (S)-1-(2-aminoethyl)pyrrolidin-3-ol in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O2.469.2/471.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.76 (s, 1H), 10.04 (br. s, 1H), 8.68 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.97-6.90 (m, 2H), 6.83 (dd, J = 12.2, 6.9 Hz, 1H), 6.53 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.43 (m, 1H), 3.68 (m, 6H), 3.41 (m, 2H), 2.15 (m, 1H), 1.88 (m, 1H). 19F NMR (376 MHz, DMSO) δ - 74.97, -127.34, -150.40, -156.84.
-
- Example 453 was made analogously to Example 333 using 1-(2-methoxyethyl)piperidin-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)piperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H24ClF3N6O2.497.2/499.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.81 (s, 1H), 9.63 (br. s, 1H), 8.68 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.96-6.88 (m, 2H), 6.81 (dd, J = 12.2, 6.9 Hz, 1H), 6.55 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 3.72 (m, 1H), 3.67 (app. t, J = 4.9 Hz, 2H), 3.50 (m, 1H), 3.35 (m, 2H), 3.32 (s, 3H), 3.25 (m, 1H), 2.95-2.70 (m, 2H), 2.05-1.75 (m, 3H), 1.48 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -75.0 (9F), -127.5 (1F), -150.6 (1F), -157.0 (1F).
-
- Example 454 was made analogously to Example 333 using 1-(2-methoxyethyl)pyrrolidin-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O2.483.3/485.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 10.19 (br. s, 1H), 8.72 (s, 1H), 7.26 (d, J = 10.0 Hz, 1H), 7.13 - 7.05 (m, 2H), 6.93 (dd, J = 6.5, 2.6 Hz, 1H), 6.87 (dt, J = 12.0, 4.8 Hz, 1H), 6.53 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 4.65 - 4.45 (m, 1H), 3.98 - 3.70 (m, 1H), 3.67 - 3.56 (m, 3H), 3.50 - 3.37 (m, 3H), 3.32 (d, J = 7.0 Hz, 3H), 3.11 (m, 1H), 2.37 - 2.25 (m, 1H), 2.07 - 1.84 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -75.04 (9F), -127.36 (1F), - 150.26 (1F), -156.63 (1F).
-
- Example 455 was made analogously to Example 333 using 1-isopropylpiperidin-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-isopropylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H24ClF3N6O.481.3/483.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 9.26 (s, 1H), 8.67 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.85 - 6.75 (m, 2H), 6.54 (m, 1H), 4.16 (m, 1H), 3.59 - 3.51 (m, 2H), 3.36 (m, 1H), 2.94 - 2.77 (m, 2H), 2.00 (m, 2H), 1.77 (m, 1H), 1.54 (m, 1H), 1.26 (t, J = 6.2 Hz, 6H). 19F NMR (377 MHz, DMSO-d6) δ -74.90 (9F), -127.52 (1F), -150.59 (1F), -157.02 (1F).
-
- Example 456 was made analogously to Example 333 using 2-(3-methoxyazetidin-1-yl)ethan-1-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(3-methoxyazetidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O2.469.2/471.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 9.94 (br. s, 1H), 8.72 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.97 - 6.90 (m, 2H), 6.85 (dd, J = 12.2, 6.9 Hz, 1H), 6.53 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 4.30 - 4.15 (m, 3H), 4.03 (m, 2H), 3.55 (m, 2H), 3.41 (m, 2H), 3.25 (s, 3H). 19F NMR (377 MHz, DMSO-d6) δ -75.03 (9F), -127.30 (1F), -150.32 (1F), -157.00 (1F).
-
- Example 457 was made analogously to Example 333 using (R)-1-methylpyrrolidin-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C19H18ClF3N6O.439.2/441.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 10.11 (br. s, 0.5H), 9.85 (br. s, 0.5H), 8.71 (s, 1H), 7.28 (d, J = 9.3 Hz, 0.5H), 7.15 - 7.01 (m, 1.5H), 6.93 (dt, J = 6.3, 2.8 Hz, 1H), 6.87 (dd, J = 12.2, 6.9 Hz, 1H), 6.53 (m, 1H), 4.53 (m, 0.5H), 4.45 (m, 0.5H), 3.71 (m, 0.5H), 3.62 (m, 0.5H), 3.35 (m, 1H), 3.23 (m, 0.5H), 3.16 - 2.97 (m, 1.5H), 2.90 (d, J = 5.0 Hz, 1.5H), 2.88 (d, J = 4.6 Hz, 1.5H), 2.56 (m, 0.5H), 2.31 (m, 0.5H), 2.06 (m, 0.5H), 1.91 (m, 0.5H). 19F NMR (377 MHz, DMSO-d6) δ -75.00, -127.38, -150.33, -156.70.
-
- Example 458 was made analogously to Example 333 using (3R,4R)-4-methoxy-1-methylpyrrolidin-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O2.469.2/471.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.76 (s, 1H), 10.13 (br. s, 1H), 8.70 (s, 1H), 7.20 (m, 1H), 7.09 (td, J = 9.1, 3.0 Hz, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.86 (m, 1H), 6.53 (dt, J = 8.9, 3.4 Hz, 1H), 4.41 (m, 1H), 4.09 (m, 1H), 3.95 (m, 1H), 3.71 (m, 1H), 3.37 (m, 3H), 3.21 (m, 1H), 3.10 (m, 1H), 2.90 (m, 3H). 19F NMR (377 MHz, DMSO-d6) δ -74.80, -127.49, - 150.49, -157.01.
-
- Example 459 was made analogously to Example 460 using (S)-N-(3-chlorophenyl)-4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate. The TFA salt of (S*)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H21ClF2N6O.435.2/437.1 (M+1);435.2/437.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.90 (s, 1H), 9.66 (br. s, 1H), 8.67 (s, 1H), 7.06 (t, J = 8.1 Hz, 1H), 6.95 (m, 1H), 6.82 (dd, J = 8.0, 2.2 Hz, 1H), 6.79 (t, J = 2.2 Hz, 1H), 6.53 (dd, J = 8.2, 2.1 Hz, 1H), 4.06 (m, 1H), 3.67 (m, 1H), 3.42 (m, 1H), 2.83 (d, J = 4.4 Hz, 3H), 2.82 - 2.73 (m, 2H), 2.00 (m, 2H), 1.75 (m, 1H), 1.45 (m, 1H).; 1H NMR (400 MHz, DMSO-d6) δ 10.88 (s, 1H), 9.63 (br. s, 1H), 8.69 (s, 1H), 7.06 (t, J = 8.0 Hz, 1H), 6.92 (m, 1H), 6.83 (m, 2H), 6.79 (t, J = 2.2 Hz, 1H), 6.52 (dd, J = 8.1, 2.2 Hz, 1H), 4.06 (m, 1H), 3.65 (m, 1H), 3.42 (m, 1H), 2.83 (d, J = 4.6 Hz, 3H), 2.81 - 2.75 (m, 2H), 1.99 (m, 2H), 1.72 (m, 1H), 1.45 (m, 1H). 19F NMR (376 MHz, DMSO-d6) δ -74.95, -150.50, -156.86.
-
- Methyl 4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was made analogously to Example 39 using 1-methylpiperidin-3-amine in place of N,N-dimethylpropane-1,3-diamine. The TFA salt of methyl 4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate was isolated as an amorphous yellow oil. C21H32F2N4O3Si. 455.2 (M+1).
- N-(3-chlorophenyl)-4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxamide was made analogously to Example 39 using methyl 4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate in place of methyl 2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxylate and 3-chloroaniline in place of 3-chloro-4-fluoroaniline. N-(3-chlorophenyl)-4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7- carboxamide was purified by silica gel chromatography (0-16% MeOH/CH2Cl2 w/ 0.5% NEt3) isolated as a white solid. C21H32F2N4O3Si. 455.2 (M+1). Each enantiomer was isolated using chiral SFC (AD-H, 15% iPrOH, 60 mL/min, 100 bar). C26H34ClF2N5O2Si. 550.3/552.1 (M+1).
- (R)-N-(3-chlorophenyl)-4,5-difluoro-2-((1-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-7-carboxamide (60 mg, 0.11 mmol, 1 equiv) was dissolved in CH2Cl2 (2 mL) and TFA (2 mL) was added. The SEM-deprotection was stirred overnight before being concentrated in vacuo. The crude product was dissolved in EtOAc, saturated aqueous NaHCO3 was added and the mixture was extracted twice with EtOAc. The combined organics were dried over MgSO4, filtered and concentrated in vacuo. The resulting residue was dissolved in CH2Cl2 (1 mL) and potassium carbonate (106 mg, 0.76 mmol, 7 equiv) and PCl5 (68 mg, 0.33 mmol, 3 equiv) were added. The reaction was stirred at room temperature for 3 hours before being concentrated in vacuo. A solution of TMSONH2 (0.132 mL, 1.1 mmol, 10 equiv) in trifluoroethanol (1.5 mL) was added at 0 °C. The reaction was slowly warmed to room temperature and stirred for 1 hour before being concentrated in vacuo. A solution of 2N HCl was added and the resulting mixture was stirred for 30 minutes before diluting with DMF/H2O and purification by reverse phase HPLC. The TFA salt of (R)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H21ClF2N6O.435.2/437.1 (M+1);435.2/437.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.90 (s, 1H), 9.66 (br. s, 1H), 8.67 (s, 1H), 7.06 (t, J = 8.1 Hz, 1H), 6.95 (m, 1H), 6.82 (dd, J = 8.0, 2.2 Hz, 1H), 6.79 (t, J = 2.2 Hz, 1H), 6.53 (dd, J = 8.2, 2.1 Hz, 1H), 4.06 (m, 1H), 3.67 (m, 1H), 3.42 (m, 1H), 2.83 (d, J = 4.4 Hz, 3H), 2.82 - 2.73 (m, 2H), 2.00 (m, 2H), 1.75 (m, 1H), 1.45 (m, 1H).;1H NMR (400 MHz, DMSO-d6) δ 10.88 (s, 1H), 9.63 (br. s, 1H), 8.69 (s, 1H), 7.06 (t, J = 8.0 Hz, 1H), 6.92 (m, 1H), 6.83 (m, 2H), 6.79 (t, J = 2.2 Hz, 1H), 6.52 (dd, J = 8.1, 2.2 Hz, 1H), 4.06 (m, 1H), 3.65 (m, 1H), 3.42 (m, 1H), 2.83 (d, J = 4.6 Hz, 3H), 2.81 - 2.75 (m, 2H), 1.99 (m, 2H), 1.72 (m, 1H), 1.45 (m, 1H). 19F NMR (376 MHz, DMSO-d6) δ -74.95, -150.50, -156.86.
-
- Example 461 was made analogously to Example 333 using N 1,N 1-dimethylcyclopentane-1,2-diamine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)cyclopentyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O.467.3/469.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.74 (s, 1H), 8.69 (s, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.83 (m, 1H), 6.52 (m, 1H), 4.34 (m, 1H), 3.63 (m, 1H), 2.85 (s, 6H), 2.15 - 2.00 (m, 2H), 1.87 (m, 1H), 1.79 - 1.63 (m, 3H).
-
- Example 462 was made analogously to Example 333 using tert-butyl (S)-3-aminoazepane-1-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (S)-2-(azepan-3-ylamino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O.453.3 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.77 (br. s, 2H), 8.66 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.86 (d, J = 6.9 Hz, 1H), 6.82 (dd, J = 12.3, 6.9 Hz, 1H), 6.58 - 6.51 (m, 1H), 4.15 (m, 1H), 3.42 (m, 1H), 3.26 (m, 1H), 3.21 - 3.11 (m, 2H), 2.04 (m, 1H), 1.92 - 1.54 (m, 5H). 19F NMR (376 MHz, DMSO-d6) δ -74.9, -127.5, -150.5, -156.8.
-
- Example 463 was made analogously to Example 333 using tert-butyl (R)-3-aminoazepane-1-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (R)-2-(azepan-3-ylamino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O.453.2/455.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H), 8.76 (br. s, 2H), 8.66 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.83 (d, J = 6.8 Hz, 1H), 6.80 (d, J = 6.7 Hz, 1H), 6.54 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.15 (m, 1H), 3.42 (m, 1H), 3.26 (m, 1H), 3.20 - 3.07 (m, 2H), 2.05 (m, 1H), 1.91 - 1.54 (m, 5H). 19F NMR (376 MHz, DMSO-d6) δ -74.8, -127.5, -150.5, -156.8.
-
- Example 464 was made analogously to Example 333 using tert-butyl 3-aminopyrrolidine-1-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(pyrrolidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C18H16ClF3N6O.425.2/427.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H), 8.89 (br. s, 1H), 8.79 (br. s, 1H), 8.70 (s, 1H), 7.12 - 7.05 (m, 2H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.85 (dd, J = 12.3, 6.9 Hz, 1H), 6.53 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 4.44 (m, 1H), 3.47 (m, 1H), 3.27 (m, 2H), 2.27 (m, 1H), 1.94 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.9 (9F), -127.4 (1F), -150.44 (1F), -156.81 (1F).
-
- Example 465 was made analogously to Example 333 using (R)-1-(oxetan-3-yl)piperidin-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(oxetan-3-yl)piperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H22ClF3N6O2.495.3/497.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.82 (s, 1H), 10.61 br. (s, 1H), 8.70 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.04 (m, 1H), 6.92 (dd, J = 6.6, 2.7 Hz, 1H), 6.84 (dd, J = 12.3, 6.9 Hz, 1H), 6.54 (dt, J = 8.9, 3.4 Hz, 1H), 4.80 - 4.65 (m, 4H), 4.40 (m, 1H), 4.14 (m, 1H), 3.53 (m, 1H), 3.38 (m, 1H), 2.84 - 2.65 (m, 2H), 2.1 - 1.90 (m, 2H), 1.77 (m, 1H), 1.53 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.8 (9F), -127.3 (1F), -150.3 (1F), -156.7 (1F).
-
- Example 466 was made analogously to Example 333 using (1,4-dimethylpiperidin-2-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1,4-dimethylpiperidin-2-yl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H24ClF3N6O.481.3/483.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 9.20 (br. s, 1H), 8.69 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.02 (m, 1H), 6.92 (dd, J = 6.5, 2.7 Hz, 1H), 6.84 (dd, J = 12.2, 6.9 Hz, 1H), 6.54 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.81 (m, 1H), 3.66 (m, 1H), 3.40 (m, 1H), 3.27 (m, 1H), 3.08 (m, 1H), 2.99 (s, 3H), 1.93 (m, 1H), 1.84 - 1.60 (m, 2H), 1.25 (m, 1H), 0.93 (d, J = 6.4 Hz, 3H). 19F NMR (376 MHz, DMSO-d6) δ -75.1 , -127.4 , -150.4, -157.0.
-
- Example 467 was made analogously to Example 333 using tert-butyl 3-(aminomethyl)morpholine-4-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((morpholin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C19H18ClF3N6O2.455.2/457.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 9.06 (br. s, 2H), 8.71 (s, 1H), 7.10 (t, J = 9.1 Hz, 1H), 7.02 (m, 1H), 6.92 (dd, J = 6.6, 2.7 Hz, 1H), 6.83 (dd, J = 12.3, 6.9 Hz, 1H), 6.53 (dt, J = 9.0, 3.4 Hz, 1H), 3.95 (m, 1H), 3.88 (m, 1H), 3.67 (m, 1H), 3.62 - 3.50 (m, 4H), 3.30 (m, 1H), 3.09 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.9 (9F), -127.2 (1F), -150.2 (1F), -156.4 (1F).
-
- Example 468 was made analogously to Example 333 using tert-butyl (3R,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3R,4S)-4-hydroxypyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C18H16ClF3N6O2.441.2/443.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.83 (s, 1H), 9.18 (br. s, 1H), 8.81 (br. s, 1H), 8.69 (s, 1H), 7.11 (t, J = 9.1 Hz, 1H), 6.95 - 6.90 (m, 2H), 6.82 (dd, J = 12.3, 6.8 Hz, 1H), 6.53 (dt, J = 8.8, 3.4 Hz, 1H), 6.13 (br. s, 1H), 4.49 (m, 1H), 4.36 (m, 1H), 3.56 (m, 1H), 3.42 (m, 1H), 3.17 (m, 1H), 3.01 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.7 (9F), -127.4 (1F), -150.3 (1F), -156.8 (1F).
-
- Example 469 was made analogously to Example 333 using (1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H22ClF3N6O. 479.3/481.1 (M+1). 1H NMR (400 MHz, DMSO-d6, 2:1 mixture of diastereomers) δ 10.82 (br. s, 1H), 9.72 (s, 1H), 8.69 (d, J = 7.8 Hz, 1H), 7.17 - 7.03 (m, 2H), 6.90 (td, J = 6.5, 2.8 Hz, 1H), 6.81 (dd, J = 12.3, 7.0 Hz, 1H), 6.55 (ddd, J = 8.9, 4.6, 3.1 Hz, 1H), 4.29 (m, 1H), 4.05 - 3.70 (m, 2H), 2.75 (d, J = 4.9 Hz, '2H'), 2.63 (d, J = 4.8 Hz, '1H'), 2.23 (m, 1H), 2.14 - 1.80 (m, 5H), 1.73 (m, 1H), 1.54 (m, 1H). 19F NMR (377 MHz, DMSO) δ -75.02, Major: -127.83, -150.68,-156.90, Minor: -127.66, -150.46, -156.51
-
- Example 470 was made analogously to Example 333 using (S)-2-(2-(trifluoromethyl)pyrrolidin-1-yl)ethan-1-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(trifluoromethyl)pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H19ClF6N6O. 521.3/523.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.99 (br. s, 1H), 8.82 (s, 1H), 7.95 (br. s, 1H), 7.13 - 7.03 (m, 2H), 6.97 (dd, J = 6.5, 2.7 Hz, 1H), 6.54 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.59 - 3.40 (m, 3H), 3.19 (m, 1H), 3.03 (dt, J = 13.6, 7.1 Hz, 1H), 2.82 (dt, J = 12.7, 5.2 Hz, 1H), 2.46 (m, 1H), 2.04 (m, 1H), 1.87 - 1.64 (m, 3H). 19F NMR (377 MHz, DMSO-d6) δ -75.31 (9F), -75.43 (d, J = 8.2 Hz, 3F), -126.82 (1F), -147.12 (1F), -155.04 (1F).
-
- Example 471 was made analogously to Example 333 using (tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanamine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((hexahydro-1H-pyrrolizin-7a-yl)methyl)amino)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H22ClF3N6O. 479.4/481.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.75 (br. s, 1H), 8.74 (s, 1H), 7.08 (t, J = 9.1 Hz, 1H), 6.93 (dd, J = 6.5, 2.7 Hz, 1H), 6.87 (dd, J = 12.2, 7.1 Hz, 1H), 6.50 (dq, J = 9.0, 3.0 Hz, 1H), 3.69 (app. d, J = 5.9 Hz, 2H), 3.46 (dq, J = 12.0, 6.1 Hz, 2H), 3.20 (m, 2H), 2.14 - 1.96 (m, 4H), 1.95 - 1.80 (m, 4H). 19F NMR (377 MHz, DMSO-d6) δ -75.1 (9F), -127.3 (1F), -149.9 (dd, J = 22.6, 12.3 Hz, 1F), -156.8 (1F).
-
- Example 472 was made analogously to Example 333 using tert-butyl 2-(aminomethyl)-3,3-dimethylazetidine-1-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((3,3-dimethylazetidin-2-yl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O. 453.2/455.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 8.97 (br. s, 1H), 8.75 - 8.65 (m, 2H), 7.09 (t, J = 9.1 Hz, 1H), 6.97 - 6.78 (m, 3H), 6.53 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.24 (m, 1H), 3.80 - 3.59 (m, 3H), 3.49 (m, 1H), 1.27 (s, 3H), 1.22 (s, 3H). 19F NMR (377 MHz, DMSO-d6) δ -75.0 (9F), -127.3 (1F), -150.3 (1F), -156.7 (d, J = 23.0 Hz, 1F).
-
- Example 473 was made analogously to Example 333 using 4-(pyrrolidin-1-yl)tetrahydro-2H-pyran-3-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((4-(pyrrolidin-1-yl)tetrahydro-2H-pyran-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C23H24ClF3N6O2. 509.3/511.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 9.65 (br. s, 1H), 8.68 (s, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 9.1 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.84 (dd, J = 12.3, 6.8 Hz, 1H), 6.54 (ddd, J = 9.0, 4.0, 2.8 Hz, 1H), 4.35 (s, 1H), 4.04 (dd, J = 12.5, 3.2 Hz, 1H), 3.83 - 3.73 (m, 2H), 3.66 (m, 1H), 3.55 - 3.40 (m, 5H), 2.13 (m, 1H), 2.00 - 1.85 (m, 4H), 1.71 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.93 (9F), -127.54 (1F), -150.41 (1F), -156.80 (1F).
-
- Example 474 was made analogously to Example 333. The TFA salt of 2-(((1S,2R)-2-aminocyclohexyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C20H20ClF3N6O. 453.2/455.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.64 (s, 1H), 7.78 (br. s, 3H), 7.12 (t, J = 9.1 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.88 (dd, J = 6.5, 2.7 Hz, 1H), 6.76 (dd, J = 12.3, 6.8 Hz, 1H), 6.53 (ddd, J = 9.0, 3.9, 2.6 Hz, 1H), 4.27 (m, 1H), 3.45 (m, 1H), 1.81 - 1.60 (m, 4H), 1.58 - 1.31 (m, 4H). 19F NMR (376 MHz, DMSO-d6) δ -74.8, -127.66, -150.5, -156.8.
-
- Example 475 was made analogously to Example 333 using 2-methyl-1,2,3,4-tetrahydroisoquinolin-4-amine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C24H20ClF3N6O. 501.3/503.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H), 10.32 (br. s, 1H), 8.69 (s, 1H), 7.49 (m, 1H), 7.45 - 7.34 (m, 2H), 7.30 - 7.20 (m, 2H), 7.07 (m, 1H), 6.95 - 6.80 (m, 2H), 6.51 (m, 1H), 5.62 (m, 1H), 5.16 (m, 1H), 4.61 (m, 1H), 4.37 (m, 1H), 3.40 (m, 1H), 3.03 (s, 3H). 19F NMR (376 MHz, DMSO-d6) δ -74.8, -127.4, -150.0 -156.9.
-
- Example 476 was made analogously to Example 333 using (3S,4S)-N 3,N 3-diethyltetrahydrofuran-3,4-diamine. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((3S*,4S*)-4-(diethylamino)tetrahydrofuran-3-yl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H24ClF3N6O2. 497.3/499.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.77 (s, 1H), 10.18 (br. s, 1H), 8.69 (s, 1H), 7.38 (s, 1H), 7.08 (t, J = 9.1 Hz, 1H), 6.97 - 6.81 (m, 2H), 6.53 (dt, J = 9.0, 3.4 Hz, 1H), 4.63 (m, 1H), 4.21 (m, 1H), 4.15 - 4.03 (m, 2H), 3.59 (m, 2H), 3.40 - 3.20 (m, 4H), 1.23 (t, J = 7.2 Hz, 6H). 19F NMR (376 MHz, DMSO-d6) δ-74.9, -127.4, -150.1, -157.2.
-
- Example 477 was made analogously to Example 333 using tert-butyl 6-amino-1,4-oxazepane-4-carboxylate in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of 2-((1,4-oxazepan-6-yl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C19H18ClF3N6O2. 455.2/457.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.81 (s, 1H), 9.01 (br. s, 2H), 8.69 (s, 1H), 7.11 (t, J = 9.1 Hz, 1H), 6.97 (d, J = 7.3 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.82 (dd, J = 12.3, 6.9 Hz, 1H), 6.53 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.33 (m, 1H), 3.99 - 3.74 (m, 4H), 3.54 (m, 1H), 3.46 (m, 1H), 3.32 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -74.9 (9F), -127.5 (1F), -150.5 (1F), -156.8 (1F).
-
- Example 478 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-((2S,6R)-2,6-dimethylmorpholino)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-((2S,6R)-2,6-dimethylmorpholino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C21H25ClFN7O2. 462.3/464.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.40 (br. s, 1H), 8.98 (s, 1H), 8.20 (br. s, 1H), 8.00 (d, J = 6.2 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.95 (d, J = 6.2 Hz, 1H), 6.57 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 3.88 - 3.78 (m, 4H), 3.63 - 3.53 (m, 2H), 3.40 - 3.31 (m, 2H), 2.77 - 2.61 (m, 2H), 1.15 (d, J = 6.3 Hz, 6H). 19F NMR (377 MHz, DMSO-d6) δ -74.60 (9F), -126.59 (IF).
-
- Example 479 was made analogously to Example 333 using (3R,4R)-4-methoxy-1-methylpyrrolidin-3-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C19H21ClFN7O2. 434.2/436.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.25 (br. s, 1H), 10.23 (br. s, 1H), 8.92 (s, 1H), 7.98 (s, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.03 - 6.90 (m, 2H), 6.67 (m, 1H), 4.49 (m, 1H), 4.11 (m, 1H), 3.97 (m, 1H), 3.72 (m, 1H), 3.36 (s, 3H), 3.30 - 3.04 (m, 2H), 2.90 (s, 3H). 19F NMR (377 MHz, DMSO-d6) δ -74.4, -126.7.
-
- Example 480 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (3R,4R)-N3,N3-diethyltetrahydrofuran-3,4-diamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((3R,4R)-4-(diethylamino)tetrahydrofuran-3-yl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C21H25ClFN7O2. 462.2/464.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.20 (br. s, 1H), 8.86 (s, 1H), 7.96 (s, 2H), 7.07 (s, 1H), 7.00 - 6.85 (m, 1H), 6.53 (s, 1H), 4.65 (m, 1H), 4.21 (m, 1H), 4.16 - 4.05 (m, 2H), 3.36 - 3.22 (m, 4H), 1.24 (t, J = 7.2 Hz, 6H).
-
- Example 481 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (S)-2-(2-(trifluoromethyl)pyrrolidin-1-yl)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(2-(trifluoromethyl)pyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C20H20ClF4N7O. 486.3/488.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.41 (br. s, 1H), 8.95 (s, 1H), 7.97 (d, J = 6.4 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.94 (d, J = 6.3 Hz, 1H), 6.59 (dt, J = 9.0, 3.5 Hz, 1H), 3.60 - 3.50 (m, 2H), 3.18 (m, 1H), 3.06 (m, 1H), 2.81 (dt, J = 11.6, 5.4 Hz, 1H), 2.45 (m, 1H), 2.02 (m, 1H), 1.87 - 1.64 (m, 4H). 19F NMR (376 MHz, DMSO-d6) δ -74.5 , -75.5, -126.5.
-
- Example 482 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (R)-(4-methylmorpholin-3-yl)methanamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of (R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C19H21ClFN7O2. 434.2/436.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.87 (br. s, 1H), 7.95 (s, 1H), 7.09 (t, J = 8.9 Hz, 1H), 7.05 - 6.8 (m, 2H), 6.57 (dt, J = 9.0, 3.4 Hz, 1H), 4.09 - 3.88 (m, 2H), 3.69 - 3.40 (m, 7H), 2.98 (s, 3H).
-
- Example 483 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(2,6-dimethylmorpholino)propan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(2,6-dimethylmorpholino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C22H27ClFN7O2. 476.3/478.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.80 (br. s, 1H), 11.31 (br. s, 1H), 8.95 (s, 1H), 7.99 (d, J = 6.0 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.00 (dd, J = 6.6, 2.7 Hz, 1H), 6.93 (d, J = 6.0 Hz, 1H), 6.57 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.98 - 3.66 (m, 7H), 2.83 - 2.65 (m, 2H), 1.28 (d, J = 6.6 Hz, 3H), 1.17 (d, J = 4.3 Hz, 3H), 1.15 (d, J = 4.2 Hz, 3H). 19F NMR (377 MHz, DMSO-d6) δ -74.5 (9H), -126.8 (1H).
-
- Example 484 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(2,6-dimethylmorpholino)-2-methylpropan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(2,6-dimethylmorpholino)-2-methylpropyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C23H29ClFN7O2. 490.2/492.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.60 (br. s, 1H), 11.27 (br. s, 1H), 8.89 (s, 1H), 7.99 (d, J = 6.0 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.00 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.0 Hz, 1H), 6.57 (ddd, J = 8.9, 3.9, 2.7 Hz, 1H), 4.00 - 3.85 (m, 2H), 3.78 - 3.50 (m, 4H), 2.70 (m, 2H), 1.32 (s, 6H), 1.19 (s, 3H), 1.17 (s, 3H). 19F NMR (376 MHz, DMSO-d6) δ -74.51 (9F),-126.81 (1F).
-
- Example 485 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(2,5-dimethylmorpholino)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(2,5-dimethylmorpholino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C21H25ClFN7O2. 462.3/464.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.28 (br. s, 1H), 8.92 (m, 1H), 7.99 (d, J = 6.0 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 6.99 (d, J = 6.3 Hz, 1H), 6.93 (t, J = 6.8 Hz, 1H), 6.58 (ddd, J = 9.3, 4.4, 2.9 Hz, 1H), 4.00 - 3.75 (m, 6H), 3.37 - 3.17 (m, 2H), 2.93 (m, 2H), 1.33 (d, J = 6.8 Hz, 2H), 1.16 (d, J = 6.2 Hz, 4H). 19F NMR (376 MHz, DMSO-d6) δ -74.5, -126.6.
-
- Example 486 was made analogously to Example 333 using (1R,2R)-N1,N1-dimethylcyclopentane-1,2-diamine in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclopentyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O. 467.3/469.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.74 (br. s, 1H), 8.69 (s, 1H), 7.09 (t, J = 9.0 Hz, 1H), 6.91 (dd, J = 6.5, 2.7 Hz, 1H), 6.84 (m, 1H), 6.52 (m, 1H), 4.34 (m, 1H), 3.61 (m, 1H), 2.85 (s, 6H), 2.17 - 1.96 (m, 2H), 1.89 (m, 1H), 1.80 - 1.59 (m, 3H). 19F NMR (376 MHz, DMSO-d6) δ -74.8, -127.4, -150.3, -157.2.
-
- To a solution of 2-(dimethylamino)ethane-1-thiol (0.01 mL, 0.096 mmol, 1.9 equiv) in 0.5 mL THF at -78 °C was added 0.04 mL of n-BuLi (0.06 mmol, 1.6 equiv). The mixture was stirred for 10 minutes before the addition of 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one (25 mg, 0.05 mmol, 1 equiv) in 0.5 mL of THF. The reaction was slowly warmed to room temperature and stirred for 3 hours before being quenched with saturated aqueous NH4Cl. The reaction mixture was extracted twice with EtOAc, the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product was dissolved in 0.75 mL CH2Cl2 and 0.75 mL of TFA was added. The reaction was stirred at room temperature for 3 hours before being concentrated in vacuo. The crude product was then dissolved in 0.4 mL THF, 0.4 mL MeOH and 0.9 mL of 2N aqueous NaOH was added. The reaction was stirred at room temperature for 30 minutes before being neutralized with 0.9 mL of 2N aqueous HCl, diluted with DMF and purified by reverse phase HPLC. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)thio)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C17H18ClFN6OS. 409.3/411.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.99 (br. s, 1H), 8.87 (s, 1H), 8.21 (d, J = 5.2 Hz, 1H), 7.15 - 7.00 (m, 2H), 6.93 (dd, J = 6.6, 2.7 Hz, 1H), 6.50 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 3.70 - 3.55 (m, 2H), 3.55 - 3.45 (m, 2H), 2.89 (s, 6H). 19F NMR (376 MHz, DMSO-d6) δ -74.69 (9F), -127.08 (1F).
-
- Example 488 was made analogously to Example 212 using 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)thio)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C18H17ClF3N5OS. 444.3/446.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.91 (br. s, 1H), 10.83 (br. s, 1H), 9.65 (s, 1H), 8.76 (s, 1H), 7.18 - 7.00 (m, 2H), 6.96 (dd, J = 6.6, 2.7 Hz, 1H), 6.49 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.61 - 3.44 (m, 4H), 2.87 (d, J = 3.0 Hz, 6H). 19F NMR (377 MHz, DMSO-d6) δ -74.5 (6F), -127.0 (1F), -149.5 (1F), -154.15 (1F).
-
- Example 489 was made analogously to Example 333 using (1-(2-aminoethyl)piperidin-2-yl)methanol in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(hydroxymethyl)piperidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C22H24ClF3N6O2. 497.3/499.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 9.56 (br. s, 1H), 8.72 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.98 (s, 1H), 6.94 (dd, J = 6.5, 2.7 Hz, 1H), 6.85 (dd, J = 12.2, 6.9 Hz, 1H), 6.52 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.88 (m, 1H), 3.80 - 3.65 (m, 2H), 3.60 - 3.40 (m, 3H), 3.35 - 3.20 (m, 2H), 3.13 (m, 1H), 1.90 - 1.65 (m, 5H), 1.50 (m, 1H). 19F NMR (377 MHz, DMSO-d6) δ -75.1 (9F), -127.3 (1F), -150.2 (1F), -156.9 (1F).
-
- Example 490 was made analogously to Example 333 using (1-(2-aminoethyl)pyrrolidin-2-yl)methanol in place of tert-butyl (2-aminoethyl)carbamate. The TFA salt of N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H22ClF3N6O2. 483.3/485.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.79 (br. s, 1H), 9.82 (br. s, 1H), 8.70 (s, 1H), 7.09 (t, J = 9.1 Hz, 1H), 7.02 (s, 1H), 6.94 (dd, J = 6.6, 2.7 Hz, 1H), 6.85 (dd, J = 12.2, 6.9 Hz, 1H), 6.53 (ddd, J = 9.0, 4.1, 2.7 Hz, 1H), 3.78 - 3.64 (m, 4H), 3.63 - 3.50 (m, 3H), 3.35 (m, 1H), 3.19 (m, 1H), 2.14 - 1.95 (m, 2H), 1.90 (m, 1H), 1.75 (m, 1H). 19F NMR (376 MHz, DMSO-d6) δ -75.1 , -127.3, -150.2, -156.9.
-
- Example 491 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(3,3-difluoropyrrolidin-1-yl)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(3,3-difluoropyrrolidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C19H19ClF3N7O. 454.3/456.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.40 (br. s, 1H), 8.97 (s, 1H), 7.98 (d, J = 6.2 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.5, 2.7 Hz, 1H), 6.94 (d, J = 6.2 Hz, 1H), 6.59 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 3.62 (m, 2H), 3.34 (m, 2H), 3.18 - 2.89 (m, 4H), 2.45 - 2.28 (m, 2H). 19F NMR (377 MHz, DMSO-d6) δ - 74.7 (9F), -92.1 (2F), -126.6 (1F).
-
- Example 492 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-aminoethane-1-sulfonamide in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-sulfamoylethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C15H15ClFN7O3S. 428.1/430.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 12.00 (br. s, 1H), 11.47 (br. s, 1H), 8.99 (s, 1H), 7.97 (d, J = 6.4 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.06 (s, 2H), 7.04 (dd, J = 6.8, 3.0 Hz, 1H), 6.92 (d, J = 6.4 Hz, 1H), 6.59 (ddd, J = 8.9, 4.0, 2.8 Hz, 1H), 3.87 (q, J = 6.5 Hz, 2H), 3.35 (t, J = 6.6 Hz, 2H). 19F NMR (377 MHz, DMSO-d6) δ -74.6 (6F), -126.5 (1F).
-
- Example 493 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(methylsulfonyl)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methylsulfonyl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C16H16ClFN6O3S. 427.1/429.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.46 (br. s, 1H), 8.97 (s, 1H), 7.99 (d, J = 6.3 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.7 Hz, 1H), 6.95 (d, J = 6.3 Hz, 1H), 6.59 (dq, J = 8.8, 3.0 Hz, 1H), 3.91 (q, J = 6.4 Hz, 2H), 3.51 (d, J = 6.4 Hz, 2H), 3.07 (s, 3H). 19F NMR (376 MHz, DMSO-d6) δ -74.6 (6F), -126.5 (1F).
-
- Example 494 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and pyrimidin-2-ylmethanamine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((pyrimidin-2-ylmethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C18H14ClFN8O. 413.2/415.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.49 (br. s, 1H), 9.00 (s, 1H), 8.83 (d, J = 4.9 Hz, 2H), 7.99 (d, J = 6.3 Hz, 1H), 7.48 (t, J = 4.9 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.05 (dd, J = 6.5, 2.7 Hz, 1H), 6.95 (d, J = 6.3 Hz, 1H), 6.60 (dt, J = 8.9, 3.3 Hz, 1H), 4.91 (d, J = 5.9 Hz, 2H). 19F NMR (377 MHz, DMSO-d6) δ -74.7 (6F), -126.6 (1F).
-
- Example 495 was made analogously to Example 333 using (R)-1-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride and N-ethyl-N-isopropylpropan-2-amine in place of tert-butyl (2-aminoethyl)carbamate and 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chlorophenyl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. The TFA salt of (R)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H23ClF2N6O2. 465.2/467.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.87 (s, 1H), 10.20 (br. s, 1H), 8.74 (s, 1H), 7.26 (m, 1H), 7.04 (m, 1H), 6.82 (m, 2H), 6.50 (m, 1H), 4.65 - 4.40 (m, 1H), 3.98 - 3.70 (m, 1H), 3.68 - 3.55 (m, 3H), 3.51 - 3.36 (m, 2H), 3.33 (m, 3H), 3.13 (m, 2H), 2.10 - 1.85 (m, 2H). 19F NMR (377 MHz, DMSO-d6) δ -75.0 (9F), -150.3 (1F), -156.7 (1F).
-
- Example 496 was made analogously to Example 333 using (R)-1-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride and N-ethyl-N-isopropylpropan-2-amine in place of tert-butyl (2-aminoethyl)carbamate and 4-(3-bromophenyl)-3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-1,2,4-oxadiazol-5(4H)-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one. The TFA salt of (R)-N-(3-bromophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide was isolated as an off-white solid. C21H23BrF2N6O2. 509.2/511.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 10.84 (s, 1H), 10.18 (br. s, 1H), 8.69 (d, J = 2.6 Hz, 1H), 7.17 (m, 1H), 7.05 (m, 1H), 7.00 - 6.91 (m, 3H), 6.84 (dd, J = 12.3, 6.9 Hz, 1H), 6.55 (dt, J = 7.7, 1.7 Hz, 1H), 4.65 - 4.35 (m, 1H), 4.00 - 3.70 (m, 1H), 3.65 - 3.55 (m, 3H), 3.51 - 3.36 (m, 2H), 3.32 (m, 3H), 3.12 (m, 2H), 2.11 - 1.85 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ -75.0 (9F), -150.4 (9F), -156.7 (9F).
-
- Example 497 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (S)-1-(oxetan-3-yl)piperidin-3-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(oxetan-3-yl)piperidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C21H23ClFN7O2. 460.2/462.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.39 (br. s, 1H), 8.95 (s, 1H), 8.16 (br. s, 1H), 7.98 (d, J = 6.2 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.94 (d, J = 6.2 Hz, 1H), 6.59 (dt, J = 8.9, 3.5 Hz, 1H), 4.75 - 4.65 (m, 4H), 4.20 - 4.05 (m, 2H), 3.80 - 3.55 (m, 2H), 2.85 - 2.60 (m, 2H), 2.05 - 1.85 (m, 2H), 1.81 - 1.45 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ -74.6, -126.7.
-
- Example 498 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 1-(2-methoxyethyl)piperidin-3-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(2-methoxyethyl)piperidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C21H25ClFN7O2. 462.1/464.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 9.70 (br. s, 1H), 8.89 (br. s, 1H), 7.96 (s, 1H), 7.10 (t, J = 9.0 Hz, 1H), 6.98 (m, 1H), 6.90 (m, 1H), 6.58 (dt, J = 8.9, 3.5 Hz, 1H), 4.20 (m, 1H), 3.75 - 3.60 (m, 2H), 3.50 - 3.25 (m, 4H), 3.32 (s, 3H), 2.95-2.80 (m, 2H), 2.09 - 1.73 (m, 3H), 1.51 (m, 1H). 19F NMR (376 MHz, DMSO-d6) δ-74.31, -126.85.
-
- Example 499 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 1-cyclopropylpyrrolidin-3-amine trifluoroacetic acid salt (1:2) and N-ethyl-N-isopropylpropan-2-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((1-cyclopropylpyrrolidin-3-yl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C20H21ClFN7O. 430.1/432.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.21 (br. s, 1H), 8.89 (s, 1H), 7.96 (m, 1H), 7.08 (t, J = 9.1 Hz, 1H), 7.05 - 6.80 (m, 2H), 6.57 (dt, J = 8.9, 3.5 Hz, 1H), 4.60 - 4.45 (m, 2H), 3.95 - 3.45 (m, 4H), 3.05 - 2.90 (m, 2H), 1.00 - 0.75 (m, 4H).
-
- Example 500 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (R)-1-(oxetan-3-yl)piperidin-3-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of (R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(oxetan-3-yl)piperidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C21H23ClFN7O2. 460.2/462.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.39 (br. s, 1H), 8.95 (s, 1H), 8.17 (br. s, 1H), 7.98 (d, J = 6.2 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.2 Hz, 1H), 6.59 (dt, J = 8.9, 3.5 Hz, 1H), 4.75 - 4.55 (m, 4H), 4.20 - 4.05 (m, 2H), 3.80 - 3.60 (m, 2H), 2.84 - 2.59 (m, 2H), 2.10 - 1.80 (m, 2H), 1.80 - 1.51 (m, 2H). 19F NMR (377 MHz, DMSO-d6) δ -74.6 (9F), -126.8 (1F).
-
- Example 501 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 4-(2-aminoethyl)-1-methylpiperazin-2-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(4-methyl-3-oxopiperazin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C20H22ClFN8O2. 461.2/463.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.36 (br. s, 1H), 8.95 (s, 1H), 7.97 (d, J = 6.2 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.59 (m, 1H), 3.80 - 3.60 (m, 3H), 3.45 - 3.35 (m, 3H), 3.25 - 3.05 (m, 2H), 3.05 - 2.90 (m, 2H), 2.85 (s, 3H). 19F NMR (377 MHz, DMSO-d6) δ -74.7 (9F), -126.7 (1F).
-
- Example 502 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 2-(3,3-difluoropiperidin-1-yl)ethan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((2-(3,3-difluoropiperidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C20H21ClF3N7O. 468.3/470.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 1H), 8.95 (s, 1H), 7.98 (d, J = 6.2 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.02 (dd, J = 6.5, 2.7 Hz, 1H), 6.93 (d, J = 6.2 Hz, 1H), 6.59 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 3.66 (m, 2H), 3.10 (m, 2H), 2.90 (m, 2H), 2.75 (m, 2H), 1.97 (m, 2H), 1.77 (m, 2H). 19F NMR (377 MHz, DMSO-d6) δ -84.9 (9F), -108.4 (2F), -136.8 (1F).
-
- Example 503 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 1-(3-aminopyrrolidin-1-yl)ethan-1-one in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of 2-((1-acetylpyrrolidin-3-yl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C19H19ClFN7O2. 432.4/434.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.40 (s, 1H), 8.96 (s, 1H), 7.98 (dd, J = 6.3, 4.2 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.3, 2.6 Hz, 1H), 6.94 (dd, J = 7.9, 6.3 Hz, 1H), 6.60 (dt, J = 9.3, 3.3 Hz, 1H), 4.54 - 4.36 (m, 2H), 3.77 (m, 1H), 3.59 (m, 1H), 2.34-2.11 (m, 2H), 2.07 (m, 1H), 1.96 (d, J = 11.3 Hz, 3H). 19F NMR (376 MHz, DMSO-d6) δ -74.5, -126.5.
-
- Example 504 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 1-(methylsulfonyl)pyrrolidin-3-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(methylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C18H19ClFN7O3S. 468.4/470.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.41 (s, 1H), 8.96 (s, 1H), 7.99 (d, J = 6.3 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.5, 2.7 Hz, 1H), 6.95 (d, J = 6.3 Hz, 1H), 6.60 (ddd, J = 9.0, 4.1, 2.8 Hz, 1H), 4.55 - 4.42 (m, 2H), 3.59 (m, 1H), 3.27 (m, 1H), 2.95 (s, 3H), 2.37 - 2.21 (m, 2H), 2.05 (m, 1H). 19F NMR (376 MHz, DMSO-d6) δ -74.5, -126.5.
-
- Example 505 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-(methylsulfonyl)propan-1-amine hydrochloride and N-ethyl-N-isopropylpropan-2-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3-(methylsulfonyl)propyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C17H18ClFN6O3S. 441.3/443.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.39 (br. s, 1H), 8.95 (s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.04 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.2 Hz, 1H), 6.59 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 3.56 (m, 2H), 3.20 (m, 2H), 3.00 (s, 3H), 2.04 (p, J = 7.1 Hz, 2H). 19F NMR (377 MHz, DMSO-d6) δ -74.2 (6F), -126.3 (1F).
-
- Example 506 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-(aminomethyl)tetrahydrothiophene 1,1-dioxide hydrochloride and N-ethyl-N-isopropylpropan-2-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-(((1,1-dioxidotetrahydrothiophen-3-yl)methyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C18H18ClFN6O3S. 453.3/455.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 8.95 (br. s, 1H), 7.97 (d, J = 6.3 Hz, 1H), 7.10 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.4, 2.7 Hz, 1H), 6.93 (d, J = 6.2 Hz, 1H), 6.59 (m, 1H), 3.56 (m, 2H), 3.24 (m, 2H), 3.08 (m, 1H), 2.91 (dd, J = 13.2, 9.5 Hz, 1H), 2.74 (d, J = 11.6 Hz, 1H), 2.25 (m, 1H), 1.86 (dq, J = 13.1, 9.3 Hz, 1H). 19F NMR (376 MHz, DMSO-d6) δ -74.4, -126.5.
-
- Example 507 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-((4-fluorophenyl)sulfonyl)propan-1-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of N-(3-chloro-4-fluorophenyl)-2-((3-((4-fluorophenyl)sulfonyl)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C22H19ClF2N6O3S. 521.4/523.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.38 (br. s, 1H), 8.94 (s, 1H), 7.97 (m, 3H), 7.51 (m, 2H), 7.10 (t, J = 9.0 Hz, 1H), 7.03 (dd, J = 6.5, 2.7 Hz, 1H), 6.92 (d, J = 6.3 Hz, 1H), 6.59 (dt, J = 9.0, 3.5 Hz, 1H), 3.50 (m, 2H), 3.43 (m, 2H), 1.89 (p, J = 7.1 Hz, 2H). 19F NMR (376 MHz, DMSO-d6) δ -74.4, -105.2,-126.5.
-
- Example 508 was made analogously to Example 229 using 3-(2-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and (R)-1-(oxetan-3-yl)pyrrolidin-3-amine in place of 3-(2-chloro-4,5-difluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one and 3-aminopropanamide hydrochloride, respectively. The TFA salt of (R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(oxetan-3-yl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide was isolated as an off-white solid. C20H21ClFN7O2. 446.4/448.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ 11.30 (br. s, 1H), 8.93 (s, 1H), 7.99 (d, J = 6.1 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.03 - 6.92 (m, 2H), 6.58 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 4.78 (t, J = 7.4 Hz, 2H), 4.69 - 4.55 (m, 3H), 4.47 (m, 1H), 3.8 - 3.3 (m, 5H), 2.09 (d, J = 11.6 Hz, 1H). 19F NMR (376 MHz, DMSO-d6) δ -74.6, -126.7.
- Activity testing was conducted in the Examples below using methods described herein and those well known in the art.
- To measure IDO1 inhibition in tissue culture, HeLa cells were treated with a test compound in the presence of IFNγ, which induces IDO1 expression. Following incubation, cell supernatants were assayed for kynurenine levels, an indicator of IDO1 activity.
- H1-HeLa cells (ATCC #CRL-1958) were seeded in 384-well plates (Greiner #82051-282) at a volume of 50 µL/well in DMEM (Corning #15-018-CM) supplemented with 10% FBS (Corning #35-011-CV) and 1% P/S/G (Corning #30-009-CL) at a density of 1,250 cells/well and incubated overnight at 37°C, 5% CO2/100% humidity. The following day, the test compounds were added in DMSO (0.5% final) at various concentrations, and IDO1 was inducibly expressed by the addition of 50 uL/well of 50ng/mL of INFγ (Peprotech #300-02) in cell plating media. As a positive control, 50 uL of the cell plating media without IFNγ was added to several wells. Following a 48 hour incubation, the plates were spun down at 1,200 RPM for 5 min at 10 °C. 65 µL/well of the supernatant was then transferred to new 384-well plates (Thermo #262160) that contained 10 uL/well of 30% TCA (Sigma #TO699), and the plates were sealed and incubated at 60°C for 30 min. The plates were then centrifuged for 15 min at 2,000 RPM at 10 °C. 40 µL/well of the supernatant was transferred to new 384-well plates (Thermo #262160) and was reacted with 40 µL/well of 2% (w/v) p-dimethlyaminobenzaldehyde (Sigma #156417) in glacial acetic acid (Sigma #A6283). The reaction was incubated at room temperature for 10 min and absorbance at 480 nm was read using a PerkinElmer Envision plate reader.
- Data in Table 1 were normalized based on positive (- IFNγ) and negative (+ IFNγ) controls and EC50 values were calculated from the fit of the dose-response curves to a four-parameter equation. All EC50 values represent geometric mean values of a minimum of four determinations. These assays generally produced results within 2-fold of the reported mean.
Table 1 Example No. Name EC50 (nM) 1 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide 1222 2 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-(trifluoromethoxy)-3H-benzimidazole-4-carboximidamide 2455 3 N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 4801 4 N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 527 5 N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 542 6 7-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide 793 7 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-(trifluoromethyl)-1H-benzimidazole-4-carboximidamide 926 8 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide 1792 9 N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide 634 10 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 438 11 6-chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide 7604 12 7-bromo-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-benzimidazole-4-carboximidamide 660 13 2-amino-N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 2739 14 2-amino-N-(3-bromo-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 494 15 2-amino-N-(3-bromophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 570 16 2-amino-N-(3-chlorophenyl)-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 607 17 2-amino-6,7-difluoro-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-3H-benzimidazole-4-carboximidamide 1092 18 2-amino-N-(3-bromophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 312 19 2-amino-N-(3-bromo-4-fluorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 456 20 2-amino-N-(3-chlorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 404 21 2-amino-7-fluoro-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-3H-benzimidazole-4-carboximidamide 725 22 2-amino-N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 382 23 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-morpholin-4-ylethylamino)-3H-benzimidazole-4-carboximidamide 346 24 N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3-methoxypropyl)amino)methyl)-1H-benzo[d]imidazole-7-carboximidamide 1923 25 N-(3-chlorophenyl)-2-(((cyclopropylmethyl)amino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1457 26 N-(3-chlorophenyl)-2-((dimethylamino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1212 27 N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((isopropylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide 839 28 N-(3-chlorophenyl)-2-((ethylamino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 801 29 N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(hydroxymethyl)-1H-benzo[d]imidazole-7-carboximidamide 1541 30 N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((methylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide 1106 31 2-(aminomethyl)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1680 32 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-morpholin-4-yl-3H-benzimidazole-4-carboximidamide 9276 33 N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-2-(2-methylsulfonylethylamino)-3H-benzimidazole-4-carboximidamide 1833 34 N-(3-Chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 6739 35 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-methylsulfonylethylamino)-3H-benzimidazole-4-carboximidamide 2153 36 N-(3-chloro-4-fluorophenyl)-2-[2-(4,4-difluoropiperidin-1-yl)ethylamino]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 712 37 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(1-morpholin-4-ylpropan-2-ylamino)-3H-benzimidazole-4-carboximidamide 514 38 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(methylamino)-3H-benzimidazole-4-carboximidamide 607 39 N-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propylamino]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 473 40 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-methoxyethylamino)-3H-benzimidazole-4-carboximidamide 1523 41 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-pyrrolidin-1-ylethylamino)-3H-benzimidazole-4-carboximidamide 240 42 N-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethylamino]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 247 43 N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 136 44 N-(3-chlorophenyl)-6,7-difluoro-N'-hydroxy-2-(1-methylpiperidin-3-yl)-3H-benzimidazole-4-carboximidamide 1645 45 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-[(3-methoxypropylamino)methyl]-1H-benzimidazole-4-carboximidamide 1324 46 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(hydroxymethyl)-3H-benzimidazole-4-carboximidamide 835 47 2-(aminomethyl)-N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 1075 48 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(methylaminomethyl)-1H-benzimidazole-4-carboximidamide 434 49 N-(3-chloro-4-fluorophenyl)-2-[(cyclopropylmethylamino)methyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 1057 50 N-(3-chloro-4-fluorophenyl)-2-(ethylaminomethyl)-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 457 51 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-[(propan-2-ylamino)methyl]-1H-benzimidazole-4-carboximidamide 566 52 N-(3-chloro-4-fluorophenyl)-2-[(dimethylamino)methyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 526 53 N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 916 54 N-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 461 55 N-(3-bromophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 379 56 N-(3-chlorophenyl)-2-[2-(dimethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 562 57 N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-[2-(methylamino)ethyl]-1H-benzimidazole-4-carboximidamide 1093 58 N-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethyl]-6,7-difluoro-N'-hydroxy-1H-benzimidazole-4-carboximidamide 786 59 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 208 60 N-(5-chloro-2-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 322 61 N-(5-bromo-2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 371 62 N-(5-chloro-2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 385 63 N-(3,5-dichloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 774 64 N-(3-chloro-2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 813 65 N-(3-cyclopropyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1809 66 N'-hydroxy-N-[4-(trifluoromethoxy)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 4871 67 N-(1-benzofuran-4-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 583 68 N-(1-benzofuran-6-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 890 69 N-(1-benzofuran-7-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1339 70 N-(1-benzofuran-5-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1479 71 N-(5-bromo-2-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 207 72 N-(3-bromo-5-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 280 73 N'-hydroxy-N-[3-(trifluoromethyl)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 373 74 N-(2,2-difluoro-1,3-benzodioxol-5-yl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 923 75 N-[3-fluoro-5-(trifluoromethyl)phenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2109 76 N-(2,5-dichlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 769 77 N-(4-fluoro-3-phenylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2289 78 N-(3-but-1-ynyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2641 79 N-[3-(2-cyclopropylethynyl)-4-fluorophenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3223 80 N-(3-bromophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 111 81 N-(3-bromo-4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 140 82 N-(3-chlorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 160 83 N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 315 84 N-(4-fluoro-3-prop-1-ynylphenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 445 85 N-(3-bromo-4-chlorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 462 86 N-(3,4-dichlorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 639 87 N-(4-chlorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 846 88 N-(4-bromophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 916 89 N-(4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 943 90 N-(3-cyano-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1047 91 N'-hydroxy-N-[4-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2240 92 N'-hydroxy-N-(3-methoxyphenyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 3892 93 N-(4-fluoro-3-propan-2-ylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 5096 94 N'-hydroxy-N-(4-methylphenyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 6350 95 N-(3-ethynylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 302 96 N-(3-ethylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 803 97 N-(3-ethynyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 380 98 N-[3-(difluoromethyl)phenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 550 99 N'-hydroxy-N-[3-(trifluoromethoxy)phenyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 602 100 N'-hydroxy-N-phenyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide 770 101 N-[4-fluoro-3-(trifluoromethoxy)phenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 845 102 N'-hydroxy-N-naphthalen-2-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1928 103 N-(3-chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 8075 104 N'-hydroxy-N-naphthalen-1-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1966 105 N-(4-chloronaphthalen-1-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3032 106 N-(4-fluoro-3-methoxyphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 5536 107 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1925 108 N-(3-chloro-4-fluorophenyl)-2-ethyl-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3192 109 N-(3-chloro-4-fluorophenyl)-2-cyclopropyl-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1386 110 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2320 111 4-(3-chloro-4-fluorophenyl)-3-[2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl]-1,2,4-oxadiazol-5-one 4452 112 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(morpholin-4-ylmethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 9531 113 N-(3-chloro-4-fluorophenyl)-2-[(dimethylamino)methyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1837 114 N-(3-chloro-4-fluorophenyl)-2-(ethylaminomethyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 927 115 2-[(benzylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1761 116 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(propan-2-ylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 740 117 N-(3-chloro-4-fluorophenyl)-2-[(cyclopropylmethylamino)methyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 765 118 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2,2,2-trifluoroethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 4644 119 N-(3-chloro-4-fluorophenyl)-2-[(cyclopropylamino)methyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2150 120 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(3-methoxypropylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1334 121 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyridin-2-ylmethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1373 122 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[[3-methoxypropyl(methyl)amino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1883 123 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[[(2-methoxyphenyl)methylamino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1909 124 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2-methoxyethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2059 125 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2-pyridin-2-ylethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2083 126 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyridin-3-ylmethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2280 127 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(oxan-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2364 128 2-(anilinomethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2399 129 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(oxan-3-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2575 130 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyrimidin-2-ylmethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2815 131 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(3-morpholin-4-ylpropylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 3016 132 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(oxan-4-ylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3433 133 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyridin-4-ylmethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 3711 134 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyrazin-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3988 135 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(oxolan-3-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 5105 136 N-(3-chloro-4-fluorophenyl)-2-[[2-(dimethylamino)ethylamino]methyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 6274 137 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2-pyrimidin-2-ylethylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 7492 138 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(3-hydroxypropylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 8239 139 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(pyrrolidin-1-ylmethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1400 140 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(piperidin-1-ylmethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1609 141 N-(3-chloro-4-fluorophenyl)-2-[(2,2-dimethylpropylamino)methyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1677 142 N-(3-chloro-4-fluorophenyl)-2-[(2,2-difluoroethylamino)methyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 5155 143 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[[(3-hydroxy-2,2-dimethylpropyl)amino]methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 7346 144 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(1,3-thiazol-2-ylmethylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 8228 145 N-[[7-[(Z)-N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl] acetamide 9760 146 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-thiophen-2-yl-3H-imidazo[4,5-b]pyridine-7-carboximidamide 4215 147 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-pyridin-3-yl-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1935 148 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-pyrrol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2229 149 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 529 150 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-pyrazol-5-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 8480 151 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(5-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 463 152 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2S)-pyrrolidin-2-yl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 4036 153 2-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 897 154 N-(3-chloro-4-fluorophenyl)-2-(cyclopropylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 529 155 2-anilino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2146 156 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-phenylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 769 157 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2,2,2-trifluoroethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1088 158 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 460 159 propan-2-yl N-[7-[(Z)-N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]carbamate 453 160 ethyl N-[7-[(Z)-N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl]-1H-imidazo[4,5-b]pyridin-2-yl]carbamate 423 161 N-(3-chloro-4-fluorophenyl)-2-(cyclopropylmethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 655 162 N-(3-chloro-4-fluorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 4017 163 N-(3-chloro-4-fluorophenyl)-2-(ethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1084 164 N-(3-chloro-4-fluorophenyl)-2-(cyclobutylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 798 165 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(propan-2-ylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 705 166 N-(3-chlorophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 383 167 N-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethylamino]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2912 168 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-morpholin-4-ylethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1158 169 N-(3-chloro-4-fluorophenyl)-2-(dimethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 6269 170 2-(chloromethyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1936 171 N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-hydroxy-2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 4000 172 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3858 173 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[hydroxy(phenyl)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 9700 174 N-(3-chloro-4-fluorophenyl)-2-[cyclopropyl(hydroxy)methyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 7086 175 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-hydroxypropan-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 6417 176 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2,2,2-trifluoro-1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 4201 177 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1674 178 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methylaminomethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1477 179 2-(aminomethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 7664 180 2-(benzenesulfonamidomethyl)-N-(3 -chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1406 181 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(methanesulfonamidomethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 8969 182 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(pyrimidin-2-ylamino)methyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 6401 183 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2401 184 N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethyl]-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 593 185 N-(3-chloro-4-fluorophenyl)-2-[2-(diethylamino)ethyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 531 186 N-(3-chloro-4-fluorophenyl)-2-[2-[cyclopropylmethyl(methyl)amino] ethyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 565 187 N-(3-chloro-4-fluorophenyl)-2-[2-[2,2-difluoroethyl(methyl)amino]ethyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3405 188 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[2-(methylamino)ethyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1513 189 2-(2-aminoethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1777 190 N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-((2-methoxyethyl)amino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1513 191 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-morpholin-4-ylethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2824 192 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-piperidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 241 193 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-pyrrolidin-1-ylethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 358 194 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[2-[2-methoxyethyl(methyl)amino]ethyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 504 195 N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)-1-hydroxyethyl]-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1158 196 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(2-methylpropylamino)methyl]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1330 197 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3-methylimidazo[4,5-b]pyridine-7-carboximidamide 5456 198 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[2-(2-methoxyethylamino)ethyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2339 199 N-(3-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propyl]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 4488 200 N-(3-chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-2-(3-morpholin-4-ylpropylamino)-3H-benzimidazole-4-carboximidamide 564 201 N-(3-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide 428 202 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(1-methylpiperidin-2-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2090 203 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-[(1-methylpyrrolidin-3-yl)amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1344 204 N-(3-chloro-4-fluorophenyl)-2-(2-(ethylamino)ethyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2195 205 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(isopropylamino)ethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2823 206 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(isobutylamino)ethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide 2295 207 N-(3-chloro-4-fluorophenyl)-2-(2-(cyclopropylamino)ethyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide 1257 209 2-(2-(2-amino-4,5-dihydro-1H-imidazol-1-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 5000 210 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(2-(methylsulfonamido)ethyl)-1H-benzo[d]imidazole-7-carboximidamide >10000 211 2-(2-aminoethyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide >10000 212 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-methoxyethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 876 213 tert-butyl (2-(7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)ethyl)carbamate 3623 214 N-(3-chloro-4-fluorophenyl)-2-((2-(4,4-difluoropiperidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1908 215 N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1195 216 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methylamino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2009 217 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-methylazepan-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2870 218 N-(3-chloro-4-fluorophenyl)-2-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000 219 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-((2-methoxyethyl)(methyl)amino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3829 220 N-(3-chloro-4-fluorophenyl)-2-((2-((2,2-difluoroethyl)(methyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2383 221 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3-morpholinopropyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 899 222 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(piperidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1521 223 N-(3-chloro-4-fluorophenyl)-2-((2-cyclohexylethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2182 224 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3735 225 N-(3-chloro-4-fluorophenyl)-2-((2,2-difluoroethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2190 226 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(oxetan-3-ylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000 227 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((tetrahydrofuran-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2195 228 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((tetrahydro-2H-pyran-4-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2135 229 3-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)propanamide >10000 230 N-(3-chloro-4-fluorophenyl)-2-((2-((2,2-difluoroethyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3836 231 N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(methyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 291 232 N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(2-methoxyethyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 460 233 2-((2-(azetidin-1-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1122 234 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3-methoxypropyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 698 235 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(2-oxopyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 4818 236 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(morpholinosulfonyl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 4765 237 N-(3-chloro-4-fluorophenyl)-2-((2-(3-fluoropiperidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 442 238 N-(3-bromo-4-fluorophenyl)-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 853 239 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methyl(tetrahydro-2H-pyran-4-yl)amino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1212 240 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(isopropyl(methyl)amino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 590 241 2-(((1-aminocyclopropyl)methyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1374 257 N-(3-bromo-4-fluorophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 241 242 2-((2-(1-aminocyclopropyl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1626 258 2-(2-(azepan-1-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 844 259 2-(2-(azetidin-1-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1299 260 (R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3205 261 (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3453 262 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(4-hydroxypiperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3238 263 N-(3-bromo-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 559 264 N-(3-chlorophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 722 265 N-(3-bromophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 501 266 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methylsulfonamido)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000 267 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(sulfamoylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000 268 N-(3-chlorophenyl)-N'-hydroxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 952 269 N-(3-bromophenyl)-N'-hydroxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 979 270 N-(2-(7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl)acetamide >10000 271 N-(3-chlorophenyl)-N'-hydroxy-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 602 272 N-(3-bromophenyl)-N'-hydroxy-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 477 273 Methyl (2-(7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl)carbamate >10000 274 N-(3-chloro-4-fluorophenyl)-2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1966 275 2-(2-(4-benzylpiperidin-1-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 675 276 2-(2-(3-azabicyclo[3.3.1]nonan-3-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 618 277 2-(2-(3-azabicyclo[3.2.1]octan-3-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 576 278 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1073 279 (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 5279 280 (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(3-hydroxypyrrolidin-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000 281 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1257 282 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000 283 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2719 287 N-(3-chloro-4-fluorophenyl)-2-((ethylamino)methyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1669 288 N-(3-chloro-4-fluorophenyl)-2-((dimethylamino)methyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1816 289 -(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((isopropylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide 2232 290 N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((methylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide 1292 291 2-(aminomethyl)-N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 2647 292 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-hydroxy-2-methylpropyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 3317 293 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-hydroxypropyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 3003 294 2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)acetamide 9954 295 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-hydroxyethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 3264 296 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((3-hydroxycyclobutyl)amino)-1H-benzo[d]imidazole-7-carboximidamide >10000 297 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((3-(pyridin-2-ylamino)propyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 1153 298 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-sulfamoylethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 9558 299 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1-methyl-1H-pyrazol-5-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 3443 300 2-((2-(1H-pyrazol-1-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 3572 301 2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)-N,N-dimethylacetamide 3960 302 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(2-hydroxy-2-methylpropyl)-1H-benzo[d]imidazole-7-carboximidamide >10000 303 N-(3-chloro-4-fluorophenyl)-2-((4-(dimethylamino)butyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 2935 304 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((piperidin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide >10000 305 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3494 306 N-(3-bromophenyl)-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 681 307 N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-4-methoxy-1H-benzo[d]imidazole-7-carboximidamide 209 325 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(piperidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000 326 N-(3-chloro-4-fluorophenyl)-2-(1-(dimethylamino)propan-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 4054 327 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methylamino)propyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 7619 328 N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)propyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3242 329 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(pyrrolidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 5000 330 N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 414 331 N-(3-bromophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 692 333 2-((2-aminoethyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1386 334 N-(2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)ethyl)acetamide 6119 335 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methylsulfonamido)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide >10000 336 N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropanesulfonamido)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide >10000 337 Methyl (2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)ethyl)carbamate 4405 338 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(sulfamoylamino)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide >10000 339 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(phenylsulfonamido)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide >10000 340 N-(3-chloro-4-fluorophenyl)-2-((2-cyanoethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1781 341 N-(3-chloro-4-fluorophenyl)-2-((2-(3-ethylureido)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide >10000 342 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((pyridin-2-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 8493 343 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((pyridin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 3857 344 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((pyridin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 3058 345 2-(((1H-imidazol-2-yl)methyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 3843 346 2-chloro-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 8468 347 2-((2-aminobenzyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 3269 348 N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)benzyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 3431 349 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1-methyl-1H-imidazol-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 2544 350 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((pyrimidin-2-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 7031 351 N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)-2,2-dimethylpropyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 432 352 N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)-2-methylpropyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 437 353 N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)butyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1295 354 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(1-methylpyrrolidin-2-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 1207 355 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(1-methylpiperidin-2-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 2021 356 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((4-methylmorpholin-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 3264 357 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((4-methylmorpholin-2-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 3239 358 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((1-methyl-1H-pyrazol-5-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 8791 368 N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 4004 369 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-N-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000 370 2-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1078 371 2-amino-N-(3-chlorophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 644 372 2-amino-N-(3-bromophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 483 373 2-amino-N-(3-bromo-4-fluorophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 736 374 N-(3-chloro-4-fluorophenyl)-2-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 2399 375 N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1190 376 N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 1258 377 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-morpholinopropyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 838 378 N-(3-chloro-4-fluorophenyl)-2-((1-(dimethylamino)propan-2-yl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1396 379 N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 435 380 N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 1388 381 N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)-2,2-dimethylpropyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 3025 382 N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 608 383 N-(3-bromophenyl)-2-((2-(dimethylamino)ethyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 319 384 N-(3-chlorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 290 385 N-(3-chlorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 580 386 N-(3-bromophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 559 387 N-(3-bromo-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 692 388 N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 939 389 N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1157 390 2-((2-(benzyl(methyl)amino)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1017 391 N-(3-chloro-4-fluorophenyl)-2-(2-((cyclohexylmethyl)(methyl)amino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1480 392 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methyl(neopentyl)amino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1226 393 N-(3-chloro-4-fluorophenyl)-2-(2-(cyclohexyl(methyl)amino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1794 394 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 332 395 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methylamino)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 757 396 2-(2-(benzyl(methyl)amino)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 790 397 N-(3-chloro-4-fluorophenyl)-2-((2-((2-ethylbutyl)(methyl)amino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1317 398 N-(3-chloro-4-fluorophenyl)-2-((2-((cyclopropylmethyl)(methyl)amino)ethyl)amino) -4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 555 399 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1329 400 2-(2-(((1,4-dioxan-2-yl)methyl)(methyl)amino)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2814 401 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methyl(2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)ethyl)-1H-imidazo[4,5-b] pyridine-7-carboximidamide 581 402 N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropylamino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 561 403 N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(ethyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 192 404 N-(2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)amino)ethyl)acetamide >10000 405 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methylsulfonamido)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 7112 406 N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(isopropyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 185 407 N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(2-hydroxyethyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2122 427 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((5-methyl-1,3,4-oxadiazol-2-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1071 429 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 1346 430 N-(3-bromophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 180 431 N-(3-chlorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 139 432 N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 253 433 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((3-morpholinopropyl)amino)-1H-benzo[d]imidazole-7-carboxamide 882 434 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((3-(pyrrolidin-1-yl)propyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 1240 435 2-(((3R)-4-amino-1-methylpyrrolidin-3-yl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1814 436 N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 2015 437 N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 998 438 N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 838 439 N-(3-chloro-4-fluorophenyl)-2-(((1S*,3S*)-3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 6799 440 N-(3-chloro-4-fluorophenyl)-2-(((1S,3R)-3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 6660 441 N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide >10000 442 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-4-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 2881 443 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 389 444 N-(3-chloro-4-fluorophenyl)-2-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 3144 445 (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(piperidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide 1946 446 (R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(piperidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide 1490 447 (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 325 448 N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)-2-hydroxypropyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1118 449 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(4-methyl-3-oxopiperazin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 6249 450 N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1586 451 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylazepan-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 205 452 (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 568 453 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)piperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 651 454 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 247 455 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-isopropylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 376 456 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(3-methoxyazetidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 274 457 (R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 271 458 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 261 459 (S)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 337 460 (R)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 193 461 N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)cyclopentyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 472 462 (S)-2-(azepan-3-ylamino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1429 463 (R)-2-(azepan-3-ylamino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1020 464 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(pyrrolidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide 2346 465 (R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(oxetan-3-yl)piperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 957 466 N-(3-chloro-4-fluorophenyl)-2-(((1,4-dimethylpiperidin-2-yl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 685 467 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((morpholin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 2116 468 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3R,4S)-4-hydroxypyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide >10000 469 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 959 470 (S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(trifluoromethyl)pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 4200 471 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((hexahydro-1H-pyrrolizin-7a-yl)methyl)amino)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 852 472 N-(3-chloro-4-fluorophenyl)-2-(((3,3-dimethylazetidin-2-yl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 2452 473 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((4-(pyrrolidin-1-yl)tetrahydro-2H-pyran-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 1034 474 2-(((1S,2R)-2-aminocyclohexyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 7584 475 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide 1993 476 N-(3-chloro-4-fluorophenyl)-2-(((3S,4S)-4-(diethylamino)tetrahydrofuran-3-yl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 468 477 2-((1,4-oxazepan-6-yl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 1525 478 N-(3-chloro-4-fluorophenyl)-2-((2-((2S,6R)-2,6-dimethylmorpholino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1011 479 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1069 480 N-(3-chloro-4-fluorophenyl)-2-(((3R,4R)-4-(diethylamino)tetrahydrofuran-3-yl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1194 481 (S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(2-(trifluoromethyl)pyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 760 482 (R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 2653 483 N-(3-chloro-4-fluorophenyl)-2-((2-(2,6-dimethylmorpholino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 668 484 N-(3-chloro-4-fluorophenyl)-2-((2-(2,6-dimethylmorpholino)-2-methylpropyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 566 485 N-(3-chloro-4-fluorophenyl)-2-((2-(2,5-dimethylmorpholino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 639 486 N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclopentyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 284 487 N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)thio)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 1361 488 N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)thio)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide 3012 489 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(hydroxymethyl)piperidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 289 490 N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide 186 491 N-(3-chloro-4-fluorophenyl)-2-((2-(3,3-difluoropyrrolidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide 917 492 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-sulfamoylethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 5660 493 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methylsulfonyl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide 7215 494 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((pyrimidin-2-ylmethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide >10000
Claims (16)
- A compound of Formula I:R1 is mono- or bicyclic aryl or heteroaryl, wherein each mono- or bicyclic aryl or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; and
wherein each C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, -N(R20)(R22) and C3-6 cycloalkyl;X is N or CR2c;R2a, R2b, and R2c are independently hydrogen, hydroxyl, halo, CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, or C1-6 alkyl;R2d and R2e are independently hydrogen, C1-6 haloalkyl, C1-6 haloalkoxy, or C1-6 alkyl;n and m are independently 0, 1, 2, or 3;each Rn and Rm is independently hydrogen, hydroxyl, halo, C1-6 alkoxy, C1-6 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl; or two Rn or Rm join to form a C3-6 cycloalkyl; and
wherein each C1-6 alkoxy, C1-6 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, -N(R20)(R22), C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, and C3-6 cycloalkyl;L is a bond, -NR3-, -C(O)-NR3-, -NR3-C(O)-, -NR3SO2-, -NR3SO2-NR3-, -SO2NR3-, -O-, -S-, or -S(O)t-, where t is 0, 1 or 2;each R3 is independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl; andR1 is hydrogen, C1-6 alkyl, C1-6 alkoxy, -C(O)R20, -C(O)OR20, -NC(O)OR20, -N(R20)(R22), -C(O)N(R20)(R22), -SO2R20, -N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), -SO2N(R21)(R22), C3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, provided that when Rt is C1-6 alkoxy, -NC(O)OR20, -N(R20)(R22), -N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), or -SO2N(R20)(R22), and m is 0, then L is a bond;
wherein said C1-6 alkyl, C1-6 alkoxy, C3-15 cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, -C(O)R20, -N(R20)(R22), -SO2R20, -N(R20)SO2(R21), -N(R20)SO2-N(R21)(R22), -SO2N(R20)(R22), C3-6 cycloalkyl, -CN, C1-6 alkoxy, C1-6 alkyl, and heterocyclyl; and wherein said heterocyclyl is optionally substituted with one or two oxo;
wherein said C3-6 cycloalkyl, C1-6 alkyl or C1-6 alkoxy is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, -N(R20)(R22), -SO2R20, -N(R20)SO2(R22), -N(R20)SO2-N(R21)(R22)-, and -SO2N(R20)(R22); and said C1-6 alkyl is optionally substituted with aryl;R20, R21, and R22 are independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, aryl, heterocyclyl, and heteroaryl;or a pharmaceutically acceptable salt or mixture thereof.
wherein said aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three halogen; - The compound of claim 1 or 2 wherein(i) R1 is bicyclic aryl or heteroaryl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl; or a pharmaceutically acceptable salt or mixture thereof;(ii) R1 is phenyl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, and wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; or a pharmaceutically acceptable salt or mixture thereof; or
- The compound of any one of the preceding claims wherein X is N; or a pharmaceutically acceptable salt or mixture thereof.
- The compound of any one of claims 1-3 wherein X is CR2c; or a pharmaceutically acceptable salt or mixture thereof.
- The compound of any one of the preceding claims wherein L is a bond; or a pharmaceutically acceptable salt or mixture thereof.
- The compound of any one of claims 1-4 wherein L is -NR3; or a pharmaceutically acceptable salt or mixture thereof.
- The compound of any one of the preceding claims wherein Rt is hydrogen; or a pharmaceutically acceptable salt or mixture thereof.
- The compound of any one of claims 1-6 wherein(a) Rt is C1-6 alkyl optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, -CN, and C1-6 alkoxy; or a pharmaceutically acceptable salt or mixture thereof; or(b) Rt is C3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein said cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, -CN, C1-6 alkoxy and C1-6 alkyl; or a pharmaceutically acceptable salt or mixture thereof.
- The compound of any one of claims 1-5 wherein L is -NR3 and Rt is C3-15 cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein said cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -NO2, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, -CN, and C1-6 alkoxy; or a pharmaceutically acceptable salt or mixture thereof.
- The compound of claim 1 selected from the group consisting of:N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-methyl-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(trifluoromethoxy)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,4-Chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(trifluoromethyl)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-6-fluoro-N'-hydroxy-7-methyl-3H-benzimidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,6-Chloro-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide,4-Bromo-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-N-(3-bromo-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-N-(3-bromophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-4,5-difluoro-N-(4-fluoro-3-(trifluoromethyl)phenyl)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-N-(3-bromophenyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-N-(3-bromo-4-fluorophenyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-N-(3-chlorophenyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-4-fluoro-N-(4-fluoro-3-(trifluoromethyl)phenyl)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-Amino-N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-morpholmoethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3-methoxypropyl)amino)methyl)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chlorophenyl)-2-(((cyclopropylmethyl)amino)methyl)-4,5-difluoro-N-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chlorophenyl)-2-((dimethylamino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((isopropylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chlorophenyl)-2-((ethylamino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(hydroxymethyl)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((methylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide,2-(Aminomethyl)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-morpholino-1H-benzo-[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((2-(methylsulfonyl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methylsulfonyl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((2-(4,4-difluoropiperidin-1-yl)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-morpholinopropan-2-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(methylamino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-methoxyethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chlorophenyl)-4,5-difluoro-N'-hydroxy-2-(1-methylpiperidin-3-yl)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(((3-methoxypropyl)amino)methyl)-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(hydroxymethyl)-1H-benzo[d]imidazole-7-carboximidamide,2-(Aminomethyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((methylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(((cyclopropylmethyl)amino)methyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((ethylamino)methyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-((isopropylamino)methyl)-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((dimethylamino)methyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Bromo-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Bromophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Chlorophenyl)-2-(2-(dimethylamino)ethyl)-6,7-difluoro-N'-hydroxy-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-6,7-difluoro-N'-hydroxy-2-(2-(methylamino)ethyl)-1H-benzo[d]imidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(2-(diethylamino)ethyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(5-Chloro-2-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(5-Bromo-2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(5-Chloro-2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3,5-Dichloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-2,4-difluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Cyclopropyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N'-Hydroxy-N-(4-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(Benzofuran-4-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(Benzofuran-6-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(Benzofuran-7-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(benzofuran-5-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(5-Bromo-2-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Bromo-5-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N'-Hydroxy-N-(3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Fluoro-5-(trifluoromethyl)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(2,5-Dichlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(6-Fluoro-[1,1'-biphenyl]-3-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-(But-1-yn-1-yl)-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-(Cyclopropylethynyl)-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Bromophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Bromo-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Fluoro-3-(trifluoromethyl)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Fluoro-3-(prop-1-yn-1-yl)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Bromo-4-chlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3,4-Dichlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Chlorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Bromophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Cyano-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N'-Hydroxy-N-(4-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N'-Hydroxy-N-(3-methoxyphenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Fluoro-3-isopropylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N'-Hydroxy-N-(p-tolyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N'-(3-Ethynylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Ethylphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Ethynyl-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-(Difluoromethyl)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-Hydroxy-N-(3-(trifluorometlioxy)phenyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-Hydroxy-N-phenyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Fluoro-3-(trifluoromethoxy)phenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-Hydroxy-N-(naphthalen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloronaphthalen-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N'-hydroxy-N-(naphthalen-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Chloronaphthalen-1-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Fluoro-3-methoxyphenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-ethyl-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-cyclopropyl-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(methoxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,4-(3-Chloro-4-fluorophenyl)-3-(2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridin-7-yl)-1,2,4-oxadiazol-5(4H)-one,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(morpholinomethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((dimethylamino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((ethylamino)methyl)-N'-hydroxy-1H-imidazo [4,5-b]pyridine-7-carboximidamide,2-((Benzylamino)methyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((isopropylamino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(((cyclopropylmethyl)amino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((2,2,2-trifluoroethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((cyclopropylamino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((3-methoxypropyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((pyridin-2-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((3-methoxypropyl)(methyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((2-methoxybenzyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((2-methoxyethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((2-(pyridin-2-yl)ethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((pyridin-3-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((((tetrahydro-2H-pyran-2-yl)methyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((phenylamino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((((tetrahydro-2H-pyran-3-yl)methyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((pyrimidin-2-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((3-morpholinopropyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((pyridin-4-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((pyrazin-2-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((((tetrahydrofuran-3-yl)methyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(((2-(dimethylamino)ethyl)amino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((2-(pyrimidin-2-yl)ethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((3-hydroxypropyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(pyrrolidin-1-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(piperidin-1-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((neopentylamino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(((2,2-difluoroethyl)amino)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((3-hydroxy-2,2-dimethylpropyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(((thiazol-2-ylmethyl)amino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-((7-(N-(3-Chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl)acetamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(thiophen-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(pyridin-3-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-pyrrol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-imidazol-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(1H-pyrazol-5-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(4-methyl-1H-imidazol-2-yl)-1H-imidazo [4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(pyrrolidin-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-Amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(cyclopropylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(phenylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(phenethylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((2,2,2-trifluoroethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,Isopropyl (7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)carbamate,Ethyl (7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)carbamate,N-(3-Chloro-4-fluorophenyl)-2-((cyclopropylmethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((3,3-difluorocyclobutyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(ethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(cyclobutylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(isopropylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chlorophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(dimethylamino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(Chloromethyl)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(4-Fluoro-3-(trifluoromethyl)phenyl)-N'-hydroxy-2-(hydroxymethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(hydroxy(phenyl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(cyclopropyl(hydroxy)methyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-hydroxypropan-2-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2,2,2-trifluoro-1-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(hydroxymethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((methylamino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(Aminomethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(phenylsulfonamidomethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(methylsulfonamidomethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((pyrimidin-2-ylamino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-hydroxyethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(2-(diethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(2-((cyclopropylmethyl)(methyl)amino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(2-((2,2-difluoroethyl)(methyl)amino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(2-Aminoethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-((2-methoxyethyl)amino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-morpholinoethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-(2-((2-methoxyethyl)(methyl)amino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-(2-(dimethylamino)-1-hydroxyethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-((isobutylamino)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-3-methyl-3H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-[2-(2-methoxyethylamino)ethyl]-3H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-[3-(dimethylamino)propyl]-6,7-difluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-7-fluoro-N'-hydroxy-2-(3-morpholin-4-ylpropylamino)-3H-benzimidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-7-fluoro-N'-hydroxy-3H-benzimidazole-4-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-[(1-methylpiperidin-2-yl)methylamino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-2-[(1-methylpyrrolidin-3-yl)amino]-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(2-(ethylamino)ethyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(isopropylamino)ethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(isobutylamino)ethyl)-3H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(2-(cyclopropylamino)ethyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(2-((cyclopropylmethyl)amino)ethyl)-N'-hydroxy-3H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(2-(2-amino-4,5-dihydro-1H-imidazol-1-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(2-(methylsulfonamido)ethyl)-1H-benzo[d]imidazole-7-carboximidamide,2-(2-aminoethyl)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-methoxyethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,tert-butyl (2-(7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)ethyl)carbamate,N-(3-chloro-4-fluorophenyl)-2-((2-(4,4-difluoropiperidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methylamino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-methylazepan-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-((2-methoxyethyl)(methyl)amino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-((2,2-difluoroethyl)(methyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3-morpholinopropyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(piperidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-cyclohexylethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2,2-difluoroethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(oxetan-3-ylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((tetrahydrofuran-3-yl)alnino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((tetrahydro-2H-pyran-4-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,3-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)propanamide),N-(3-chloro-4-fluorophenyl)-2-((2-((2,2-difluoroethyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(methyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidarnide,N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(2-methoxyethyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-(azetidin-1-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3-methoxypropyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(2-oxopyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(morpholinosulfonyl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(3-fluoropiperidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromo-4-fluorophenyl)-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methyl(tetrahydro-2H-pyran-4-yl)amino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(isopropyl(methyl)amino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(((1-aminocyclopropyl)methyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-(1-aminocyclopropyl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-(2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-(7-oxa-4-azaspiro[2.5]octan-4-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(R)-(3-chloro-4-fluorophenyl)-2-((2-(3-fluoropyrrolidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(S)-(3-chloro-4-fluorophenyl)-2-((2-(3-fluoropyrrolidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-(2-azabicyclo[4.1.0]heptan-2-yl)ethyl)amino)-Ar-(3-chloro-4-fluorophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-(4-azaspiro[2.5]octan-4-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(3-fluoroazetidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(3,3-difluoroazetidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-(4-azaspiro[2.4]heptan-4-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(3-fluoropiperidin-1-yl)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(phenylamino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methyl(phenyl)amino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1,1-dioxidotetrahydro-2H-thiopyran-3-yl)methyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-ethoxycyclopropyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromo-4-fluorophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(2-(azepan-1-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(2-(azetidin-1-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(4-hydroxypiperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromo-4-fluorophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chlorophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromophenyl)-2-(2-(dimethylamino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methylsulfonamido)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(sulfamoylamino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chlorophenyl)-N'-hydroxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromophenyl)-N'-hydroxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(2-(7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl)acetamide,N-(3-chlorophenyl)-N'-hydroxy-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromophenyl)-N'-hydroxy-2-(2-(piperidin-1-yl)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,Methyl (2-(7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)ethyl)carbamate,N-(3-chloro-4-fluorophenyl)-2-(2-((2,4-dimethoxybenzyl)amino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(2-(4-benzylpiperidin-1-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(2-(3-azabicyclo[3.3.1]nonan-3-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(2-(3-azabicyclo[3.2.1]octan-3-yl)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(3-hydroxypyrrolidin-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((4-((methylsulfonyl)methyl)tetrahydro-2H-pyran-4-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methylsulfonyl)benzyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((1-acetylpiperidin-3-yl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((ethylamino)methyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((dimethylamino)methyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((isopropylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((methylamino)methyl)-1H-benzo[d]imidazole-7-carboximidamide,2-(aminomethyl)-N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-hydroxy-2-methylpropylamino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-hydroxypropyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)acetamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-hydroxyethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((3-hydroxycyclobutyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((3-(pyridin-2-ylamino)propyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-sulfamoylethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1-methyl-1H-pyrazol-5-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,2-((2-(1H-pyrazol-1-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)-N,N-dimethylacetamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(2-hydroxy-2-methylpropyl)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((4-(dimethylamino)butyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((piperidin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-methylpiperidin-2-yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromophenyl)-N'-hydroxy-2-((2-morpholinoethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-4-methoxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((pyridin-2-ylmethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-(1H-pyrazol-1-yl)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((1-methyl-1H-pyrazol-3-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((4,4,4-trifluorobutyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3,3,3-trifluoropropyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(2-methoxyethoxy)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(cyclopropyl(methyl)amino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(cyclopropylamino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(cyclopropyl(ethyl)amino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(4-fluoropiperidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(2,2,2-trifluoroethoxy)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3-(2,2,2-trifluoroethoxy)propyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(3-methoxypiperidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(difluoromethoxy)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((tetrahydrofuran-2-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((tetrahydrofuran-2-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(tetrahydrofuran-2-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(piperidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7 -carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(1-(dimethylamino)propan-2-yl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methylamino)propyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(2-(dimethylamino)propyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(pyrrolidin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-bromophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-bromo-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,2-((2-aminoethyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)ethyl)acetamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methylsulfonamido)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropanesulfonamido)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,Methyl(2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-4,5-difluoro-1H-benzo[d]imidazol-2-yl)amino)ethyl)carbamate,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(sulfamoylamino)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(phenylsulfonamido)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-cyanoethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(3-ethylureido)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((pyridin-2-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((pyridin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,2-(((1H-imidazol-2-yl)methyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-chloro-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-((2-aminobenzyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)benzyl)amino)-4,5-difluoro-N-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1-methyl-1H-imidazol-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((pyrimidin-2-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)-2,2-dimethylpropyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)-2-methylpropyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)butyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(1-methylpyrrolidin-2-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(1-methylpiperidin-2-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((4-methylmorpholin-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((4-methylmorpholin-2-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((1-methyl-1H-pyrazol-5-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((7-(N-(3-chloro-4-Fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)amino)-N,N-dimethylacetamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(3-(hydroxymethyl)azetidin-1-yl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((oxetan-3-ylmethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(1-methyl-1H-imidazol-2-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3-(pyridin-2-ylamino)propyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidainide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(neopentylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(isobutylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((tetrahydro-2H-pyran-2-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((tetrahydrofuran-3-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-N-methyl-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-amino-N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-amino-N-(3-chlorophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-amino-N-(3-bromophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-amino-N-(3-bromo-4-fluorophenyl)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(diethylamino)ethyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4-fluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-morpholinopropyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((1-(dimethylamino)propan-2-yl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-5-fluoro-N'-hydroxy-2-((2-(pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluoropbenyl)-2-((3-(dimethylamino)-2,2-dimethylpropyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-bromophenyl)-2-((2-(dimethylamino)ethyl)amino)-4-fluoro-N-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chlorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chlorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-bromophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-bromo-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-4-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)propyl)amino)-5-fluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-((2-(benzyl(methyl)amino)ethyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(2-((cyclohexylmethyl)(methyl)amino)ethyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methyl(neopentyl)amino)ethyl)-N'-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(2-(cyclohexyl(methyl)amino)ethyl)N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(methylamino)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,2-(2-(benzyl(methyl)amino)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-((2-ethylbutyl)(methyl)amino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-((cyclopropylmethyl)(methyl)amino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(2-(((1,4-dioxan-2-yl)methyl)(methyl)amino)ethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(2-(methyl(2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)ethyl)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropylamino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(ethyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)amino)ethyl)acetamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methylsulfonamido)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(isopropyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropyl(2-hydroxyethyl)amino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((2-aminoethyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((5-oxopyrrolidin-3-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(((1H-pyrazol-5-yl)methyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)amino)propyl)acetamide,2-((3-aminopropyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-Fluorophenyl)-N'-hydroxy-2-((2-(sulfamoylamino)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(phenylsulfonamido)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,Methyl (2-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)amino)ethyl)carbamate,N-(3-chloro-4-fluorophenyl)-2-((2-(cyclopropanesulfonamido)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-((trifluoromethyl)sulfonamido)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(((1H-imidazol-2-yl)methyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-(((1H-imidazol-5-yl)methyl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((3-methyl-1,2,4-oxadiazol-5-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromophenyl)-N'-hydroxy-2-(methylamino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,Methyl (3-((7-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1H-imidazo[4,5-b]pyridin-2-yl)amino)propyl)carbamate,N-(3-bromophenyl)-N'-hydroxy-2-methoxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromophenyl)-N'-hydroxy-2-((2-(methylsulfonyl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromophenyl)-N'-hydroxy-2-((2-(methylsulfonamido)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-bromophenyl)-N'-hydroxy-2-((2-sulfamoylethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((5-methyl-1,3,4-oxadiazol-2-yl)methyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1-methylpiperidin-2-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((4-methylmorpholin-3-yl)methyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-bromophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chlorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-bromo-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-((3-morpholinopropyl)amino)-1H-benzo[d]imidazole-7-carboxamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((3-(pyrrolidin-1-yl)propyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,2-(((3R)-4-amino-1-methylpyrrolidin-3-yl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)-2-phenylethyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclopentyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1S,3S)-3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1S,3R)-3-(dimethylamino)cyclohexyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclobutyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-4-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1S,2S)-2-(dimethylamino)cyclohexylamino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(piperidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide,(R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(piperidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-(dimethylamino)-2-hydroxypropyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(4-methyl-3-oxopiperazin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1-(dimethylamino)cyclohexyl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylazepan-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)piperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-isopropylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(3-methoxyazetidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,(R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,(S)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,(R)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-methylpiperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)cyclopentyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,(S)-2-(azepan-3-ylamino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,(R)-2-(azepan-3-ylamino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(pyrrolidin-3-ylamino)-1H-benzo[d]imidazole-7-carboximidamide,(R)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(oxetan-3-yl)piperidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1,4-dimethylpiperidin-2-yl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((morpholin-3-ylmethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((3R,4S)-4-hydroxypyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-(((1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(trifluoromethyl)pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-2-(((hexahydro-1H-pyrrolizin-7a-yl)methyl)amino)-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((3,3-dimethylazetidin-2-yl)methyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((4-(pyrrolidin-1-yl)tetrahydro-2H-pyran-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,2-(((1S,2R)-2-aminocyclohexyl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((3S,4S)-4-(diethylamino)tetrahydrofuran-3-yl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,2-((1,4-oxazepan-6-yl)amino)-N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide.N-(3-chloro-4-fluorophenyl)-2-((2-((2S,6R)-2,6-dimethylmorpholino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((3R,4R)-4-(diethylamino)tetrahydrofuran-3-yl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(2-(trifluoromethyl)pyrrolidin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-(((4-methylmorpholin-3-yl)methyl)amino-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(2,6-dimethylmorpholino)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-Fluorophenyl)-2-((2-(2,6-dimethylmorpholino)-2-methylpropyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(2,5-dimethylmorpholino)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1R,2R)-2-(dimethylamino)cyclopentyl)amino)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)thio)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(dimethylamino)ethyl)thio)-4,5-difluoro-N'-hydroxy-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(hydroxymethyl)piperidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-4,5-difluoro-N'-hydroxy-2-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)ethyl)amino)-1H-benzo[d]imidazole-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(3,3-difluoropyrrolidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-sulfamoylethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(methylsulfonyl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((pyrimidin-2-ylmethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(R)-N-(3-chlorophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,(R)-N-(3-bromophenyl)-4,5-difluoro-N'-hydroxy-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)amino)-1H-benzo[d]imidazole-7-carboximidamide,(S)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(oxetan-3-yl)piperidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(2-methoxyethyl)piperidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((1-cyclopropylpyrrolidin-3-yl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,(R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(oxetan-3-yl)piperidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((2-(4-methyl-3-oxopiperazin-1-yl)ethyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((2-(3,3-difluoropiperidin-1-yl)ethyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,2-((1-acetylpyrrolidin-3-yl)amino)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(methylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((3-(methylsulfonyl)propyl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-(((1,1-dioxidotetrahydrothiophen-3-yl)methyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide,N-(3-chloro-4-fluorophenyl)-2-((3-((4-fluorophenyl)sulfonyl)propyl)amino)-N'-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide, and(R)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-2-((1-(oxetan-3-yl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5-b]pyridine-7-carboximidamide;or a pharmaceutically acceptable salt or mixture thereof.
- A pharmaceutical composition comprising a compound of any one of claims 1 to 12 or a pharmaceutically acceptable salt or mixture thereof, and at least one pharmaceutically acceptable vehicle.
- A compound of any one of claims 1 to 12 or a pharmaceutically acceptable salt or mixture thereof for use in(I) a method of treating a human, who has or is suspected of having a disease or condition responsive or believed to be responsive to the inhibition of IDO1 activity;(II) a method of inhibiting the activity of an IDO1 protein;(III) a method of inhibiting growth or a proliferation of cancer cells;(IV) a method of inhibiting immunosuppression in a patient; or(V) a method of treating cancer, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disease in a patient.
- The compound for use of claim 14(V) wherein the method further comprises administering to said patient an anti-viral agent, a chemotherapeutic, an immunosuppressant, radiation, an anti-tumor vaccine, an antiviral vaccine, cytokine therapy, or a tyrosine kinase inhibitor, such as an HBV inhibitor or an HIV inhibitor.
- The compound, a pharmaceutically acceptable salt or a mixture thereof of any of claims 1-12 for use in therapy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562162531P | 2015-05-15 | 2015-05-15 | |
PCT/US2016/032152 WO2016186967A1 (en) | 2015-05-15 | 2016-05-12 | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3294732A1 EP3294732A1 (en) | 2018-03-21 |
EP3294732B1 true EP3294732B1 (en) | 2019-09-25 |
Family
ID=56134561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16730065.6A Active EP3294732B1 (en) | 2015-05-15 | 2016-05-12 | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
Country Status (17)
Country | Link |
---|---|
US (1) | US9951065B2 (en) |
EP (1) | EP3294732B1 (en) |
JP (2) | JP2018515541A (en) |
KR (1) | KR20180004811A (en) |
CN (1) | CN107849024A (en) |
AR (1) | AR104642A1 (en) |
AU (1) | AU2016263083B2 (en) |
BR (1) | BR112017024331A2 (en) |
CA (1) | CA2985642A1 (en) |
EA (1) | EA201792259A1 (en) |
ES (1) | ES2761824T3 (en) |
HK (2) | HK1244796A1 (en) |
IL (1) | IL255294A0 (en) |
MX (1) | MX2017014613A (en) |
NZ (1) | NZ736709A (en) |
TW (1) | TWI657079B (en) |
WO (1) | WO2016186967A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
BR112017013858A2 (en) | 2014-12-26 | 2018-02-27 | Univ Emory | n4-hydroxycytidine and related antiviral derivatives and uses |
CN106905256A (en) * | 2017-03-06 | 2017-06-30 | 中国药科大学 | Benzo five-membered heterocyclic IDO1 inhibitor, its preparation method and application |
JOP20180040A1 (en) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
EP3661909B1 (en) * | 2017-08-02 | 2023-08-16 | Merck Sharp & Dohme LLC | Novel substituted phenyl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
WO2019027856A1 (en) | 2017-08-02 | 2019-02-07 | Merck Sharp & Dohme Corp. | Novel substituted pyridine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
KR102626210B1 (en) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EP3747875B1 (en) * | 2018-02-02 | 2022-12-07 | Hinova Pharmaceuticals Inc. | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof |
PL3752501T3 (en) | 2018-02-13 | 2023-08-21 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
EP3781556A1 (en) | 2018-04-19 | 2021-02-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
UA125163C2 (en) | 2018-05-14 | 2022-01-19 | Гіліад Сайєнсіз, Інк. | Mcl-1 inhibitors |
JP7199502B2 (en) * | 2018-07-06 | 2023-01-05 | ギリアード サイエンシーズ, インコーポレイテッド | Therapeutic heterocyclic compounds |
PT3820572T (en) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
US11987579B2 (en) * | 2018-07-30 | 2024-05-21 | Duke University | Niclosamide analogues and therapeutic use thereof |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
CN110054627B (en) * | 2019-01-10 | 2020-06-30 | 北京华氏开元医药科技有限公司 | Novel IDO inhibitor, preparation method, pharmaceutical composition and application thereof |
CR20220316A (en) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
CN111153850B (en) * | 2020-01-17 | 2021-08-13 | 中国药科大学 | Indole compound, preparation method thereof, pharmaceutical composition and application |
PE20231744A1 (en) * | 2020-08-07 | 2023-10-31 | Italfarmaco Spa | NEW OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS |
CN112898206A (en) * | 2021-02-05 | 2021-06-04 | 河北凡博医药科技有限公司 | Preparation method of 5, 6-dimethylbenzimidazole |
BR112023017582A2 (en) | 2021-03-05 | 2023-12-05 | Univ Basel | COMPOSITIONS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH EBV |
EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
CN117794920A (en) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamides as sodium channel modulators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643935A (en) * | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
CA2634198C (en) * | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CN101415702B (en) * | 2006-04-03 | 2011-08-10 | 安斯泰来制药有限公司 | Hetero compound |
US20080119491A1 (en) * | 2006-09-19 | 2008-05-22 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
EP2139478A4 (en) * | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
JP2016028016A (en) * | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | Oxadiazole derivatives and pharmaceutical uses thereof |
US9617272B2 (en) * | 2013-03-14 | 2017-04-11 | Newlink Genetics Corporation | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
TWI527811B (en) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | Benzimidazole derivatives as bromodomain inhibitors |
ES2719327T3 (en) * | 2013-07-01 | 2019-07-09 | Bristol Myers Squibb Co | IDO inhibitors |
-
2016
- 2016-05-12 US US15/153,527 patent/US9951065B2/en active Active
- 2016-05-12 AU AU2016263083A patent/AU2016263083B2/en not_active Expired - Fee Related
- 2016-05-12 ES ES16730065T patent/ES2761824T3/en active Active
- 2016-05-12 MX MX2017014613A patent/MX2017014613A/en unknown
- 2016-05-12 EP EP16730065.6A patent/EP3294732B1/en active Active
- 2016-05-12 BR BR112017024331-8A patent/BR112017024331A2/en not_active Application Discontinuation
- 2016-05-12 WO PCT/US2016/032152 patent/WO2016186967A1/en active Application Filing
- 2016-05-12 EA EA201792259A patent/EA201792259A1/en unknown
- 2016-05-12 KR KR1020177035775A patent/KR20180004811A/en not_active Application Discontinuation
- 2016-05-12 CN CN201680040764.0A patent/CN107849024A/en active Pending
- 2016-05-12 CA CA2985642A patent/CA2985642A1/en active Pending
- 2016-05-12 JP JP2017559523A patent/JP2018515541A/en not_active Ceased
- 2016-05-12 NZ NZ736709A patent/NZ736709A/en not_active IP Right Cessation
- 2016-05-13 TW TW105115008A patent/TWI657079B/en not_active IP Right Cessation
- 2016-05-16 AR ARP160101418A patent/AR104642A1/en unknown
-
2017
- 2017-10-26 IL IL255294A patent/IL255294A0/en unknown
-
2018
- 2018-03-26 HK HK18104140.1A patent/HK1244796A1/en unknown
- 2018-06-15 HK HK18107798.9A patent/HK1248235A1/en unknown
-
2019
- 2019-01-22 JP JP2019008501A patent/JP2019070042A/en active Pending
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
TW201706251A (en) | 2017-02-16 |
US9951065B2 (en) | 2018-04-24 |
MX2017014613A (en) | 2018-03-01 |
EP3294732A1 (en) | 2018-03-21 |
EA201792259A1 (en) | 2018-06-29 |
TWI657079B (en) | 2019-04-21 |
JP2019070042A (en) | 2019-05-09 |
IL255294A0 (en) | 2017-12-31 |
CA2985642A1 (en) | 2016-11-24 |
WO2016186967A1 (en) | 2016-11-24 |
KR20180004811A (en) | 2018-01-12 |
NZ736709A (en) | 2019-05-31 |
HK1248235A1 (en) | 2018-10-12 |
AU2016263083A1 (en) | 2017-11-16 |
US20160333009A1 (en) | 2016-11-17 |
JP2018515541A (en) | 2018-06-14 |
BR112017024331A2 (en) | 2018-07-24 |
AU2016263083B2 (en) | 2019-04-04 |
ES2761824T3 (en) | 2020-05-21 |
AR104642A1 (en) | 2017-08-02 |
HK1244796A1 (en) | 2018-08-17 |
CN107849024A (en) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3294732B1 (en) | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase | |
AU2018319538B9 (en) | Therapeutic heterocyclic compounds | |
AU2019297428B2 (en) | Therapeutic heterocyclic compounds | |
AU2019297362B2 (en) | Therapeutic heterocyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20171208 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1244796 Country of ref document: HK |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20181025 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190411 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1183710 Country of ref document: AT Kind code of ref document: T Effective date: 20191015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016021243 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191225 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191225 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191226 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602016021243 Country of ref document: DE Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1183710 Country of ref document: AT Kind code of ref document: T Effective date: 20190925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200127 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2761824 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200521 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016021243 Country of ref document: DE |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200126 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20200626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200531 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200512 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230412 Year of fee payment: 8 Ref country code: ES Payment date: 20230605 Year of fee payment: 8 Ref country code: DE Payment date: 20230314 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240312 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240321 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240308 Year of fee payment: 9 |